

Nutrition compartments are important factors in healthy life and stress biology. Not only modification on the diet but also changes in frequency of nutrition intake cause changes in endocrine and monoamine synthesis. These changes may affect the susceptibility to stress. Increased brain serotonin activity appears to be a prerequisite for maintaining control over cognitive information processes and involvement in learning and memory. Dietary modification may affect the availability of L-Trp, which has been reported to result in increased brain levels of L-Trp and elevated rates of serotonin synthesis and metabolism. The presence of large amounts of omega-3 PUFAs in the brain is indicative of the major role that these compounds play in the structure and function of this organ.

The effects of meal size on attention and mood indicated that subjects who ate a larger than usual lunch made more errors on attention and search tasks than those who ate a normal-sized lunch or one smaller than usual. Performance improved to a greater degree after the small lunch in subjects who typically ate a heavy lunch than in those who ate a light lunch. Further, afternoon snacks may also have positive effects on cognitive performance. For positive influences on stress, mood and cognitive function foods of plant origin have to be preferred. They are rich in minerals, phytochemicals, trace elements and vitamins, which show wide variety of positive effects on health.

ISBN: 978-3-940934-04-8

Nutrition and Stress Biology

Ali-Reza Waladkhani, BSc, PhD

Nutrition and Stress Biology

Nutrition and Stress Biology

Nutrition and Stress Biology

Impression

Dr. Ali-Reza Waladkhani, BSc, PhD

FPP – Center for Psychobiology and Psychosomatic Research, University of Trier,
Germany

waladkha@uni-trier.de

Reprinted material is quoted with permission. Reasonable efforts have been made to publish reliable information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming and recording or by any information storage or retrieval system, without prior permission in writing form from publisher.

© Waladkhani, MindBooks, February 2011

<http://www.mindbooks.org>

First edition 2011

Design by Mindbooks

Printed by Krüger in Dillingen, Germany

ISBN: 978-3-940934-04-8

1. Introduction	1
2. Importance of Macronutrients	3
2.1. Importance of Carbohydrate	4
2.1.1. Importance of Sucrose	6
2.2. Importance of Fat	6
2.2.1. Importance of Saturated Fat	8
2.2.2. Importance of MUFA	8
2.2.3. Importance of PUFA	8
2.2.4. Importance of L-Carnitine	19
2.2.5. Importance of Choline-lecithin	20
2.3. Importance of Protein	20
2.3.1. Effects of dietary protein on cortisol	22
2.3.2. Importance of Essential Amino Acids	23
3. Importance of Micronutrients	34
3.1. Importance of Vitamins	34
3.1.1. Importance of Folic Acid	34
3.1.2. Importance of Vitamin A	37
3.1.3. Importance of Vitamin B6	37
3.1.4. Importance of Vitamin B12	38
3.1.5. Importance of Vitamin C	38
3.1.6. Importance of Vitamin D	39
3.1.7. Importance of Vitamin E	39
3.2. Importance of Minerals, and trace elements	40
3.2.1. Importance of Calcium	40
3.2.2. Importance of Iodine	41
3.2.3. Importance of Iron	41
3.2.4. Importance of Magnesium	42
3.2.5. Importance of Selenium	43
3.2.6. Importance of Zinc	43
4. Importance of Phytochemicals	45
4.1. Importance of Carotenoids	45
4.2. Importance of Polyphenols	46
4.3. Importance of Sulphides	47
5. Importance of Functional foods	48
5.1. Importance of Acetyl-L-Carnitine	48
5.2. Importance of Phosphatidylserine	48
5.3. Importance of Probiotics	49
6. Importance of Endocrine	53
6.1. Importance of CCK	53

6.2.	6.2. Importance of Cortisol	54
6.3.	Importance of CRF	56
6.4.	Importance of CRH	57
6.5.	Importance of Cytokines	57
6.6.	Importance of Glucocorticoids	57
6.7.	Importance of Ghrelin	59
6.8.	Importance of Insulin	60
6.9.	Importance of Leptin	60
6.9.1.	Effects of Dietary Fat on Leptin	61
6.10.	Importance of SHBG	61
6.11.	Importance of Thyroid Hormones	61
6.12.	Importance of Testosterone	64
6.12.1.	Effects of Alcohol on Testosterone	66
6.12.2.	Effects of Nutrition and Testosterone	66
7.	Importance of Ageing	67
7.1.	Importance of Dietary restriction in brain ageing	68
8.	Importance of Foods	70
8.1.	Importance of Caffeine	70
8.1.1.	Effects of caffeine on behaviour	71
8.1.2.	Effects of caffeine on Anxiety	71
8.1.3.	Effects of caffeine on Sleep	72
8.1.4.	Effects of caffeine on cognitive performance	72
8.1.5.	Effects of caffeine on Anxiety	72
8.1.6.	Effects of caffeine withdrawal	72
8.1.7.	Effects of caffeine tolerance	73
8.1.8.	Effects of caffeine abuse	73
8.1.9.	Effects of caffeine on mood	73
8.1.10.	Effects of caffeine on anxiety	73
8.1.11.	Effects of caffeine on information processing	74
9.	Feeding behaviour	76
9.1.	Caloric Restriction	76
9.2.	Meal Frequency	76
9.3.	Meal Size	77
9.4.	Meal composition	77
9.5.	Appetite	77
9.6.	Behavioural Decrements	78
9.7.	Ageing and oxidative stress	78
9.8.	Plant Foods	78
10.	Oxidation	80

10.1. Nitric oxide	80
11. Antioxidant	82
11.1. Vitamin E	82
11.2. Coenzyme Q10	83
11.3. Creatine	83
11.4. Gingko biloba	83
11.5. N-acetylcysteine	83
12. Neurogenesis	85
12.1. Effect of PUFA on neurogenesis	85
12.2. Effects of neurotrophins on neurogenesis	85
13. Emotion	87
14. Metabolic Acidosis	88
15. Monoamine	90
15.1. Histamine	90
15.2. Serotonin	91
15.2.1. Serotonin and Cortisol	92
15.3. Dopamine	92
16. Exercise	93
17. BDNF gene	95
18. Stress	96
18.1. Effect of stress on food choice	97
18.2. Effects of stress on female reproduction	98
18.3. Effects of stress on prenatal life	99
18.3.1. Effects of stress on early life	100
18.4. Effects of stress on sleep	101
18.5. Effects of Stress during Exam	101
19. Food deprivation	102
19.1. Caloric restriction	102
19.1.1. Fasting	104
19.1.2. Brain in choosing foods	105
19.1.3. Energy balance	105
20. Stress during Pregnancy	106
21. Food intake	108
22. Diseases and Stress	109
22.1. Adiposity	109
22.2. Alzheimer Disease	110
22.3. Anorexia nervosa	110
22.4. Autoimmune disorders	111
22.5. Bulimia	112

22.6.	Cancer	112
22.7.	Cardiovascular diseases	114
22.8.	Dementia	114
22.9.	Immunological diseases	115
22.10.	Immunosuppression	115
22.11.	Inflammatory bowel disease	115
22.12.	Insulin resistance	116
22.13.	Intestinal Disorders	118
22.14.	Neurodegenerative diseases and mental disorders	119
23.	References	120

11 β -HSD 1	11 β -hydroxysteroid dehydrogenase type 1
5-HT	5-Hydroxytryptamine (Serotonin)
ACTH	Adrenocorticotrophic hormone
AD	Alzheimer Disease
ALA	α -Linolenic Acid
ALC	Acetyl-L-carnitine
AN	Anorexia Nervosa
BCAA	branched-chain amino acids
Bcl-2	B-cell lymphoma 2
BDNF	Brain-derived neurotrophic factor
BED	binge eating disorder
BMI	body mass index
BN	Bulimia Nervosa
cAMP	cyclic AMP
CBG	corticosteroid-binding globuline
CCK	Cholecystokinin
CeA	Central nucleus of the amygdala
CMA	Chronic Metabolic Acidosis
cNOS	constitutive Nitric Oxide Synthase
CNS	Central nervous system
CR	Caloric Restriction
CRF	corticotrophin Releasing Factor
CRH	Corticotropin-releasing hormone
DA	Dopamine
DHA	Docosahexaenoic acid
DHT	Dihydrotestosterone
DOPA	Dihydroxyphenylalanine
EMS	Eosiniphilia myalgia syndrome
eNOS	endothelial Nitric Oxide Synthase
EODF	every-other-day fasting
EPA	Eicosapentaenoic acid
ERK	Extracellular signal-regulated kinase
FA	fatty acid
FFA	Free Fatty Acids
FSH	follicle-stimulating hormone
fT3	Free Triiodothyronine
fT4	Free prohormone thyroxine
GABA	γ -Aminobutyric acid
GC	Glucocorticoid

GD50	Gestation Day 50
GH	Growth Hormone
GIT	Gastrointestinal Tract
Glu	Glutamine
GnRH	Gonadotropin releasing hormone
HD	Huntington's Disease
HIAA (5-HIAA)	5-hydroxyindolacetic acid
His	Histidine
HPA	hypothalamic-pituitary-adrenal
IGF	Insulin Growth Factor
IL	Interleukin
INF	Interferon
iNOS	inducible Nitric Oxide Synthase
IQ	intelligence quotient
LC-PUFA	Log chain PUFA
LH	Luteinizing Hormone
LNAA	large neutral amino acids
LPS	Lipopolysaccharides
Lys	Lysine
MDD	Major depressive disorder
MHC	Major Histocompatibility Complex
MPTP	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MRI	Magnetic resonance imaging
MSG	Monosodium glutamate
MUFA	Mono unsaturated fatty acid
NE	Norepinephrine
NK	cell natural killer cell
nNOS	neuronal Nitric Oxide Synthase
NO	Nitric Oxide
NPC	Neural precursor cells
NPY	Neuropeptide Y
OCD	Obsessive Compulsive Disorder
OS	Oxidative Stress
PBLs	peripheral blood leukocytes
PC	Phosphatidylcholine
PD	Parkinson's disease
Phe	Phenylalanine
PS	Phosphatidylserine
PS60	prenatal stress

PUFA	Poly Unsaturated Fatty Acids
PVN	paraventricular nucleus
REM	Rapid eye movement
ROS	Reactive oxygen species
rT3	Reverse Triiodothyronine
SHB	Sex hormone binding
T3	Triiodothyronine
T4	Prohormone thyroxine
TNF	Tumor necrosis factors
TRH	thyrotropin-releasing hormone
TSH	thyroid-stimulating hormone
Trp	Tryptophan
TSST	Trier Social Stress Test
Tyr	Tyrosine
WHR	Waist Hip ratio

1. Introduction

The term "stress" describes the state of the organism under the influence of external or internal forces or "stressors", which threaten to alter its dynamic equilibrium or homeostasis. Stress needs stressful stimuli. This can be anatomical, mental, physical or physiological reactions. Stress can be positive or negative. While distress is the most commonly referred to have negative implications, eustress is a positive form of stress, usually related to desirable events in person's life.

Distress and eustress are cumulative in nature, depending on a person's way of adapting to a change that has caused it. The adaptive changes occurring in response to stressors are both behavioural and physical. Stress may lead to illness through e.g. unhealthy changes in nutritional behaviour. Food choices have often been considered as one of a range of health-related behaviours that might be responsive to life stress or emotional well-being, either inadvertently, or as a deliberate strategy for coping with stress (1,2). Also, stress may affect health not only through its direct biological effects but also through changes in health behaviours (3,4).

Stress is associated with biological changes, such as adrenaline-induced glycogenolysis, slowed gastric emptying, autonomic shunting of blood from gut to musculature, and activation of the hypothalamic-pituitary-adrenal (HPA) axis (5,6). The HPA axis is activated during stress, resulting in the release of glucocorticoids (GC) from the adrenal cortex in blood, and subsequently the appearance in saliva (7). Increases of CRH, ACTH and cortisol levels in anticipation of or during stressful stimulation are interpreted as allostatic (8).

There is evidence that the HPA axis as well as peripheral cortisol metabolism may be differently regulated according to sex, and age factors (9, 10). The diversity of health implications now associated with control, and consequences of the release of cortisol, together with its sensitivity to psychological stress, has given this major human adrenal GC hormone much importance in behavioural medicine (11). Also, the HPA axis is closely associated with systems responsible for caloric flow in the body (12,13,14). HPA axis function can profoundly influence expression of appetite, and regulation of body weight (6), whereas HPA axis activity can be modified by changes in feeding patterns (15). In humans the fasting induced changes in

adrenocortical responsiveness (16). In sheep isolated from the flock compared with stressed sheep fed *ad libitum* a prolonged fasting of 4 days decreased cortisol responses to stress (17). Further rats fasted for 14–24h showed a blunted corticosterone response to novelty (18), and reduced ACTH levels following restraint stress compared with controls (19,20). However, despite lower ACTH levels, restraint stress after fasting was associated with an increased corticosterone response (20). Systematic studies demonstrated an association between meals and the midday increase in plasma cortisol (21). Also, increases in plasma cortisol could occur in some subjects after breakfast, the midday meal or an evening meal, the greatest effect occurred after the midday meal (22).

Stress may lead to illness through unhealthy changes in nutritional behaviour (22a). There is evidence that stress may evoke a change in diet, although taken together the data is inconsistent and suggests that the stress effects on the diet are dependent on the type of stress and individual responses. While an identical stressor may cause in some people an increase in food intake whilst others to decrease their intake (23). However irrespective of whether eating increased or decreased, sweet foods and chocolate intake increased in both groups whilst fruit, vegetables, meat and fish intake decreased in both groups (24).

Recent studies indicated that consumption of high carbohydrate/low protein meals raise the plasma ratio of Tryptophan (Trp), which produced anti-depressant effects on clinical populations (25). In the randomised placebo controlled clinical study in high stress prone subjects a high carbohydrate/low protein meal, which increased plasma ratio of Trp:LNAA (large neutral amino acids) by 42%, reduced the cortisol response to a laboratory stressor (26). In other randomised placebo controlled study a dietary protein enriched in Trp (in the form of lactalbumin) had a similar effect in reducing cortisol responses to a laboratory stressor (27). Trp is the precursor to the neurotransmitter serotonin. Also, the availability of this amino acid to brain neurons that synthesize serotonin directly influences the rate at which it is converted to a neurotransmitter (28). Administering either the amino acid itself (29) or meals that raise Trp access to serotonin neurons (30, 31) rapidly stimulates serotonin production. Increases in brain serotonin appear to modulate adrenocortical reactivity probably through alterations in Trp1a and Trp2 receptor sites located at the hypothalamic and pituitary brain area (32).

2. Importance of Macronutrients

Meal compartments can be divided in macronutrients, micronutrients, and phytochemicals. Chemically macronutrients are classified in three categories carbohydrate, fat and protein. Diets have to contain adequate amounts of macronutrients for physical and mental growth and development. Not only the meal composition but also food ingestion is a well-known inducer of several peptides that may, in turn, directly influence the activity of the HPA axis (33). Animal studies indicated that both food intake and the light-dark cycle represent independent synchronizers for the circadian periodicity of cortisol secretion (34). Also, not only the food composition but also the meal timing and the duration of pre-meal fasting have been shown to exert an important effect on cortisol secretion (22,35).

In humans normal physiological variations in cortisol have a significant direct influence on macronutrient metabolism (36,37). Cortisol seems to increase lipolysis and proteolysis, as well as increasing gluconeogenesis, thereby raising the contribution of protein and fat to energy substrate supply, while protecting glycogen stores. Further, the ability of cortisol to increase plasma free fatty acid (FFA) levels may underlie the emerging link between cortisol and abdominal obesity, together with its associated metabolic syndrome (38).

In humans, stress may alter macronutrient selection. Women tend to prefer high fat or sweet foods when moderately stressed (39,40). Cortisol reactivity may be a marker for vulnerability to stress induced eating and thus may help to explain who eats more versus who eats less after stress (41). Women who were high cortisol reactors to stress ate more food than low reactors during recovering from stress (41). On the rest day, however, high reactors tended to eat less and low reactors tended to eat more, eliminating the difference between groups. Interestingly the high cortisol reactors tended to consume more sweet foods than low reactors across days (41). Animal experiments show that adrenal steroids influence macronutrient selection by increasing appetite for carbohydrate, primarily, and for fat and regulating the timing of eating (42, 43). In humans it has been found that food ingestion, particularly proteins, can stimulate α 1-adrenoreceptors possibly via the activation of neurotransmitter amines (44).

Previous studies indicated that post meal plasma cortisol levels could be affected by the proportions of macronutrients consumed. Meals containing 20-40% protein (as % total energy) produced a greater plasma cortisol response

than meals with high carbohydrate or fat levels (45). By comparison, meals containing 10% protein resulted in weaker secretion of plasma cortisol (46) and protein-free glucose or fat loads did not stimulate cortisol release (34). There is some evidence that maintaining a very high-protein diet may chronically stimulate the HPA axis (47) and increase release of vasoactive hormones (48). Further, reducing the carbohydrate:protein ratio of diets chronically has also been associated with deterioration in mood (49,50).

2.1. Importance of Carbohydrate

Carbohydrate consists of monosaccharide sugars or larger molecules of these unit joint together:

- Disaccharides (two units of monosaccharides),
- Oligosaccharides (a few units of monosaccharides) and
- Polysaccharides (many units of monosaccharides).

For instance, glucose is a monosaccharide and starch is a polymer of glucose units. Polysaccharides are sometimes called complex carbohydrate and sugar simple carbohydrate. Carbohydrate or saccharides fill numerous roles in living things such as the storage and transport of energy in form of glycogen and starch and structural components in form of cellulose¹ in plants and chitin² in animals. Carbohydrate supplies around 4 kilocalories per gram.

Diets with high carbohydrate content may prevent deterioration of mood in stress-prone subjects when submitted to a stressful task (51). Different studies indicated that carbohydrate supplementation result in significantly lower plasma levels of Trp and the branched-chain amino acids (BCAA; leucine, isoleucine and valine) by 120 minutes of exercise (52,53). The decrease of plasma Trp concentration can be caused by higher brain Trp uptake. Early studies indicated that carbohydrate ingestion stimulate brain Trp uptake and serotonin synthesis (31). Further, carbohydrate supplementation causes attenuation in FFA levels. Increasing levels of plasma FFA result in increased plasma levels of Trp by displacing Trp from albumin (53,54). In contrast, declines in plasma BCAA levels during carbohydrate supplementation and

¹ Cellulose is a polysaccharide consisting of a linear chain of several hundred to over ten thousand D-glucose units. It is the structural component of the primary cell wall of green plants, many forms of algae and the oomycetes. About 33% of all plant matter is cellulose (the cellulose content of cotton is 90% and that of wood is 40–50%). Some animals can digest cellulose with the help of symbiotic microorganisms that live in their guts. Also, humans can digest cellulose to some extent.

² Chitin is a long-chain polymer of N-acetylglucosamine, a derivative of glucose. It is the structural component of the primary cell wall of many animals. Chitin may be compared to the polysaccharide cellulose.

exercise are thought to be due to the maintenance of plasma insulin levels during exercise (54,55). Further, carbohydrate supplementation during prolonged exercise attenuated increases in plasma cortisol and decreases in plasma insulin (52,56).




FIG. 1. Effect of high carbohydrate intake

Different studies indicated that carbohydrate supplementation result in lower plasma levels of both amino acids tyrosine and phenylalanine. Since movement of these amino acids into the muscle and the liver can also be enhanced by insulin (53,57). Also, glucose load leads to a rapid rise in insulin levels in nondiabetics and thereby to an increased transport of Trp into the CNS. This is followed by an increased synthesis of serotonin, which is known to have a stimulatory influence on the HPA axis at the hypothalamic level (58). Human studies suggest that ready availability of energy is a prerequisite for significant acute stress responses of the HPA axis (13). Following Trier Social Stress Test (TSST) subjects with high blood glucose levels showed the well-established response pattern of a 2-fold increase in free cortisol levels (59,60). Further, brain derived neurotrophic factor (BDNF) expression can be inhibited by a diet high in saturated fat and sucrose (61,62).

2.1.1. Importance of Sucrose

Sucrose (saccharose) is a disaccharide of glucose and fructose. It is formed only by plants. Sucrose prevents a marked reduction in caloric intake after stress. The effects of sucrose are to damp subsequent activity in the HPA axis (63). Nutritive sweet drinks also block stress-induced effects on avoidance behaviour in rats (64,65), reduce pain perception (66,67) and reduce perceived exertion and the hormonal responses to intense exercise (68). The interaction of sucrose with stress-induced ACTH secretion depends on whether the studies use acute or chronic stress. In rats (19) and man (69) sucrose or glucose have been shown to augment ACTH responses to acute stress.

2.2. Importance of Fat

Fats in diets consist largely of a heterogeneous mixture of triacylglycerol molecules that are each combined with three fatty acids (FAs). Dietary fat has long been recognized as an important source of energy for mammals. The FAs can be divided into two categories, based on chemical properties: saturated FAs and unsaturated FAs.

TABLE 1
Fat composition of some Nutrition (in 100 g)

	Fat (g)	MUFA (g)	PUFA (g)	n6 FA* (g)	n3 FA** (g)
Buckling	15.8	8	3	0.3	1.4
Flounder	3.8	0.8	1.1	0.2	0.4
Greenland halibut	14.6	3.4	4.6	1	1.8
Halibut	2	0.5	0.7	0.1	0.3
Lye rolls	2.6	0.7	0.8	0.6	0.1
mackerel	13.9	5.4	3.6	0.3	1.8
Olive (green)	13.9	9.9	1.3	1.2	0.1
Red perch	4.3	1	1.1	0.2	0.6
Salmon	6.3	2.4	1.6	0.1	0.9
Stockfish	2.9	0.3	1.1	0.1	0.7
Trout	2.9	0.9	1	0.2	0.6
Tuna	17.3	4.5	5.8	0.5	3.9
Walnut	62.5	10.1	42.7	35.8	6.3
White bread	3.3	1	0.9	0.5	0.3

* Sum of Arachidonic acid and linolic acid

** Sum of α -linolenic acid, DHA and EPA

Unsaturated FAs can be monounsaturated FAs (MUFA), or polyunsaturated FAs (PUFAs). PUFAs can be categorized according to their chain length. Mammalian cells can introduce double bonds into all positions on the FA chain except the n-3 and n-6 position. Thus, the shorter-chain α -linolenic acid (18:3 n-3) and linoleic acid (18:2 n-6) are essential FAs. The 18-carbon n-3 and n-6 shorter-chain PUFAs are precursors to the longer 20- and 22-carbon PUFAs, called very-long chain PUFAs. Despite their differences in structure, all fats contain approximately the same amount of energy (9kcal/g).




FIG 2. Effect of high fat diet on neurological and physiological response

FAs play a variety of physiological roles. The specific biological functions of a FA are determined by the number and position of the double bonds and the length of the acyl chain. A high-fat diet has suppressive effects on the thermoregulatory and behavioural responses to the stress (70). Feeding rats with a high-fat diet reduces some of the behavioural and physiological responses to the psychosocial and physiological stressors such as social defeat and administration of the endotoxin Lipopolysaccharides (LPS) (70). Also, feeding rats chronically a high-fat diet increased their basal and stress-induced HPA activity (71). Continuous high-fat feeding may act as a chronic stressor, not only enhancing baseline adrenocortical activity but also increasing the neuroendocrine stress responses. Feeding rats with a high-fat diet resulted in a lower anxiety level in an elevated plusmaze paradigm compared to feeding

with a high carbohydrate diet (72). Also, consumption of a high-fat diet decreases the hypothalamic levels of Trp immediately (73). Further, the defeat-induced desensitization of central nervous Trp1a receptors is absent in animals on a high-fat diet (70).

2.2.1. Importance of Saturated Fat

Consumption of a diet high in saturated fat and sucrose inhibited the BDNF expression (61,62). Saturated fats did not enhance the affinity constant of corticosteroid-binding globuline (CBG) for cortisol, whereas oleic acid enhances this three-fold (74). The Italian Longitudinal Study on ageing (5632 subjects) has shown that high intakes of total fat, saturated fat and cholesterol, have been associated with an increased risk of dementia (75).

2.2.2. Importance of MUFA

In-vitro the addition of physiological concentrations of the exogenous FFAs confirms that the stimulation of CBG binding properties is mainly due to MUFA (the primary constituents of olive and canola oils) classes. Addition of MUFA to purified human CBG enhanced CBG binding activity in a concentration dependent fashion (76). Also, oleic acid alone mimicked the in-vivo situation by increasing the affinity constant of CBG for cortisol (three-fold) and reducing the number of binding sites (two-fold), whereas saturated fats did not enhance the binding (74).

The Italian Longitudinal Study on Ageing has shown that a typical Mediterranean diet, with high MUFAs intakes, appear to be protective against age-related cognitive decline (77).

2.2.3. Importance of PUFA

PUFAs are long chain omega-3 and omega-6 FAs of plant (the primary constituents of corn, sunflower, flax seed and many other vegetable oils) and marine origin. These essential FAs cannot be synthesized in the human body. Due to their greater availability and low cost, there is excessive consumption of omega-6 FAs in developing countries. Junk foods are also loaded with omega-6 FAs and trans-FAs. The omega-3 FA (α -linolenic acid) can be metabolized in the liver to the longer-chain eicosapentaenoic (EPA) and docosahexaenoic acid (DHA). This conversion is limited in human beings. It is estimated that only 5–15% of α -linolenic acid is ultimately converted to DHA

(78). Ageing, illness and stress, as well as excessive amounts of omega-6 rich oils (corn, safflower, sunflower, and cottonseed) can all compromise this conversion (79). The ideal dietary ratio of omega-6 to omega-3 has been recommended by an international panel of lipid experts to be approximately 2:1 (80). It is reported that corn oil has an omega-6:omega-3 ratio of 60:1, and safflower a ratio of 77:1 (81).

The biological importance of PUFA derives in part from their role as precursors of important second messengers (prostaglandins, prostacyclins and leukotrienes) (82,83) and as constituents of structural lipids in cellular membranes, which influence the activities of membrane-linked functional molecules (receptors, enzymes and transporters) (84,85). The presence of large amounts of omega-3 PUFAs in the brain is indicative of the major role that these compounds play in the structure and function of this organ (86). About 50 to 60% of the dry weight portion of the human brain consists of lipids. PUFAs constitute approximately 35% of that lipid content (87). Omega-3 FAs, particularly EPA and DHA play important roles in the development and maintenance of normal CNS structure and function. Along with the omega-6 FA, arachidonic acid, DHA is a major constituent of neuronal membranes, making up about 20% of the brain's dry weight (88). Synapses contain a high concentration of DHA, which appears to play a role in synaptic signal transduction (89). DHA is also important for normal cognitive development (90). In transgenic mouse models, dietary DHA improved memory, increased synapse density and decreased amyloid- β toxicity, thus providing evidence of protection against the Alzheimer Disease (AD) and cognitive decline (91,92). The omega-3 FAs are an essential component of CNS membrane phospholipid-acyl chains and, as such, they are critical to the dynamic structure of neuronal membranes (93). DHA is continuously secreted by astrocytes, bathing the neuron in omega-3 FA (94). Fish provide varying amounts of omega-3 PUFA in the form of DHA and EPA.

2.2.3.1. Effects of PUFA on CNS membrane Fluidity

PUFAs in general play important roles in structural and functional maintenance of neuronal membranes, neurotransmission and eicosanoid biosynthesis (87,95), as well as in the maintenance of membrane fluidity and flexibility and in the modulation of ion channels, receptors and ATPases. Omega-3 PUFA can alter neuronal fluidity by displacing cholesterol from the membrane (96). Alterations in the membrane lipids can alter their function by changing fluidity. An optimal fluidity is required for neurotransmitter binding and the signalling within the cell (97). In healthy adults, higher concentrations

of plasma DHA predict higher cerebrospinal fluid 5-hydroxyindolacetic acid, a metabolite that reflects serotonin turnover, particularly in the frontal cortex (98). Numerous studies link low cerebrospinal fluid 5-hydroxyindolacetic acid with psychiatric conditions, including violent and suicide attempts during depression (99). Animal studies with an omega-3 PUFA deficient diet showed reductions in DHA levels although reductions are particularly pronounced in the frontal cortex (40% reduction). Another area with a marked DHA reduction is the olfactory bulb (35% reduction), which may also have behavioural consequences (100).

Omega-3 PUFAs are essential components of CNS membrane phospholipidacyl chains and as such they are critical to the dynamic structure of neuronal membranes (93). DHA is continuously secreted by astrocytes, bathing the neuron in omega-3 PUFA (94). Reduction in omega-3 PUFA intake (in the form of α -linolenic acid) results in a reduction of omega-3 PUFA content throughout the brain cells and organelles along with a compensatory rise in omega-6 PUFA acid content. This alteration is accompanied by a 40% reduction in the Na-K-ATPase of the nerve terminals, an enzyme that controls ion transport produced by nerve transmission and that consumes half the energy used by the brain (86). There is also a 20% reduction in 5'-nucleotidase activity, a decrease in fluidity in the surface polar part of the membrane (101) and a significant reduction in the cell body size of the hippocampal CA1 pyramidal neuron (102). A 30% reduction in the average densities of the synaptic vesicles in the terminals of the hippocampal CA1 region has also been observed as a result of an omega-3 deficiency combined with a learning task (103). Deficiency of omega-3 PUFA also results in a 30-35% reduction in phosphatidylserine in the rat brain cortex, brain mitochondria and olfactory bulb (104).

2.2.3.2. Effects of PUFA on Monoamines

A number of studies have specifically examined the effect of an omega-3 deficient diet on the DA and serotonin levels in animals. In animal studies omega-3 PUFA deficient diet resulted in a reduction of the dopaminergic vesicle pool (105) along with a 40-60% decrease in the amount of DA in the frontal cortex and an increase in the nucleus accumbens (105,106). Although overall DA levels in the nucleus accumbens are higher in an omega-3 deficiency. Function of the nucleus accumbens-dopaminergic system appears to be abnormal. In rats omega-3 PUFA deficiency reduced the release of DA from the vesicular storage pool under tyramine stimulation by 90% compared to receiving an adequate omega-3 PUFA intake (105). In the animal model of

depression, although overall nucleus accumbens-DA levels are higher, the extracellular levels of DA in the nucleus accumbens are lower than normal controls and do not respond to normal serotonin stimulation (107). The increase in DA in the nucleus accumbens of omega-3 deficient rats is thought to be a result of loss of normal inhibitory control by reductions in frontal cortex DA input (108). Also, omega-3 PUFA deficiency induces changes at several levels of the dopaminergic mesocortico limbic pathway (109).




FIG 3. Consequences of reduced omega-3 FA intake for a long time on CNS

The binding of serotonin to the astroglial 5-HT_{2A} receptor can mobilize DHA to supply the neuron (110). Also essential FAs can act as sources for second messengers within and between neurons (111).

TABLE 2.
Effect of omega-3 deficiency in the CNS

Parameters showing decrease	Parameters showing increase
<ol style="list-style-type: none"> 1. 5'-nucleotidase activity. 2. Blood-brain barrier integrity. 3. Cell body size of the hippocampal CA1 pyramidal neuron. 4. Cerebrospinal fluid 5-hydroxyindolacetic acid. 5. Dopamine (DA) content in frontal cortex. 6. DA content in olfactory bulb. 7. DA vesicle pool. 8. DA release from vesicle storage. 9. Fluidity at surface polar membrane. 10. Glucose uptake by neurons. 11. Hippocampal CA1 pyramidal neuron cell body size. 12. Neuronal cytochrome oxidase activity. 13. Normal cerebral microperfusion. 14. Normal inhibitory control over nucleus accumbens³ dopamine. 15. Phosphatidylserine in cortex, olfactory bulb, and mitochondria. 16. Pre/post synaptic dopamine receptor DR2 in frontal cortex. 17. Sodium/potassium ATPase at nerve terminal. 18. Vesicular monoamine transporter. 	<ol style="list-style-type: none"> 1. DA content in nucleus accumbens. 2. Pre/post synaptic DA receptor DR2 in nucleus accumbens. 3. Serotonin receptor density in frontal cortex.

2.2.3.3. Effects of PUFA on densities of synaptic vesicles

A 30% reduction in the average densities of synaptic vesicles in the terminals of the hippocampal CA1 region has also been observed as a result of an omega-3 PUFA deficiency combined with a learning task (103). Chronic dietary deficiency in α -linolenic acid impairs performance in learning ability

³ The nucleus accumbens is a collection of neurons within the striatum. Each half of the brain has one nucleus accumbens. It plays an important role in addiction, aggression, fear, laughter, pleasure, reward, and the placebo effect. The nucleus accumbens and the olfactory tubercle collectively form the ventral striatum, which is part of the basal ganglia. The nucleus accumbens can be divided into two structures: the nucleus accumbens core and the nucleus accumbens shell.

and motivational processes (112). Also, deficiency of omega-3 PUFA results in a 30-35% reduction in phosphatidylserine concentration in the rat brain cortex, brain mitochondria and olfactory bulb (104).

2.2.3.4. Effects of PUFA on gene expression

The amount of omega-3 PUFAs in the diet might act on the regulation of cerebral gene expression (109,113).

2.2.3.5. Effects of PUFA on CBG

Addition of PUFA to purified human CBG enhanced CBG binding activity in a concentration dependent fashion (76). A clinical study in burn patients showed that low-fat nutrition support (i.e., 15% of total calories as fat) modulated CBG and the concentration of free circulating cortisol after a severe stress. In contrast to in-vitro studies additional intake of fish oil did not seem to add clinical benefit to low-fat solutions (114).

2.2.3.6. Effects of PUFA on phosphatidylserine

Animal studies in rats indicated that fish oil supplementation can increase phosphatidylserine (PS) composition of the cerebral membrane (115). PS has antidepressant activity in adults (116,117). PS can activate various enzymes, including protein kinase C, Na-K-ATPase and tyrosine hydroxylase, as well as regulating calcium uptake. It is therefore suggested that altering PS in cerebral membranes can alter neurotransmission (115).

2.2.3.7. Effects of PUFA on neuronal functional activity

An omega-3 PUFA deficiency has also been shown to decrease glucose uptake of brain cells by 30% and decrease cytochrome oxidase activity by up to 40% (118). Glucose uptake and cytochrome oxidase activity are indicators of neuronal functional activity. Also, an omega-3 PUFA deficiency can alter the delivery of amino acids and sucrose across the blood-brain barrier (119). Further, this deficiency may compromise normal cerebral microperfusion, whereas supplementation may improve cognitive abnormalities related to cerebral hypoperfusion (120,121).

2.2.3.8. Effects of PUFA on neuronal protection

PUFAs protect neurons directly by preventing neuronal apoptosis (122) and suppressing the production of neurotoxic TNF⁴ (123,124). TNF is believed to have a role in these conditions by inducing the death of neurons (123).

⁴ TNF (Tumour necrosis factors) refers to a group of cytokines family that can cause cell death.

Moreover, PUFAs augment acetylcholine and endothelial nitric oxide formation and release in the brain, enhance glucose uptake by neuronal cells and thus improve memory (125). The findings of epidemiological studies suggest that a high fish intake reduces the risk of dementia (50). Recently, a seven-year follow-up study of 1600 elderly people also showed that those who ate fish or seafood at least once a week were less likely to develop any form of dementia (126).




FIG. 4. Possible mechanisms of omega-3, and omega-6 FA in BDNF

2.2.3.9. Effects of PUFA on Depression

Case reports in the literature indicate flaxseed oil which is a source of α -linolenic acid may be of benefit in the treatment of bipolar depression and agoraphobia (127).

One well-designed trial demonstrated four months of treatment with 9.6 g omega-3 PUFA can be of benefit in the treatment of bipolar disorder. This study showed a highly significant effect of omega-3 PUFA in lengthening remission and a highly significant effect in treating depression ($p < 0.001$ Hamilton Rating Scale for Depression scores) (128). One double-blind, placebo-controlled study ($n=22$) showed that the addition of 2 g EPA to standard antidepressant medication enhance the effectiveness of that medication compared to the medication plus placebo after three weeks of treatment (129). EPA had an effect on insomnia, depressed mood and feelings of guilt and worthlessness (129). In a 12-week, randomized, double-blind, placebo-controlled trial, patients who experienced persistent depression, despite ongoing standard pharmacotherapy received 1 g EPA. The patients showed a 53% reduction on Hamilton depression scores. Intake of 1 g EPA dose led also to improvements in depression, anxiety, sleep, lassitude, libido and suicidal ideation (130). The 2-g/d group showed little evidence of efficacy, whereas the 4-g/d group showed non-significant trends toward improvement.

A number of investigations have also found decreased omega-3 PUFA content in the blood of depressed patients (131-134). Further, there is a significant negative correlation between worldwide fish consumption and prevalence of depression (135). Frequent fish consumption in the general population is associated with a decreased risk of depression and suicidal ideation (136). Also, fish consumption is significantly associated with higher self-reported mental health status (137). Separate research involving a random sample within a nation confirms the global findings, as frequent fish consumption in the general population is associated with a decreased risk of depression and suicidal ideation (136). In addition, a cross-sectional study from New Zealand found that fish consumption is significantly associated with higher self-reported mental health status (137). In fact, EPA content in red blood cell phospholipids is negatively correlated with the severity of depression, while the ratio of omega-6 PUFA arachidonic acid to omega-3 PUFA EPA positively correlates with the clinical symptoms of depression (131). In addition, a negative correlation between adipose tissue DHA and depression has been

observed. In a clinical study mildly depressed subjects had 34.6% less DHA in adipose tissue than non-depressed subjects (138). Depressive symptoms associated with premenstrual syndrome have also been shown to be responsive to marine oil extracted from Antarctic krill. Krill oil is particularly rich in phospholipids as well as EPA and DHA (240 mg and 120 mg per g, respectively). Canadian researchers compared 2 g krill oil to 2 g standard fish oil capsules (180 mg EPA and 120 mg DHA per g) in the treatment of premenstrual syndrome and dysmenorrhoea. In the three-month trial (n=70), patients took 2 g krill oil or fish oil capsules daily for one month, then for eight days prior to, and two days during menstruation for the following two months. Evaluations at 45 and 90 days revealed the patients taking krill oil showed a significant improvement in depressive symptoms of premenstrual syndrome. The same effect was not observed with the standard fish oil capsules, indicating that the presence of the phospholipids and/or higher amounts of EPA may be responsible for the therapeutic effect of krill oil (139). Another possibility is the presence of some naturally occurring substances in the Krill oil with positive health effects in contrast to the fish oil capsules.

Logistic regression analysis indicated that a 1% increase in plasma DHA is associated with a 59% reduction in the reporting of depressive symptoms (140). It is well known that during pregnancy there is a significant transfer (up to 2.2 g/day) of PUFA to the developing foetus (79). Also, increased risk of post-partum depressive symptoms has recently been associated with a slower normalization of DHA levels after pregnancy (141). Higher concentrations of DHA in mother's milk and greater seafood consumption both predicted lower prevalence of post-partum depression (142).

MRI studies indicated a decrease in volume of various areas of the brain in depressed patients (143,144). Omega-3 PUFA can augment antidepressant pharmacotherapy and alleviate depression by entirely different means than standard medications (130). With regard to DHA or a combination of EPA and DHA, there have been three negative reports. In a trial on DHA alone as mono-therapy in the treatment of MDD⁵ 2 g pure DHA or placebo was administered to 36 patients with depression for six weeks. The response differences between the groups, as measured by scores on the "Montgomery-Asberg Depression Rating Scale" did not reach statistical significance (145). Further, in an open label pilot study the combination of 1.7 g of EPA and 1.2 g

⁵ Major depressive disorder is a mental disorder characterized by an all-encompassing low mood accompanied by low self-esteem and by loss of interest or pleasure in normally enjoyable activities.

of DHA failed to show benefits among seven women with a past history of post-partum depression. The omega-3 PUFA mono-therapy was initiated between the 34th – 36th weeks of pregnancy and was assessed through 12 weeks post-partum. In these women the fish oil combination did not reduce the risk of relapse (146). Finally, a pure DHA supplement, at low doses of 200 mg per day for 4 months post-partum, did not improve self-rated or diagnostic measures of depression over placebo. However, the women enrolled ($n = 89$) in the study were not clinically depressed as a group, which precludes interpretation that DHA is ineffective in post-partum depression (147).




FIG. 5. Potential interactions between omega-3 FA, omega-6 FA, and inflammatory cytokines

2.2.3.10. Effects of PUFA on BDNF

Omega-3 PUFA may exert significant influence in major depression via cytokine modulation. A growing body of research has documented an association between depression and the production of these pro-inflammatory immune chemicals. These cytokines, including IL-1 β , -2 and -6, INF- γ and TNF- α , can have direct and indirect effects on the CNS. Some of the documented activities of these cytokines include lowered neurotransmitter

precursor availability, activation of the HPA axis and alterations of the metabolism of neurotransmitters and neurotransmitter mRNA (148).

Recent data indicated that elevations of IL-1 β and TNF- α is associated with the severity of depression (149). It has been suggested that the anti-inflammatory role of omega-3 PUFA may influence BDNF in depression (150). BDNF is a polypeptide that supports the survival and growth of neurons through development and adulthood. Serum BDNF has been found to be negatively correlated with the severity of depressive symptoms (151). Antidepressant medications and voluntary exercise can enhance BDNF (150). In contrast BDNF expression can be inhibited by:

- Physical and psychological stress (152) and
- A diet high in saturated fat and sucrose (61,62).

2.2.3.11. Effects of PUFA on cognitive function

In a single prospective cohort study that evaluated the effects of omega-3 PUFA on cognitive function in normal ageing, there was no significant association between omega-3 PUFA intake in the form of fish consumption and cognitive decline (153).

2.2.3.12. Effects of PUFA on incidence of dementia

Among three prospective cohort studies that assessed the effects of omega-3 PUFA on the incidence of dementia, fish consumption was associated with a statistically and clinically significant reduction in the incidence of the non-Alzheimer's dementia (126,154,155). Also, fish consumption was significantly associated with a reduced risk of the Alzheimer's dementia (155) and nearly so in the two other studies (126,154). While total omega-3 PUFA consumption and consumption of DHA were associated with a significant reduction in the incidence of AD for the general population consumption of α -linolenic acid and EPA were not (154).

2.2.3.13. Effects of PUFA on Suicide

In a study involving 100 suicide attempt cases in China compared to 100 hospital admission controls, there was an eightfold difference in suicide attempt risk between the lowest and highest red blood cells EPA level quartiles (156). Also, low level of EPA in red blood cells was associated with suicide attempts.

2.2.3.14. Effects of PUFA on Aggression

In a small pilot study (n = 30), the intake of 1 g EPA could reduce aggression (modified Overt Aggression Scale) and depressive symptom scores (Montgomery-Asberg Depression Rating Scale) among borderline personality disorder patients (157).

2.2.3.15. PUFA sources and requirements

Both α -linolenic acid and linoleic acid are present in a variety of foods. The major dietary sources of α -linolenic acid and linoleic acid are PUFA-rich vegetable oils. Linoleic acid is present in high concentrations in many commonly used oils, including corn oil, safflower, soy and sunflower. α -Linolenic acid is present in some commonly used oils, including canola and soybean oil and in some leafy green vegetables. The proportion of linoleic acid to α -linolenic acid as well as the proportion of those PUFAs to others varies considerably by the type of oil.

Table 3
Omega-3 and omega-6 FA content (%) of some dietary oils

Dietary source	Omega-3 FA	Omega-6 FA
Canola oil	9	20
Corn oil	1	60
Cottonseed oil	0	50
Flax oil	57	14
Peanut oil	0	32
Safflower oil	1	77
Sesame oil	0	45
Soybean oil	7	51
Sunflower oil	0	65
Walnut oil	10	52

2.2.4. Importance of L-Carnitine

Carnitine transports long-chain acyl groups from FAs into the mitochondrial matrix. In the mitochondrial matrix they can be broken down through oxidation to acetate and energy. It plays an important role in diseases associated with metabolic compromise, especially mitochondrial-related disorders. Humans take in carnitine primarily from diet 75% with the remaining 25% coming from endogenous synthesis. It is synthesised from L-lysine and L-methionine (158).

A deficiency of carnitine is known to have major deleterious effects on the CNS. Carnitine possesses neuro-protective ability in conditions of mitochondrial dysfunction, oxidative stress and possibly in neurodegenerative disorders such as PD and AD (159). Carnitine deficiency can be caused due to:

- Decreased natural synthesis of carnitine in the body,
- Altered transport of carnitine across the cellular membrane,
- Dietary lack,
- States causing abnormal loss or
- Overutilization of carnitine (160).

L-Carnitine and acetyl L-carnitine possess unique neuroprotective, neuro-modulatory and neurotrophic properties among their neurophysiological roles that are relevant in counteracting various disease processes (161). Neuro-protective actions of L-carnitine have also been reported against 3-nitropropionic acid induced neurotoxicity (162,163). The common underlying process in neurodegenerative processes is the increased metabolic stress due to mitochondrial dysfunction and formation of reactive oxygen species which has been linked to neurodegenerative disorders such as PD and AD (164,165). Part of the neuroprotective actions of carnitines could be related to their neurotrophic actions. For instance acetyl L-carnitine has been shown to accelerate regeneration of neurons in various in-vitro and in-vivo studies (166).

2.2.5. Importance of Choline-lecithin

Choline is the precursor of neurotransmitter acetylcholine. The synthesis of acetylcholine is influenced by the availability of choline within the cholinergic neurons. Neuronal choline concentrations can be altered by dietary choline intake, in the form of either free choline or phosphatidyl choline (lecithin) (167,168). Also, the lecithin is a mixture of various phospholipids and the composition depends on the dietary origin of the lecithin. The main phospholipids from soy and sunflower are phosphatic acid, phosphatidyl choline, phosphatidyl ethanolamine and phosphatidyl inositol. Oral choline and phosphatidyl choline have been used to treat Huntington disease without any success (169,170). Further, in patients with AD neither choline nor phosphatidyl choline offers much improvement in memory (171-173).

2.3. Importance of Protein

The protein content and the amino acid composition of the diet play a crucial role for human health. The net protein utilization is profoundly affected by the

limiting amino acid content (the essential amino acid found in the smallest quantity in the foodstuff) and somewhat affected by salvage of the essential amino acids in the body. A relationship between fluctuations in serum amino acids and appetite in humans has been showed (174,175). Dietary protein induces satiety in the short term (176) and consumption of protein-deficient diets leads to increased appetite for protein-containing foods (177). Increase consumption of high protein diet by reducing the carbohydrate:protein ratio of diets chronically has also been associated with deterioration in mood (49,50). Further, maintaining a very high-protein diet may chronically stimulate the HPA axis (47) and increase release of vasoactive hormones (48). Increased HPA activity and cortisol release have been linked to increased risk of insulin resistance, hypertriglyceridemia and hypercholesterolemia (178,179). Also, hypercholesterolemia can be caused by high intake of animal proteins (180).




FIG. 6. Effect of high dietary protein

Amino acids may influence food intake either via direct actions within the CNS, via receptors located in the liver or portal vein (181). The rates of synthesis and release of the neurotransmitters DA, norepinephrine (NE) and epinephrine are directly modified by the brain concentrations of their amino acid precursors, Trp, Phe (phenylalanine) and Tyr (tyrosine; catecholamines), which in turn are influenced by their availability from blood (182). Physiologic and pathophysiologic factors that influence blood concentrations of Trp, Phe, Tyr and others that compete with them for a common transporter across the blood brain barrier are LNAA. Also, LNAA predictably alter aromatic amino acid concentrations in brain, the formation and release of these monoamine transmitters and consequently brain function (28,182). Also, administration of amino acids such as Phe and Trp that are precursors to monoamine neurotransmitters suppresses food intake in humans (183). The ratio of plasma Trp to other amino acids may influence brain serotonin levels, which are known to have an inhibitory influence on food intake (184). In animal studies deficiencies of certain amino acids in the diet of rats lead to rapid reduction of food intake that is mediated via specific pathways in the brain (185).

2.3.1. Effects of dietary protein on cortisol

There is some evidence that maintaining a very high-protein diet may chronically stimulate the HPA axis (47) and increase release of vasoactive hormones (48). After a protein-rich meal (30 to 40% energy as protein) salivary cortisol increases substantially (approximately one and one-half- to two-fold on average). Also, a meal intake of at least 20 g of protein may be necessary to show an effect. The higher the intake of protein, the greater the secretion of cortisol is likely to be (46,186). The increase begins toward the end of a 30-minute meal period and peaks at approximately 1 hour after the start of the meal. After approximately 2 hours, salivary cortisol levels declined and were no longer significantly different from those seen either in the absence of a meal or after a low-protein meal. Changes greater than 5% protein (as percent total energy) are required to detect a reliable increase in salivary cortisol (186). Results of studies measuring plasma cortisol suggested that at least 10% protein (as percent total energy) may be needed for reliable stimulation of cortisol (46). This acute stimulation of cortisol release may be part of a homeostatic mechanism in response to a high influx of amino acids (186).

2.3.2. Importance of Essential Amino Acids

Essential amino acids are called essential not because they are more important to life than the others, but also because the body does not synthesize them. It is essential to include them in one's diet in order to obtain them. Nine amino acids are generally regarded as essential for humans: histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), threonine (Thr), tryptophan (Trp) and valine (Val). In addition, the amino acids arginine (Arg), cysteine (Cys), glycine (Gly), glutamine (Glu) and tyrosine (Tyr) are considered conditionally essential, while they are not normally required in the diet, but have to be supplied exogenously to specific populations that do not synthesize them in adequate amounts.

TABLE 4.

Essential and Non-essential Amino Acid content of some Nutrition (in 100 g)

	Essent. AA (g)	Non-essent. AA (g)	His (g)	Try (g)
beef	15,7	12,6	1	0,3
boletus	17,1	7,5	2,1	2
Codfish	10,5	8,8	0,5	0,2
Flax seed	12,2	12,1	0,5	0,4
gelatine	20,4	59,5	0,5	0,1
liver pie	9,2	7,7	0,6	0,2
Peanut	10,2	9,9	0,5	0,2
Pork	9,8	8,6	0,7	0,2
pumpkin seed	14	10,3	0,6	0,4
Salami	10,3	8,8	0,7	0,2
soya bean	18,3	17,8	0,9	0,4
Trout	12,4	10,3	0,6	0,2
Wheat germ	12,8	13,5	0,7	0,3

Dietary inadequacy of an essential amino acid leads to nonspecific signs of protein deficiency, such as lowered resistance to disease, decreased blood proteins and stunting in children. Low protein or amino acid poor diet yields degeneration of both filiform and fungiform papillae of taste buds (187) and decreases serum Zn^{2+} concentration (188). It has been shown that somatostatin containing inter-neurons are widely distributed in the anterior piriform cortex (189), an area thought to be responsible for the perception and recognition of essential amino acid levels in the diet (185). Animal studies indicate that rats reduce food intake if they are pre fed a low-protein basal diet and then switched to a diet with an imbalance or lack of essential amino acids (191-192).

Also, animal studies indicate that lack of an indispensable amino acid in the diet induces a decrease in food intake that leads to impaired body weight gain and growth and in the long term may result in death (193-195). Further, it has previously been reported that rats rapidly recognize the adverse metabolic effects of a diet lacking an indispensable amino acid and learn to avoid this diet (193,194,196).

Ligand binding studies have suggested that Trp is involved in the anorectic response to an amino acid deficient diet (195,197). Moreover, there is a specific involvement of the central nucleus of the amygdala (CeA) in the learned aversion to a threonine-imbalanced diet (198,199). The CeA Trp is involved in the conditioned taste aversion response to an amino acid deficient diet (200).

An important characteristic of the behavioural response to the lack of an essential amino acid is the delay of the establishment of the aversive response depends on the nature of the limiting amino acid. The most often quoted hypothesis is a direct brain detection of the decrease in the plasma and brain level of the limiting amino acid that usually follows the ingestion of a meal lacking this amino acid (185,190,200). An alternative mechanism could be alterations in the postprandial catabolism of the amino acids which may generate signals sensed in the brain to stop food intake. These signals may also be endotoxic signals through production of large amounts of ammonia (201,202) or physiological satiety signals produced through an increased postprandial amino acid oxidation, generating an aminostatic (174), an energostatic (203) or an ischymetric signal (204).

2.3.2.1. Importance of Glutamate

Glutamic acid (Glu) is one of the dispensable amino acids. Glu functions in all cells in the body as a metabolic intermediate and protein constituent. In the brain, it has the added role of being an excitatory neurotransmitter (205). Neurons utilizing excitatory amino acids as neurotransmitters participate in hypothalamic function, particularly in the control of pituitary hormone secretion (206,207). Thirty years ago, a link was forged between dietary MSG (monosodium glutamate) and brain function through the report that the repeated injection of very large doses of the amino acid into neonatal rodents could produce visible brain damage, notably in the hypothalamus (208). Glu occurs naturally in many foods (e.g., tomatoes, cheeses) and in prepared stocks and soups (in meat, soups and fish stocks the Glu released by protein hydrolysis becomes a key flavouring agent). The flavour attributed to MSG becomes more complex and the tongue's sensitivity to it is enhanced markedly

in the presence of certain nucleotides. This taste is readily identified in Asian cultures as being distinct from the four basic tastes (sweet, sour, salty, bitter) and has been named "umami" by the Japanese (209). The importance attached by the body to the perception of this taste appears underscored by the identification in the hypothalamus and the orbital prefrontal cortex of neurons that respond selectively to the application of MSG to the tongue (210,211). Glu receptors likely occur on the tongue, on vagal afferent fibres and also on a variety of other cell types in the periphery, where they may have subserve signalling functions (212,213).




FIG. 7. Effect of high dietary Glutamic acid (Glu) intake

Dietary Glu is a major energy source for the intestines, accounting for half of the energy consumed during digestion (214). From big importance is the role of Glu as a co-substrate in the trans-amination and de-amination of several other amino acids which provide carbon skeletons for gluconeogenesis or ATP generation (215). The Glu is present in the brain and is used by it as a neurotransmitter. It has been found to be synthesized within neurons and actively removed from the synapses. The glial cells are primary participants in the process of synaptic Glu removal and recycling (216,217). In the face of large Glu influxes secondary to greatly elevated blood Glu concentrations the Glu concentrating power of Tanycytes, a specialized glial cell present throughout the median eminence, may fail, leading to local Glu increases and neuronal toxicity (218).

In humans a high oral dose of Glu (10 g, ~150 mg/kg body weight) caused a rise of plasma Glu to 500nmol/mL over baseline values, a 5- to 10-fold increment over typical values (219). Increments in plasma prolactin and cortisol were noted (219). This dose of Glu, given as a single load, is extremely

large, approximating the amount of Glu a human would ingest over an entire day as a component of 100 g of dietary protein. Also, the administration of excitatory amino acids (at very high doses) or their more active analogue has been reported previously in monkeys to stimulate the secretion of one or more pituitary hormones (prolactin, GH, ACTH, cortisol, and LH and/or FSH) (220-224). Further, arcuate neurons bearing Glu receptors thus become exposed to high local Glu concentrations are subjected to excessive excitation. Such excitation is postulated to produce metabolic and functional exhaustion of the affected neurons and subsequently neuronal death. Such effects might possibly lead to neuro-endocrine dysfunction in humans (225).

2.3.2.2. Importance of Histidine

His is an extremely bioactive essential amino acid which has multiple physiological functions. Some of His derivatives such as carnocine are endogenous antioxidants that are stimulated by stress (226). The neurotransmitter histamine is synthesized in the brain by the enzymatic decarboxylation of His. Systemic administration of His in large doses has an increasing effect on histamine concentration in the rodent brain (227,228). Conversion of His to histamine in the hypothalamus is necessary to produce the suppressive effect of His on feeding behaviour. His induces suppression of food intake by a direct effect on zinc metabolism (229-231). It plays a major role in zinc metabolism acting as the major zinc binding moiety in serum (229-231). Normally, zinc is bound to one or two of the available 16 His moieties on albumin (229,230). His administration to animals (231) or humans (232) strips zinc from its albumin binding sites initiating a Zn-His complex which produces significant tissue zinc depletion. It also causes zinc deficiency leading to functional losses of taste, smell, appetite, food intake and other neurological abnormalities (232). These effects are reversed completely by zinc administration while maintaining His intake at any given level, indicating that His-induced suppression of appetite relates specifically to this mechanism of zinc depletion (232). Indeed, loss of appetite with His administration through this induced zinc deficiency was used as a novel technique to induce reduced food intake in humans and to induce weight loss (233,234). With this use there can be significant side effects due to the effects of zinc depletion on multiple organ systems (232).

Natural foodstuffs such as marine products including tuna, sardine, Pacific saury and so on are quite rich in L-His.

2.3.2.3. Importance of Isoleucine, Leucine and Valine

The branched-chain amino acid Ile (Isoleucine) participates directly and indirectly in a variety of important biochemical functions in the brain. These include protein synthesis, the production of energy, the compartmentalization of the neurotransmitter glutamate in the brain and the synthesis of the neurotransmitters serotonin and the catecholamines DA and NE, which are derived from the aromatic amino acids Trp, Phe and Tyr (182,235,236). 15–20% of the amino acid content of animal-based dietary proteins contains considerable amounts of the branched-chain amino acids (237). While a major fraction of the ingested branched-chain amino acids is not metabolized by the liver and passes into the systemic circulation after a meal, causing plasma concentrations to rise appreciably (238,239). Also, the ingestion of the branched-chain amino acids causes:

- Rapid elevation of their plasma concentrations,
- Increases their uptake into brain and
- Decrease the brain uptakes and levels of the aromatic amino acids (240).

Reductions in the brain levels of the aromatic amino acids that follow the ingestion of amino acid mixtures containing the branched chain amino acids diminish the synthesis of some neurotransmitters (241-243). Also, the synthesis and the release in the CNS of serotonin and the catecholamines vary directly and rapidly with changes in concentrations of their precursor amino acids (Phe, Trp and Tyr) (182). In human studies with bipolar subjects during periods of mania, daily administration of the branched chain amino acids (60 g) for 7 d produced a significant reduction in manic symptoms, consistent with an effect on brain catecholamines (244).

2.3.2.4. Importance of Lysine

Lys is the one of all indispensable amino acid most strongly conserved, due to its capacity for storage and slower catabolism (236). A diet deficient in Lys decreases the whole-brain content of Lys (245) and affects NE activity in the hypothalamus (246). Animal studies indicated that rats are sensitive to changes in dietary Lys concentration (as small as 0.01%), when adapted to a Lys-deficient diet (247). The neural modifications that have been detected consistently in Lys-deficient rats (248) and the participation of Lys and its metabolites in normal brain functions (249) raise the possibility of psycho behavioural alterations during Lys-deficiency. The whole-brain content of Lys has been shown to be lower in Lys-deficient rats, with no specific modifications in the amygdala (200,245).

In animal studies within 24 h after a Lys-deficient diet no changes in daily food intake volume were found, whereas a significant decline was found during 4 days period of deficiency (246). Inhibition of protein synthesis (due to the low content of Lys) is improbable, but direct effects of Lys and/or its metabolites on Trp neurotransmission in the CeA or in other functionally interconnected brain areas are possible (250). The increased CeA Trp activity in the Lys-deficient rats triggered an anxiogenic effect in Lys-deficient rats but not in controls. The rats fed a Lys-deficient diet for 4 days, compared with normally fed rats, were characterized by increases in circadian release of CeA Trp, stress-induced anxiety and faecal excretion (251). Also chronic intake of a Lys-deficient diet affects the amygdala Trp and alters complex behaviours, such as stress perception. Further, a dietary deficiency of Lys increased stress-induced colonic transit and anxiety, because of an enhanced transmission of Trp in the amygdala. Further, increased anxiety and stress-induced faecal excretion were found in Lys-deficient rats (251). In contrast prolonged Lys treatment had anxiolytic effects in normally fed, stressed rats (252) and the metabolic effects of Lys were stress-specific (253,254). Moreover, a part of the Lys effect is traced to the Trp system (251). Lys blocks stress-induced faecal excretion and reduces the severity of diarrhoea in a manner similar to the action of synthetic Trp receptor antagonists (255).

Microbial synthesis of Lys was shown in the gastrointestinal tract (GIT) (256). This Lys is made available through protein breakdown and its intestinal uptake. Also, it is possible that the high dietary Lys load block this protein breakdown in an unspecified way (255). A partial blocking effect of Lys on anxiolytic responses but not on normal behaviour has been shown (255). In contrast to Lys-deficiency there is an improvement of stress responses in rats and pigs receiving Lys loads (252,257). Prolonged Lys supplementation reduced plasma cortisol in animals by inhibiting long-term anxiety (257) but without directly affecting the adrenal gland (258). Further, it has been shown that Lys fortification did not reduce normal levels of alertness and social apprehension (259). The anxiogenic response to Lys inadequacy in rats was mediated via serotonin alterations in the central amygdala (251).

Daily requirement for lysine is 1–1.5 g. It is in all cereal grains and in all pulses (legumes).

2.3.2.5. Importance of Trp

Trp serves as the immediate precursor for serotonin synthesis and Trp-induced serotonergic activity in the brain has been implicated in the regulation of many behavioural and physiological processes such as mood, aggression, susceptibility to stress, sleep patterns and food intake (27,260-263). Trp administration is also known to enhance serotonin release in neurons that are actively firing (264). The availability of Trp to brain neurons that synthesize serotonin directly influences the rate at which it is converted to a neurotransmitter (28). Trp has been shown to affect brain and nervous system function through interference with serotonergic neurotransmission (262,265,266). Administering either the amino acid itself (29) or meals that raise Trp access to serotonin neurons rapidly stimulates serotonin production (30,31). In clinical populations an elevated plasma Trp:LNAA ratio has been shown to improve mood (25,267). In healthy subjects such evidence has been weak and often inconsistent (268,269). In stress-vulnerable subjects the plasma Trp:LNAA ratio increased after a carbohydrate rich – protein poor diet and prevented a stress-induced rise in depressive mood and cortisol (51). Such functional effects are also reputed to accompany the ingestion of carbohydrates (270). In rats carbohydrate ingestion stimulated brain Trp uptake and serotonin synthesis (31). The dietary Trp may reduce aggression and alleviate stress in many species such as pigs (271), rats (260) and chickens (272-274).

Reduced serotonin concentrations resulting from the exhaustion of its plasma precursor Trp was found to provoke sleep abnormalities seen in depression (275,276), whereas increases in available plasma Trp for uptake into the brain improved sleep in different subjects (277-279). In humans administration of oral Trp can modify sleep and mood via its actions to stimulate neuronal serotonin production and release (280,281). Also, dietary Trp supplementation increased both Trp and 5-HIAA (5-hydroxyindolacetic acid) concentrations in the hypothalamus of piglets. The turnover of serotonin or the activity of the serotonergic nervous system is generally expressed as the ratio between Trp and its direct metabolite 5-HIAA (282). Reduced alertness after poor sleep often deteriorates cognitive-behavioural functioning (283). Sleepiness progressively reduces attention and efficient stimulus detection (284), as evidenced by lower behavioural responsiveness and reduced attention processing (285).

An increased availability of Trp and brain serotonin can be reached with dietary proteins containing high Trp. As a consequence, the serotonergic

system may become more sensitive because of compensatory receptor sensitization (286,287). α -lactalbumin has the highest Trp concentration of all bovine protein fractions (288). α -lactalbumin enriched whey protein increased the plasma Trp:LNAA ratio in subjects both highly vulnerable and relatively invulnerable to stress (27). In contrast, a protein-rich diet decreases the plasma Trp:LNAA ratio, because proteins are poor in Trp (1–2%) but rich in the LNAAs valine (Val), Tyr, Leu, Ile and Phe (25%). These dietary effects on the plasma Trp:LNAA ratio have frequently been shown (25,51,289).

Table 5.

Trp, LNAAs and Trp:LNAAs of some Nutrition (in 100 g)

	Energie	Trp (g)	LNAAs (g)	Trp:LNAAs
almond	569,6 kcal	0,2	4,5	0,04
Boletus	148,9 kcal	2	4,5	0,44
cashew nut	594,6 kcal	0,3	4,5	0,07
chanterelle	120,2 kcal	0,5	4,1	0,12
cocoa	342,5 kcal	0,2	3,5	0,06
flax seed	372,4 kcal	0,4	6	0,07
Hen's egg	154,4 kcal	0,2	4,1	0,05
Liver pie	299,5 kcal	0,2	4,5	0,04
Meat	223,0 kcal	0,3	7,2	0,04
milk	64,3 kcal	0	1,1	0,00
Soya bean	416,3 kcal	0,4	8,5	0,05
Soya milk	152,2 kcal	0,2	4	0,05
Sunflower seed	574,8 kcal	0,3	5,5	0,05
Whole-grain bread	187,9 kcal	0,1	1,4	0,07
Yeasts	288,0 kcal	0,4	9,4	0,04

Following dietary components may have Trp raising ability:

- Carbohydrate ingestion show no or only small behavioural effects due to modest Trp alterations (269,290).
- The rise in Trp:LNAAs show 20–45% increases after the consumption of foods such as carbohydrates (290).
- A carbohydrate-rich, Protein-poor diet raise the ratio of plasma Trp:LNAAs ratio and give Trp the advantage in the competition for access to the brain (30,291,292).
- Evening consumption of α -lactalbumin (4.8 g/100 g Trp) resulted in a 130% increases in the plasma Trp:LNAAs ratio as compared with placebo (293).

While Trp binds to albumin in blood (294) the free Trp pool in blood ranges between 5–50% of the total Trp pool, depending on the physiologic or pharmacologic conditions (295-299). Albumin-bound Trp molecules in blood are readily available for transport across the blood-brain barrier. In blood nonesterified FAs also bind to albumin which is competitive with Trp (300). The proportion of Trp in blood that associates with albumin is thus affected by changes in blood nonesterified FA concentrations. Hence, as serum nonesterified FA concentrations influence the binding of Trp to albumin, changes in serum nonesterified FA should directly influence the free Trp pool and thus brain Trp uptake and levels (295,301). While insulin reduces plasma nonesterified FA concentrations the ingestion of a carbohydrate meal by rats rapidly would raise brain Trp levels and stimulate serotonin synthesis, which is linked to insulin secretion (30). Ingestion of a carbohydrate meal containing either 0 or 45% fat (or remained fasting) to overnight-fasted streptozotocin diabetic rats showed that the 45% fat meal raised serum nonesterified FA and produced a 2-fold rise in serum free Trp concentrations (compared with values in fasting rats or rats ingesting the 0 percent fat meal) and no changes in serum total Trp or the summed concentrations of the other LNAAs in serum (302). The changes in serum nonesterified FA and free Trp are as great as those seen following exercise in rats (303-306). The ingestion of a fat-containing meal rapidly raises plasma nonesterified FA concentrations. This effect is dose dependent. Hence, the response of brain Trp soon after fasting rats consumed a meal containing 20% protein (307) and one of several levels of fat (0, 15, 30, or 45%) showed that as the fat content of the meal increased, serum nonesterified FA concentrations and free Trp concentrations rose and yet brain Trp concentrations did not (307). The rise in plasma nonesterified FA caused by forced treadmill exercise in rats (20m/min for 1 h) was also associated with an increase in plasma free Trp, but not total Trp concentrations, as well as increases in brain Trp concentrations and the principal serotonin metabolite, 5-HIAA (304,305). Exercise-induced rise in plasma nonesterified FA is caused by sympathetic activation (308).

Recent investigations indicated that the intake of commercial available Trp causes toxic reactions, which was termed as eosinophilia myalgia syndrome (EMS). It is characterized primarily by an increased blood eosinophil count and an often debilitating myalgia (309,310) and in some cases with neurological and pulmonary complications (311). This syndrome was appeared to be correlated with the use of Trp from a single manufacturer. Also, a contaminant in a production batch could be responsible for EMS (312). The absence of EMS in subjects ingesting pharmaceutical-grade Trp, which

meets high standards of purity, is consistent with this assessment (54). Also, pharmaceutical-grade Trp preparations in humans have never been associated with symptoms of EMS (54,313).




FIG. 8. Effect of macronutrients on Trp level in brain

2.3.2.6. Importance of Tyr

Tyr is the precursor to the catecholamine neurotransmitters DA, NE and epinephrine. Elevating Tyr concentrations in brain can stimulate neurotransmitter production in catecholamine neurons (particularly DA and NE neurons). It is observable in catecholamine neurons in both rat retina and brain in response to the large changes in Tyr concentrations produced either acutely or chronically by the ingestion of protein-containing foods (314,315). This effect occurs in actively firing neurons but not in catecholamine neurons that are quiescent or firing slowly (316,317). Brain Tyr concentrations raise as dietary protein content of diet increases from very low (2% energy) to moderate (10% energy) levels, with catecholamine synthesis following the change in Tyr (315). The ingestion of a protein-containing meal was known to produce a rapid increase in Tyr concentrations in the brain (318). Also, raising brain Tyr concentrations could rapidly stimulate L-3,4-dihydroxyphenylalanine (DOPA) synthesis in rat brain (319). Further, Tyr administration could stimulate DA synthesis in the corpus striatum, but pre-treatment of animals with a DA receptor antagonist to activate the neurons was required (320). Tyr concentrations in the brain are influenced by protein ingestion when the protein content of the diet is modified over several days or more (321,322). Physiologically, this relation might have the potential as a signal to inform the brain about the animal's success in acquiring protein in its diet (323). Tyr administration appears to improve cognition and performance in soldiers

under stressful conditions (324,325). In depressed patients the Tyr administration enhanced catecholamine production without any effects on mood (326).

In patients with PD Tyr administration elevated the DA production in the CNS (327). Variations in Tyr supply affect not only Tyr hydroxylation rate (DOPA synthesis) but also affect overall catecholamine production and release (328-330). In rats, Tyr depletion by itself does not appear to reduce DA (prefrontal cortex) or NE (hippocampus) release (329,331). However, it reduced the increase in DA and NE release produced by drugs either block catecholamine reuptake or receptors (329,331) and attenuates in rats the behavioural activation produced by amphetamine (332). In normal humans, Tyr depletion increases plasma prolactin concentrations (333), impairs features of spatial recognition memory and performance (333) and attenuates subjective psychostimulant effects of amphetamine (334,335). Tyr depletion has also been reported to reduce clinical ratings of manic symptoms in patients diagnosed with mania (335) and to lower some indices of mood in normal subjects that are reputedly consistent with the DA depletion (336,337). It has been observed that Phe inhibits Tyr hydroxylation (338). Reducing Tyr levels in brain can be accomplished by providing an oral dose of a mixture containing amino acids in addition to the LNAA, because this combination lowers plasma concentrations of Tyr (an effect originally unanticipated) while raising those of the other LNAA, thus enhancing the antagonism of competitive Tyr transport across the blood-brain barrier (243,339). The Tyr depletion paradigm, when applied to humans, seems to moderate striatal DA release (244).

3. Importance of Micronutrients

Micronutrients are essential constituents of diets needed in small quantities. These are vitamins, minerals and trace elements. Deficiencies and over doses of any micronutrients cause debility, disease and eventually death.

3.1.Importance of Vitamins

Chronically insufficient vitamin supply for vitamin C, thiamin, riboflavin, cobalamin and folate causes many unfavourable psychometric changes (340). In volunteers with an initial mild to moderate vitamin C deficiency, vitamin supplementation led to decreased nervousness, less depression and decreased emotional instability (340). In a clinical trial administration of folic acid, vitamin C and to a lesser extent thiamin, as compared to placebo, in men with an initial suboptimal folate status, led to a decreased emotional instability, increased activeness and concentration, higher extroversion and lower introversion, greater self-confidence and a markedly improved mood (340).

3.1.1. Importance of Folic Acid

Folate is important in 1-carbon metabolism (341), contributing carbon atoms to purines, thymidine and amino acids. In addition, methylation reactions involving folate may be important in the formation and maintenance of neuronal and glial membrane lipids (342). Folate is involved in maintaining adequate methionine pools for the synthesis of S-adenosylmethionine (343), a cofactor in methylation reactions in catecholamine synthesis and metabolism (344). Folic acid is important for functioning of the nervous system at all ages (345-348). It has also been linked to the maintenance of adequate amounts of tetrahydrobiopterin (349), a key cofactor in the synthesis of serotonin and the catecholamine neurotransmitters (344). Little information is available to illuminate the mechanisms by which folic acid deficiency causes the improper formation of the spinal cord. Folate supplementation produced a 72% protective effect against the occurrence of neural tube defects (350). Numerous studies have shown a high incidence of folate deficiency correlated with mental symptoms, especially depression and cognitive decline in epileptic, neurological, psychiatric, geriatric and psycho-geriatric populations (347,348). In neonates, infants, children and adolescents, inborn errors of folate transport and metabolism are associated with developmental delay, cognitive deterioration, motor and gait abnormalities, behavioural or psychiatric

symptoms, seizures, signs of demyelination⁶ or failure of myelination and vascular changes seen on magnetic resonance imaging or postmortem examination (348).




FIG. 9. Effect of low folic acid level

Patients with megaloblastic anemia who had a clear folate deficiency in the absence of vitamin B12 deficiency showed an incidence of affective (mood) disturbances of >50% (351). Depressed patients may have low plasma and red blood cell folate concentrations (352-354). Low intake of folic acid has been linked to other psychiatric conditions as well as to deficits in learning and memory, particularly in the elderly (355). The few controlled clinical trials of vitamin therapy in addition to standard psychotropic medication have all reported positive effects on patient's mental state. There are small clinical trials showing a beneficial effect of folic acid in depression and its ability to enhance the effectiveness of antidepressant medications (356,357). In a double blind placebo controlled trial in depressive patients treated with lithium, the addition of 200 µg/d of folic acid for one year significantly improved affective morbidity (358). Similarly, the addition of 500 µg/d of the vitamin to fluoxetine for 10 weeks significantly improved antidepressant response, especially in women (357). In folate deficient depressed and schizophrenic groups addition of 15 mg methylfolate to standard psychotropic

⁶ The damage of the myelin sheath of the neurons is a demyelinating disease. This disease of the nervous system impairs the conduction of signals in the affected nerves, causing impairment in sensation, movement, cognition, or other functions depending on which nerves are involved.

medication over six months showed significant and increased clinical and social recovery (359). Earlier studies indicated improvement in both mood and neuropsychological function in a controlled trial of 15 mg daily intake folic acid alone for four months in depression (346). In a survey of nutritional status and cognitive functioning in 260 healthy elderly subjects aged 60 to 94 years in the community, there was a significant relation between impaired abstract thinking ability and memory and lower folate levels and intake (360). In the New Mexico ageing process study of 137 community residents aged 66 to 90 years, weak but significant associations were found between measures of abstract thinking and folate concentration (361). Several of the earliest reports of neurological disease associated with severe folate deficiency emphasise that dementia and depression are reversible with vitamin therapy (346,362-364).

The mechanism by which folate modifies mood is hypothesized to be related to its role in 1-carbon metabolism (341). In the form of methylentetrahydrofolate, the methyl donor in methionine synthesis from homocysteine, folate may help maintain adequate methionine pools for S-adenosylmethionine synthesis (343). The link to mood involves S-adenosylmethionine's role as a cofactor in methylation reactions in catecholamine synthesis and metabolism (344). Folic acid deficiency results in depletion of S-adenosylmethionine and a reduction in the methylation of cytosine in DNA. The decreased DNA methylation that can result from folic acid deficiency may enhance gene transcription and DNA strand breakage which can trigger malignant transformation (365,366). Recent studies have demonstrated direct consequences of folic acid deficiency on neurons by showing that simply depriving cultured embryonic brain cells of folate can induce apoptosis in developing neurons (367). Folic acid has been shown to increase omega-3 PUFAs status when supplemented and decrease omega-3 PUFAs status when it is in deficiency in the animal model (368). In addition, a folic acid deficient diet can enhance lipid peroxidation (369). A deficiency of folate can occur:

- When folate requirement is increased due to e.g. smoking and alcohol,
- When dietary intake is inadequate and
- When folate losses is more than usual.

Medications that interfere with body's ability to use folate may also increase the need for this vitamin. Major sources of folate are green vegetables, citrus fruits, liver and whole grains.

3.1.2. Importance of Vitamin A

Vitamin A actually refers to the family of retinoids. Its important part the retinyl group can be found in several forms. Vitamin A and its derivatives, the retinoids, have been implicated in the synaptic plasticity of the hippocampus and might, therefore, play a role in associated cognitive functions (370). While adequate levels of vitamin A are required for appropriate CNS development and either too much or too little is equally harmful (370).




FIG. 10. Physiological effects of vitamin B6 deficiency

3.1.3. Importance of Vitamin B6

Dietary deficiency of vitamin B6 affects tissue concentrations of amino acids and neurotransmitters in rats and humans (371,372). The physiologically active forms of vitamin B6 are enzymatic cofactors in many reactions of mammalian nitrogen metabolism, including the metabolism of most amino acids and neurotransmitters. In general, vitamin B6 deficiency leads to a decrease in the concentrations of most amino acids. Most commonly affected brain amino acids by deficiency are serotonin, DA and GABA (371,372). In human plasma vitamin B6 concentration is associated with the best performance on the “Backward Digit Span Test” and performance improved on the “Activity Memory Test” with increased plasma

vitamin B6 concentration (373). Early studies indicated that excess dietary vitamin B6 affect brain and serum concentrations of some amino acids and binding properties of cortical serotonin receptors in a biphasic pattern (374). Also, large doses of vitamin B6 can affect CNS function (374,375) and neurotransmitter concentration (376). Further, high concentrations of pyridoxal phosphate suppress activation of transcription, while vitamin deficiency enhances responsiveness to steroid hormone (377) and increased CNS irritability (378). Vitamin B6 is a cofactor in the production of neurotransmitters including DA, NE, serotonin and GABA. Taurine deficiencies in vitamin B6 have been associated with defects in the CNS in rats (379). Also, pyridoxine is essential in the conversion of L-dihydroxyphenylalanine to DA. Side effects of excessive L-dihydroxyphenylalanine include dystonia and dyskinesia (378).

3.1.4. Importance of Vitamin B12

Vitamin B12 is important for the normal functioning of the brain and nervous system and for the formation of blood. Vitamin B12 is required as coenzymes in the synthesis of serotonin and catecholamine neurotransmitters and also of S-adenosylmethionine, which has antidepressant properties (380-382). Further, it is involved in the metabolism of every cell of the body, affecting DNA synthesis and regulation FA synthesis and energy production. Lack of cobalamin causes a wide variety of neurologic symptoms and signs such as ataxia, loss of dermal sensation, diminished or hyperactive reflexes, dementia, memory loss, psychoses and disturbances of mood (383,384). Vitamin B12 deficiency may lead to severe neurologic disorders, which have been described in strict vegetarians, especially in infants and toddlers (385,386). Also, its deficiency may result in demyelination (387). In contrast vitamin B12 supplementation improves complete or partial memory loss (384), depression (388) and psychosis (389). Vitamin B12 level can be affected e.g. in following cases:

- Alcohol intake decrease vitamin B12 absorption from the GIT.
- The effects of most antibiotics on gastrointestinal bacteria can have clinically negative significant effects on vitamin B12 levels.
- An increased bacterial load can bind significant amounts of vitamin B12 in the gut and thus preventing its absorption.
- Nicotine can reduce serum vitamin B12 levels.

3.1.5. Importance of Vitamin C

Ascorbic acid is required for a range of essential reactions in all animals and plants. In living organisms, ascorbic acid is an antioxidant, since it protects the organism

against oxidative stress and is a cofactor in several vital enzymatic reactions. It is essential for optimal steroid hormone functions and this suggests an involvement of ascorbic acid in steroid synthesis mechanisms (390). Also, it affects the regulation of the levels of the circulating thyroid and adrenal cortical hormones (391). In animal studies, ascorbic acid deficiency caused an increase in plasma cortisol concentration (392) without an increase in ACTH (393). In rats, vitamin C pre-treatment enhanced the release of endogenous GCs such as to delay the turnover of the tracer cortisol in plasma (394). In humans about 2h after vitamin C application there was a distinct increase of plasma cortisol which was associated with an increase in urinary 17-hydroxycorticosteroids (395).

3.1.6. Importance of Vitamin D

The actions of 1,25-dihydroxy vitamin D₃ at the plasma membrane and nuclear level may effectively enhance local cortisol availability and action in adipose tissue and may suppress pathways designed to limit expansion of adipose tissue stores (396). In vitro, cortisol promotes adipocyte triglyceride accumulation by reducing basal and catecholamine-stimulated lipolysis while also enhancing the activity of lipoprotein lipase (397). Suppression of 1,25-dihydroxyvitamin D₃ levels by increasing dietary calcium may reduce local cortisol levels by reducing expression of 11 β -hydroxysteroid dehydrogenase and, thereby, attenuate local GC action specifically in the truncal region (398).

3.1.7. Importance of Vitamin E

Vitamin E, as the major chain-breaking lipid-soluble antioxidant, would be expected to be important for functional integrity of all biological membranes. It is apparent from the information currently available that the primary role of vitamin E in nutrition is that of a biological antioxidant. As such, vitamin E is thought to play an integral role in maintaining membrane integrity in nearly all mammalian cells (399). In vitamin E deficient rats a defect in the fast anterograde and retrograde axonal transport has been reported (400). Cerebellum seems to be active in the metabolic utilization of vitamin E. This could be the reason for cerebellar damage during experimental vitamin E deficiency and for the incidence of cerebellar symptoms in clinical vitamin E deficiency (401). The neuropathological changes of vitamin E deficiency in humans are very similar to those in rats and rhesus monkey (402). The resulting neurological syndrome is characterized by areflexia, peripheral neuropathy, cerebellar involvement with gait and limbic ataxia and decreased proprioception and vibration sense (403).

3.2. Importance of Minerals, and trace elements

Dietary minerals and trace elements are required by living organisms. At least seven minerals are required to support biochemical processes, many playing a role as electrolytes or in cell structure, and function. Deficiencies of micronutrients have been shown to be associated with behavioural and developmental problems (404,405). Certain minerals balance is crucial for a healthy nervous system and neuronal susceptibility. Several reports suggested that the body electrolytes (calcium, chloride, magnesium, phosphorus, potassium and sodium) and the level of some trace elements (cobalt, copper, fluorine, iodine, iron, molybdenum, nickel, selenium, sulphur and zinc) play an important role in stress susceptibility.

3.2.1. Importance of Calcium

Low-calcium diets accelerate body weight and fat gains in animals fed an obesity-promoting diet and impede fat loss during energy restriction (398,406). In contrast, high-calcium diets suppress fat deposition and fat loss during modest energy restriction (398). Increasing intracellular Ca^{2+} using a variety of agonists, including 1,25-dihydroxyvitamin D₃, results in a marked augmentation of human adipocyte cortisol production (406). Higher calcium intakes are associated with higher rates of whole-body fat oxidation measured in a whole-room calorimeter, with significant effects noted over a 24-hour period, during sleep and during light exercise. Also, dairy sources of calcium were shown to exert significantly greater anti-obesity effects than supplemental calcium carbonate, possibly due to the effects of other bioactive compounds in milk (407). Observational studies have found an inverse relationship between dairy and calcium intake and body fat in both younger and older women (408,409), calcium and BMI in African-American women (410), dairy products and obesity in children (411) and dietary calcium and body fat accumulation in preschool children (412). Reanalysis of a randomized controlled trial has demonstrated a calcium treatment effect of 0.325 kg weight loss/yr over 4 years with no intentional change in caloric intake (413). Increasing dietary calcium from 400 to 1000 mg/d for 1 year resulted in a 4.9 kg reduction in body fat (406). Indeed, there have been several isolated reports over the last 18 years of an inverse relationship between dietary calcium and/or serum calcium and indices of obesity (414-417).

Increasing intracellular Ca^{2+} results in an increase in human adipocyte energy storage and fat mass by stimulating de novo lipogenesis and inhibiting lipolysis (418-420), whereas treatment of obesity-prone mice with a calcium channel antagonist (nifedipine) results in significant reductions in adipose tissue mass (421). A clinical trial for determining the effects of dietary calcium on body weight and fat loss, secondary to energy-restriction diets producing an energy deficit of

500 kcal/d indicated that the high-dairy diet exhibited a significant increase in insulin sensitivity, as indicated by reductions in both circulating insulin and the area under the glucose tolerance curve (422).

3.2.2. Importance of Iodine

Epidemiological studies indicate that school-aged children living in iodine-deficient villages were found to have poorer levels of IQ, cognitive and motor function than school children in iodine-sufficient villages (423-428). Hypothyroid patients show slowing of intellectual function and speech and have memory deficits (429). Also, intrauterine iodine deficiency is well established as the cause of cretinism and lesser degrees of cognitive and motor disability (430). There is a suggestion that low serum thyroxine (T4), secondary to iodine deficiency, is linked to poor intellectual performance of the people residing in iodine-deficient areas (431). Triiodothyronine seems to be the active hormone with respect to neurological development in the foetus and is synthesised in the brain from thyroxine transported from foetal plasma across the blood-brain barrier (432). In case of severe hypothyroidism maternal transfer is insufficient for foetal requirements (433), while maternal thyroxine contributes substantially to foetal thyroxine in the later weeks of pregnancy (434).

3.2.3. Importance of Iron

The physiological manifestation of iron deficiency has also been noted in immune function, thermoregulatory performance, energy metabolism and exercise or work performance (435,436). Iron is involved in numerous neurological functions. Iron deficiency is strongly related to the severity of anaemia with a 50% decrease in muscle myoglobin content, cytochrome oxidase activity and electron transport capacity in skeletal muscle, concurrent with a 50% decreased oxygen transport capacity due to anaemia (437). Restless legs syndrome has been described as being causally related to iron-deficiency anaemia (438).

The mechanisms of Fe transport in the brain commonly involve transferrin and transferrin receptors, as well as the divalent metal transporter 1 (439). Iron in neurons is stored as ferritin (440). The developing brain can be particularly sensitive to changes in iron status not only because of its rapid growth and development, but also because certain developmental events occur in a small window of time during which the timing and duration of a nutrient insult can have a significant, long-term effect on brain maturation and function (441). Several epidemiologic studies suggest that for anaemic children, iron supplementation is

correlated with improved performance outcomes, including attention and learning (442-445), as well as motor development (442). A study of non-anaemic adolescent girls also demonstrated a positive correlation between iron supplementation and improved verbal learning and memory (446). Short-term trials (<15 d) of iron supplementation among anaemic infants have shown no differences in children's motor or mental performance (447). In contrast, long-term iron supplementation trials have shown a significant improvement in children's behaviour (448). Also, the iron supplemented children were more socially interactive and displayed more positive affect than did the non-supplemented children (448).

Iron deficiency is reported to have an effect on cognition (449). Iron deficiency is thought to affect myelination, neurotransmitter metabolism and Fe-containing enzymes (450). Rats with postweaning iron deficiency had significantly lower concentrations or activity levels of myelination markers than controls (451). Post-weaning iron deficiency was also associated with changes in the PUFA content in myelin fractions (451,452). Both neonatal and postnatal iron deficiency in rats affected D1, D2 receptor and levels of DA transport in the striatum and prefrontal cortex (453,454). Also, Iron deficiency during lactation in the rat results in significant loss of regional brain iron that is distinct from those regions that lose iron with dietary restrictions later in life (455). Restoration of brain iron with later aggressive dietary iron repletion also resulted in incomplete restoration of abnormalities in DA metabolism and in behaviours related to DA (455,456). The rate of iron uptake into the brain is increased when the iron status of the subject is low and is decreased when the iron status is higher (457). Interestingly, regions of the brain rich in iron, i.e., the substantia nigra, globus pallidus and nucleus accumbens, are far less affected by dietary iron deficiency than are other regions such as the cortex or the striatum that have less iron content (458).

3.2.4. Importance of Magnesium

Extra- and intracellular magnesium levels have been shown to be genetically controlled in humans (459) and genetic differences in magnesium utilization may account for differences in vulnerability to magnesium deficiency and differences in body response to stress (460). Magnesium supplementation has beneficial effect in a wide variety of conditions, such as neuropsychiatric disorders, ischemic heart disease, cardiac arrhythmias, asthma, diabetes and chronic fatigue, in which magnesium deficiency has not always been substantiated (461,462).

3.2.5. Importance of Selenium

The preferential retention of selenium in the brain suggests that it has an important function. It seems to influence compounds with hormonal activity and neurotransmitters and this is postulated to be the reason why selenium affects mood in humans and behaviour in animals. Lowered levels of selenium have been associated with negative mood scores in at least 5 studies (463). It has been reported that a low selenium intake was associated with anxiety, depression and tiredness and that selenium therapy for five weeks alleviated these symptoms. Selenium deficiency can interfere with the normal conversion of α -linolenic acid into EPA and DHA and results in an increase in the omega-6:omega-3 ratio (464).

3.2.6. Importance of Zinc

Zinc is a trace mineral that is involved with RNA and DNA synthesis and is critical to cellular growth, differentiation and metabolism (465,466). Zinc levels are lower among patients with depression and a recent study found that 25 mg zinc supplementation may improve depressive symptoms (467). Zinc is known to be essential element for neurogenesis and also to play an important role in neurotransmission. The hippocampus, which participates in spatial learning and memory, contains the highest concentration of zinc of any other brain region. Zinc is concentrated in the synaptic vesicles of specific glutaminergic neurons, which are found primarily in the forebrain and connect with other cerebral cortices and limbic structures. During synaptic events, zinc is released and passes into postsynaptic neurons, serving as a neurotransmitter (468). Further, Zn^{2+} may participate in the storage, release and uptake of glutamate and modulation of glutamate receptors (469). The following 3 types of Zn^{2+} signals have been proposed (470):

- 1) Transmitter-like signals involving action potentials, the release of Zn^{2+} from synaptic vesicles and its binding to glutamate or GABA receptors.
- 2) The flux of Zn^{2+} into postsynaptic neurons during long-term potentiation.
- 3) Intracellular signalling for sequestration of Zn^{2+} into vesicles.

The involvement of vesicular Zn^{2+} in cognitive functions such as memory and learning has been suggested (468). Therefore, zinc deficiency may affect cognitive development by alterations in attention, activity, neuropsychological behaviour and motor development. Zinc deficiency may compromise behaviours necessary for cognitive functioning including activity and attention (465,471). In psychiatric patients zinc deficiency may affect emotionality and response to stress (472,473). Studies of severe zinc deprivation in monkeys before weaning showed that zinc-

deficient animals were emotionally less mature this was demonstrated by their difficulty with separation and the increased protective behaviour by their mothers (474). The association between zinc deficiency and an increased risk of anxiety and depression may be related to the stress reaction observed in zinc-deprived animals (475). Weekly administration of a micronutrient supplementation containing iron and zinc had a beneficial effect on infant motor development and exploration (orientation-engagement) (476). Trials in Chinese children and Mexican-American children from Texas have found that zinc-supplemented children demonstrated superior neuropsychological performance, particularly in reasoning, when compared with controls (477,478). Also, supplementation of 25 mg of zinc for two months has also been shown to significantly increase omega-3 status in the plasma phospholipids at the expense of saturated fat (479).

4. Importance of Phytochemicals

Fruits, vegetables and common beverages as well as herbs have been shown to be rich sources of the micro chemicals with the different healthy effects. Due to the absence of consideration they are not identified as nutrients and essential. The food chemists and natural product scientists have identified hundreds of the phytochemicals e.g., carotenoids, chlorophyll, flavonoids and sulphides. They have the potential e.g., to modulate stress. Persons who eat green or yellow vegetables every day show a lower incidence of the stress syndrome (irritation, sleeplessness) than those who do not eat them daily. Extracts of various fruits and vegetables exhibit neuroprotective properties in cell culture, and animal models that are relevant to the pathogenesis of many neurodegenerative conditions including stroke, AD and PD (480). The previous findings have suggested that reversals in age-related declines might be accomplished by increasing the dietary intake of the fruits and vegetables (481,482). Several studies have shown, that aqueous strawberry, spinach and particularly blueberry extracts were able to reverse several parameters of the brain ageing (e.g., deficits in cell communication) such as DA release (483,484) and age-related motor and cognitive deficits when fed to rats from 19 to 21 months of age (483-486).




FIG. 11. Effect of high dietary β -carotene intake

4.1. Importance of Carotenoids

Carotenoids include compounds as diverse as α - and β -carotene, lycopene, lutein and xanthophylls. Carotenoids are found in almost all coloured vegetables. They are a diverse group of over 600 structurally related compounds synthesized by the bacteria and plants. Several studies have shown that α -carotene prevents DNA

damage induced by carcinogenic chemicals (487-490). Also, α -carotene has been shown to attenuate hepatic drug metabolising enzymes (491). Human studies indicated that β -carotene suppresses the secretion of CRH dose dependently (492). It is also suggested that the effective site of β -carotene is the hypothalamus, where β -carotene suppressed the secretion of CRH induced by the exercise stress and consequently the secretion of ACTH in the pituitary. As CRH stimulates the sympathetic neurons (493), β -carotene also inhibited the stimulation of noradrenaline and adrenaline secretion through the suppression of CRH secretion (492).

4.2. Importance of Polyphenols

Flavonoids are the most abundant polyphenols in our diets with antioxidant activity. They can be divided into the several classes according to the degree of oxidation of the oxygen heterocycle: flavones, flavonols, isoflavones, anthocyanins, flavanols, proanthocyanidins and flavanones. They are involved in the photosensitization and energy transfer, the actions of plant growth hormones and growth regulators, the control of respiration, photosynthesis, morphogenesis and sex determination, as well as defence against infection. After consumption, the plant flavonoids undergo many metabolic conversions by the intestinal bacteria and both the metabolites and parent compounds are absorbed into the blood and then excreted, mainly in the urine (494). Rats fed diets containing extracts high in the both flavanoid as well as total antioxidant activity for 6 weeks before being subjected to 48h of exposure to 100% normobaric O₂ showed no loss in the striatal muscarinic or cerebellar GABAergic receptor sensitivity (495). These oxygen-induced decreases in the neuronal function have been shown to be sensitive to ageing and have been associated with the behavioural deficits (496). Flavonoids have been shown to be effective in protecting the neurons against the oxidative insults, possibly by acting selectively within the protein and lipid kinase signalling cascades and not through their potential to act as the antioxidants (497,498).

Flavonoids may have a multiplicity of the direct and indirect effects that can profoundly affect the different neuronal parameters that lead to alterations in the motor and cognitive behaviours (499). In support to the concept of the multiple and complementary flavonoid effects beyond the simple antioxidant function, a prospective study of dementia in the subjects older than 65 years reported an inverse relation between the baseline intake of dietary flavonoids and development of dementia (500). Some flavonoids also have anti-inflammatory properties by being potent inhibitors of the nitric oxide synthase-2 induction and also increase the endothelial nitric oxide synthase-3 activity (501). Multiple studies have shown that the protein kinase activity is important in the memory formation in the

particular spatial memory (502) and that ERK (Extracellular signal-regulated kinase) is involved in the striatal-dependent learning and memory (503) and the hippocampal-dependent spatial memory (504). Changes in the hippocampal plasticity parameters such as the hippocampal neurogenesis, extracellular receptor kinase activation, insulin-like growth factor-1 (IGF-1) and IGF-1 receptor levels were increased in the blueberry-supplemented aged animals (505). Therefore, the cognitive improvements afforded by the polyphenolic-rich fruits such as blueberries appear in part to be mediated by their effects on the hippocampal plasticity (506).

In a neuronal cell model resveratrol activated the ERK-1 and ERK-2 (507). Recent studies have shown that resveratrol stimulates sirtuins and can exert anti-ageing effects at the cellular level. Interestingly, resveratrol is the phytochemical responsible for the health benefits of red wine (508,509).

4.3. Importance of Sulphides

The organosulphur compounds present in the *Allium* vegetables, which are either lipid or water soluble, are considered responsible for the beneficial effects of these herbs. The *Allium* genus includes approximately 500 species, the most widely used of which are onions (*Allium cepa*), garlic (*Allium sativum*), leeks (*Allium porrum*), chives (*Allium schoenoprasum*) and shallots (*Allium ascalonicum*). Recent studies indicated preventive effects of the garlic extracts for the brain atrophy (510) as well as the learning and memory impairments (511) in the senescence-accelerated mouse.

5. Importance of Functional foods

Functional foods are any fresh or processed foods with a health-promoting or disease-preventing property beyond the basic nutritional function. Also, they contain a wide variety of the compounds with such a property.

5.1. Importance of Acetyl-L-Carnitine

Acetyl-L-carnitine (ALC) is an orthomolecule which offers major metabolic benefits to the brain. ALC is a metabolic cofactor for the conversion of the FAs into energy within the mitochondria of the nerve cells, thereby helping to keep them supplied with energy (512). ALC also provides acetyl equivalents for the production of acetylcholine, one of the chemical transmitters. In controlled trials, ALC improved depression as well as cooperation, sociability and attention to personal appearance, though it did not consistently improve anxiety (513). A number of double-blind clinical trials suggested ALC may have clinical utility for the management of some forms of cognitive dysfunction (514-518). In one double-blind trial conducted with cognitively impaired ex-alcoholics aged 30-60 years, ALC improved memory, visuo-spatial capacity and vocabulary recall when given at two grams per day over a test period of three months (519). ALC's beneficial effects on the brain also extend beyond cognition enhancement. In the trials with cognitively impaired subjects, intakes ranged from 1.5 to 3 grams per day, with most trials using two grams or more. At these intake levels, ALC can intensify dream activity and it may be contraindicated for subjects with epilepsy or bipolar conditions (512).

5.2. Importance of Phosphatidylserine

Phosphatidylserine (PS) has been first obtained from bovine cortex. An alternative PS product has been made by enzymatic head group exchange from soy phosphatidylcholine. Animal studies demonstrated that soy PS has absolutely similar effects on cognitive performance as compared to bovine PS (520-522). Human studies with 300 mg soy PS (523) and 400 mg soy lecithin phosphatidic acid and PS complex (524) have shown positive effects on stress and mood. In a recently performed clinical investigation 300 mg of milk PS in a drink matrix have resulted in dampening psychological and endocrine stress response (525). Another human study indicated that the daily intake of phospholipid concentrate rich in PS and sphingomyelin compared to placebo-exposed individuals showed a tendency for shorter reaction times in the working memory task, suggesting better performance in phospholipid-treated subjects. The two treatment groups did not significantly differ in their endocrine stress response. However, phospholipid-treated subjects with a higher stress load showed a blunted psychological stress response (526).

5.3. Importance of Probiotics

Psychological stress can alter the integrity of indigenous micro-flora for several days (527). In primates after maternal separation GIT micro-flora was evaluated in 20 infant rhesus Macaques ages 6-9 months who were separated from their mothers for the first time. All infant monkeys were found to have typical faecal bacterial concentrations at baseline. A brief increase in Lactobacilli⁷ shedding on the first day post separation ($p < 0.05$) was followed by a significant decrease in the concentration of Lactobacilli in the faeces ($p < 0.001$). An inverse relationship was also found between the faecal concentration of shed pathogens and shed Lactobacilli. Also, on the first day of stress there is an increased shedding of Lactobacilli, followed by a dramatic decrease in numbers of Lactobacilli over the next six days (527). The Lactobacilli population responds to stress-induced changes in GIT physiology, such as:

- Inhibition of gastric acid release (528),
- Alteration in GIT motility (529) or
- Increased duodenal bicarbonate production (530).

The micro-flora of the GIT represents an ecosystem of the highest complexity (531). The micro-flora is believed to be composed of over 50 genera of bacteria (532) accounting for over 500 different species (533). The adult human GIT is estimated to contain 10¹⁴ viable microorganisms, which is 10 times the number of eukaryotic cells found within the human body (534). The micro-flora plays many critical roles in the body such as:

- Stimulation of the immune system,
- Synthesis of vitamins (B group and K),
- Enhancement of GIT motility and function,
- Digestion, and nutrient absorption,
- Inhibition of pathogens (colonization resistance),
- Metabolism of plant compounds/drugs and
- Production of short-chain FAs and polyamines (531,535,536).

Many factors can harm the beneficial members of the GIT micro-flora:

- Use of antibiotic is a significant cause of major alterations in normal GIT micro-flora (537).

⁷ Lactobacillus is a genus of gram-positive bacteria. They are a major part of the lactic acid bacteria group. In humans they are present in the vagina, and the GIT. The production of lactic acid makes its environment acidic, which inhibits the growth of some harmful bacteria.

- The potential for an antimicrobial agent to influence gut micro-flora is related to its spectrum of activity (537), pharmacokinetics and dosage (538) and length of administration (539).
- Oral antimicrobials well absorbed in the small intestine have minor impact on the colonic flora, whereas agents that are poorly absorbed can cause significant changes. In general, the greater the dosage and length of administration are the larger the impact on the micro-flora (539).
- Use of antimicrobial agents for parenteral administration is not free from these consequences, as some of these agents can be secreted in their active forms in bile, saliva or from the intestinal mucosa and result in considerable alterations in the colonic flora (540).
- Psychological stress can alter the integrity of indigenous micro-flora for several days (527).
- Physical stress, radiation, altered GIT peristalsis and dietary changes alter the GIT micro-flora.

Since both mucin and acidic mucopolysaccharides are important for inhibiting adherence of pathogenic organisms to the gut mucosa and their decrease contributes significantly to successful colonization by pathogenic organisms (541). Exposure to psychological stress has been shown to result in a significant reduction in the production of mucin and a decreased presence of acidic mucopolysaccharides on the mucosal surface (542). Further, exposure to stress results in decreased production of immunoglobulin-A (542).

In response to anger or fearful situations a 20-30% rise in the proportion of *Bacteroides fragilis* subsp. *thetaiotaomicron*^s in the faeces of individuals has been noted. After resolving these situations the concentration of these organisms in the faeces decreased to normal levels (543). As growth of *B. fragilis* subsp. *thetaiotaomicron* is enhanced by bile, this may partly explain the increased numbers of organisms in response to increased epinephrine release (544).

The composition of the diet has been shown to have a significant impact on the content and metabolic activities of the human faecal flora (545). Sulphur compounds, including sulphate and sulphite have been shown to increase production of potentially harmful bacterial products in the GIT. In the colon there

^s *Bacteroides fragilis* is a gram-negative bacillus of the gut. *Bacteroides fragilis* acts primarily at the surface of the mucosa. *Bacteroides* species also benefit their host by excluding potential pathogens from colonizing the gut. Some species are opportunistic human pathogens, causing infections of the peritoneal cavity, gastrointestinal surgery, and appendicitis via abscess formation, inhibiting phagocytosis and inactivating beta-lactam antibiotics. *Bacteroides thetaiotaomicron* can harvest.

is a specialized class of gram-negative⁹ anaerobes known as sulphate-reducing bacteria (546). Reduction of sulphite to sulphide by sulphate-reducing bacteria (547) results in the production of a potentially toxic hydrogen sulphide which can contribute to abdominal gas-distension (546). These hydrogen sulphides can also damage colonic mucosa by inhibiting the oxidation of butyric acid¹⁰, which is essential for absorption of ions, mucus synthesis and lipid synthesis for colonocyte membranes (548).

The amount of dietary sulphate that reaches the colon appears to be the primary factor in determining the growth of sulphate-reducing bacteria. On the other hand, endogenous sources of sulphate (e.g., sulphated glycoproteins and chondroitin sulphate) appear to have little impact on sulphate-reducing bacteria levels (549). Ingestion of foods rich in sulphur-containing amino acids encourages both the growth of sulphate-reducing bacteria and the production of sulphide in the large bowel (547). Sources of dietary sulphate include:

- With sulphur dioxide preservatives and dried fruits,
- Dehydrated vegetables,
- Shellfish (fresh or frozen) (550),
- Packaged fruit juices,
- Baked goods (551),
- White bread and
- The majority of alcoholic beverages (552).

Consumption of a high-protein diet can also increase the production of potentially harmful bacterial metabolites. Consumption of large amounts of sulphur-containing amino acids may significantly increase sulphide production in the colon (548). Elimination of milk, cheese and eggs from the diet of ulcerative colitis sufferers resulted in substantial therapeutic benefit, suggesting that reducing the intake of sulphur-containing amino acids decreases colonic production of sulphide (553).

In the GIT undigested protein is fermented by the colonic micro-flora with the resultant end-products of short chain FAs, branched-chain FAs and potentially harmful metabolites (ammonia and amines) (548,554,555). Ammonia production

⁹ Gram-negative bacteria do not retain crystal violet dye in the gram staining protocol. On the other hand, gram-positive bacteria will retain the crystal violet dye when washed in a decolorizing solution. Gram-negative bacteria have pathogenic capability. It is often associated with certain components of Gram-negative cell walls, in particular, the lipopolysaccharide. Lipopolysaccharide triggers an innate immune response characterized by cytokine production and immune system activation.

¹⁰ Butyric acid is produced as end-product of a fermentation process solely performed by obligate anaerobic bacteria in the gut.

and accumulation is also involved in the pathogenesis of portal-systemic encephalopathy (556). Ammonia has been shown to alter the morphology and intermediate metabolism, increase DNA synthesis and reduce the lifespan of mucosal cells (552). It is also considered to be more toxic to healthy mucosal cells than transformed cells and, thus, may potentially select for neoplastic growth (554). The production of these potentially harmful by-products can also be attenuated by the consumption of diets high in fibre (557) and/or indigestible starch (558). They will reduce intestinal pH.




FIG. 12. Negative effects of high protein diets on gut.

Diets high in simple sugars slow bowel transit time, increase fermentative bacterial activity and faecal concentrations of total and secondary bile acids in the colon (559). A consequence of slower bowel transit time may be an increased exposure to potentially toxic bowel contents (560). Refined sugars are metabolized quickly in the ascending colon. In contrast foods containing substantial amounts of insoluble fibre are metabolized more slowly, releasing fermentation end-products (e.g., hydrogen gas and short chain FAs) more gradually (561).

6. Importance of Endocrine

The endocrine system is instrumental in the regulation of development, growth, metabolism, puberty and tissue function. It plays a part in determining mood and stress.

6.1. Importance of CCK

Cholecystokinin (CCK) is a hormone of the GIT. It was originally identified in the gut, where it is involved in the secretion of pancreatic enzymes, gallbladder contractions and gut motility. Some known facts about CCK are:

- CCK production is located in the CNS.
- CCK is localized in several brain areas involved in food intake regulation (562).
- CCK is released from hypothalamic neurons during feeding (563,564).
- CCK is released by the duodenum in the presence of digestive products of fats and proteins in the intestine (565).
- CCK is involved in the control of food intake in both man and animals (566-568).
- CCK mediates gastric emptying under physiological conditions (569).
- CCK inhibits food intake and increase satiety in humans (570).

In humans, CCK pathways modulate sensations induced by gastric distension (571). It has also been hypothesized that CCK plays an etiologic factor in panic disorder and anxiety (572). CCK is more abundant in the brain than in the periphery and is one of the most abundant neuropeptides in the brain (573,574). Its concentration in cortex and limbic regions (575,576) supports its role in the regulation of many behavioural phenomena, including satiety and appetite (577), anxiety (577-582), memory (583), sexual behaviour (580,581), thermoregulation (578,579) and response to drugs of abuse (584). It is localized in cell bodies and terminals with many other neurotransmitters such as GABA (585,586), DA (587), serotonin and opiates (588). Also, there is evidence of a major corticostriatal CCK-containing pathway that is thought to contain glutamate as well (589). It meets the criteria for designation as a neurotransmitter (573).

CCK is responsible for stimulating the digestion. It acts as a hunger suppressant and plays a major role in inducing drug tolerance to opiates. CCK is likely to transmit vagal afferent signals to the hindbrain by acting on receptors located in the pylorus and liver. There is a large body of data from studies investigating the role of CCK in food intake regulation (590,591). Also, CCK is a potent inhibitor of gastric emptying (592), some of its effects to limit food intake may be indirectly mediated by the retention of food in the stomach. Both depression and chronic

tension can present with abdominal symptoms (593,594). It is known that CCK or CCK receptors interact with other neurotransmitters in the CNS (monoaminergic, serotonergic, GABAergic) known to be involved in anxiety and affective disorders (595-597). CCK-B receptor plays an important role in anxiety states and panic attacks (572,598,599). CCK-B receptors can modulate activity within the HPA axis (599,600), which is involved in the stress response. Psychological stress is widely believed to precipitate exacerbation of symptoms in functional dyspepsia. Inhibition of gastric emptying and stimulation of colonic transit is the most consistent motility response of the GIT to acute stress (601). Early life stress and trauma in the form of abuse, neglect or loss play a major role in the vulnerability of individuals to develop functional GI disorders. It is proposed that in the genetically predisposed individual both early life stress and severe life-threatening stress can result in permanent alteration in central stress circuitry and predisposes the individual to the development of functional disorders later in life (601). Although CCK reduces meal size, long-term peripheral administration of CCK does not reduce overall energy intake or induce sustained weight loss (602).

6.2.6.2. Importance of Cortisol

Cortisol has been implicated as a potential mediator for increased energy intakes in healthy males (603) and females (41). It is involved in appetite regulation (604) and energy balance by increasing available energy through gluconeogenesis and lipolysis (41). Studies in dogs suggest that cortisol treatment enhances *de novo* glucose synthesis through increased amino acid uptake in the liver (605,606). In animals, GC administration (607) and corticosterone replacement (608) led to hyperphagia and weight gain. Corticosterone also increased fat intake in a dose-dependent fashion in rats (608).

Depression is positively related to basal cortisol levels (609). Although the acute elevation of cortisol plays a protective role during stress, chronic elevations can promote insulin resistance and cause abdominal obesity (610,611). A 'chronic stress-response network' in rats, based on greater consumption of sucrose following administration of GCs, led to increased abdominal fat depots. In humans overeating of 'comfort foods' may be stimulated by cortisol in response to stress, which can result in abdominal obesity (612).

After acute stressor, the rapid increase in HPA activity interacts with elevated epinephrine, glucagon, and sympathetic neural activity to elevate blood glucose concentrations, ensuring adequate substrate for brain and muscle that may be life-saving. Also, high cortisol secretion in response to an acute laboratory stressor is related to voluntary increases in sweet, high-fat food ingestion after the stressor.

Individuals with high cortisol responses consumed more calories on the stress day compared to low reactors, but ate similar amounts on the control day (41).

Stress and negative affect are the most frequently cited precursors of binge eating (613). However, negative emotions have been associated with both increased and decreased food intake (614,615). Stress reactivity may distinguish stress overeaters from stress under-eaters (616). Cortisol secretion is a major component of the stress response (617) and could play a role in binge eating, given that exogenous GCs induce obesity by increasing food intake (603). An exaggerated cortisol response after laboratory stress tests has been observed in women with anorexia nervosa (AN) (618), bulimia nervosa (BN) (617,619) and obesity (620), although a blunted cortisol response has been found (621).

Cortisol is released during stress and can increase hunger and feeding behaviour (603). Also endogenous cortisol release stimulated by stress may mediate stress-induced eating. Among lean women, high cortisol reactors ate significantly more food after a stress task (41). Stress plays a confirmed role in the onset and maintenance of BN (616) and in the initiation of binge eating episodes (622,623).

Increased cortisol is positively related to central fat distribution in both obese and lean individuals (624,625) and morning cortisol has been shown to be positively associated with waist-hip ratio (WHR) and insulin (626). A large WHR, reflecting central obesity, appears to be a health risk factor independent of obesity (624) and is related to greater HPA activation (611), associated with increased cortisol levels and vulnerability to stress (620,625). Obese women with binge eating disorder (BED) have higher morning basal cortisol levels compared with non-BED (627). Additionally, a greater cortisol area in the BED group is observed during a cold stress test (627). Women with BED have similar to those with BN greater basal cortisol levels (621,627,628) and increased cortisol after stress (617,619,627,629). In relation to health, dysfunction of the HPA axis has been implicated in particular in dysphoric disorders, such as major depression (630), whereas hypercortisolemia in Cushing's syndrome is accompanied by physical symptoms, such as accumulation of abdominal adipose tissue, together with muscular atrophy of the limbs, providing powerful evidence of the well-established metabolic and nutritional consequences of chronic hypercortisolemia (178). Normal physiological variations in cortisol level in humans have a significant direct influence on macronutrient metabolism (36,37). Also, the ability of cortisol to increase plasma FFA levels may underlie the emerging link between cortisol and abdominal obesity, together with its associated metabolic syndrome (38). Cushing's patients with elevated cortisol levels selected high-fat foods twice as often as normal weight subjects and three

times as often as overweight controls (608). Laboratory test indicated that among healthy women, high cortisol reactors ate significantly more food following a cognitive stress task compared to low cortisol reactors (41). In an earlier study (631) subjects undergoing a stressful task before a meal showed increased plasma cortisol during the task, which was then followed by a suppressed cortisol response to the meal.

In healthy men administration of cortisol for four days led to slightly increased energy expenditure. In contrast to this slight increase the food intake increased dramatically (603). Approximately 90-95% of plasma cortisol is bound to CBG, albumin and erythrocyte membranes (632) whereas only the free fraction is thought to be physiologically active. Cortisol in saliva is a valid measure of free cortisol levels and is easily sampled repeatedly without distress (11,632).

6.3. Importance of CRF

Corticotrophin-releasing factor (CRF) is a peptide that is released in the brain by stress to integrate the endocrine, behaviour, autonomic and visceral responses (633,634). CRF functions both as a neuroendocrine hormone and neurotransmitter, via the HPA axis and hypothalamic and extra-hypothalamic neuronal pathways (635). CRF also modulates the actions of other neuropeptides and hormones that regulate food intake, such as neuropeptide Y (NPY) and leptin (636). For instance, blockade of CRF signalling in the brain by selective antagonists or CRF antibody enhances NPY-induced food intake in rats (637,638). Further, CRF acts in the brain to induce a rapid onset reduction of food intake, gastric emptying in rodents and plays a role in stress-related alterations of food intake and gastric motor function (634,639-641).

CRF cells in the amygdala innervate monoaminergic neurons in brainstem. In the locus coeruleus, CRF increases the basal firing rates of the locus coeruleus neurons and NE secretion in the forebrain (642), probably increasing arousal and attention. Moreover, the electrical response of the locus coeruleus to hypotension requires amygdala CRF input and chronically stressed rats have increased CRF tone in the locus coeruleus (643,644). Activity of serotonergic neurons in the dorsal raphe is similarly affected by CRF and stress (645-647). Both the locus coeruleus and dorsal raphe had greater c-Fos responses in chronically stressed rats than in naive rats provided with a novel acute-restraint stress (648). Possibly it is elaborating behavioural, autonomic and neuroendocrine motor outputs characteristic of chronic stress by administering CRF (649-651). The amygdala appears to be a very important component of the chronic stress-response network, both because of its

far-reaching innervation of cortical, subcortical and brainstem structures and its important role in memory consolidation (652).

6.4. Importance of CRH

Corticotropin-releasing hormone (CRH) is a neurotransmitter as well as a neuro-hormone (653). Stressors increase the firing rate of regions in the brain stem, particularly noradrenaline–NPY neurones in the A1 (VLM), A2 (NTS) and A6 (locus coeruleus; LC) regions. There are synaptic contacts between noradrenaline–NPY nerve fibres and CRH perikarya in the paraventricular nucleus (PVN), although there have been no confirmatory retrograde or anterograde double-labelled studies to confirm the location of the perikarya of these axons (654).

6.5. Importance of Cytokines

Peripheral or central administration of a number of cytokines, including IL-6 and TNF, inhibit food intake (655). Cytokines may also influence food intake indirectly via actions on insulin sensitivity (656) or leptin production (657,658).

6.6. Importance of Glucocorticoids

GCs were named by Hans Selye for their major combined actions on both mobilization of small substrate molecules from peripheral fat and muscle stores and augmented gluconeogenesis in the liver (659). GCs are also known to affect development (660,661), memory (662,663), fear, anxiety (7) and the immune system (664–666). GCs as prime regulators of both energy balance and stress (667) are controlled by a wide range of variables, including hunger (668), feeding (669,670), aversive stimuli, expectancy (669,671,672) and circadian factors (667,670,673). Adaptive anorexia (674), anxiety symptoms (675) and increased HPA responsiveness (648) indicate facilitation of centrally driven defensive strategies. Elevated GCs stimulate appetitive activities, such as drug-taking behaviours (676,677), result in dose-dependent increases in wheel running (678) and palatable feeding (612,679,680) and may generally reduce thresholds for pleasurable stimulation. The HPA response is blunted in rats consuming high-calorie diets (63,681), a finding paralleled in some human subjects (26,682). Many studies find a positive correlation between plasma GCs and the expression of feeding behaviour. Food intake is normally highest at the time of day when baseline GCs show a peak and intensity of feeding can be shifted with GC treatment (12). Food intake may be mediated through GC-induced stimulation of NPY (14,683–685) and catecholamines (14) or through inhibition of the anorexigenic peptide CRF (686,687).

GC levels above the seasonal baseline are generally correlated with protein utilization and muscle tissue breakdown (688,689). Experimental manipulations confirm the involvement of elevated GC levels in such metabolic changes: induces protein loss and muscle atrophy in a variety of species (690-693). Further, GCs may promote gluconeogenesis through enhanced substrate delivery. Studies in a variety of vertebrate species verify the role of GCs in the acute provisioning of glucose. Treatment with GC equivalents increases plasma glucose in birds (694,695) and can reverse hypoglycaemic effects of insulin injections (696). In contrast, a characteristic change in transformed cells is a 5- to 7-fold increase in glucose uptake and utilization (697,698). Also, GC manipulations may not always affect plasma glucose levels (699,700). In many peripheral tissues GC decrease glucose uptake (701). The size of the GC stress response can either be enhanced, diminished or remain the same (702,703). GCs support a heightened physiological state by promoting availability of lipid energy from adipose tissue stores (12,664). For example, cortisone administration significantly reduces the stored triglyceride fraction of adipose tissue in lizards (704). Also, GCs increase lipogenesis and fat deposition in the liver (695,704,705). GCs may contribute to the process of FA oxidation by making available amino acids for use as citric acid cycle intermediates (706). Further, GCs may promote fat mobilization by inhibiting glucose uptake in adipose tissue (664).

In healthy males, exogenous GC administration increased daily food intake compared to placebo (603). Adrenalectomy and GC receptor antagonists prevent or reverse obesity (707), whereas administering corticosterone leads to increased appetite for sucrose (680), hyperphagia and weight gain (708). In cancer patients, prednisolone significantly increased appetite, compared to a control group (709).

GCs decrease DA and NE transporter activity and consequently increase signalling by these transmitters (710,711). In relation to health, dysfunction of the HPA axis has been implicated in particular in dysphoric disorders, such as major depression (630).

- Chronically high concentrations of GCs act in three ways that are functionally congruent (612).
- GCs increase the expression of CRF mRNA in the central nucleus of the amygdala, a critical node in the emotional brain.
- CRF enables recruitment of a chronic stress-response network.
- GCs increase the salience of pleasurable or compulsive activities (ingesting sucrose, fat and drugs or wheel-running). This motivates ingestion of "comfort food."
- GCs act systemically to increase abdominal fat depots. This allows an

increased signal of abdominal energy stores to inhibit catecholamines in the brainstem and CRF expression in hypothalamic neurons regulating adrenocorticotropin.

Under a persistent stressor or long after administration of a single stressor of high intensity, there is marked diminution of the efficacy of GC feedback inhibition of stimulated, but not basal, ACTH secretion (712,713). After the first 24-h period of the onset of a chronic stressor, the direct long-term effects of GCs on brain are to enable the “chronic stress-response network” and thus modify a variety of mechanisms associated with coping, including enhancing stimulus salience and its attendant compulsions (612). There are three modes of GC action that are important during stress (612):

- Canonical,
- Chronic direct and
- Chronic indirect.

In rats high levels of GCs inhibit growth hormone secretion, reducing linear growth, reducing sympathetic neural outflow and reducing some types of fat mobilization (684,714). Adrenalectomized rats replaced with clamped corticosterone concentrations for 5 days and allowed to drink sucrose ad libitum showed a significant positive relationship between corticosterone and sucrose ingestion and corticosterone and mesenteric fat (680). By contrast, neither chow intake nor sc white fat depot weights were affected by corticosterone (680). Also, passively increasing corticosterone concentrations into the stress range in rats redistributes stored energy toward an intra-abdominal distribution (715).

6.7. Importance of Ghrelin

Ghrelin is a recently discovered peptide hormone which is structurally related to motilin.

- Ghrelin is also produced in the hypothalamus (716).
- Circulating ghrelin concentrations increase during fasting (717).
- Circulating ghrelin concentrations are reduced by the nutrient's presence in the stomach (717).
- Circulating ghrelin concentrations are in obese lower versus lean human subjects (718).
- Central ghrelin administration also increases hypothalamic expression of the NPY (719).

6.8. Importance of Insulin

Physiological amounts of insulin are required for normal neuronal activity but the sudden exposure to bolus insulin injections will activate the HPA axis, as will many other stressors, for example, transport, restraint or isolation. The HPA axis responds together with acute increases in insulin after meals in both rats and man (72,720,721). In vitro, insulin synthesis and secretion from the pancreas are directly inhibited by the actions of GCs (722). In vivo, increasing GCs are associated with increasing insulin secretion (723), possibly because of a marked anti-insulin effect on liver (723), which appears to be particularly vulnerable to the negative effects of GCs on insulin action (724). Hepatic insulin resistance is strongly associated with abdominal obesity (725). The relatively selective increase of abdominal fat in the presence of elevated GCs and insulin may be a consequence of the differentiating effects of these hormones on stromal fat precursor cells (726), as well as increased abundance of GC receptors on omental compared with sc adipocytes (727). In cases of very low energy stores and high GCs, the normal inhibitory effects of GCs on HPA axis activity are reduced, if not abolished (728). This should enhance GC elevations and their effects on omental fat.

6.9. Importance of Leptin

The adipose-derived hormone leptin is thought to regulate energy homeostasis by stimulating coordinated changes in energy intake and expenditure in response to changes in energy stores (729-731). Leptin is synthesized in fat cells and secreted into the bloodstream in concentrations that are proportional to total adipose stores (732-735). Leptin also increases release, from adjacent neurons, of anorexigens α -melanocyte stimulating hormone and cocaine- and amphetamine-regulated transcript, which are also coexpressed (736). Plasma leptin concentrations in humans correlate strongly with adiposity (732,733,735). Additional functions for leptin among his roles are signalling the neuroendocrine response to starvation (737-739), the timing of puberty (740-742) and regulation of the HPA axis (743-745). Several lines of evidence suggest that leptin can regulate the HPA axis at the level of hypophysiotrophic CRH and the adrenal gland (743-745). Since the circadian rhythm of the HPA axis is affected by feeding (746,747) and diurnal levels of leptin are also influenced by food intake (737,748).

Studies in spontaneously feeding rodents and humans have revealed an inverse relationship between the levels of leptin and GCs (737,749,750). In normal adult mice housed under 12-h light and 12-h dark cycles and fed ad libitum, maximum food intake occurs during the dark cycle (737). GCs increase early in the dark cycle, coinciding with the onset of feeding and decrease to a nadir at the beginning of the light cycle (737,746,747). In contrast, plasma leptin peaks late in the dark cycle and

decreases during the light cycle (737,748). Also, plasma leptin levels appear to be pulsatile and circadian (750) and leptin peaks early in the dark cycle, whereas cortisol peaks before wakefulness (749,750).

Fasting results in a decrease in leptin and an increase in corticosterone in adult mice (734,737,751). Further, diet-induced weight loss causes leptin concentrations to fall in proportion to the loss of adiposity (732). During acute weight loss (during fasting), however, leptin concentrations fall much more than expected from the amount of fat lost (735), suggesting that negative energy balance reduces the amount of leptin secreted per unit of fat mass.

6.9.1. Effects of Dietary Fat on Leptin

Inducing obesity by feeding rodents a high-fat or high-energy diet by changing diet from chow to a high-fat diet was associated with leptin resistance. This leptin resistance occurred rapidly and was apparent before any change of body composition could take place (752). Also, dietary fat, per se, can induce leptin resistance. Importantly, in rats maintained on chow, leptin sensitivity predicts the development of diet-induced obesity when the animals are subsequently placed on a high-energy diet (753).

6.10. Importance of SHBG

Depressed plasma testosterone levels consistently occur as a result of obesity. This could be caused due to the elevated metabolism of testosterone in fat tissue and a decrease in binding capacity of the sex hormone-binding globulin (SHBG) (754). Also, a low protein diet may elevate SHBG levels in elderly men (755). Further, the levels of growth hormone and IGF are reduced, which inhibit SHBG production in hepatocytes (756).

6.11. Importance of Thyroid Hormones

The liver and to a lesser degree the kidneys play a dominant role in the metabolism of thyroid hormones. As the liver and to a lesser extent kidney have primary influence on the circulating levels of thyroid hormone metabolites, the health and function of these organs play a critical and under-appreciated role in thyroid hormone function (757). The majority of the most metabolically active thyroid hormone, 3,5,3'-triiodothyronine (T3), is generated in peripheral tissue. Similarly, the preponderance of its competitive inhibitor, 3,3',5'-triiodothyronine (rT3; reverse T3) is generated outside the thyroid gland. Further transformations to T2 and T1 isomers also occur almost exclusively in peripheral tissue. These transformations are all catalyzed by deiodination enzymes. This stepwise deiodination results in

both active and inactive metabolites (758). People subjected to cold exposure-induced stress responded with an increase in serum rT3 (759). In an academic anxiety examination twenty-two male and 27 female medical students were monitored. Both male and female students experienced an increase in rT3 levels on examination days. The increase among female students was substantially higher than observed in the male students (760). In other study with military cadets the combination of several stressful situations showed a synergistic and dramatic effect on altering thyroid hormone metabolism. During a training exercise the cadets had been subjected to a combination of sleep deprivation, calorie deficiency and intense physical activity. Parallel to increased levels of cortisol along with abolition of circadian rhythm T4, fT4 and T3 consistently declined. While T4 and fT4 returned to normal levels within 4-5 days following the cessation of the training exercise, T3 and fT3 remained depressed (761). A correlation between increased rT3 and elevated levels of IL-6 has been reported in elderly patients undergoing emergency surgery (762). Elevated levels of IL-6, TNF- α and interferon- α have also been reported to have a strong association with the reduced T3 and increased rT3 found under stressful conditions (763,764). On the other hand, IL-6 administration also results in a significant increase in cortisol levels (765). In any type of situation characterized by increased endogenous secretion of cortisol, a predictable pattern of altered thyroid hormone metabolism may occur. The generalized pattern is characterized by a trend toward lowered thyroid-stimulating hormone (TSH) production and a blunted TSH response to thyrotropin-releasing hormone (TRH), a decline in T3 and an increase in rT3 (760,766-773). Even changes in serum cortisol levels within the normal range can cause significant alterations in thyroid hormone parameters (774). Abnormal plasma levels of the thyroid hormones are typically associated with reproductive deficiency (775). Hypothyroidism as well as hyperthyroidism also can modulate the reproductive capacity of experimental animals. Excessive levels of plasma thyroid hormones stunts growth and development, inhibits sexual behaviour (776), decreases plasma LH levels and thus impairs gonadal function (777). In accordance with hyperthyroidism hypothyroidism is associated with abnormal menstrual cycles and disrupted follicular development (775,778).

Enzyme activity can be modulated by numerous foreign compounds, such as common chemicals and drugs (779). Many of these enzyme inducers can increase the glucuronidation of T4, resulting in a decrease of serum T4 and a subsequent increase in TSH (780). Specific drugs and environmental toxins have been shown to influence the sulphotransferase activity responsible for thyroid hormone metabolism. While the role of most nutrients on sulphation of thyroid hormones is unknown, in rats selenium deficiency significantly increases the mean serum

concentrations of sulphated T4, T3 and rT3 (T4S, T3S, rT3S) secondary to reduction in 5'-deiodinase activity (781). Exposure to toxic metals such as cadmium or lead can result in an alteration in peripheral metabolism of thyroid hormones. A substantial reduction in T3 without any significant alteration of serum T4 concentrations has consistently been observed in animal models (782-784). Also, activity of hepatic 5'-deiodinase has decreased by as much as 90% subsequent to exposure to toxic metals. Coupled with the decline in T3 and hepatic 5'-deiodinase activity and the impairment in antioxidant enzyme systems, a concomitant increase in lipid peroxidation by as much as 200% has also been reported (782-784).




FIG. 13. Effect of psychological stress on thyroid hormone

Nutritional status and caloric expenditure influences thyroid function centrally at the level of TSH secretion, at the level of monodeiodination and possibly elsewhere. Since an increase of rT3 is found at the expense of T3 during caloric restriction, it is possible the hepatic peripheral pathways play a substantial role in metabolic control during energy balance. Also, the increase in rT3 during fasting might be a result of increased production of and decreased clearance of this metabolite (785). In healthy male subjects following a 30-hour fasting serum T3 levels were significantly lower than in the non-fasting state, while rT3 levels increased during fasting. After re-feeding, TSH tended to increase and rT3 to decrease slightly, these values remained perturbed when compared with values observed prior to fasting (786). In contrast to short periods of fasting caloric restrictions longer than three weeks cause a return of T4 and rT3 levels to normal values (787).

Serum thyroid hormones are sensitive to marginal changes in energy intake and expenditure. A hypo-caloric, low carbohydrate diet consisting of 800kcal/day for four days resulted in a striking decrease in both T3 and fT3 and an increase in rT3 (788). In a study of obese individuals, irrespective of carbohydrate content of the diet, when caloric content of the diet dropped to 600kcal/day T3 levels were compromised. Reverse T3 was not significantly influenced by the carbohydrate content of the diet and seemed to be most impacted by the caloric content (787). In a study with the non-obese subjects, T3 levels decreased and rT3 levels increased when carbohydrate intake was dramatically reduced (789).

In animal models, ethanol intake was associated with impaired hepatic 5'-deiodination (790). Among patients with alcohol-induced liver cirrhosis, low T3 and T4, elevated rT3 and normal TSH values have been observed. In these subjects an abolished circadian rhythm and elevated cortisol levels have frequently been observed (791).

6.12. Importance of Testosterone

Sex hormones can influence regions of the CNS which contain hormone receptors. Two decisive phases have been identified in the effects of testosterone on brain structures and consequently on behaviour. Testosterone is qualitatively the most potent androgen in males (792), which is also present in females at approximately one-tenth of the male serum concentration (793). During foetal and neonatal life relatively high concentrations of testosterone are thought to influence brain development by organizing the undifferentiated brain in a sex-specific manner. It has been shown that the hypothalamus, the hippocampus, the preoptic-septal region and the limbic system are important target areas for sex steroid action (794-796). These brain structures and hence the corresponding behavioural repertoires are then thought to be activated at the beginning of puberty when the production of sex hormones increases (797). Stressful situations as experienced during work, before tournaments or anticipating exams have been shown to decrease testosterone levels (798-804). The same effect was seen in men undergoing workplace reorganisation and threatened by unemployment. After the workplace situation changed for the better, testosterone levels clearly rose with a marked variation between subjects (805). Studies exploring the relationship between gonadal function and depressive episodes showed that testosterone secretion as well as mean levels was decreased significantly in patients (806,807). Decreased testosterone levels in depressive illness can be seen as a permanently down-regulated secretion, partially maintaining a state of mood that initiated it in the first place. Contrary, stress release can have an elevating effect on androgen levels, which is demonstrated by a controlled study involving volunteers practicing

transcendental meditation (808). Strength training can have an acute effect on endocrine functions. Measurements immediately and 5 minutes post-exercise show an age-dependent increase in testosterone levels (809-813). Regardless of the kind of sport, maximal or submaximal exercise (5–30 min) normally results in significant increases in testosterone levels in males which are independent of luteinizing hormone (LH) and follicle-stimulating hormone secretion (814). The apparent disagreement between the effects of submaximal, prolonged exercise and 5–30 minutes exercise on testosterone levels in males are explained by the early (non-LH dependent) rise in testosterone concentrations (815) and a decreased metabolism of testosterone due to a drop in hepatic blood flow (816). Acute effects of submaximal, prolonged exercise in marathon runners or cross-country skiers resemble hormonal changes found in endurance-trained men during the resting state. A highly significant decline in testosterone concentrations compared with pre-competition baselines was observed (817-819). In contrast to men young sportswomen had significantly increased testosterone levels after a long-distance run (820). Testosterone concentrations of trained subjects were only 60–85% of the age-matched untrained men, although no difference in mean plasma SHBG capacity could be detected between the trained and untrained men (821).

In settings combining the mental and physical aspects of stress, testosterone can drop to clearly hypogonadal levels (822,823). External administration of testosterone is considered for the treatment of depressive states (824,825). In a representative study, ten cynomolgus monkeys received injections of either testosterone propionate or a sham solution. Testosterone administration led to a significant increase in aggression, which was mediated by social status. Dominant animals were much more likely to present aggressive behaviour than subordinate ones (826). To determine a possible role of testosterone in status ranking, chess players were tested before and after competition. Before and after tournaments, winners/ winners-to-be had higher testosterone levels than losers (827). Similar results in regard to post-competition levels were described during tennis matches and wrestling competitions (828,829). Also a history of previous success or membership in the host team can lead to an elevation of testosterone levels after the match (830). Interestingly in a socially homogeneous group of German volunteers, levels of saliva testosterone did not change during exposure to aggressive and violent films (831).

Any sexual behaviour can significantly alter sex hormone levels. The majority of data on eugonadal men refer to effects on ejaculation. Orgasmic frequency in males, whether through sexual intercourse or masturbation, correlated positively

with free, biologically active testosterone, serum testosterone or dihydro-testosterone (832-834).

6.12.1. Effects of Alcohol on Testosterone

Excessive alcohol consumption has toxic effects on hepatocytes and leads to hypothalamic dysfunction associated with lower testosterone levels. In general, alcohol consumption leads to a significant decrease in testosterone and DHT levels in males, regardless of whether beer or wine is consumed. Even 10–20 hours after drinking testosterone levels can still be significantly suppressed (754). Moderate consumption of alcohol will have no effect, but a personality trait of sensation-seeking behaviour has been described as associated with higher testosterone levels and higher frequency of alcohol consumption (835).

6.12.2. Effects of Nutrition and Testosterone

Nutrition has the potential to affect testosterone production and metabolism. Depressed plasma testosterone levels also consistently occur as a result of obesity, due to the elevated metabolism of testosterone in fat tissue and a decrease in binding capacity of the SHBG (754). Urinary secretion of androgens (representing a fraction of bio-available testosterone) in black and white North American men and rural black South African men was found to be significantly higher in those subjects living on a meat-rich western diet (836). Comparing total serum testosterone levels in omnivorous men to those on a vegetarian diet showed no differences, but in the latter group there were significantly higher levels of SHBG, leading to decreased levels of bio-available testosterone (837). Also, the kind of diet is most likely to influence the fraction of bio-available testosterone, but not total levels of this hormone (838-842).

7. Importance of Ageing

There is ample evidence that intelligence (843,844), life span (845-847) and the risk of various neurological disorders (848-850) would be determined, in part, by heritable factors. One gene that appears to have an influence on ageing in general and on the risk of age-related neurodegenerative disorders is apolipoprotein E (851). Other genes linked to life span that may influence brain ageing are those encoding the growth hormone (852) and major histocompatibility complex (MHC) proteins (853). Growth hormone levels decrease with ageing and this change is ameliorated by caloric restriction. The density of micro-vessels in the brains of rodent decreases during ageing and this can be reversed by treating the animals with growth hormone, which may increase production of IGF-I in the brain (854).

During ageing in many brain regions, there is very little or no decrease in numbers of neurons, while in some brain regions neuronal loss may occur but may be compensated by expansion of dendritic arbors and increased synaptogenesis in the remaining neurons (855). It is thought that many neurons remain in the brain for a lifetime, although in some brain regions such as the olfactory bulb and dentate gyrus of the hippocampus, there may be a continuous replacement of neurons from a pool of progenitor (stem) cells (856,857). Changes in the cellular structure of the brain and the functions of its neuronal circuits are controlled by an intricate array of intercellular signalling molecules and intracellular signal transduction pathways. Signalling mechanisms affected by ageing include e.g.:

- Cellular calcium homeostasis (858),
- Gene transcription (859) and
- Protein phosphorylation (alterations in kinases, and phosphatases) (860).

The major classes of signal molecules important in brain ageing include neurotrophic factors, neurotransmitters, cytokines and steroids. In addition to their roles as mediators of synaptic transmission, neurotransmitters such as glutamate, acetylcholine and DA also play important roles in regulating the formation of neuronal circuits during development and in influencing the neurodegenerative process in brain disorders during ageing (858). Among neurotransmitter systems, dopaminergic signalling appears to be consistently altered during ageing with a progressive decrease in signalling (861). Three major classes of intercellular signalling proteins that regulate neuronal survival and synaptic plasticity are neurotransmitters, neurotrophic factors and hormones. Glutamate and GABA play pivotal roles in regulating neuronal survival (862) and synaptic plasticity (863). By inducing the expression of neurotrophic factors such as BDNF, glutamate can promote neuronal survival (864). On the other hand, over-activation of glutamate

receptors can cause neuronal death, particularly under conditions of increased levels of oxidative and metabolic stress, as occurs during ageing and in age-related neurodegenerative disorders (865). GABA can protect neurons in experimental models of neurodegenerative disorders by reducing neuronal excitability (862). Other neurotransmitters that can modify neuronal vulnerability in cell culture and animal models of neurodegenerative disorders include acetylcholine, DA, NE and serotonin (866-868).

Increased oxidative stress and accumulation of oxidatively damaged molecules (proteins, nucleic acids and lipids) promote dysfunction of various metabolic and signalling pathways (869). Neurons may also face energy deficits as the result of alterations in the cerebral vasculature and in mitochondrial function (870). DNA and RNA bases are subject to oxidative modification with a prominent example being the formation of 8-hydroxydeoxyguanosine (871). Further, the double bonds in membrane lipids are oxidized resulting in the production of a variety of lipid peroxides and aldehydes (872). These modifications of proteins, nucleic acids and lipids are greatly exacerbated in neurodegenerative disorders such as AD and PD consistent with a major role for oxidative stress of ageing in the pathogenesis of those disorders (873).

There are numerous dietary factors that have been reported to affect brain physiology in ways that could modify brain ageing and the pathogenesis of neurodegenerative disorders (874). These range from amino acids such as Trp (875), caffeine and related stimulants (876) and omega-3 PUFA (877).

7.1. Importance of Dietary restriction in brain ageing

The mean and maximum life spans of many different organisms including yeast, roundworms, rodents and monkeys can be increased by up to 50% simply by reducing their food intake (878-880). Data from clinical and epidemiological studies in humans support the anti-ageing and disease prevention effects of dietary restriction. Thus a low-calorie diet decreases the risk of the most prominent age-related diseases in humans including cardiovascular disease, diabetes and cancers (881-883). Biochemical and molecular analyses of the brains of old rats and mice that had been maintained on calorie-restricted diets reveal a retardation of changes that occur during ageing of animals fed *ad libitum* including increases in levels of Glial fibrillary acidic protein and oxidative damage to proteins and DNA (884,885). Oxidative stress and energy metabolism are counteracted by dietary restriction. Dietary restriction attenuates age-related deficits in learning and memory ability and motor function in rodents (886,887). In animal studies where restricted animals are given food pellets that contain 30–40% fewer calories than the pellets given to

the control animals there was an increase in the life spans of restricted rats and mice by 30–40% (880,888). Further, when rats were maintained for several months on dietary restriction, damage to hippocampal neurons was decreased. Further, learning and memory were preserved compared with rats fed *ad libitum* (889). Also, the motor function was improved in the restricted mice (890). In human individuals with a low calorie intake have lower risk of the developing AD, PD and stroke (891,892). There is a strong correlation between per capita food consumption and the risk for AD (893). Population-based case-control studies indicated that individuals with the lowest daily calorie intakes had the lowest risk of AD (892) and PD (894). Interestingly, the risk of PD and AD was more strongly correlated with calorie intake than with weight or body mass index. Other population-based longitudinal prospective study indicated that the incidence of AD increases among individuals living in industrialized countries compared with genetically similar individuals that live in non-industrialized countries (895). Evidence for an important role for neurotrophic factors in the beneficial effects of dietary restriction in the brain is suggested by studies showing that infusion of a BDNF blocking antibody into the lateral ventricles of dietary restriction mice significantly attenuates the protective effect of dietary restriction (896). In animal studies levels of BDNF are increased in neurons in the cerebral cortex, hippocampus and striatum maintained on dietary restriction (896,897). It is known that BDNF can protect neurons in culture and *in vivo* against excitotoxic, metabolic and apoptotic insults (898). Also, BDNF and other neurotrophic factors might counteract the adverse effects of ageing on synaptic function because they can modify synaptic plasticity in ways that facilitate learning and memory (899,900). In every neurodegenerative disorder increased oxidative stress, perturbed cellular calcium homeostasis and impaired energy metabolism occur (901,902). It has been shown that dietary restriction can stabilize mitochondrial function and reduce oxidative stress in brain cells of rodents (903). Also, caloric restriction can increase neurogenesis in the brains of rats and mice (897,904).

8. Importance of Foods

There are some known effects of foods on mental performance and stress susceptibility which will be discussed here.

8.1. Importance of Caffeine

Caffeine is a mild stimulant that may improve mental alertness and performance (905). In humans, coffee, tea and soft drinks, as well as cocoa, chocolate and certain medications are the major sources of caffeine (906). The content of caffeine of the various food items ranges from 40 to 180 mg/150 ml for coffee, 24 to 50 mg/150 ml for tea, 15 to 24 mg/150 ml for cola, 2 to 7 mg/150 ml for cocoa and 1 to 36 mg/28 g for chocolate (907,908). Caffeine absorption from the GIT is rapid and reaches 99% in humans in about 45 minutes after ingestion (909-912). Due to the hydrophobic properties of the drug, it can cross the placenta and the brain-blood barriers. Caffeine half-life is lower in rodents than in humans and it is increased during pregnancy and the neonatal period (876). Also, very large doses of caffeine have toxic effects, with an LD₅₀¹¹ of about 200 mg/kg in rats (913). Deaths have been reported after the intravenous, oral and rectal administration of caffeine or coffee (914), the lethal dose being about 100 or 170 mg per kg, which is equivalent to 75 cups of coffee, 125 cups of tea or 200 cans of cola. There are no differences in caffeine half-life in young and elderly humans (911). The half-life of caffeine is about 80 ± 23 h for the full-term newborn infant (915,916) and can be over 100 h in premature infants (917). In adult smoker males, caffeine half-life is reduced by 30 to 50% compared with non-smokers (918-920). It is approximately doubled in women taking oral contraceptives (921) and greatly prolonged (up to 15 h) during the last trimester of pregnancy (922-924). Only at extremely high doses caffeine is teratogenic in mammals with the threshold dose for malformations appearing to be within the range of 80–100 mg/kg/day, depending on the method of administration and the species tested (925).

Caffeine may be a potential drug of abuse (926) and more recently caffeine has been described as "a model drug of abuse" (927). Also, the possibility that caffeine abuse, dependence and withdrawal should be added to diagnostic manuals has been seriously considered (928-931). Reduced foetal body weight and delayed skeletal ossification have been observed at relatively high doses of caffeine (932). The primary action of caffeine may be to block adenosine receptors, which leads to very important secondary effects on many classes of neurotransmitters, including

¹¹ LD₅₀ (the median lethal dose) of a toxic substance is the dose required to kill half the members of a tested population after a specified test duration.

noradrenaline, DA, serotonin, acetylcholine, glutamate and GABA (933). Further, it cause a dose-dependent (30-75 mg/kg) increase in DA in the striatum (934). Caffeine as a potent adenosine antagonist is a CNS stimulant that easily crosses the blood-brain barrier due to its lipophilic properties (935). It has also been shown to counteract most of the inhibitory effects of adenosine on arousal (936), neuro-excitability (876,937), neurotransmitter release (938) and spontaneous activity (939). Adenosine concentrations increase in muscle and plasma during muscular contraction. Also, adenosine concentrations increase progressively in the brain during wakefulness and then decrease during sleep (936,940). Further, adenosine plays an important role in regulation of blood flow and as an inhibitory modulator of neuronal excitability and synaptic transmission of the brain via activation of adenosine receptors (941). It inhibits the release of most brain excitatory neurotransmitters (876,938), especially DA (942). These inhibitions are associated with reduced arousal, increased sleep (936) and suppression of spontaneous behavioural activity (939,943).

A caffeine withdrawal syndrome is well described. Withdrawal symptoms include headache and fatigue. Anxiety, impaired psychomotor performance, nausea and vomiting or an intense desire for coffee occurs less commonly (944).

8.1.1. Effects of caffeine on behaviour

Caffeine is well known to cause nervousness, restlessness, anxiety and insomnia. The effects of caffeine on children's behaviour have been of interest for several years (945-947). In boys with a mean age of 10.6 years 10 mg/kg of caffeine resulted in increased vigilance (sustained attention), motor activity and ratings of fidgetiness (945). Further, caffeine intake at concentration of 10 mg/kg in 7- to 12-year-old children increased motor activity and sustained attention (948). Caffeine has only small and inconsistent effects on the behaviour of young children (949).

8.1.2. Effects of caffeine on Anxiety

A disorder known as "caffeinism" was first described in 1974. Caffeinism is currently listed in the Diagnostic and Statistical Manual of Mental Disorders (950,951). It refers to a constellation of symptoms associated with very high caffeine intake that are virtually indistinguishable from severe chronic anxiety (951). Caffeinism is usually associated with daily intakes of between 1000 and 1500 mg caffeine. A study based on case reports suggested that symptoms of "caffeinism" can be indistinguishable from anxiety neurosis (952). A double blind placebo crossover study of 19 pre-pubertal and 20 college-age boys showed no significant

differences on self-reported anxiety symptoms after administration of caffeine (953). Also, caffeine ingestion potentiates the slowed reaction time induced by alcohol consumption, so coffee is not an "antidote" for intoxication (914,954-958).

8.1.3. Effects of caffeine on Sleep

Caffeine has substantial effects on sleep. Ingesting caffeine 30 to 60 minutes before sleep will increase sleep latency, decrease total sleep time and substantially worsen subjective estimations of sleep quality. There are large variations in sensitivity to sleep disturbance, with the effects being greater in persons who do not drink caffeinated beverages regularly (959). Several studies have shown that blood flow is decreased by caffeine-induced cerebro-vascular vasoconstriction (960,961).

8.1.4. Effects of caffeine on cognitive performance

The effects of caffeine on psychomotor and cognitive performance have been investigated in different studies. Also, caffeine alters hand steadiness, reaction times and tapping rate (962). It is more likely that caffeine acts by facilitating the sensory input and motor output rather than the central processing functions (963). Also, minimal abstinence duration of 1 hour affects mental performance and a low dose of caffeine after this brief abstinence gives improvements in attention, problem solving and delayed recall compared to the control condition (964).

8.1.5. Effects of caffeine on Anxiety

Human studies indicate that caffeine reduces self-rated depression when administered in moderate doses (965). Individuals who choose a high dose of caffeine reported positive mood changes whereas non-choosers reported anxiety and dysphoria (966). Caffeine reduces fatigue but also lead to increased tension and nervousness (967). Further, caffeine intake either 3 or 6 mg/kg increased anxiety (968,969).

8.1.6. Effects of caffeine withdrawal

Data indicated that caffeine withdrawal was associated with feelings of fatigue and decreased feelings of alertness (970). Indeed, about 10% of volunteers with a moderate daily caffeine intake (235 mg per day) reported increased depression and anxiety when caffeine was withdrawn (971). Also, the withdrawal symptoms include anxiety, apathy, decreased motor behaviour, headaches, increased heart rate, increased muscle tension, weakness and weariness and occasionally tremor,

nausea, vomiting and flu-like feelings (929,970-975). Withdrawal symptoms generally begin about 12 to 24 h after sudden cessation of caffeine consumption and reach its peak after 20 to 48 h. However, in some individuals, these symptoms can appear within only 3 to 6 h and can last for 1 week (962,973,976,977).

8.1.7. Effects of caffeine tolerance

In humans and experimental animals it is known that tolerance develops to some, but not to all effects of caffeine (978,979). Following long-term caffeine consumption the number of adenosine A1 receptors is increased (980). A change in adenosine A1 receptors occurs when animals are fed or injected with higher doses of caffeine that are still able to produce tolerance (981,982). This effect appears to be due to the blockade of a down-regulation induced by the endogenous agonist adenosine (983).

8.1.8. Effects of caffeine abuse

The effective dosage of caffeine, without apparent adverse effects, ranges from 3 to 9 mg/kg. At this dose, caffeine can increase exercise time to fatigue by 20-50% in humans during intensive running and cycling (984-990). The lethal dose for caffeine has been estimated to be in the range of 10 g (991), which would correspond to about 100 strong coffees. In case of providing adequate emergency measures patients appear to survive levels up to 1mM or even slightly above, but still higher levels are fatal (992).

8.1.9. Effects of caffeine on mood

There is ample evidence that lower doses (20-200 mg) of caffeine are reliably associated with "positive" subjective effects i.e. feel energetic, imaginative, efficient, self-confident and alert (972,975,993). Schoolchildren consuming more than 50 mg of caffeine per day, mainly from soft drinks, report higher wakefulness than a control group consuming less than 10 mg per day (994).

8.1.10. Effects of caffeine on anxiety

There are well-documented effects of caffeine on anxiety in humans (995). Outpatients undergoing treatment for psychiatric disorders who consumed more than 1000 mg of caffeine per day had symptoms of generalized anxiety (618). In human studies the administration of high doses of caffeine leads to a clear increase in measures of anxiety (966). Patients who report being anxious in response to

caffeine had higher pre-study anxiety scores (996). Interestingly subjects with high anxiety scores tended to have a lower caffeine intake (996,997). There are reports that high caffeine intake can exacerbate the symptoms of schizophrenia (998). Also, among psychiatric patients, caffeine consumption is highest among patient's diagnosed schizophrenics and lowest among depressed patients and those with anxiety disorders (997). The anxiogenic effects of caffeine are related not only to the dose of caffeine but also to its plasma levels (999).

8.1.11. Effects of caffeine on information processing

There is a complex interaction between the effects of caffeine on performance and parameters such as personality and time of day (1000). In a vigilance test where caffeine significantly improved performance, caffeine caused neither increasing nor decreasing changes on the mood that occur after such stressful tasks (1001). Also, increases in caffeine consumption over an already high normal level (400-1000 mg/day) did not impair performance even in a complex setting (1002).

8.5. Importance of Coffee

Coffee was first discovered around 850 AD by Khaldi in Abyssinia (Upper Egypt). The coffee bean is a seed. The seeds are hulled and dried from berries of coffee tree blossoms. The best coffees are picked just as the berries ripen. The outer skin is immediately scraped loose, exposing the bean. There are hundreds of coffee species. Instant coffee differs chemically from regular coffee. The "instantiation" process conserves about 48% of the solids from the original bean. This is much higher than the 24% solid component conserved by household coffee brewing techniques. In most instances, coffee is decaffeinated by removing the caffeine from the beans before roasting. Hundreds of chemicals have been identified in coffee (1003). Chemical substances in coffee include chlorogenic acid, reducing sugars, other carbohydrates, peptides and potassium. Chlorogenic acid is present in even greater quantities than caffeine (914,1004).

There are substances in coffee which binds to the opiate receptor. Animal studies indicated that this compounds compete with tritiated naloxone for binding to opiate receptors in rat brain and has been characterized as one of several isomeric (iso)feruloylquinic lactone compounds present in coffee (954). Also, a cup of instant coffee contains effectively a third of an ampule of naloxone. Recent data have shown that the regular consumption of 6 to 11 cups of coffee per day may produce persistent small elevations in NE levels and FFA release after caffeine metabolism is saturated (956). Coffee consumption seems to correlate with diagnosis of depression and with various measures of stress and anxiety (1005).

8.6. Importance of Lactalbumin

Lactalbumin is the albumin which is contained in milk and obtained from whey. It has been found in the milk of many mammals. There are α - and β -lactalbumin in milk. A human study with twenty-three recovered depressed patients and 20 healthy matched controls without a history of depression indicate that α -lactalbumin had no effect on mood, but improved abstract visual memory and impaired simple motor performance. These effects were independent of history of depression (1006).

8.7. Fish

There is a significant negative correlation between worldwide fish consumption and the prevalence of depression (135). Data indicated that frequent fish consumption in the general population is associated with a decreased risk of depression and suicidal ideation (136). A recent cross-sectional study conducted in New Zealand found that fish consumption is significantly associated with higher self-reported mental health status (137). In contrast there are negative correlation between total seafood (including shellfish) consumption and the prevalence of postpartum depression in 22 countries. Also higher concentrations of DHA in mother's milk and greater seafood consumption both predicted lower prevalence of post-partum depression (142). Fish provide varying amounts of omega-3 PUFAs in the form of DHA and EPA.

The brain contains a high concentration of PUFA (approximately 20% of dry weight). In the nervous system one out of every three FAs belong to the PUFA group (88,93). Beneficial effects of omega-3 PUFAs have been linked to AD (126), anxiety (1007), autism (1008), attention deficit hyperactivity disorder (1009), bipolar disorder (128), hostility (1010) and schizophrenia (1011).

9. Feeding behaviour

9.1. Caloric Restriction

The ability of caloric restriction (CR) during adult life to lengthen life span has been observed consistently in many different species of mammals (880). In a study with rhesus monkeys CR (30% reduction in calories) improved the health of the monkeys and their life span increased compared with the monkeys on the control diet (1012). In contrast overeating promotes diseases in multiple organ systems that usually shorten life.




FIG. 14. Positive effects of low caloric intake.

9.2. Meal Frequency

There are data which indicate that reduced meal frequency can increase the resistance of organisms to various types of stress. For example, intermittent fasting increased the resistance of rats to cold stress and resulted in changes in collagen

and bone consistent with an anti-ageing effect (1013). Timing of meal can influence the effects of meals on cognitive behaviour. The effects of an evening meal on cognitive performance and mood indicated that subjects had stronger feeling and were more proficient and interested 1-3 h after meal consumption than subjects who did not consume the meal (1014). Additionally, 90 minutes after intake of the meal, the subjects completed more sentences on a logical-reasoning task than those who had not eaten. Early Studies indicate that stunted and previously malnourished 9- and 10-year-old Jamaicans performed less well on tests of short-term memory and problem-solving ability when they had not eaten breakfast than when they had eaten a morning meal (1015). Also undernourished children's performance on a test of verbal fluency was significantly better when they had consumed a school breakfast than when they had not (1016). Experimental evidence suggests that omitting breakfast negatively affects cognitive functioning (1017). Further, afternoon snacks may also have positive effects on cognitive performance (1018).

9.3. Meal Size

In a study investigating the effects of meal size on attention and mood subjects, who ate a larger than usual lunch, made more errors on attention and search tasks than those who ate a normal-sized lunch or one smaller than usual (1019). Also, there was not any difference in mood as a function of meal size. In other study young men made significantly more errors on a letter-cancellation project after eating a large lunch, but tended to make less error after small lunch. Further the performance improved to a greater degree after the small lunch in subjects who typically ate a heavy lunch than in those who ate a light lunch (1020).

9.4. Meal composition

There is strong suggestion that the proportion of the main dietary components can modulate longevity (1021). For instance, restriction of protein intake significantly increased mean and maximum longevity in different rat strains (1022-1024). Further, when animals were fed a diet restricted in the essential amino acid Met, mean and maximum life spans were enhanced as well (1025). More recently, protein restriction without strong caloric restriction has similar effects on the mitochondrial free radical generation rate and mitochondrial DNA oxidative damage in rat liver as the reduction of the total intake of calories (1026).

9.5. Appetite

Appetitive behaviour is complex and multifaceted. There is much evidence from animal studies that HPA axis function can profoundly influence expression of appetite and regulation of body weight (6). The stress-sensitive adrenal steroids

modulate neurotransmitters which affect appetite, such as B-noradrenergic systems, NPY and galanin (42). Stress reactivity, both physiological and psychological, may distinguish overeaters from under eaters (616). The recently discovered new gut peptide, ghrelin, an endogenous ligand for the growth hormone secretagogue receptor (1027), seems to be involved in the control of food intake and energy balance. In fact, centrally injected ghrelin produces a sustained food intake in rodents and ghrelin blood concentrations and mRNA expression in the stomach are increased by fasting and decreased by feeding (717). Recent data have suggested a possible stimulatory effect of ghrelin on the HPA axis activity in experimental animals (1028). In humans ghrelin has a positive effect on glucose levels and negative effects on insulin concentrations (1029). Interestingly ghrelin concentrations are decreased in human obesity (1030).

9.6. Behavioural Decrements

Substantial research indicates that factors such as oxidative stress (1031) and inflammation (1032,1033) may be major contributors to the behavioural decrements seen in ageing. The occurrence of numerous neuronal and behavioural deficits during normal ageing may include decrements in calcium homeostasis (1034) and in the sensitivity of several receptor systems, most notably the dopaminergic (1035,1036), muscarinic (1037,1038), opioid (1039) and adrenergic (1040) receptor systems. These losses in neuronal function may be expressed ultimately as alterations in both cognitive (1041) and motor (1042) behaviours. Alterations in memory appear to occur primarily in secondary memory systems and are reflected in the storage of newly acquired information (1043).

9.7. Ageing and oxidative stress

Different treatments (e.g. heavy-particle irradiation, chemotherapy) that increase oxidative and/or inflammatory stressors may produce behavioural deficits that parallel those seen in ageing (1044-1046). One of the most important factors mediating the deleterious effects of ageing on behaviour and neuronal function is oxidative stress (1047). It has been shown that, not only the CNS particularly is vulnerable to oxidative stress, but also this vulnerability increases during ageing (1048,1049). Age-related changes in the neuronal plasma membrane molecular structure and physical properties (e.g. increased rigidity) may play a role in increasing vulnerability to oxidative stress and inflammation (1048,1050).

9.8. Plant Foods

Antioxidants have been studied for their effectiveness in reducing the deleterious effects of brain ageing and behaviour in many studies (1051-1053). The combinations of antioxidant/anti-inflammatory polyphenolic compounds found in

fruits and vegetables may show efficacy in ageing (1054). Plants, including food plants (fruits and vegetables), synthesize a vast array of secondary chemical compounds that, although not involved in primary metabolism, are important for a variety of ecologic functions that enhance the plant's ability to survive. Interestingly, these compounds may be responsible for the multitude of beneficial effects that have been reported for fruits and vegetables, with an array of health-related bioactivities (1054). In animal studies long-term feeding of rats with diets supplemented with strawberry or spinach extract (1–2% of the diet) or vitamin E (500 IU) retarded age-related decrements in cognitive and neuronal function compared to an AIN-93 diet alone (1054). Also, the supplemented diets could prevent the onset of age-related deficits in several indices (e.g. cognitive behaviour, and Morris water maze performance) (496).

Phytochemicals can selectively regulate multiple signalling pathways at the level of transcription especially signals involving mitogen-activated protein kinase (1055). In this regard there was significant increase in several indices of neuronal signalling (e.g. muscarinic receptor sensitivity) (1056).

10. Oxidation

The high demand for molecular oxygen, the high levels of PUFAs in neural membrane phospholipids and the high iron contents in the brain are important factors rendering cells in the CNS to oxidative stress. Oxidative stress is an important underlying factor for a number of neurodegenerative diseases (1057). Dietary antioxidants are known to influence the antioxidant defence system and dietary antioxidants can influence omega-3 status. Omega-3 PUFAs have been shown to decrease lipid peroxidation in vivo (1058). A diet devoid of antioxidants lowered essential FA levels in the plasma of trained athletes, even though the amount and types of fats were not altered (1059). A recent human study found that depressive symptoms are independently correlated with lipid peroxidation (1058). Patients with obsessive compulsive disorder (OCD) and co-morbid depression have higher levels of lipid peroxidation than those with OCD alone (1060). Animal studies indicated that antioxidant supplementation can prevent the negative influence of saturated fat on BDNF levels and cognitive function (1061).

10.1. Nitric oxide

Nitric oxide (NO) is a free radical that is constantly produced/released throughout the body by diverse tissues, i.e. endothelium (1062,1063). NO is involved in the stress physiology and apparently also takes part in stress-related disease processes (1063-1066). NO seems to be capable of principally exerting either beneficial/ameliorating or deleterious effects (1062,1063,1067-1069). The actual distinction depends on a multitude of factors, such as duration of (an enhanced) NO release, amount of produced NO and type of synthesis of NO molecules (1062-1067). Additionally, NO inhibits the release of other monoamine transmitter molecules, e.g. DA (1070) and here, auto-regulatory pathways that involve different signalling molecules (like opiates, and endocannabinoids) are implicated (1064,1067,1070). NO is produced via two different mechanisms. Immediate release of NO is of constitutive nitric oxide synthase (cNOS) origin (1062). Thereby, cNOS is a calcium-dependent enzyme that is constitutively and permanently expressed, in endothelial (eNOS), neuronal (nNOS) and immune cells and produces NO at a low levels. This 'basal' NO can be increased for a short time via additional cNOS stimulation in response to certain signals (1067). Hence, cNOS-derived NO release is part of acute response mechanisms that occur in many biological states (1062-1065,1067,1071). In contrast, the inducible nitric oxide synthase (iNOS) is a calcium-independent enzyme that is prevalent in many tissues, yet only expressed 'on demand' in specific situations, and under the influence of various signalling molecules, i.e. pro-inflammatory cytokines (1067). Following its induction, iNOS

produces NO at higher levels after a latency period and this NO release lasts for an extended period of time, i.e. days (1067).

11. Antioxidant

Oxidative stress is one of the most important factors mediating the deleterious effects of ageing on behaviour and neuronal function (1047). The CNS appears to be especially vulnerable to the effects of oxidative stress, partially as a result of additional factors such as increases in the ratio of oxidized glutathione to total glutathione (1072), significant lipofuscin accumulation (1073) with bcl-2 increases (1074), increases in the membrane lipid peroxidation (1075), reductions in the glutamine synthetase (1076), reductions in redox-active iron (1073, 1077) and alterations in membrane lipids (1078).

Most dietary agents used to alter behavioural and neuronal effects with ageing included nutritional supplements such as vitamins C and E, garlic (1051) and herbal supplements (e.g. ginseng and Ginkgo biloba) (1052). Long-term (from 6 to 15 months of age) feeding of F344 rats with an AIN-93 diet supplemented with strawberry or spinach extract (1–2% of the diet) or vitamin E (500 IU) retarded age-related decrements in cognitive and neuronal function compared to an AIN-93 diet alone. Results indicated that the supplemented diets could prevent the onset of age-related deficits in several indices (e.g. cognitive behaviour and Morris water maze performance) (496).

There are tens of thousands of natural and synthetic compounds that possess antioxidant activity and a rapidly growing number of these agents have been reported to have beneficial effects in one or more experimental models of age-related disorders. These include vitamin E, coenzyme Q10, lipoic acid, creatine and Ginkgo biloba extract.

11.1. Vitamin E

Vitamin E (tocopherol) is a lipid-soluble antioxidant that is very effective in suppressing membrane lipid peroxidation. Chronic treatment of rodents with vitamin E can preserve learning and memory function, which otherwise declines during ageing (1079). Treatment of rat hippocampal slices with vitamin E enhanced long-term potentiation of synaptic transmission, a cellular correlate of learning and memory (1080). Clinical trials of vitamin E in AD patients have yielded positive results with patients receiving this antioxidant exhibiting a slowing of disease progression compared with those receiving placebo (1081). As evidence, vitamin E can protect cultured neurons and synaptosomes against dysfunction and death (1082,1083) and can protect against amyloid-induced learning and memory deficits in adult rats (1084). Vitamin E has also been reported

to be effective in animal and cell culture models of PD (1085), although clinical benefit in human patients has not yet been established.

11.2. Coenzyme Q10

Coenzyme Q10 (ubiquinone) is associated with the mitochondrial oxidative phosphorylation enzyme complexes where it serves an antioxidant function. Administration of ubiquinone to rodents can enhance learning and memory (1086). Ubiquinone protected cultured neural cells against insults relevant to the pathogenesis of AD (1087). Dietary supplementation with ubiquinone resulted in increased resistance of midbrain dopaminergic neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced damage in a mouse model of PD (1088).

11.3. Creatine

Creatine increases phosphocreatine levels in muscle and brain cells and may thereby improve cellular energetics and reduce oxy-radical production (1089). Creatine is now widely employed as a dietary supplement by athletes to improve their performance (1090). The possibility that creatine may protect against neurodegenerative conditions has been tested in several animal models. Dietary supplementation with creatine protected dopaminergic neurons against MPTP toxicity in mice (1091) and increased the survival of Purkinje cells in a transgenic mouse model of spinocerebellar ataxia type 1 (1092).

11.4. Ginkgo biloba

The public has recently been barraged with advertisements touting the health benefits of Ginkgo biloba with a particular emphasis on its benefits for the brain (1093). Ginkgo biloba extract enhanced performance of aged mice in a learning and memory task (1094). In a rat model of severe diabetes, Ginkgo biloba was effective in improving learning and memory performance (1095). Ginkgo biloba supplementation in a double-blind and placebo-controlled trial was effective in improving cognitive function in healthy middle-aged subjects (1096). However, other trials of Ginkgo extracts on memory performance in normal adults (1097) and elderly patients with mild cognitive impairment (1098) have not revealed a significant effect of this dietary supplement (1097). Ginkgo extracts reduced damage to dopaminergic neurons caused by MPTP in a mouse model of PD (1099).

11.5. N-acetylcysteine

N-acetylcysteine has proven effective in reducing age-related deficits in learning and memory (1100). Encouraging beneficial effects of N-acetylcysteine supplementation were recently reported in a clinical trial in patients with probable

AD (1101), suggesting that this antioxidant may soon be used as a dietary supplement for patients in the early stages of neurodegenerative disorders.

12. Neurogenesis

The process by which neurons are created is neurogenesis. It is responsible for populating the growing brain. Neurogenesis have been linked to the beneficial actions of certain antidepressant, suggesting a connection between decreased hippocampal neurogenesis and depression (1102,1103).

12.1. Effect of PUFA on neurogenesis

A few weeks of dietary manipulation of LC-PUFA (long chain PUFA) content can increase the numbers of new neurons born in the lobster brain (1104). Specifically, the correlation between levels of neurogenesis and the ratio of omega-3:omega-6 PUFA and α -linolenic acid levels, suggests that one of these two dietary factors is responsible for the increase in neurogenesis (1104). The ratio of omega-3:omega-6 PUFAs is potentially important because undesirable ratios can inhibit the conversion of α -linolenic acid to DHA and EPA (1105). Increased neurogenesis is a result of a favourable omega-3:omega-6 ratio, likely caused by the increase of α -linolenic acid in the enriched *Artemia* diets. The increases in neuronal proliferation seen with LC-PUFA enrichment imply that the nervous system benefits from this nutritional enhancement (1104).

Omega-3 PUFAs have the potential to influence neurogenesis through at least two distinct mechanisms. First, omega-3 PUFAs are incorporated into neuronal membranes, where they influence the quaternary structure of membrane proteins, some of which act as transporters and receptors (93). They also can alter membrane fluidity (96), which is important for neurotransmitter binding as well as signalling within cells.

Omega-3 PUFAs also influence levels of neurotrophins, molecules that promote neuronal survival and growth. Among the neurotrophins, BDNF levels are altered by dietary intake of omega-3 PUFAs (1106) and BDNF is associated with alterations in neurogenesis and neuronal survival (1107).

12.2. Effects of neurotrophins on neurogenesis

Although the specific effects of cytokines and neurotrophins on neurogenesis, cell fate and survival are still being clarified, the association between omega-3 PUFAs and the regulation these classes of molecules is no longer debatable. These connections between the omega-3 PUFAs, cytokines, neurotrophins and neurogenesis are also intriguing from the clinical perspective. Cytokines appear to play a potentially critical role in depressive illness (1108). Stress can cause an

elevation in cytokines and selective serotonin reuptake inhibitors reduce cytokine levels.

Oxidative stress and inflammation are thought to be major factors in brain ageing and in age-related neurodegenerative disease (1031-1033,1109). Humans and animals show increased motor and cognitive declines with ageing (1110-1112) that are thought to be due to increased susceptibility to the long-term effects of oxidative stress and inflammation (1031). Deficits in brain functions due to oxidative stress may be due in part to a decline in the endogenous antioxidant defence mechanisms and to the vulnerability of the brain to the deleterious effects of oxidative damage (1075,1113).

13. Emotion

Emotional arousal has been associated with both increased or decreased food intake and weight (1114,1115). In humans the effects of variation in workload on food intake and serum lipids has been studied with a small group of female office workers (1116). The workers reported a higher energy intake and a higher percentage of energy as fat, in two high workload periods, compared with the normal work period. Higher energy intakes were reported from a study of dietary habits associated with exam time among university students (1117). The dietary data support modest increases in energy, fat and sugar intake in periods of high work stress compared with low work stress (1116,1118). Psycho-physiological response to stress influences subsequent eating behaviour (41). Self-reported increases in negative mood during the stressor were also significantly positively related to caloric consumption, whereas mood reactivity on the control day was not related to consumption that day. Cortisol reactivity and mood are as two somewhat independent indices of stress reactivity and found that both were related to eating after stress, but not after rest. It is possible that women more vulnerable to stress, in their mood responses and cortisol reactivity, may be at particular risk of stress-induced eating and weight gain (41). Behavioural factors as one of the psychobiological mechanisms can affect health (1118). Also, either prolonged or frequent work stress could result in increasing the likelihood of weight gain and increased cardiovascular risk (1118).

Individual variability in dietary responses to stress in relation to levels of dietary restraint have been identified in a number of experimental studies (613,1119-1121). Restrained eaters did not just eat more overall, they specifically ate more sweet and fatty foods in the high-work-stress session and the hyperphagic response was greater among those who had a larger increase in perceived stress between the low-and high-workload sessions, implicating emotional reactions in the response (1118).

14. Metabolic Acidosis

The modern Western-type diet in humans, which is rich in animal protein, has been implicated as a cause of lifelong mild chronic metabolic acidosis (CMA) with secondary bone catabolism caused by the induction by this diet of an obligatory daily acid load (endogenous acid production), due largely to endogenous oxidation of cationic and sulphur-containing amino acids (9). CMA is a frequent acid-base disturbance generated by extra-renal loss of base (e.g. diarrhoea), increased acid production (e.g., organic acidosis such as ketoacidosis) or impaired renal acid excretion. CMA has also been shown to cause a significant increase in corticosteroid excretion (1122,1123). In a small human study experimental induced acidosis was also associated with an increase in cortisol excretion (1124). Another similar study in humans did not show any increase in cortisol secretion, although plasma aldosterone levels significantly increased (1125). Animal and human studies suggest that metabolic acidosis stimulates an increase in cortisol production (1122-1124). Also, CMA can increase cortisol production and both acidosis and cortisol induce osteopenia. In muscle, acidosis is known to stimulate protein and essential amino acid breakdown through the ubiquitin-proteasome proteolytic pathway, a mechanism that requires GCs (1122). GCs lead to a dramatic decrease in bone mineral density, either when endogenously in excess or when administered exogenously (1126). The mechanism by which GCs decrease bone density is multifactorial. The osteopenia appears due to a complex combination of direct effects on bone formation (1127-1130) and resorption (1127,1128,1131) and indirect effects on calcium homeostasis, including decreased intestinal calcium absorption (1131). GCs decrease bone formation via suppression of osteoblast maturation and promotion of apoptosis (1130). The net osteopenia observed *in vivo* after GC treatment is probably due to a complex combination of direct effects on bone formation and resorption as well as indirect effects to inhibit intestinal calcium absorption and increase renal calcium excretion (1128,1131,1132).

A very mild Western diet-induced CMA results in a state of increased cortisol secretion and plasma concentration and provides several novel findings in humans regarding the possible causality of the Western diet in the aetiology of osteoporosis (1133). In humans CMA results in hyper-secretion of cortisol (1124). Previous studies reported a non-significant 77% increase in urinary cortisol excretion in acid-fed compared with non-acid-fed human subjects (1134). Further, plasma bicarbonate concentration decreases progressively when endogenous acid production is increased by menu changes among normal foodstuffs in normal subjects (1135). Ingestion of neutralizing alkali *per se*, as exchanged for chloride in the absence of other experimental maneuvers (e.g. concomitant potassium

supplement) can result in urinary calcium retention and suppression of biochemical markers of bone resorption (1133).




FIG. 15. Negative health effects of CMA

15. Monoamine

Monoamine neurotransmitters are neuro-modulators which are derived e.g. from aromatic amino acids by the action of decarboxylase enzymes. Dietary aromatic amino acids are Phe, Tyr and Trp. Neurotransmitters convey the information to be passed and processed through some 10¹⁴ to 10¹⁶ interconnections linking approximately 10¹⁰ to 10¹¹ neurons in the human brain. Each of the many neurotransmitters (including as yet unidentified ones) acts through a receptor, which in general will have numerous subtypes (1136).

15.1. Histamine

The precursor of histamine is the His an extremely bioactive essential amino acid which has multiple physiological functions. Histamine is synthesized in the brain by the enzymatic decarboxylation of His. Conversion of His to histamine in the hypothalamus is necessary to produce the suppressive effect of His on feeding behaviour. Also, the hypothalamic histamine neurons are an essential component in the regulation of energy intake and energy expenditure. Hypothalamic neuronal histamine suppresses food intake through H₁-receptors in the ventromedial hypothalamic nucleus and the para-ventricular nucleus (1137). As for drinking behaviour, activation of hypothalamic histamine neurons showed excitatory but not inhibitory effect on water intake (1138,1139). Further, histamine neurons are involved in the action of leptin on hypothalamic control of feeding behaviour and energy metabolism (1140,1141). Central administration of leptin increased histamine turnover in the hypothalamus (1140).

Increase in hypothalamic histamine concentration has an raising effect on the peripheral glucose concentration (1137,1142), accelerated lipolysis in the adipose tissue (1143,1144) and decreased body temperature (1137,1142). Central exogenous administration of histamine has been found to be effective in reducing body weight and adiposity in leptin resistant obese db/db mice and mice with diet-induced obesity (1145). On the other hand, the concentration and turnover rate of hypothalamic neuronal histamine are increased by neuro-glucoprivation induced by starvation, insulin and 2-deoxy-D-glucose in the brain (1146,1147), elevation of ambient temperature (1137,1142,1148) and cytokines such as IL-1 β (1149).

The hypothalamic histamine neurons are involved as targets for leptin action in the brain (1140,1141). Central administration of leptin increased histamine turnover in the hypothalamus (1140). Depletion of neuronal histamine using α -fluoromethyl-histidine attenuated the suppression of feeding induced by leptin (1140). Exogenously sustained central administration of histamine has proved effective on

reduction in food intake, body weight and adiposity even in leptin resistant db/db mice (1145). This effect could be caused by His role in zinc metabolism acting as the major zinc binding moiety in serum (229,230,231). Normally, zinc is bound to one or two of the available 16 His moieties on albumin (229,230). His administration to animals (231) or humans (232) strips zinc from its albumin binding sites initiating a Zn-His complex which produces significant tissue zinc depletion. It also causes zinc deficiency leading to functional losses of taste, smell, appetite, food intake and other neurological abnormalities (232). These effects are reversed completely by zinc administration while maintaining His intake at any given level, indicating that His induced suppression of appetite relates specifically to this mechanism of zinc depletion (232).

15.2. Serotonin

Serotonin (5-hydroxytryptamine) is a monoamine neurotransmitter which is synthesized in serotonergic neurons in the CNS and in the GIT. It is synthesized from the essential amino acid L-Trp, and the first and rate-limiting step in the biosynthesis of serotonin is the hydroxylation of L-Trp to 5-hydroxyTrp. Since the enzyme Trp-hydroxylase, catalysing the hydroxylation of L-Trp, does not seem to be saturated by L-Trp in-vivo, the rate of this reaction appears to be restricted by L-Trp availability in mammals (1150). Elevated dietary intake of L-Trp has been reported to result in increased brain levels of L-Trp and elevated rates of serotonin synthesis and metabolism (1151,1152). Serotonin is an evolutionarily conserved neurotransmitter that regulates the development and function of the mammalian brain and serves important roles in the regulation of energy metabolism in diverse organisms (1153,1154). Further, it is involved in the regulation of the HPA axis in mammals (1155,1156). An increased activity of serotonergic neurons in the brain is an established consequence of stress and a decline activity of these serotonergic neurons has been demonstrated in disturbances of mood and depressive disorders (1157). Increased brain serotonin activity appears to be a prerequisite for maintaining control over cognitive information processes (1158) and is involved in learning and memory (1159). Levels of serotonin are decreased in the brains of rats during ageing and treatment of the aged rats with the antioxidant α -lipoic acid increased serotonin levels, which suggests that serotonin depletion during ageing may result, at least in part, from oxidative stress (1160). Chronic stress may decrease brain serotonin availability and increase serotonin receptor function by the way of a compensatory mechanism (287,1161). A deficient central serotonin function has been shown in mood disorders like depression (32,1162). Accordingly, changes in serotonin receptor sensitivity are believed to mediate the effect of Trp administration or antidepressant treatment on depression (1163,1164). As serotonin function increases under acute stress, brain serotonin concentrations may be

exhausted under continuous stress exposure. As a consequence the serotonergic system of subjects prone to stress (high stress-vulnerable subjects) may become more sensitive to dietary-induced alterations in L-Trp availability, because of compensatory receptor sensitization (287,1161). Depletion of the precursor of serotonin synthesis, Trp, has been found to increase depressive mood in healthy subjects and subjects with a prior history of depressions (1164).

Brain levels of L-Trp is not only depend on plasma levels of L-Trp, but also on plasma levels of other LNAA (i.e. Tyr, Phe, Leu, Ile and Val) competing for the same carrier (1150,1151). A carbohydrate-rich, protein-poor diet increases the ratio of plasma Trp to the sum of the other LNAAs, giving Trp an advantage in the competition for access into the brain (25,51,291,1165). A carbohydrate-rich, protein-poor food diminished the depressive mood and cortisol response to controllable as well as uncontrollable laboratory-induced stress in highly stress-prone human subjects (1166). Acute stress elevates brain L-Trp concentrations (1167), an effect that appears to be mediated by a stress-induced elevation of sympathetic activity and circulating plasma catecholamines (1168). An activation of the sympathetic system stimulates lipolysis, resulting in elevated plasma levels of non-esterified FAs, competing with L-Trp for binding to albumin and thus elevating the plasma pool of free L-Trp available for uptake into the brain (1155). Sympathetic activation may also increase brain L-Trp uptake by affecting the permeability of the blood–brain barrier (1155).

15.2.1. Serotonin and Cortisol

In several studies the ratio of 5-hydroxyindoleacetic acid (the major serotonin metabolite) to serotonin brain concentrations has been found to correlate with plasma levels of cortisol, suggesting that the action of brain serotonin on the HPA axis is stimulatory (1169,1170). The administration of serotonin precursors is usually found to stimulate cortisol secretion (32). Stress adaptation is associated with a reduction in cortisol concentration and depression (286,1171).

15.3. Dopamine

DA is a neurotransmitter occurring in a wide variety of animals, which is biosynthesized from the amino acid L-Tyr. Further, it can be processed into NE. Tyr administration elevate DA production in the CNS of patients with PD the cause of which is thought to involve a loss of DA neurons and which is typically treated by administering the immediate DA precursor, L-dopa (327).

16. Exercise

Regular physical exercise benefits the nervous system, as well as the musculoskeletal and cardiovascular system. The beneficial role of exercise is evident in many neurodegenerative disorders (1172). In humans exercise may improve mood and cognition (1173) and data suggest that regular exercise can also promote maintenance of cognitive function during ageing (1174). Studies of elderly populations suggest that regular exercise can also promote maintenance of cognitive function during ageing (1175,1176). Other studies have shown that regular exercise in elderly men is particularly effective in improving cognitive performance on tasks that require visuo-spatial processing (1177). Fourteen-month-old rats that exercised regularly (swimming 1 h/day, 5 days/wk for 9 wk) exhibited improved performance in a learning and memory task and reduced levels of membrane lipid peroxidation and oxidative damage to DNA (1178). Exercise results in an increase in the level of BDNF in the hippocampus in rats (1179). The increased levels of BDNF likely play an important role in increased dendritic complexity and improved function in animals maintained in complex environments because BDNF over-expression is sufficient to increase dendritic complexity (1180) and a BDNF-blocking antibody impairs learning and memory (1181). Intravenous administration of IGF-1-blocking antibody abolished the neuroprotective effect of exercise (1182). Research has also provided evidence that circulating IGF-1 plays an important role in the stimulation of hippocampal neurogenesis by physical exercise (1183).

When rats or mice are housed in complex environments or exercised on a regular basis, there are increases in the complexity of dendrites in cortical neurons and increased numbers of synapses (1184,1185). Somato-sensory deprivation reduces dendritic complexity in the neocortex of monkeys (1186) and psychosocial stress and other models of depression result in reduced neuritic and synaptic complexity (1187). Environmental enrichment can also enhance recovery and regeneration of damaged neural circuits. For example, enriched rehabilitative therapy enhances dendritic growth and function recovery after focal ischemic brain injury (1188). Epidemiological studies show that regular vigorous physical activity can reduce risk for ischemic stroke (1189). For example, exercise after brain injury improved functional outcome in rats and the improved outcome was associated with enhanced structural plasticity in the motor cortex (1190).

In response to stressor the autonomic nervous system and HPA axis are known to react and participate in the maintenance of homeostasis and the development of physical fitness. This includes elevation of cortisol and catecholamines in plasma.

However, physical conditioning is associated with a reduction in pituitary-adrenal activation in response to exercise (1191). Excessive and prolonged stress (as in heavy exercise) can lead to depression, mild, and irregular (non-linearly applied, hormetic) stress can actually improve depression (1192). The deleterious behavioural effects of stress were less pronounced in the "exercised and stressed" animals and the beneficial effects became more pronounced with time (more prolonged exercise), as indicated by the results of the behavioural tests (1193-1195). The beneficial effects of regular exercise are partly based on the reactive oxygen species (ROS) generating capacity of exercise, which is in the stimulation range of ROS production (1196). Therefore, exercise-induced ROS production plays a role in the induction of antioxidants, DNA repair and protein degrading enzymes, resulting in decreases in the incidence of oxidative stress-related diseases (1196).

Exercise intensity impacts the affective response during and after exercise, with higher intensity exercise being associated with more negative affect during exercise (1197). Exercise can also influence other brain parameters such as blood flow, antioxidant activities, neuronal apoptosis, receptor sensitization, glutamate secretion and many other unknown factors, which in various combinations can have some effect on depression (1192). Concomitant diet regulation and exercise were shown to reduce muscle sympathetic nerve activity during mental stress (1198).

17. BDNF gene

The BDNF gene is one prominent target of dietary restriction and physical and mental exercise that appears to mediate many of the beneficial effects of these dietary and behavioural stimuli (1199). There is a reciprocal relationship between BDNF and serotonergic signalling, in which BDNF enhances serotonin production and release (1200,1201) and serotonergic signalling stimulates BDNF production (1202). Serotonin can activate receptors coupled to cAMP production and cAMP can induce BDNF expression by a cAMP response element-binding protein mediated mechanism (1202). Collectively, the emerging data suggest that activation of BDNF and serotonergic pathways may provide protection against a variety of neurodegenerative conditions and possibly disorders linked to overeating and obesity, including type 2 diabetes and cardiovascular disease (1203-1206).

Recent studies have shown that BDNF is a very important neurotrophic factor that plays roles in feeding, learning, memory, locomotion, stress responses and affective behaviours (1207). BDNF promotes neuronal differentiation and survival synapto-genesis and synaptic plasticity (152,1208,1209). BDNF may serve in adaptive responses of mammals to a variety of environmental stimuli because BDNF expression in the hippocampus increases in response to cognitive stimulation and EODF (every-other-day fasting), but decreases under conditions of chronic uncontrollable stress (1210,1211). Decreased BDNF levels occur in several neurodegenerative disorders including AD, PD and Huntington's diseases (1212-1214). BDNF suppresses feeding and improves glucose metabolism, as demonstrated in studies of BDNF+/- mice (1204,1215). When BDNF+/- mice are maintained on an EODF diet, levels of BDNF increase in their brains and blood glucose levels and body weights are normalized (1204). The increased level of BDNF in the brain with regular exercise and intermittent fasting may be important in the improved glucose regulation because intra-cerebroventricular infusion of BDNF can increase peripheral insulin sensitivity in normal rodents (1216) and ameliorates diabetes in mice (1217). Moreover, mice in which BDNF was eliminated from the brain after birth were hypersensitive to stress, had elevated plasma glucose and insulin levels and were obese (1218). Thus, EODF and exercise enhance BDNF signalling, which, in turn, may stimulate signalling pathways that improve glucose metabolism and increase cellular stress resistance, thereby protecting against several different diseases.

18. Stress

Stress describes the effects of psychosocial and environmental factors on physical or mental well-being (1219-1221). Also, stress refers to the mental or physical conditions resulting from various disturbing physical, emotional or chemical factors. Stress implies a stimulus that requires behavioural, psychological and physiological changes to be successfully met and a state of hyper-arousal for the initiation of necessary counteracting reactions (1222-1224). The effects of the stressors on the body constitute the "stress response", which may be measured by behavioural, biochemical and genetic modifications. Organism has different factors that play a major role in the allostatic stress response:

- The HPA axis (cortisol),
- The sympatho-adrenal medullary system (NE/epinephrine) (1225-1228) and
- The connection of nitric oxide (1062-1066), melatonin (1229) and anandamide (1064).

The key hormonal pathway that governs the endocrine response to stress is the HPA axis. Elevation of serum corticosterone, the endpoint of stress-induced activation of the HPA system, is frequently used as a stress indicator and a convincing number of studies have found several measures indicative of a hyperactive HPA axis in depressed patients (1230). Cortisol secretion as a response to perceived stress is a powerful factor regulating disease-generating events in the periphery. This seems to be particularly the case when the HPA axis functions with low reactivity and poor feedback control (1063). Most studies have observed that chronic stress over-activates the HPA axis and fuels insulin release, in turn activating abdominal fat storage (1065). Insulin resistance might be followed by both dyslipidemia and elevated blood pressure (1066). In contrast to the tendency of chronic stress to elevate baseline cortisol, it appears to decrease testosterone, both in animals and humans (1231,1232). While psychological stress seems to increase oxidative stress (1233), it decreases DNA repair (1232) and inhibits radiation-induced apoptosis (1234) in human blood cells. This may mean that oxidative damage may persist during psychological stress and may increase the likelihood of a pathological development (1233).

Exaggerated cortisol responses to stress have been observed in women with AN (1234), BN (617) and obesity (620). Eating is thought to be suppressed during stress, due to anorectic effects of CRH and increased during recovery from stress, due to appetite stimulating effects of residual cortisol (41,1235). Cortisol secretion is a major component of the stress response (617) and it has been implicated as a

potential mediator for increased energy intake in healthy males (603) and females (41).

18.1. Effect of stress on food choice

The chronic mild stress in rats decreased sucrose intake per unit body weight, while sucrose intake in a non-stressed control group did not change (1236). There was not any correlation between body weight and sucrose intake. Interestingly the reduction of sucrose intake did not affect body weight. The largest effect was obtained after 2 weeks of the stress protocol, this effect was attenuated afterwards (1236). Overeating has been observed in rats following a stress and a period of caloric restriction (1237) only in those given highly palatable food (1238). In humans dieters are more likely to report stress hyperphagia compared to non-dieters who are more likely to report stress hypophagia (1239). In humans overeating of 'comfort foods' may be stimulated by cortisol in response to stress, which can result in abdominal obesity (612). Stress has been implicated as a primary trigger of overeating (614). Also, the repeated acute stress induces a chronic change in weight independent of stress-induced hypophagia and may represent a change in homeostasis initiated by repeated acute activation of the central CRF system (1240). Delay in gastrointestinal transit time (an indirect measure of gastric emptying and intestinal motility) has been observed in lean participants, but not in the obese, after exposure to both active and passive coping tasks (1241).

Prospective (1116,1118,1242) and self-reported retrospective data (24,1243) suggest that food choice does change under stress, with a tendency toward a relative increase in sugary and fatty (often snack-type) foods. There is a gender difference by food choice after stress. While men and unrestrained eaters show either little difference or a reduction in food intake under stress (40,1244), women and restrained eaters consume more calories and fat under stress (1116,1118) and shift their food choices away from meal-type foods, such as meat and vegetables, toward snack-type foods (1239). Also, stress did increase intake of sweet fatty foods in emotional eaters. In addition, women scored more highly on emotional eating than men (24). These gender differences may have reflected differences in dietary restraint, which is higher in women (1245-1247). There is evidence that snack consumption may be more susceptible to stress than meals (1239,1248). An alternative neuro-hormonal mechanism for stress-induced preferential selection of sweet fatty foods is suggested by evidence that such highly palatable foods can themselves relieve stress through release of endogenous opiates (1249,1250).

18.2. Effects of stress on female reproduction

Secretion of the gonadotrophin hormones LH and FSH from the anterior pituitary is under the control of GnRH (Gonadotropin releasing hormone). These two gonadotrophin hormones (LH and FSH) play a primary role in the regulation of peripheral reproductive tissue function. Stress induces adrenal stimulation and delays or even inhibits the pre-ovulatory GnRH-LH surge. Pulsatile activity is an essential intrinsic property of hypothalamic GnRH neurons and the intricate balance between GnRH synthesis and release is important to ensure that GnRH neurons are in a state of constant readiness to respond to changes in the environment (1251). Also, the pulsatile nature of GnRH secretion is essential for the physiological maintenance of normal gonadotrope function and ultimately for normal reproductive capacity (1252). Slow GnRH pulse input preferentially increases FSH secretion while fast frequency pulses, e.g. hourly, favour LH secretion (1253). It has been shown that circulating insulin can directly regulate GnRH and subsequently LH secretion (1254,1255). Central administration of insulin, as well, has also been shown to directly stimulate GnRH neurons, resulting in LH pulsatile release (1256,1257).

The metabolic status of an animal, dependent on its access to food, controls multiple diverse physiological factors in both males and females (1258). The connectivity between food intake and reproduction is especially evident in the female, where pregnancy and lactation are linked to the considerable energetic drain needed for the nurture of embryos and newborns (1259). One of the most profound alterations that take place with these dietary regimes is disruption of the complex neuroendocrine feedback axes centred the anterior pituitary. Reduced energy intake typically suppresses the reproductive axis and activates the HPA axis and/or somatotrophic axes (1260,1261). The maternal adaptations described above, with the significant attenuation of hormonal stress responses in pregnancy and lactation, are important for the healthy prenatal development of the offspring by preventing excessive levels of circulating GCs (1262-1265). For example, it has recently been demonstrated that lactating dams, whose mothers were exposed to stressful stimuli during pregnancy, do not display the normal adaptations observed in pregnancy (1266). In more detail, these dams had elevated CRF and vasopressin mRNA expression within the PVN suggesting a dys-regulation of the stress circuitries, which in turn leads to the elevated HPA axis reactivity found in these rats (1266). Animal and human studies in late pregnancy and lactation showed profound physiological adaptations of neuroendocrine and behavioural stress responses occurring at various brain levels. The adaptations ensure the

healthy development of the offspring by preventing excess prenatal GC exposure and appropriate maternal care in the postpartum period (1267).

18.3. Effects of stress on prenatal life

Animal studies together with retrospective studies in the human have shown that prenatal maternal stress is associated with reduced growth in uterus and can lead to an increased risk for a number of pathologies, including impaired behavioural/emotional development and depression (1268,1269). Studies in non-human primates have demonstrated altered HPA axis activity and stress-related behaviour in offspring of mothers stressed during pregnancy (1270,1271). An early study in the guinea pig demonstrated that exposure to a strobe light for 3 hours on GD60 (gestation day) and GD67 increased maternal and foetal plasma ACTH and cortisol concentrations (1272) and subsequently resulted in decreased plasma ACTH and cortisol responses to stress in juvenile and adult mixed-sex offspring (1273). Moderate prenatal psychological stress has profound effects on growth, behaviour and endocrine function (HPA axis activity and testosterone) in male offspring (1274). Under basal, non-stressed conditions, foetal plasma ACTH levels are rising at GD50, though plasma cortisol concentrations remain low (1275,1276). This suggests that the central drive of the HPA axis is increasing in the foetus, but that the adrenal is relatively insensitive to ACTH at this time in gestation. Maternal food withdrawal (48 h) at GD50 results in significant increases in maternal HPA axis activity and foetal plasma cortisol (2.5-fold), but no change in foetal plasma ACTH levels (1277).

Plasma cortisol responses to ACTH challenge were significantly elevated in PS60 (prenatal stress) offspring and this could reflect a difference in adrenal sensitivity and/or steroidogenesis (1274). Hypercortisolaemia, as observed in the PS50 offspring, is one of the defining features of the metabolic syndrome (1278). This disease is associated with increased central obesity, high blood pressure, glucose intolerance, depression, emotional irritability and cognitive deficits (1278). In a model of chronic prenatal nutrient restriction, male guinea pig offspring exhibited elevated blood pressure (1279). Discreet periods of moderate maternal stress can have a negative impact on adult body weight (1274). Another recent study demonstrated that prenatal stress resulted in aged male rat offspring (24 months) that exhibit hyperglycaemia, glucose intolerance and decreased basal leptin but no difference in the body weight (1280). It is possible that prenatal stress causes male offspring to react more severely to the stress of weaning, inducing temporary hypophagia similar to that reported in models of chronic stress (1240). In humans, low birth weight, which is considered an index of an adverse foetal environment, has been associated with the development of obesity and altered body composition

in later life (1281-1283). Brain sparing is often observed in cases of intrauterine growth restriction in both animals and humans (1284,1285).

Increased anxiety-related behaviour following prenatal stress has been reported in rats and primates (1270,1271,1286-1288). In humans, prenatal stress is a risk factor for the development of major depression and dysregulation of the HPA axis is present in approximately 20–30% of patients experiencing depression (1268). Pregnant rhesus monkeys exposed daily to extended periods of stress delivered offspring that exhibited decreased exploratory behaviour compared with controls (1271,1286). Adult rats exposed to excess endogenous GCs in uterus display decreased grooming and rearing in an open field and increased immobility in a forced swim test (1288).

18.3.1. Effects of stress on early life

HPA axis can be altered prenatally by nutrient restriction, maternal adversity or exposure to synthetic GCs and postnatally by neonatal handling, maternal deprivation or infection (1289). Low birth weight babies have raised cortisol concentrations in umbilical cord blood and raised urinary cortisol excretion in childhood (1290,1291). A number of studies suggest that low birth weight is related to an increased resting pulse rate and fasting plasma cortisol concentrations in adulthood (1292,1293). A study of a subset of 205 men showed that those with lower birth weight had enhanced responses of plasma cortisol to ACTH (1294,1295). Also, plasma cortisol levels in adulthood are correlated with birth weight and risk for glucose intolerance, hypertension and dyslipidaemia (metabolic syndrome) (1295-1297).

In a large cohort of Swedish army recruits there was a continuous relationship between size at birth and stress susceptibility in a psychological assessment of suitability for military combat duties (1298). Also, low birth weight is associated with enhanced blood pressure and heart rate responses to psychological stressors in women but not men (1299). Further, there are marked sex differences in the relationship between birth weight and the stress response, with boys who are small at birth having an enhanced HPA and girls a predominantly sympatho-adrenal response (1300). This observation is supported by increasing animal evidence that foetal programming of the HPA axis differs by sex (1301). Further, birth weight is associated with modulation of both sympathetic and parasympathetic function (1302) and is associated with features of hyperactivity and reduced attention and that this effect was observed across the range of birth weights (1303,1304).

18.4. Effects of stress on sleep

Sleep is commonly considered a restorative process with supportive influences on immune functions. There is considerable circadian rhythm of the immune system, which is likely to be linked with both circadian and sleep dependent hormone release (1305). As a stress hormone cortisol is known to peak in the early morning inducing an influx of neutrophils from the bone marrow and GH is secreted during sleep promoting T-cell function (1306). Sleep deprivation has a negative effect on cognitive and psychomotor performance and mood state, partially because of decreased creatine levels in the brain (1307). A study examining the effect of a single night of sleep deprivation on the antibody response to Hepatitis A vaccination on the previous day showed that subjects who had regular sleep after vaccination displayed nearly a two fold higher antibody titre ($p = 0.18$) after 4 weeks compared to sleep deprived subjects (1308). In addition, the quality and depth of sleep may be a more important determinant of immune function. Increased secretion of IL-6 during sleep was associated with stages 1–2 and “REM sleep”¹² (Rapid eye movement sleep) whereas IL-6 secretion during slow wave sleep was comparable to the levels found whilst awake (1305). In a human study men participating in a 5–7 day military training exercise that involved continuous light physical exercise (35% VO 2max), sleep deprivation (2–3 hrs of sleep during the whole course) and calorie restriction (with a daily intake less than 3,000 kJ) there was a significant reductions in CD4+ T cells, CD8+ T cells, B cells and NK cells. Also, serum levels of immunoglobulin were decreased (IgG 6–7%; IgA 10–20%; IgM 20–35%) (1309).

18.5. Effects of Stress during Exam

The effect of a six week cadet basic training period (a combination of physical and mental stress) followed by academic exams on the reactivation of three latent herpes viruses showed that Epstein-Barr virus antibody titers were significantly higher during the examination week compared with baseline and during the six week basic training (1310). Also academic stress and not basic training modulated the expression of latent Epstein-Barr virus suggests the type of stressor is important in determining the immunological effect.

¹² During a normal night of sleep, humans usually experience about four or five periods of REM sleep. It is characterized by the rapid movement of the eyes. In adult humans REM sleep typically occupies 20–25% of total sleep, about 90–120 minutes of a night's sleep.

19. Food deprivation

19.1. Caloric restriction

The lifespan of all mammals studied to date can be significantly increased by reducing their caloric intake. Also, the lifespan of rats and mice can be increased by up to 50% if dietary restriction (DR) regimens are begun in young adults and maintained throughout the life (880). Studies of tissues from animals on CR and fasting diets have provided evidence for two major mechanisms by which meal size and frequency affect health and disease susceptibility. One mechanism involves the production and removal of free radicals and the second involves stress resistance (880,1311,1312). The vulnerability of cells to being damaged and killed by oxidative insults (radiation, mitochondrial toxins, ischemia, iron, etc.) is decreased in animals maintained on CR or EODF diets (889,890,1313,1314). CR and EODF may suppress oxidative stress by reducing the amount of superoxide anion radicals produced in the mitochondria and by stimulating the expression of genes that encode antioxidant enzymes and protein chaperones (903,1315). Animal studies indicate that DR may prove beneficial in reducing the incidence and/or severity of the corresponding human neurodegenerative disorders. The results of some studies performed in last years suggest that a meal-skipping DR regimen can reduce the risk of each of the major neurodegenerative disorders (e.g. AD, PD, Huntington's disease) (889,890,1316-1318). Rats maintained on DR for 2 to 4 months exhibit increased resistance to kainate-induced damage to hippocampal neurons and associated learning and memory deficits (889). Also, learning and memory is preserved in ageing rodents maintained on DR (886) and that suppression of NPC proliferation can impair learning and memory (1319). Increasing data suggest that the brain may control life span by regulating energy metabolism of the entire organism (1320). Because systems that regulate energy metabolism, such as the insulin signalling pathway, are believed to play major roles in the ageing process (1321), they are likely to have an important influence on brain ageing. It has been hypothesized that the HPA-GC system plays a protective role against the moderate stress of DR (1322) and neuroprotective properties have been described for increased GC in restricted animals (1323). Key signalling pathways involved in the regulation of energy metabolism by the brain include BDNF, IGF and neuropeptides that control feeding behaviour in the brain and insulin in peripheral tissues. Animals maintained on DR exhibit increased levels of GCs consistent with an increased level of stress (1324). In animals fed ad libitum, increased GCs associated with chronic stress have been shown to promote neuronal degeneration (1325) and impair neurogenesis (1326). A different profile of changes in the expression of GC and mineralocorticoid receptors in the hippocampus in response to DR has been seen in animals subjected to psychosocial

stress (1327). Stress and GCs decrease the expression of BDNF in the hippocampus (1328) and BDNF can protect neurons against the adverse effects of GCs (1329).




FIG 16. Positive health effects of dietary restriction

In mice maintained on DR food deprivation increases NPY and AgRP mRNA and decreases that of proopiomelanocortin in the arcuate nucleus. These changes are largely reversed 6 h after re-feeding (1330). The adult brain contains populations of cells in the sub-ventricular zone and in the sub-granular layer of the dentate gyrus of the hippocampus that are capable of dividing and then differentiating into neurons or glial cells (1199). Also, DR can increase neurogenesis in the brains of rats and mice (897,1331). It does not affect the proliferation rate of the neural stem cells, but promotes the survival of newly generated neural cells (897,904). Other studies have shown that, in mice, DR can enhance performance of learning and memory tasks (886), which could also be mediated by BDNF (1332). Levels of BDNF are increased in neurons in the cerebral cortex, hippocampus and striatum of rats and mice maintained on DR (896,897,1317,1331). It is known that BDNF can protect neurons in culture and in vivo against excitotoxic, metabolic and apoptotic insults (1333). Neurotrophic factors may protect neurons by stimulating the production of proteins that suppress oxidative stress (antioxidant enzymes, and Bcl-2) and stabilize cellular calcium homeostasis (1334).

In human studies participants who were forced to eat a low-calorie diet over a period of approximately two years exhibited highly significant decreases in blood pressure and insulin and cholesterol levels (1335). Health benefits of smaller and more frequent meals are suggested from survey-based evaluations of the association between meal frequency and obesity, hypercholesterolemia and glucose intolerance (1336) and from the assessment of the effects of short-term (days to weeks) high and low meal-frequency diets on glucose regulation (1337,1338). It has been suggested that skipping breakfast is unhealthy (1338). Further data suggest that both reduced-energy and reduced-meal-frequency diets can reduce inflammatory responses, as indicated by reduced production of TNF by macrophages (1339). T-lymphocyte responses to concanavalin A and responses of B-lymphocytes to pokeweed mitogen were reduced in obese subjects compared with normal weight controls and these impairments in immune responsiveness were reversed by CR (1340). In female mice CR (40%) during their adult life prevented age-related declines in learning and motor coordination (1341). Age-related alterations in neurotransmitter-synthesizing enzymes and neurotransmitter receptors in the brain were suppressed in rats that had been maintained on an EODF diet during their adult life compared with rats fed *ad libitum* (1342). The adult mammalian brain contains population of self-renewing stem cells that are capable of forming new neurons and glial cells. EODF increases the survival of newly generated neurons in the dentate gyrus of the hippocampus in adult mice (1343). On the other hand, CR did not increase hippocampal neurogenesis, but did enhance glial cell genesis by increasing the survival of newly generated glial cells (1344).

19.1.1. Fasting

Studies of different human populations that periodically fast as part of their religion, suggest health benefits of reduced meal-frequency diets (1345). Consistent with a cardioprotective effect of regular fasting in humans, Moslems who fast during the month of Ramadan have reduced levels of LDL cholesterol and increased levels of HDL cholesterol (1346). In animal studies memory impairment was preserved in the intermittent-fasted rats compared to the control rats fed *ad libitum* (889). Intermittent fasting results in increased excitability of the CNS (1347). CR may reduce and overeating increases activity of the sympathetic nervous system, which likely contributes the opposite effects of CR and overeating on blood pressure (1348). The increased activity in nerve cell circuits in animals on CR or intermittent fasting likely contributes to several beneficial effects of the reduced meal size and frequency within the brain. It appears that the brain's perception of

CR and intermittent fasting as stressors is central to activation of stress-resistance mechanisms that may protect against disease (1349).

19.1.2. Brain in choosing foods

The brain is evolved as the major regulator of food acquisition and energy metabolism (1320). It is responsible for the behaviours involved in the identification and ingestion of food. Further, it regulates energy allocation and usage in various organs.

19.1.3. Energy balance

Energy homeostasis is regulated through a complex network of central and peripheral signals, including brain neuropeptides and systemic hormones, which provide converging inputs to the CNS (736,1350). The satiating effect of nutrients is strongly dependent on their oxidation and the energy released from this oxidation rather than on their blood concentration (1351,1352).

20. Stress during Pregnancy

Human and animal studies have indicated that many different types of prenatal stressors have significant effects on postnatal behaviour (1353). In the offspring of pregnant animals significant changes have been found in both behaviour and regulation of the HPA axis, regardless of the specific prenatal stressor used. In humans significant effects on postnatal behaviour have been found for prenatal exposure to many different types of maternal stress or anxiety (1354).




FIG. 17. Factors experienced during pregnancy may results in changing HPA axis activity in the developing fetus

In several studies prenatal exposure to natural disasters significantly increased the risk for a variety of behavioural disorders. Significant relations have been found between prenatal stress and postnatal problems in a variety of behavioural domains, such as attention, language and learning (1355). Also, prenatal stress can

have a variety of effects on brain development including: delayed myelination, elevated sensitivity of the amygdala to GCs and abnormal development of the dopaminergic system (1356-1358). Further, maternal stress and the resultant release of catecholamines can cause uterine vasoconstriction and reduced blood flow to the placenta, resulting in foetal hypoxia and a spectrum of foetal injuries that range from spontaneous abortion to varying degrees of cerebral damage (1356,1359). In the normal gestational environment, the mother transfers GCs to the developing foetus in proportion to the adversity of her environment (1360). The HPA axis is particularly sensitive to effects of prenatal exposure to excess levels of GCs (1361). Prolonged maternal exposure or severe stress can cause the offspring to develop a pathological, life-long hyper-activation of the HPA axis as well as elevation of stress hormone levels (1362). Also, prenatal exposure to environmental stress or GCs can lead to postnatal HPA hyperactivity in response to stress (1363).

21. Food intake

In healthy males exogenous GC administration increased daily food intake compared to placebo (603). Amylin and CCK function as satiety signals to terminate meals, whereas ghrelin has among its actions the stimulation of food intake. The satiety signalling effect of CCK was confirmed in humans. Also, treatment with a CCK type-A receptor antagonist increased caloric intake and sensation of hunger (1364). Antagonist studies in rats provided evidence that CCK is important to postprandial sleeping (1365). Amylin is a pancreatic peptide and is secreted with insulin that has actions similar to those of CCK. Several central sites of amylin signalling were reported including the amygdala (1366) and area postrema (1367). Both dopaminergic (1368) and histaminergic (1369) receptors have been implicated in processing of amylin signals. There is strong evidence that restrained and emotional eaters overeat in response to stress (1370). Restrained eaters consumed more than unrestrained following a reaction time task, while the opposite was observed following a relaxation condition (1371). Following an interpersonal stressor, restrained eaters ate more than did non-restrained eaters (1372). Moreover, the greater the restraint, the more participants ate (1373). Stressed emotional eaters ate more sweet, high-fat foods and a more energy-dense meal than unstressed and non-emotional eaters following a speech preparation task (24). Overeating has been observed in rats following a stress and a period of CR (1237) only in those given highly palatable food (1238). Bulimic patients reported increases in hunger and desires to binge eat compared to restrained eaters and controls following an interpersonal imagery task (1374). Emotional eating has been associated with both increased and decreased food intake (614) and little is known about the mechanisms that underlie the direction of change. In rats, both a single social defeat stressor (1624) and a 2-h immobilization stressor (1375) resulted in a significant reduction of food intake and body weight. More recently, however, incongruent paradigms of stress physiology have emerged (1376).

22. Diseases and Stress

The association between different diseases and stress has been discussed in literature. Some diseases will be discussed here.

22.1. Adiposity

For any given body mass index (BMI), mortality is higher if fat is distributed centrally (visceral adiposity) compared with a more generalized pattern of distribution (1377). This has renewed interest in the factors that control adipose tissue distribution in addition to adipose tissue mass and function (1378). Several studies have indicated positive correlations between high-energy diets and obese animals (1379). It has been suggested that dietary fat is a prime contributor to the development of obesity (70). In rats, a forced high-fat diet increased both basal and stress-induced hormone secretion, it was suggested that chronic dietary fat was itself a stressor (71,1380). In contrast to reports of positive correlations between apparent HPA function and obesity, a number of studies have suggested protective effects of high-energy diets against stress. Rats eating a high-fat diet for 2–3 months had reduced sympathetic responses to stressors, compared with animals eating high carbohydrate diets (70). Most preclinical studies have focused on the effect of stress on ongoing feeding behaviour (612,1238,1381). Humans seem to be vulnerable to maladaptive eating habits of stress and anxiety-like states during dieting (1382,1383). Short-term exposure to high fat diet also reduced anxiety on the elevated plus maze (72). Foods with high simple carbohydrate and fat contents have been reported to be highly palatable, as compared to foods with high fibre content which are less palatable (1384).

In women, visceral fat was associated with high cortisol levels. However, women with low WHR failed to habituate to repeated stress, whereas those with higher WHR habituated (625). Measurements of mesenteric fat weight together with hypothalamic CRF mRNA from either adrenalectomized or from intact rats, showed significant negative correlation between mesenteric fat weight and CRF expression in the PVN (612). Also, mesenteric (but not sc) fat stores serve as a signal of energy stores that feed back to inhibit CRF activity in the HPA axis (612).

Although men tend to progressively increase abdominal fat depots with increasing total adiposity at each age, a tendency to develop different obesity phenotypes throughout the lifespan occurs more clearly in women, particularly after the menopausal age (1385). The response of the HPA axis to a high-lipid/protein meal or high simple carbohydrate meal in obese women depends on their pattern of body fat distribution and that the activation of the HPA following the ingestion of

large amounts of complex carbohydrate may have some patho-physiological relevance, specifically in women with the abdominal obesity phenotype (1386). In obese women, different mechanisms may be responsible for the regulation of the HPA axis following a high-lipid/protein meal or high simple carbohydrate meal, depending on their phenotype (1386). Further, the rate of FA oxidation and its effect on adenylate charge in the liver are involved in regulating food intake (1387). Transport mechanisms (1388) and enzymes for fat oxidation (1389) and fat synthesis (1390) are also present in the brain and administration of inhibitors of fat synthesis produces a centrally mediated inhibition of food intake in rodents (1390,1391). Despite the potential for fat and fat metabolism to inhibit food intake, there is abundant evidence that consumption of diets high in energy from fat leads to increased energy intake, weight gain and obesity in animals and humans (1392-1395).

Local adipose tissue GC levels and intracellular GC availability are controlled by the activity of 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD-1), which functions almost exclusively as a high-affinity reductase *in vivo*, generating active cortisol from inactive cortisone (1396). Obesity increases the expression of 11 β -HSD-1 in human subcutaneous and visceral adipose tissue and both 11 β -HSD-1 transcription and activity are higher in omental versus subcutaneous adipocytes from obese subjects (1397,1398). GCs appear to provide metabolic inhibitory feedback on central networks through redistribution of peripheral energy stores. Removal of GCs by adrenalectomy suppresses food intake and weight gain (679). A major problem in the dietary treatment of obesity is the high rates of relapse to maladaptive eating habits (1399). This relapse is commonly triggered by stress and anxiety-like states (1383,1400).

22.2. Alzheimer Disease

There is a strong correlation between per capita food consumption and risk for AD and stroke (1401,1402). In a population-based longitudinal prospective study of Nigerian families in which some members moved to the United States, it was shown that the incidence of AD among individuals living in the United States was increased compared to their relatives who remained in Nigeria (895). Case-control studies showed that individuals with the lowest daily calorie intakes had the lowest risk of AD and PD (894,1403).

22.3. Anorexia nervosa

Anorexia nervosa (AN) is a complex condition that can lead to death in severe cases. It involves neurobiological, psychological and sociological components. Individuals with anorexia are known to control body weight commonly through

the means of voluntary starvation, purging, vomiting, excessive exercise or other weight control measures. Starvation suppresses sympathetic nervous system activity (1404) and reproductive function (1405) while stimulating the HPA axis (1406,1407) and feeding behaviour (1408). Starvation-induced activation of the HPA axis (1406,1407) appears to involve factors additional to CRH, since hypothalamic synthesis of CRH is reduced (1409,1410) or unchanged (1411) after weight loss induced by starvation or restricted access to food. In contrast, hypothalamic expression of the CRH gene is typically increased during acute stress (1412). Complementing its role as a primary controller of the HPA axis, CRH also acts in the hypothalamus to reduce food intake (1413) and stimulate sympathetic nervous system outflow (686), causing increased energy expenditure and sustained weight loss. After the first few days of starvation, FFAs and ketone bodies, rather than glucose, become the predominant fuels (1414,1415). After depletion of glycogen stores in the liver, plasma glucose is maintained solely by gluconeogenesis, a process that depends in part on catabolism of muscle. Starvation inhibits insulin secretion while increasing the concentrations of glucagon, epinephrine and cortisol. This physiologic combination reduces glucose use while stimulating lipolysis and ketogenesis. Insulin secretion is proportional to both body adiposity and the prevailing energy balance (1416) and insulin enters the CNS through a transport process that appears to be localized to the endothelium of the blood–brain barrier (1417,1418). Insulin provides a negative-feedback signal to the brain (1419). In fasting animals, insulin (1420) and leptin (737,1421) inhibit the expression of the NPY gene, whereas GCs have the opposite effect (684,1422). NPY also activates the HPA axis, but at a hypothalamic site rather than directly in the pituitary (1423–1425). Activation of the HPA axis during starvation, in both animals (1423) and humans (1424) may therefore facilitate the mobilization of fuel in peripheral tissues and CNS responses that promote the restoration of depleted adipose stores. Since the increase in NPY signalling during starvation depends on GCs (1422) the activation of the HPA axis by NPY during starvation may stimulate further hypothalamic synthesis of NPY, creating a positive-feedback loop between NPY and GCs (1426).

22.4. Autoimmune disorders

Stress has been shown to play a major role in autoimmune disorders (1223). NO may be inductor and effector of cellular damage and consequently iNOS has been described to be generally associated with the pathogenesis of chronic inflammation (1427). NO release has also been demonstrated to limit auto-reactive T cell determined spreading and diversification of the antibody repertoire, a process driven by macrophages (1428). NO may be important for silencing auto-reactive T

cells and may further restrict bystander autoimmune reactions following an innate immune response (1428,1429).

22.5. Bulimia

Disordered eating syndromes consist of overeating calories in a bingeing fashion (1430). Persons with disordered eating, whether it is bingeing or ingesting most of the daily calories intake occurs during the night, generally characterize themselves as chronically stressed (1430,1431) and are obese. The foods that are overindulged-in typically have high fat and carbohydrate caloric content and may be characterized as comfort food. GC concentrations in these patients are slightly but not markedly elevated (1432,1433).

22.6. Cancer

Stress is speculated to be part of the cancer aetiology (1228,1434-1436). Already some indications exist from prospective studies that there is no relation between stressful events and cancer. The results of a large scale study in the United Kingdom provide little evidence for an association between bereavement in men or women and later cancer (1437). Longitudinal study of Japanese men living in Hawaii showed no relation between stressful life situations, and later cancer (1438). A growing body of research linking psychological and behavioural factors to the incidence and progression of cancer suggests that psychosocial factors may have an impact on some types of cancer (1439-1444). A characteristic of a certain subset of tumours, particularly virally induced ones, is their ability to grow faster in animals undergoing either somatic or psychogenic stress (1445-1449). Cancers that are induced by chemical carcinogens (e.g. lung cancer) may be less influenced by psychological, behavioural and immunological factors than cancers that are associated with a virus, such as Epstein-Barr Virus, which are immunogenic (1450). Also, stress can accelerate the growth of certain tumours, particularly those that are virally derived (1445-1449). It has often been theorized that stress-induced acceleration of tumour growth is a result of immuno-suppression (1446,1448). Further, it is not clear if stress-related immune changes are of either the type or the magnitude to influence tumour growth and metastases (1441,1451). The mediating mechanisms for such accelerated growth are concentrated on the inhibition of the immune system by GCs during stress because:

- Exogenous GCs, like stress, can accelerate growth of some tumours (1446,1449).
- GCs, as part of their general inhibitory effect upon immunity, inhibit immune constituents known to be tumouricidal, including natural killer cells, antibody-dependent killer cells, macrophages and polymorphonuclear lymphocytes (1452).

- Immuno-suppression can be associated with the enhanced establishment and accelerated growth of tumours (1448).
- Virally derived tumours are most accelerated by stress. Also, the tumour types are most sensitive to immune status (1446,1448).

Psychosocial factors associated with cancer diagnosis include stress, depression, anxiety and distress (1453). In cancer patients cognitive function, defined as higher-order mental processes, may be altered along two distinct and interacting pathways (1454):

- The cancer diagnosis, which can lead to anxiety, stress, distress and depression.
- The direct physiologic effects of cancer treatment.

Changes in cognitive function have been identified as a likely consequence of cancer treatment since the 1980s (1455,1456). A number of known psychological and social effects are related to the challenges of confronting potentially terminal illness. The effects include anxiety, depression and stress. Physiologic and psychosocial factors have been implicated in cognitive function (1457-1460). Despite potentially contributing factors, chemotherapy has long been implicated as the prime suspect in cognitive decline among patients (1456,1461,1462). Further, changes in cognitive function may be dependent on chemotherapy dose or duration (1463-1466). Patients receiving chemotherapy perform only slightly lower on specific cognitive measures compared to age-matched, healthy counterparts (1467-1469). Specific agents are implicated in cognitive changes (1470,1471):

- Chemotherapies associated with CNS neurotoxicity,
 - Chemotherapies that cross the blood-brain barrier (e.g., 5-fluorouracil, cytarabine, methotrexate, ifosfamide, cisplatin),
 - Concomitant medications used with chemotherapy (e.g., GCs, dexamethasone),
- Certain biologic (e.g., interferon) and
- Hormonal therapies (e.g., tamoxifen).

The impact of the drugs on cognitive function may be dose dependent, with patients who are exposed to higher doses or treated for longer periods of time having greater declines in cognitive function (1460,1465,1472,1473). Anaemia can result in reduced brain oxygenation and is a common side effect of chemotherapy treatment (1474). Chemotherapy-induced anaemia has been implicated as a factor contributing to changes in cognitive function (1464,1470,1475). Interventional studies showed that a year of weekly supportive group therapy sessions with self-hypnosis for pain was associated with extended survival time in women with

metastatic breast cancer (1476). In contrast other studies showed no difference in survival for metastatic breast cancer patients who received supportive-expressive group therapy when compared with controls, but the support group did exhibit improved mood and perception of pain compared with controls (1477).

NO is implicated in the control of malignancies. The significance of specific (clinical) NO pathways has been demonstrated in a variety of malignancies. NO is prominently involved in skin cancer (melanoma) (1478), brain tumours (1071,1479,1480), breast tumours (1071,1479-1482), lung tumours (1071,1483,1484), pancreatic cancer (1485) and GIT cancer (1071,1486-1489). The expression of iNOS in tumour cells is generally associated with apoptosis, suppression of tumorigenicity, reduction of tumour growth, abrogation of metastasis and even regression of already established cancer metastases (1478,1490). Stress may alter the DNA repair process (1491). In addition to the effects of stress on DNA repair, additional research has documented the impact of stress on apoptosis, a process of genetically programmed alterations in cell structure that leads to failure of proliferation and differentiation and eventual cell suicide (1234). Stress may also enhance carcinogenesis through alterations in DNA repair and/or apoptosis (1491-1493).

22.7. Cardiovascular diseases

Stress has been shown to be important in vascular hypertension (1222). In part stress may even cause or contribute to the clinical onset of arterial hypertension in certain cases (1494-1496). It may serve as a risk factor (1497), that induces blood pressure spikes or increases an already elevated blood pressure (1228,1498,1499).

22.8. Dementia

Dementia affects about 5% of the elderly population (aged 65 years and older) and has an unexplained predominance in women (1500). The importance of B vitamins and folic acid for the well being and the normal functioning of the brain have been described (1501). Inadequacies of B vitamins can result in hyper-homocysteinemia, a well-known risk factor for atherosclerosis and which recently has been associated with cognitive impairment in old age (1502). Elevated plasma homocysteine levels are, in many cases, indicative of suboptimal B vitamins status (1503). Deficiencies of other essential nutrients, such as the antioxidant vitamins C, E and β -carotene and the subsequent increased risk of oxidative stress, have also been identified as nutrition-related risk factors for cognitive impairment (1504).

22.9. Immunological diseases

It is widely accepted that acute stress tends to enhance immune functioning, whereas chronic stress more likely suppresses it (1434). However, the effects triggered by stress can be beneficial for some types of immune responses and deleterious for others (1498,1505-1507). Inflammation, infection, autoimmune processes and perhaps even the onset and development of malignant tumours may occasionally be associated with the stress phenomenon (1223).

22.10. Immunosuppression

Stress can be immunosuppressive through a variety of humoral and neural mechanisms (1508). Decreased lymphocyte proliferation and reduced NK cell cytotoxicity are consistently observed during stress (1509). Further, NK cell cytotoxicity can be down-regulated by stress, presumably through neuroendocrine mechanisms (1443,1510,1511). NK cells play an important role in a variety of immune functions, including defence against viral infections (1512) and surveillance of tumour cells (1513). Bereaved spouses had elevated cortisol and decreased NK cell activity (1514). Among spouses of cancer patients, those who reported lower levels of social support had lower levels of NK cell cytotoxicity (1515). In rodents social stressors not only decrease NK cell cytotoxicity, but also they enhance metastasis of transplantable tumours (1516,1517). Also, depression and smoking had synergistic effects on reduced NK cell lysis (1518). Several aspects of the cellular immune response are also adversely affected by psychosocial stress (1509,1519). In a study of 45 healthy, older adults who were randomly assigned to one of three protocols (relaxation training, social contact or no intervention), relaxation subjects showed a significant enhancement in NK cell activity at the end of the 1-month intervention, with concomitant decreases in distress-related symptomatology in comparison to non-significant changes in the other two groups (1520). Also, stress-reducing interventions can improve immune function (1521). Further, there is evidence that stress can modulate cytokines synthesis such as INF- α and IL-2 by mitogen treated peripheral blood leukocytes (1522,1523). Also, INF- α , and IL-2 can enhance NK cell and lymphocyte-activated killer cell cytotoxicity (1513).

22.11. Inflammatory bowel disease

Positive associations have been found between inflammatory bowel disease activity with psychiatric diagnoses (1524,1525). Some clinical studies (1526-1528) but not all controlled studies (1524,1529-1531) showed that ulcerative colitis patients recall increased life stress before an exacerbation. The association between

stress and disease activity has been shown to relate not only to subjective symptoms, but also to objective endoscopic measures (1532). Recently, it has been shown that short-term stress does not appear to trigger exacerbations in ulcerative colitis, but that long-term perceived stress increases the risk of exacerbations over a period of months to years (1533). Psychological treatments have been used as a management modality in inflammatory bowel disease. It has been shown that inflammation can develop spontaneously in animals subjected to stressful situations. For example, Gibbon monkeys subjected to social upheaval developed a fatal colitis (1534). In animal studies chronic stress induced primary inflammation in a naive host (1535-1537). Also, rats were exposed to mild repetitive psychological stress in the form of water avoidance stress for 10 consecutive days, as a model of chronic ongoing life stress in humans. A three- to fourfold increase in inflammatory cells was noted in the lamina propria of stressed rats compared with sham stressed controls. Also, longer-term life stresses, at least those that pertain to early maternal deprivation used in animal models may predispose the mucosal barrier to permeability abnormalities when there is an additional acute stressor (1538).

Animal and human studies showed an increase in intestinal permeability in response to stress with acute (1539-1542) and chronic (1536,1537,1543) stress. Changes in permeability as an initial event in inflammatory bowel disease have been described. It has been shown that first degree relatives of patients with Crohn's disease, a sub-group with an increased risk of developing the disease, have an increased intestinal permeability (1544-1548). Also, it seems that relapses in patients with Crohn's disease are preceded by an increase in small intestinal permeability (1549).

Secretion of ions and water is a primary defence mechanism of the epithelial barrier. A change in secretion occurs with acute and chronic stress in animals and humans (1539,1540,1543,1550,1551). In humans stress was induced by dichotomous listening and acute stress resulted in excessive jejunal secretion (1550). In human jejunal water secretion was increased by cold pain stress (1551).

22.12. Insulin resistance

Acute stress is clearly associated with a severe, yet reversible, form of insulin resistance (1552). Also, psychosocial stress might be associated with insulin resistance (804). In Westernized countries 25-35% of the population have a degree of insulin resistance and the health consequences associated with this metabolic derangement (1553). Insulin resistance means that the ability of insulin to dispose of glucose in the liver, skeletal muscle and other peripheral tissues is

compromised. Insulin resistance seems to be a common feature and a possible contributing factor to several frequent health problems, including type 2 diabetes mellitus (1554), cardiovascular disease (1555-1559), certain hormone-sensitive cancers (1554,1560,1561), dyslipidemia (1562), hypertension (1563,1564), polycystic ovary disease (1565,1566), sleep apnoea (1567) and obesity (1568-1571).

TABLE 6

Dietary components with possible increasing effect on insulin resistance

-
- Low fibre intake
 - Low vegetable intake
 - High fat intake
 - Deficiency of omega-3 FA intake
 - Deficiency in Micronutrients
 - High intake of refined carbohydrate
 - High glycemic meals
 - Lack of exercise
 - Smoking
 - High stress
-

While both cortisol and the catecholamine stress hormones are capable to elevate blood sugar, chronic elevation of cortisol resulted in increased plasma insulin levels (1572). Also, consistently elevated levels of cortisol greatly inhibit non-hepatic glucose utilization (1572,1573). Further, stress, secondary to cortisol production, may impact insulin resistance directly or indirectly through interaction with leptin. Cortisol might be capable of both increasing leptin levels and inhibiting the action of leptin, thereby promoting a state of leptin resistance (1574-1576). Also, the amount of leptin found in the blood directly correlates with insulin levels and with insulin resistance. In effect, leptin levels decrease in parallel with insulin and leptin resistance decreases as a person becomes more sensitive to insulin (1577-1579). Obesity is commonly characterized by a state of leptin resistance (1580). There is an increased prevalence of insulin resistance in patients with schizophrenia and chronic depression compared with the general population (1581). Overweight and insulin resistance have also been associated with bipolar disorder (1582). Since evidence supports the association between abdominal body fat distribution, insulin resistance and obesity. Also, among obese men loss of weight and a decrease in the WHR are closely associated with improved insulin sensitivity (1583). Epidemiological data suggests that increased consumption of saturated and total fat and decreased intake of fibre is associated with insulin resistance (1584-1586). Further, the macronutrient composition of the diet might

play an important role in fat deposition (1587) and so might consequently influence insulin resistance. Also, low fat, high simple carbohydrate diets might contribute to metabolic problems and certainly do not appear to be capable of reversing insulin resistance, obesity or Syndrome X (1588,1589). In contrast high-carbohydrate, high-fibre diets certainly appear to improve peripheral tissue insulin sensitivity in healthy young and old individuals (1590,1591). Further, exercise can improve insulin resistance. Also, available research demonstrates that postmenopausal women can improve insulin resistance through consistent appropriate exercise (1592).

Dietary micronutrient deficiencies might also promote insulin resistance. Diets higher in vitamin A have shown an inverse relationship with insulin resistance (1593). Deficiencies of minerals including calcium, magnesium, potassium, chromium, vanadium and zinc might also promote insulin resistance (1594-1600). While severe reduction of salt intake may contribute to an increased serum lipid and insulin levels and a deterioration of insulin sensitivity in both healthy volunteers and patients with hypertension (1601-1603). Possibly high sodium intake exacerbates insulin resistance (1604).

22.13. Intestinal Disorders

Intestine is extending from the stomach to the anus. It is an important segment of the GIT. It consists of two segments, the small and large intestine. Diet has an important role in intestinal pathologies (1605-1607). It is complicated by symptomatic association to psychological disorders (1608-1611). Stress can have negative impact on the intestine. Also, stress and stress-induced anxiety play a major role in functional intestinal disorders (1612). The stimulation of intestinal contraction and colonic transit are the most consistent patterns in the motility response of the intestinal tract to acute stress (1613,1614). Within the cells and neurons of the GIT Trp4 receptors are located (1615,1616). Disturbances in gut and the brain Trp account for the majority of intestinal and psychological illnesses (1617). Both stress-induced anxiety and intestinal disorders are traced, from among other molecular pathologies, to the inappropriate responses of the central and/or peripheral serotonin system (1617,1618). Antagonists on the Trp4 receptor do not affect normal, healthy gut function (1619) but prevent the disturbances caused by stress (1617) or high Trp activity (1620). In addition to their effect on the GIT, Trp4 antagonists block corticosteroid secretion in the adrenal cortex (1621), Trp-induced tachycardia (1622,1623) and stress-induced anxiety (1624).

22.14. Neurodegenerative diseases and mental disorders

In neurodegenerative diseases and mental disorders stress clearly plays a significant role. Also, stress has been shown to be involved in neurodegeneration (1223). It has been demonstrated to cause deficits especially in spatial memory performance (1625-1628). Stress may lead to a loss of neurons, particularly in the hippocampal area (1223,1627). Moreover, the ageing hippocampus apparently is more susceptible to stress and this vulnerability may yet be increased in AD (1629).

Neurodegenerative disorders result from insurmountable cellular stress. In AD, synaptic dysfunction and neuronal degeneration result from the ageing process in combination with increased production and accumulation of neurotoxic forms of amyloid β -peptide and perturbed cellular calcium homeostasis (1630). Membrane lipid peroxidation and engagement of apoptotic cascades may be pivotal events in AD. The degeneration of dopaminergic neurons in PD may result from age-related oxidative stress and impairment of mitochondrial ATP production, perhaps in combination with exposure to environmental toxins (1631). The abilities of antioxidants and drugs that stabilize cellular calcium homeostasis to reduce ischemic brain injury in animal models attest to the involvement of free radicals, energy impairment and perturbed calcium regulation in stroke-induced neuronal death (898). In animal and cell culture models neuronal dysfunction and death have been ameliorated in AD, PD and Huntington's disease by manipulations that reduce levels of oxidative stress and by agents that maintain ATP levels and ion homeostasis (1632).

23. References

- (1) Folkman S, et al. 1980. An analysis of coping in a middle-aged community sample. *J Health Soc Behav* 21:219.
- (2) Langlie JK. 1977. Social events, health beliefs, and preventive health behaviours. *J Health Soc Behav* 18:244.
- (3) Adler N, Matthews K. 1994. Health psychology: why do some people get sick and some stay well? *Annu Rev Psychol* 45:229.
- (4) Steptoe A. 1991. The links between stress and illness. *J Psychosom Res* 35:633.
- (5) Johnson EO, et al. 1992. Mechanisms of stress: a dynamic overview of hormonal and behavioural homeostasis. *Neurosci Biobehav Rev* 16:115.
- (6) York DA. 1992. Central regulation of appetite and autonomic activity by CRH, glucocorticoids and stress. *Prog Neuroendocrinimmunol* 5:153.
- (7) Korte SM. 2001. Corticosteroids in relation to fear, anxiety and psychopathology. *Neurosci. Biobehav. Reviews* 25:117.
- (8) Schulkin J, et al. 1994. Allostasis, amygdala, and anticipatory angst. *Neurosci Biobehav Rev* 18:385.
- (9) Sebastian A, et al. 1994. Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. *N Engl J Med* 330:1776.
- (10) Frassetto L, et al. 1996. Effect of age on blood acid-base composition in adult humans: role of age-related renal functional decline. *Am J Physiol* 271:1114.
- (11) Kirschbaum C, Hellhammer DH. 1994. Salivary cortisol in psycho-neuroendocrine research: recent developments and applications. *Psycho-neuro-endocrinology* 19:313.
- (12) Dallman MF, et al. 1993. Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. *Front Neuroendocrinol* 14:303.
- (13) Kirschbaum C, et al. 1997. Effects of fasting and glucose load on free cortisol responses to stress and nicotine. *J Clin Endocrinol Metab* 82:1101.
- (14) Tempel DL, Leibowitz SF. 1993. Glucocorticoid receptors in PVN: interactions with NE, NPY and Gal in relation to feeding. *Am. J. Physiol.* 265:E794.
- (15) Honma K, et al. 1984. Feeding-associated corticosterone peak in rats under various feeding cycles. *Am J Physiol* 246:R721.
- (16) Adamson U, et al. 1989. Fasting for 72 h decreases the response of counterregulatory hormones to insulin-induced hypoglycaemia in normal man. *Scand J Clin Lab Invest.* 49:751.
- (17) Wronska D, et al. 1990. Food deprivation suppresses stress-induced rise in catabolic hormones with a concomitant tendency to potentiate the increment of blood glucose. *Physiol Behav.* 48:531.
- (18) De Boer SF, et al. 1989. Effects of fasting on plasma catecholamine, corticosterone and glucose concentrations under basal and stress conditions in individual rats. *Physiol Behav.* 45:989.
- (19) Hanson ES, et al. 1994. The diurnal rhythm in adrenocorticotropin responses to restraint in adrenalectomized rats is determined by caloric intake. *Endocrinology* 134:2214.
- (20) Akana SF, et al. 1994. Regulation of activity in the hypothalamus-pituitary-adrenal axis is integral to a larger hypothalamic system that determines caloric flow. *Endocrinology.* 135:1125.
- (21) Quigley ME, Yen SSC. 1979. A mid-day surge in cortisol levels. *J Clin Endocrinol Metab* 49:945.
- (22) Follenius M, et al. 1982. Diurnal cortisol peaks and their relationships to meals. *J Clin Endocrinol Metab* 55:757.
- (22a) Waladkhani AR, Hellhammer J. 2008. Dietary modification of brain function: effects on neuroendocrine and psychological determinants of mental health and stress related disorders. *Advan Clin Chem* 45: 99.
- (23) Hamer M, et al. 2004. Using Stress Models to Evaluate Immuno-Modulating Effects of Nutritional Intervention in Healthy Individuals. *Journal of the American College of Nutrition* 23(6):637.
- (24) Oliver G, et al. 2000. Stress and food choice: a laboratory study. *Psychosom Med* 62:853.
- (25) Rosenthal NE, et al. 1989. Psychobiological effects of carbohydrate- and protein-rich meals in patients with seasonal affective disorder and normal controls. *Biol Psych* 25:1029.
- (26) Markus R, et al. 2000. Effects of food on cortisol and mood in vulnerable subjects under controllable and uncontrollable stress. *Physiol Behav* 70:333.
- (27) Markus CR, et al. 2000. The bovine protein alpha-lactalbumin increases the plasma ratio of tryptophan to the other large neutral amino acids, and in vulnerable subjects raises brain serotonin activity, reduces cortisol concentration, and

- improves mood under stress. *Am J Clin Nutr* 71:1536.
- (28) Fernstrom JD. 1983. Role of precursor availability in control of monoamine biosynthesis in brain. *Physiol Rev* 63:484.
- (29) Ashcroft GW, et al. 1965. 5-Hydroxyindole metabolism in rat brain: a study of intermediate metabolism using the technique of tryptophan loading-I. *J Neurochem* 12:483.
- (30) Fernstrom JD, Wurtman RJ. 1971. Brain serotonin content: increase following ingestion of carbohydrate diet. *Science* 174:1023.
- (31) Fernstrom MH, Fernstrom JD. 1995. Brain tryptophan concentrations and serotonin synthesis remain responsive to food consumption after the ingestion of sequential meals. *Am J Clin Nutr* 61:312.
- (32) Maes M, Meltzer H. 1995. The serotonin hypothesis of major depression. In Bloom FE, Kupfer FE: "Psychopharmacology: The Fourth Generation of Progress." New York: Raven, pp933.
- (33) Wingate DL. 1991. The brain-gut axis. In: Textbook of gastroenterology, vol 1. New York: JB Lippincott Co., pp50.
- (34) Ishizuka B, et al. 1983. Pituitary hormone release in response to food ingestion: evidence for neuroendocrine signals from gut to brain. *J Clin Endocrinol Metab* 57:1111.
- (35) Leal AM, Moreira AC. 1997. Food and the circadian activity of the hypothalamic-pituitary-adrenal axis. *Braz J Med Biol Res* 30:1391.
- (36) Dinneen S, et al. 1995. Effects of the normal nocturnal rise in cortisol on carbohydrate and fat metabolism in IDDM. *Am J Physiol* 31:E595.
- (37) Divertie GD, et al. 1991. Stimulation of lipolysis in humans by physiological hypercortisolemia. *Diabetes* 40:1228.
- (38) Bjorntorp P. 1991. Metabolic implications of body fat distribution. *Diabetes Care* 14:1132.
- (39) Klein L, et al. 1996. Gender differences in eating after exposure to a noise stressor. *Annals of Behavioural Medicine* 18:S103.
- (40) Grunberg NE, Straub RO. 1992. The role of gender and taste class in the effects of stress on eating. *Health Psychol* 11:97.
- (41) Epel ES, et al. 2001. Stress may add bite to appetite in women: A laboratory study of stress-induced cortisol and eating behaviour. *Psychoneuroendocrinology* 26:34.
- (42) McEwen BS, Stellar E. 1993. Stress and the individual. Mechanisms leading to disease [see comments]. *Arch Intern Med*. 153:2093.
- (43) Tempel D, et al. 1994. Adrenal steroid receptors: interactions with brain neuropeptide systems in relation to nutrient intake and metabolism. *Journal of Neuroendocrinology* 6:479.
- (44) Al-Damluji S, et al. 1987. Food induced cortisol secretion is mediated by central adrenoreceptor modulation of pituitary ACTH secretion. *Clin Endocrinol (Oxf)* 26:629.
- (45) Van Cauter E, et al. 1992. Circadian modulation of glucose and insulin responses to meals: relationship to cortisol rhythm. *Am J Physiol* 262:E467.
- (46) Slag MF, et al. 1981. Meal stimulation of cortisol secretion: a protein-induced effect. *Metabolism* 30:1104.
- (47) Anderson KE, et al. 1987. Diet-hormone interactions: protein-carbohydrate ratio alters reciprocally the plasma levels of testosterone and cortisol and their respective binding globulins in man. *Life Sci* 40:1761.
- (48) Daniels BS, Hostetter TH. 1990. Effects of dietary protein intake on vasoactive hormones. *Am J Physiol* 258:R1095.
- (49) Schweiger U, et al. 1987. Macronutrient intake and mood during weight-reducing diets. *Ann NY Acad Sci* 499:335.
- (50) Keith RE, et al. 1991. Alterations in dietary carbohydrate, protein, and fat intake and mood state in trained female cyclists. *Med Sci Sports Exerc* 23:212.
- (51) Markus CR, et al. 1998. Does carbohydrate-rich, protein-poor food prevent a deterioration of mood and cognitive performance of stress-prone subjects when subjected to a stressful task? *Appetite* 31:49.
- (52) Bailey SP, et al. 2000. Effect of menstrual cycle phase on carbohydrate supplementation during prolonged exercise to fatigue *J Appl Physiol* 88:690.
- (53) Davis JM, et al. 1992. Effects of carbohydrate feedings on plasma free tryptophan and branched-chain amino acids during prolonged cycling. *Eur. J. Appl. Physiol.* 65:513.
- (54) Davis JM, Bailey SP. 1997. Possible mechanisms of central nervous system fatigue during exercise. *Med. Sci. Sports Exerc.* 29: 45.
- (55) Mittleman KD, et al. 1998. Branched-chain amino acids prolong exercise during heat stress in men and women. *Med. Sci. Sports Exerc.* 30:83.
- (56) MacLaren DP, et al. 1994. Hormonal and metabolite responses to glucose and maltodextrin

- ingestion with or without the addition of guar gum. *Int. J. Sports Med.* 15:466.
- (57) Martin-Du-Pan R, et al. 1982. Effect of increasing oral glucose doses on plasma neutral amino acid levels. *Metabolism* 31:937.
- (58) Spinedi E, Gaillard RC. 1991. Stimulation of the hypothalamo- pituitary-adrenocortical axis by the central serotonergic pathway: involvement of endogenous corticotropin-releasing hormone but not vasopressin. *J Endocrinol Invest.* 14:551.
- (59) Kirschbaum C, et al. 1992. Heritability of cortisol responses to h-CRH, ergometry, and psychological stress in humans. *J Clin Endocrinol Metab.* 75:1526.
- (60) Kirschbaum C, et al. 1995. Preliminary evidence for reduced cortisol responsivity to psychological stress in women using oral contraceptive medication. *Psychoneuroendocrinology* 20:509.
- (61) Molteni R, et al. 2002. A highfat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. *Neuroscience* 112:803.
- (62) Wu A, et al. 2003. A saturated-fat diet aggravates the outcome of traumatic brain injury on hippocampal plasticity and cognitive function by reducing brain-derived neurotrophic factor. *Neuroscience* 119:365.
- (63) Strack AM, et al. 1997. A hypercaloric load both activates thermogenesis and decreases stress responses in the sympathetic and adrenocortical systems. *Am J Physiol* 272:R840.
- (64) Minor TR, Saade S. 1997. Poststress glucose mitigates behavioral impairment in rats in the "learned helplessness" model of psychopathology. *Biol Psychiatry* 42:324.
- (65) Dess NK, et al. 1998. The interaction of diet and stress in rats: high-energy food and sucrose treatment. *J Exp Psychol Anim Behav Process* 24:60.
- (66) Carbajal R, et al. 1999. Randomized trial of analgesic effects of sucrose, glucose and pacifiers in term neonates. *BMJ* 319:1393.
- (67) D'Anci KE. 1999. Tolerance to morphine-induced antinociception is decreased by chronic sucrose or polycose intake. *Pharmacol Biochem Behav* 63:1.
- (68) Utter AC, et al. 1999. Effect of carbohydrate ingestion and hormonal responses on ratings of perceived exertion during prolonged cycling and running. *Eur J Appl Physiol* 80:92.
- (69) Gonzalez-Bono E, et al. 2002. Glucose but not protein or fat amplifies the cortisol response to psychosocial stress. *Horm Behav* 41:328.
- (70) Buwalda B, et al. 2001. Behavioural and physiological responses to stress are affected by high-fat feeding in male rats. *Physiol Behaviour* 73: 371.
- (71) Tannenbaum BM, et al. 1997. High-fat feeding alters both basal and stress-induced hypothalamic-pituitary-adrenal activity in the rat. *Am J Physiol* 273:E1168.
- (72) Prasad A, Prasad C. 1996. Short-term consumption of a diet rich in fat decreases anxiety response in adult male rats. *Physiol Behav* 60:1039.
- (73) Rouch C, et al. 1999. Determination, using micridialysis, of hypothalamic serotonin variations in response to different macronutrients. *Physiol Behav* 65:653.
- (74) Haourigui M, et al. 1995. Postprandial free fatty acids stimulate activity of human corticosteroid binding globulin. *Am J Physiol* 296(6, Pt. 1):E1067.
- (75) Kalmijn S. 2000. Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. *J. Nutr. Health Aging* 4:202.
- (76) Martin ME, et al. 1988. Selective changes in binding and immunological properties of human corticosteroid binding globulin by free fatty acids. *Endocrinology* 123:1178.
- (77) Solfrizzi V, et al. 1999. High monounsaturated fatty acids intake protects against age-related cognitive decline. *Neurology* 52:1563.
- (78) Holub BJ. 2002. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. *CMAJ* 166:608.
- (79) Bourre JM. 2004. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. *J Nutr Health Aging* 8:163.
- (80) Simopoulos AP, et al. 1999. Workshop on the Essentiality of and Recommended Dietary Intakes for Omega-6 and Omega-3 Fatty Acids. *J Am Coll Nutr* 18:487.
- (81) Simopoulos AP. 1998. Overview of evolutionary aspects of omega 3 fatty acids in the diet. *World Rev Nutr Diet* 83:1.
- (82) Innis SM. 1991. Essential fatty acids in growth and development. *Prog Lipid Res* 30:39.

- (83) Connor WE, et al. 1992. Essential fatty acids: the importance of n-3 fatty acids in the retina and brain. *Nutr Rev* 50:21.
- (84) Brenner RR. 1984. Effect of unsaturated acids on membrane structure and enzyme kinetics. *Prog Lipid Res* 23:69.
- (85) Spector AA, Yorek MA. 1985. Membrane lipid composition and cellular function. *J Lipid Res* 26:1015.
- (86) Bourre JM, et al. 1993. Brain phospholipids as dietary source of (n-3) polyunsaturated fatty acids for nervous tissue in the rat. *J Neurochem* 60:2018.
- (87) Lauritzen L, et al. 2001. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. *Progress in Lipid Research* 40(1-2):1.
- (88) Yehuda S, et al. 1999. Essential fatty acids are mediators of brain biochemistry and cognitive functions. *Journal of Neuroscience Research* 56(6):565.
- (89) Jones C, et al. 1997. Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. *Neurochem. Res* 22:663.
- (90) Uauy R, et al. 2001. Essential fatty acids in visual and brain development. *Lipids* 36(9):885.
- (91) Westerman M, et al. 2002. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. *J. Neurosci* 22:1858.
- (92) Calon F, et al. 2004. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. *Neuron* 43:633.
- (93) Bourre JM, et al. 1991. Essentiality of omega 3 fatty acids for brain structure and function. *World Rev Nutr Diet* 66:103.
- (94) Williard DE, et al. 2001. Docosahexaenoic acid synthesis from n-3 poly-unsaturated fatty acids in differentiated rat brain astrocytes. *J Lipid Res* 42:1368.
- (95) Tapiero H, et al. 2002. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. *Biomedicine & Pharmacotherapy* 56(5):215.
- (96) Yehuda S, et al. 1998. Modulation of learning and neuronal membrane composition in the rat by essential fatty acid preparation: time-course analysis. *Neurochem Res* 23:627.
- (97) Heron DS, et al. 1980. Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. *Proc Natl Acad Sci USA* 77:7463.
- (98) Hibbeln JR, et al. 1988. Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. *Biol Psychiatry* 44:235.
- (99) Mann JJ, Malone KM. 1997. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. *Biol Psychiatry* 41:162.
- (100) Carrie I, et al. 2000. Specific phospholipid fatty acid composition of brain regions in mice. Effects of n-3 polyunsaturated fatty acid deficiency and phospholipid supplementation. *J Lipid Res* 41:465.
- (101) Bourre JM, et al. 1993. Function of dietary polyunsaturated fatty acids in the nervous system. *Prostaglandins Leukot Essent Fatty Acids* 48:5.
- (102) Ahmad A, et al. 2002. A decrease in cell size accompanies a loss of decosahexaenoate in the rat hippocampus. *Nutr Neurosci* 5:103.
- (103) Yoshida S, et al. 1997. Synaptic vesicle ultrastructural changes in the rat hippocampus induced by a combination of alpha-linolenate deficiency and a learning task. *J Neurochem* 68:1261.
- (104) Hamilton L, et al. 2000. n-3 fatty acid deficiency decreases phosphatidylserine accumulation selectively in neuronal tissues. *Lipids* 35:863.
- (105) Zimmer L, et al. 2000. Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. *Neurosci Lett* 284:25.
- (106) Delion S, et al. 1996. alpha-Linolenic acid dietary deficiency alters age related changes of dopaminergic and serotonergic neurotransmission in the rat frontal cortex. *J Neurochem* 66:1582.
- (107) Zangen A, et al. 2001. Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens. *Psychopharmacology(Berl)* 155:434.
- (108) Chalon S, et al. 2001. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. *Lipids* 36:937.
- (109) Zimmer L, et al. 2002. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. *American Journal of Clinical Nutrition* 75(4):662.
- (110) Garcia MC, Kim HY. 1997. Mobilization of arachidonate and decosahexaenoate by stimulation of the 5-HT2A receptor in rat C6 glioma cells. *Brain Res* 768:43.

- (111) Ryback R. 2001. Bioelectrical modulators and the cell membrane in psychiatric medicine. *Psychopharmacol Bull* 35:5.
- (112) Wainwright PE. 1997. Essential fatty acids and behaviour. In: Yehuda S, Mostofsky DI, eds. *Handbook of essential fatty acid biology: biochemistry, physiology, and behavioural neurobiology*. Totowa, NJ: Humana Press; pp. 299.
- (113) Sessler AA, Ntambi JM. 1998. Polyunsaturated fatty acid regulation of gene expression. *J Nutr* 128:923.
- (114) Garrel D, et al. 1995. Improved clinical status and length of care with low fat nutritional support in burn patients. *J Parenteral Enteral Nutr* 19(6):482.
- (115) Chalon S, et al. 1998. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. *J Nutr* 128:2512.
- (116) Brambilla F, Maggioni M. 1998. Blood levels of cytokines in elderly patients with major depressive disorder. *Acta Psychiatr Scand* 97:309.
- (117) Maggioni M, et al. 1990. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. *Acta Psychiatr Scand* 81:265.
- (118) Ximenes da Silva A, et al. 2002. Glucose transport and utilization are altered in the brain of rats deficient in n-3 polyunsaturated fatty acids. *J Neurochem* 81:1328.
- (119) Ziyilan ZY, et al. 1992. Effect of dietary n-3 fatty acid deficiency on blood-to-brain transfer of sucrose, alphaaminoisobutyric acid and phenylalanine in the rat. *Neurosci Lett* 137:9.
- (120) Ellis EF, et al. 1992. Effect of dietary n-3 fatty acids on cerebral microcirculation. *Am J Physiol* 262:H1379.
- (121) de Wilde MC, et al. 2002. The effect of n-3 polyunsaturated fatty acid-rich diets on cognitive and cerebrovascular parameters in chronic cerebral hypoperfusion. *Brain Res* 947:166.
- (122) Kim HY, et al. 2000. Inhibition of neuronal apoptosis by docosahexaenoic acid. (22:6n-3) *J. Biol. Chem.* 275:35215.
- (123) Venters HD, et al. 1999. A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide. *Proc. Nat. Acad. Sci. USA.* 96:9879.
- (124) Das UN. 2000. Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. *Mol. Cell. Biochem.* 215:145.
- (125) Das UN. 2000. Long-Chain Polyunsaturated Fatty Acids in the Growth and Development of the Brain and Memory. *Nutrition* 19:62.
- (126) Barberger-Gateau P, et al. 2002. Fish, meat and risk of dementia: cohort study. *BMJ* 325:932.
- (127) Rudin DO. 1981. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. *Biol Psychiatry* 16:837.
- (128) Stoll AL, et al. 1999. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. *Arch Gen Psychiatry* 56:407.
- (129) Nemets B, et al. 2002. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. *Am J Psychiatry* 159:477.
- (130) Peet M, Horrobin DF. 2002. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. *Arch Gen Psychiatry* 59:913.
- (131) Adams PB, et al. 1996. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. *Lipids* 31:S157.
- (132) Maes M, et al. 1999. Lowered omega3 polyunsaturated fatty acids in the serum phospholipids and cholesteryl esters of depressed patients. *Psychiatry Res* 85:275.
- (133) Peet M, et al. 1998. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. *Biol Psychiatry* 43:315.
- (134) Tiemeier H, et al. 2003. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. *Am J Clin Nutr* 78:40.
- (135) Hibbeln JR. 1998. Fish consumption and major depression. *Lancet* 351:1213.
- (136) Tanskanen A, et al. 2001. Fish consumption, depression, and suicidality in a general population. *Arch Gen Psychiatry* 58:512.
- (137) Silvers KM, Scott KM. 2002. Fish consumption and self-reported physical and mental health status. *Public Health Nutr* 5:427.
- (138) Mamalakis G, et al. 2002. Depression and adipose essential polyunsaturated fatty acids. *Prostaglandins Leukot Essent Fatty Acids* 67:311.
- (139) Sampalis F, et al. 2003. Evaluation of the effects of Neptune Krill Oil on the management of premenstrual syndrome and dysmenorrhea. *Altern Med Rev* 8:171.

- (140) Makrides M, et al. 2003. Docosahexaenoic acid and post-partum depression – is there a link? *Asia Pac J Clin Nutr* 12(Suppl):S37.
- (141) Otto SJ, et al. 2003. Increased risk of postpartum depressive symptoms is associated with slower normalization after pregnancy of the functional docosahexaenoic acid status. *Prostaglandins Leukot Essent Fatty Acids* 69:237.
- (142) Hibbeln JR. 2002. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. *J Affect Disord* 69:15.
- (143) Bremner JD, et al. 2002. Reduced volume of orbitofrontal cortex in major depression. *Biol Psychiatry* 51:273.
- (144) Steingard RJ, et al. 2002. Smaller frontal lobe white matter volumes in depressed adolescents. *Biol Psychiatry* 52:413.
- (145) Marangell LB, et al. 2003. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. *Am J Psychiatry* 160:996.
- (146) Marangell LB, et al. 2004. Omega-3 fatty acids for the prevention of postpartum depression: negative data from a preliminary, open-label pilot study. *Depress Anxiety* 19:20.
- (147) Llorente AM, et al. 2003. Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. *Am J Obstet Gynecol* 188:1348.
- (148) Maes M, Smith RS. 1998. Fatty acids, cytokines, and major depression. *Biol Psychiatry* 43:313.
- (149) Suarez EC, et al. 2003. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. *Psychosom Med* 65:362.
- (150) Logan AC. 2003. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. *Altern Med Rev* 8:410.
- (151) Shimizu E, et al. 2003. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. *Biol Psychiatry* 54:70.
- (152) Russo-Neustadt A. 2003. Brain-derived neurotrophic factor, behavior, and new directions for the treatment of mental disorders. *Semin Clin Neuropsychiatry* 8:109.
- (153) Kalmijn S, et al. 1997. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. *Am J Epidemiol* 145(1):33.
- (154) Morris MC, et al. 2003. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. *Archives of Neurology* 60(7):940.
- (155) Kalmijn S, et al. 1997. Dietary fat intake and the risk of incident dementia in the Rotterdam study. *Annals of Neurology* 42(5):776.
- (156) Huan M, et al. 2004. Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in China. *Biol Psychiatry* 56:490.
- (157) Zanarini MC, Frankenburg FR. 2003. omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. *Am J Psychiatry* 160:167.
- (158) Hoppel CL, Davis AT. 1988. Inter-tissue relationships in the synthesis and distribution of carnitine. *Biochem Soc Trans* 14:673.
- (159) Beal MF. 2003. Bioenergetic approaches for neuroprotection in Parkinson's disease. *Ann Neurol* 53 (Suppl 3):S39.
- (160) Kerner J, Hoppel C. 1998. Genetic disorders of carnitine metabolism and their nutritional management. *Annu Rev Nutr* 18:179.
- (161) Virmani A, Binienda Z. 2004. Role of carnitine esters in brain neuropathology. *Mol Aspects Med* 25(5-6):533.
- (162) Binienda Z, et al. 1999. Protective effect of L-carnitine in the neurotoxicity induced by the mitochondrial inhibitor 3-nitropropionic acid (3-NPA). *Ann N Y Acad Sci* 890:173.
- (163) Binienda Z, Virmani A. 2003. The mitochondriotropic effects of L-carnitine and its esters in the central nervous system. *Curr Med Chem – Central Nervous System Agents* 3:275.
- (164) Beal MF, et al. 1993. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. *J Neurosci* 13:4181.
- (165) Hinerfeld D, et al. 2004. Endogenous mitochondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. *J Neurochem* 88:657.
- (166) Manfredi A, et al. 1992. Culture of dorsal root ganglion neurons from aged rats: effects of acetyl-L-carnitine and NGF. *Int J Dev Neurosci* 10:321.
- (167) Cohen EL, Wurtman RJ. 1976. Brain acetylcholine: control by dietary choline. *Science* 191:561.
- (168) Hirsch MJ, Wurtman RJ. 1978. Lecithin consumption elevates acetylcholine

- concentrations in rat brain and adrenal gland. *Science* 202:223.
- (169) Growdon JH, et al. 1977. Huntington's disease: clinical and chemical effects of choline administration. *Ann Neurol* 1:418.
- (170) Rosenberg GS, Davis KL. 1982. The use of cholinergic precursors in neuropsychiatric diseases. *Am J Clin Nutr* 36:709.
- (171) Rathmann KL, Conner CS. 1984. Alzheimer's disease: clinical features, pathogenesis and treatment. *Drug Intell Clin Pharm* 18:684.
- (172) Thal LJ, et al. 1981. Choline chloride in Alzheimer disease. *Ann Neurol* 10:580 (letter).
- (173) Etienne P, et al. 1981. Alzheimer disease: lack of effect of lecithin treatment for 3 months. *Neurology* 31:1552.
- (174) Mellinkoff SM, et al. 1956. Relationships between serum amino acid concentration and fluctuations in appetite. *J Appl Physiol* 8:535.
- (175) Bray GA. 1997. Amino acids, protein, and body weight. *Obes Res* 5:373.
- (176) Porrini M, et al. 1997. Weight, protein, fat, and timing of preloads affect food intake. *Physiol Behav* 62:563.
- (177) Gibson EL, et al. 1995. Disguised protein in lunch after low-protein breakfast conditions food-flavor preferences dependent on recent lack of protein intake. *Physiol Behav* 58:363.
- (178) Peeke PM, Chrousos GP. 1995. Hypercortisolism and obesity. *Ann NY Acad Sci* 771:665.
- (179) Kissebah AH, Krakower GR. 1994. Regional adiposity and morbidity. *Physiol Rev* 74:761.
- (180) Sanchez A, Hubbard RW. 1991. Plasma amino acids and the insulin/ glucagon ratio as an explanation for the dietary protein modulation of atherosclerosis. *Med Hypotheses* 35:324.
- (181) Nijima A, Meguid MM. 1995. An electrophysiological study on amino acid sensors in the hepatoportal system in the rat. *Obes Res* 3(Suppl 5): 741S.
- (182) Fernstrom JD. 1990. Aromatic amino acids and monoamine synthesis in the central nervous system: influence of the diet. *J Nutr Biochem* 1: 508.
- (183) Rogers PJ, Blundell JE. 1994. Reanalysis of the effects of phenylalanine, alanine, and aspartame on food intake in human subjects. *Physiol Behav* 56: 247.
- (184) Fernstrom JD, Wurtman RJ. 1971. Brain serotonin content: physiological dependence on plasma tryptophan levels. *Science* 173: 149.
- (185) Gietzen DW. 1993. Neural mechanisms in the responses to amino acid deficiency. *J Nutr* 123: 610.
- (186) Gibson EL, et al. 1999. Increased Salivary Cortisol Reliably Induced by a Protein-Rich Midday Meal. *Psychosomatic Medicine* 61: 214.
- (187) Ohara I, et al. 1995. Decline of taste sensitivity in protein deficient adult rats. *Physiol Behav* 57: 921.
- (188) Tabuchi R, Ohara I. 1998. The timing of protein feeding and dietary protein levels affect taste preference, serum zinc concentration and glossal epithelial morphology in growing rats. *J Am Coll Nutr* 17: 79.
- (189) Cummings SL. 1997. Neuropeptide Y, somatostatin, and cholecystokinin of the anterior piriform cortex. *Cell Tissue Res* 289: 39.
- (190) Harper AE, et al. 1970. Effects of ingestion of disproportionate amounts of amino acids. *Physiol Behav* 50: 428.
- (191) Gietzen DW, et al. 1987. Serotonin and feeding responses of rats to amino acid imbalance: initial phase. *Am J Physiol Regul Integr Comp Physiol* 253: R763.
- (192) Leung PMB, Rogers QR. 1986. Effect of amino acid imbalance and deficiency on dietary choice patterns of rats. *Physiol Behav* 37: 747.
- (193) Gietzen, DW, et al. 1986. Time course of food intake and plasma amino acid concentrations in rats fed amino acids imbalanced or deficient diets. In: *Interaction of the Chemical Senses with Nutrition*, edited by Kare MR, and Brand J.. New York: Academic, pp. 415.
- (194) Rogers QR, Leung PMB. 1977. The control of food intake: when and how are amino acids involved? In: *The Chemical Senses and Nutrition*, edited by Kare MR, and Maller O. New York: Academic, pp. 213.
- (195) Jiang JC, Gietzen DW. 1994. Anorectic response to amino acid imbalance: a selective serotonin₃ effect? *Pharmacol Biochem Behav* 47: 59.
- (196) Beverly JL, et al. 1990. Effect of dietary limiting amino acid in prepiriform cortex on meal pattern. *Am J Physiol Regulatory Integrative Comp Physiol* 259: R716.
- (197) Terry-Nathan VR, et al. 1995. Serotonin₃ antagonists block aversion to saccharin in an amino acid imbalanced diet. *Am J Physiol* 268: R1203.
- (198) Meliza LL, et al. 1981. Effect of anterior prepyriform and medial amygdaloid lesions on acquisition of taste-avoidance and response to

- dietary amino acid imbalance. *Physiol Behav* 26: 1031.
- (199) Wang Y, et al. 1996. Temporal-spatial pattern of c-fos expression in the rat brain in response to indispensable amino acid deficiency. *Mol Brain Res* 40: 35.
- (200) Gietzen DW, et al. 1998. Neurochemical changes after imbalanced diets suggest a brain circuit mediating anorectic responses to amino deficiency in rats. *J Nutr* 128: 771.
- (201) Noda K. 1975. Possible effect of blood ammonia on food intake of rats fed amino acid imbalanced diets. *J Nutr* 105: 508.
- (202) Leung, PMB, Rogers QR. 1987. The effect of amino acids and protein on dietary choice. In: *Umami: a Basic Taste*, edited by Kawamura Y, and Kare MR.. New York: Dekker, pp. 565.
- (203) Booth DA, Toates FM. 1974. Control of food intake by energy supply. *Nature* 251: 710.
- (204) Nicolaïdis S, Even P. 1990. The ischymetric control of feeding. *Int J Obes* 14: 35.
- (205) Fonnum F. 1984. Glutamate: a neurotransmitter in mammalian brain. *J Neurochem* 42: 1.
- (206) Brann DW. 1995. Glutamate: a major excitatory transmitter in neuroendocrine regulation. *Neuroendocrinology* 61: 213.
- (207) van den Pol AN, et al. 1990. Glutamate, the dominant excitatory transmitter in neuroendocrine regulation. *Science (Washington DC)* 250: 1276.
- (208) Olney JW. 1969. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. *Science (Washington DC)* 164: 719.
- (209) Yamaguchi S, Ninomiya K. 2000. Umami and food palatability. *J Nutr* 130: 921S.
- (210) Nishijo H, et al. 2000. Hypothalamic and amygdalar neuronal responses to various tastant solutions during ingestive behavior in rats. *J Nutr* 130: 954S.
- (211) Rolls ET. 2000. The representation of umami taste in the taste cortex. *J Nutr* 130: 960S.
- (212) Dingledine R, Conn PJ. 2000. Peripheral glutamate receptors: molecular biology and role in taste sensation. *J Nutr* 130: 1039S.
- (213) Erdo SL. 1991. Excitatory amino acid receptors in the mammalian periphery. *Trends Pharmacol Sci* 12: 426.
- (214) Reeds PJ, et al. 2000. Intestinal glutamate metabolism. *J Nutr* 130: 978S.
- (215) Brosnan JT. 2000. Glutamate, at the interface between amino acid and carbohydrate metabolism. *J Nutr* 130: 988S.
- (216) Daikhin Y, Yudkoff M. 2000. Compartmentation of brain glutamate metabolism in neurons and glia. *J Nutr* 130: 1026S.
- (217) Yudkoff M, et al. 1993. Brain glutamate metabolism: neuronal-astroglial relationships. *Dev Neurosci* 15: 343.
- (218) Goldsmith PC. 2000. Neuroglial responses to elevated glutamate in the medial basal hypothalamus of the infant mouse. *J Nutr* 130: 1032S.
- (219) Carlson HE, et al. 1989. Stimulation of pituitary hormone secretion by neurotransmitter amino acids in humans. *Metabolism* 38: 1179.
- (220) Arslan M, et al. 1991. Possible modulation of N-methyl-D,L-aspartic acid induced prolactin release by testicular steroids in the adult male rhesus monkey. *Life Sci* 49: 1073.
- (221) Gay VL, et al. 1987. N-Methyl-D,L-aspartate elicits hypothalamic gonadotropin-releasing hormone release in prepubertal male rhesus monkeys (*Macaca mulatta*). *Endocrinology* 120: 2289.
- (222) Medhamurthy R, et al. 1992. Repetitive injections of L-glutamic acid, in contrast to those of N-methyl-D,L-aspartic acid, fail to elicit sustained hypothalamic GnRH release in the prepubertal male rhesus monkey (*Macaca mulatta*). *Neuroendocrinology* 55: 660.
- (223) Urbanski HF, et al. 1997. Alpha-adrenergic receptor antagonism and N-methyl-D-aspartate (NMDA) induced luteinizing hormone release in female rhesus macaques. *Brain Res* 744: 96.
- (224) Wilson RC, Knobil E. 1982. Acute effects of N-methyl-DL-aspartate on the release of pituitary gonadotropins and prolactin in the adult female rhesus monkey. *Brain Res* 248: 177.
- (225) Olney JW. 1994. Excitotoxins in foods. *Neurotoxicology* 15: 535.
- (226) Kohen R, et al. 1988. Antioxidant activity of carnosine, homocarnocine, and anserine present in muscle and brain. *Proc Natl Acad Sci* 85: 3175.
- (227) Schwartz JC, et al. 1972. Histamine formation in rat brain in vivo: Effects of histidine loads. *J Neurochem* 19: 801.
- (228) Taylor KM, Snyder SH. 1972. Dynamics of the regulation of histamine levels in mouse brain. *J Neurochem* 19: 341.

- (229) Giroux EL, Henkin RI. 1972. Competition for zinc among serum albumin and amino acids. *Biochim. Biophys. Acta.* 273: 6472.
- (230) Giroux EL, Henkin RI. 1972. Macromolecular ligands of exchangeable copper, zinc and cadmium in human serum. *Bioinorg. Chem.* 2: 125.
- (231) Henkin RI. 1974. Metal-albumin-amino acid interactions: chemical and physiological interrelationships, in *Protein-Metal Interactions*, (Friedman M. Ed.), Plenum Publishing Co., N.Y., pp. 299.
- (232) Henkin RI, et al. 1975. A syndrome of acute zinc loss. *Arch. Neurol.* 32: 745.
- (233) Henkin RI. 1977. New aspects in the control of food intake and appetite. *Ann. N.Y. Acad. Sci.* 300: 321.
- (234) Henkin RI. 1978. Zinc dependent control of food intake, taste and smell function, in *Trace Element Metabolism in Man and Animals III*, (Kirchgessner M, Ed.). Arbeitskreis für Tierernährungsforschung, Weihenstephan, Freising-Weihenstephan, West Germany, pp.190.
- (235) Suryawan A, et al. 1998. A molecular model of human branched-chain amino acid metabolism. *Am. J. Clin. Nutr.* 68: 72.
- (236) Flodin NW. 1997. The metabolic roles, pharmacology and toxicology of lysine. *J. Am. Coll. Nutr.* 16: 7.
- (237) Nutrient Data Laboratory ARS. 2004. USDA Nutrient Database for Standard Reference, Release 17, 2004, USDA Washington DC.
- (238) Platell C, et al. 2000. Branched-chain amino acids. *J. Gastroenterol. Hepatol.* 15: 706.
- (239) Grimes MA, et al. 2000. Cerebral spinal fluid concentrations of tryptophan and 5-hydroxyindoleacetic acid in macaca mulatta: diurnal variations and response to chronic changes in dietary protein intake. *Neurochem. Res.* 25: 413.
- (240) Fernstrom MH, et al. 1986. In vivo inhibition of tyrosine uptake into rat retina by large neutral but not acidic amino acids. *Am. J. Physiol.* 251: E393.
- (241) Young SN, et al. 1989. Biochemical aspects of tryptophan depletion in primates. *Psychopharmacology (Berl)* 98: 508.
- (242) Williams WA, et al. 1999. Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. *J. Neurochem.* 72: 1641.
- (243) Fernstrom MH, Fernstrom JD. 1995. Acute tyrosine depletion reduces tyrosine hydroxylation rate in rat central nervous system. *Life Sci.* 57: PL97.
- (244) Montgomery AJ, et al. 2003. Reduction of brain dopamine concentration with dietary tyrosine plus phenylalanine depletion: an [¹¹C]raclopride PET study. *Am. J. Psychiat.* 160: 1887.
- (245) Mori M, et al. 1991. Taste preference, protein nutrition and L-amino acid homeostasis in male Sprague-Dawley rats. *Physiol Behav* 49: 987.
- (246) Smriga M, et al. 2000. Circadian release of hypothalamic norepinephrine in rats in vivo is depressed during early L-lysine deficiency. *J Nutr* 130: 1641.
- (247) Hrupka BJ, et al. 1999. Lysine deficiency alters diet selection without depressing food intake in rats. *J Nutr* 129:424.
- (248) Torii K, et al. 1996. Recognition of deficient nutrient intake in the brain of rats with the L-lysine deficiency monitored by functional magnetic resonance imaging, electrophysiologically and behaviorally. *Amino Acids* 10:73.
- (249) Bernasconi R, et al. 1986. Does pipecolic acid interact with the central GABA-ergic system? *J Neural Transm* 67:175.
- (250) Chang YF. 1982. Lysine metabolism in the human and the monkey: demonstration of pipecolic acid formation in the brain and other organs. *Neurochem Res* 7:577.
- (251) Smriga M, et al. 2002. Dietary L-Lysine Deficiency Increases Stress-Induced Anxiety and Fecal Excretion in Rats. *J. Nutr.* 132:3744.
- (252) Smriga M, Torii K. 2003. Prolonged treatment with L-lysine and L-arginine reduces stress-induced anxiety in an elevated plus maze. *Nutr Neurosci* 6:125.
- (253) Smriga M, Torii K. 2003. Metabolic interactions between restraint stress and L-lysine: the effect on urea cycle components. *Amino Acids* 24:435.
- (254) Galili G, et al. 2001. Lysine catabolism: a stress and development super-regulated metabolic pathway. *Curr Opin Plant Biol* 4:261.
- (255) Smriga M, Torii K. 2003. L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats. *Proc Natl Acad Sci USA* 100:15370.

- (256) Van der Schoor SRD, et al. 2002. The high metabolic cost of a functional gut. *Gastroenterology* 123:1931.
- (257) Srinongkote S, et al. 2003. A diet fortified with L-lysine and L-arginine reduces plasma cortisol and blocks anxiogenic response to transportation in pigs. *Nutr Neurosci* 6:283.
- (258) Nesse RM. 1999. Proximate and evolutionary studies of anxiety, stress and depression: synergy at the interface. *Neurosci Biobehav Rev* 23:895.
- (259) Smriga M, et al. 2004. Lysine fortification reduces anxiety and lessens stress in family members in economically weak communities in Northwest Syria. *PNAS* 101:8285.
- (260) Leathwood PD. 1987. Tryptophan availability and serotonin synthesis. *Proc. Nutr Soc* 46:143.
- (261) Baranyiova E. 1991. Effect of serotonin on food intake by piglets during the early postnatal period. *Acta Vet. (Brno)* 60:127.
- (262) Huether G, et al. 1999. Tryptophan, serotonin, and melatonin: Basic aspects and applications. Kluwer Academic/Plenum Publ., New York, NY
- (263) Sève B. 1999. Physiological roles of tryptophan in pig nutrition. In *Tryptophan, Serotonin, and Melatonin: Basic Aspects and Applications*. Huether, ed. Kluwer Acad./Plenum Publ., New York, NY, pp 729.
- (264) Sharp T, et al. 1992. Effect of acute administration of L-tryptophan on the release of 5-HT in rat hippocampus in relation to serotonergic neuronal activity: an in vivo microdialysis study. *Life Sci* 50:1215.
- (265) Adeola O, Ball RO. 1992. Hypothalamic neurotransmitter concentrations and meat quality in stressed pigs offered excess dietary tryptophan and tyrosine. *J. Anim. Sci.* 70:1888.
- (266) Pethick DW, et al. 1997. Nutritional manipulation of meat quality. In *Manipulating Pig Production VI*, P. D. Cranwell, ed. Australian Pig Sci. Assoc, pp 91.
- (267) Lieberman HR, et al. 1986. Changes in mood after carbohydrate consumption among obese individuals. *Am J Clin Nutr* 44:772.
- (268) Christensen L. 1997. The effects of carbohydrates on affect. *Nutrition* 13:503.
- (269) Spring B, et al. 1987. Carbohydrates, tryptophan, and behavior: a methodological review. *Psychol Bull* 102:234.
- (270) Sayegh R, et al. 1995. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. *Obstet Gynecol* 86:520.
- (271) Sève B, et al. 1991. Impact of dietary tryptophan and behavioral type on growth performance and plasma amino acids of young pigs. *J. Anim. Sci.* 69:3679.
- (272) Shea-Moore MM, et al. 1996. Decreases in aggression in tryptophan-supplemented broiler breeder males are not due to increases in blood niacin levels. *Poult Sci* 75:370.
- (273) Rosebrough RW. 1996. Crude protein and supplemental dietary tryptophan effects on growth and tissue neurotransmitter levels in the broiler chicken. *Br J Nutr* 76:87.
- (274) van Hierden YM, et al. 2004. Chronic increase of dietary L-tryptophan decreases gentle feather pecking behavior. *Appl Anim Behav Sci* 89:71.
- (275) Bhatti TJ, et al. 1998. Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood. *Biol Psychiatry* 43:52.
- (276) Riemann D, et al. 2002. The tryptophan deletion test: impact on sleep in primary insomnia: a pilot study. *Psychiatry Res* 109:129.
- (277) Hartmann E, Greenwald D. 1984. Tryptophan and human sleep: an analysis of 43 studies. In: Schlossberger HG, Kochen W, Linzen B, Steinhart H, eds. *Progress in tryptophan and serotonin research*. New York, NY: DeGruyter, pp297.
- (278) Hartmann E. 1983. Effects of L-tryptophan on sleepiness and sleep. *J Psychiatr Res* 17(2):107.
- (279) Schnieder-Helmert D, Spinweber CL. 1986. Evaluation of L-tryptophan for treatment of insomnia: a review. *Psychopharmacology* 89:1.
- (280) Borbély A, Youmbi-Balderer G. 1987. Effects of tryptophan on human sleep. *Interdisciplinary Top Gerontol* 22:111.
- (281) Young SN, Gauthier S. 1981. Tryptophan availability and the control of 5-hydroxytryptamine and tryptamine synthesis in human CNS. *Adv Exp Med Biol* 133:221.
- (282) van Hierden YM, et al. 2002. Adrenocortical reactivity and central serotonin and dopamine turnover in young chicks from a high and low feather pecking line of laying hens. *Physiol Behav* 75:653.
- (283) Pilcher JJ, Huffcutt AJ. 1996. Effects of sleep deprivation on performance: a meta-analysis. *Sleep* 19(4):318.
- (284) Dinges DF, Kribbs NB. 1991. Performing while sleepy: effects of experimentally-induced

- sleepiness. In: Monk TH, ed. Sleep, sleepiness and performance. Chichester, United Kingdom: Wiley & Sons, pp97.
- (285) Polich J, Kok A. 1995. Cognitive and biological determinants of P300: an integrative review. *Biol Psychol* 41:103.
- (286) Mason JW. 1968. A review of psychoendocrine research on the pituitary-adrenal cortical system. *Psychosom Med* 30:576.
- (287) Adell A, et al. 1988. Chronic stress increases serotonin and noradrenaline in rat brain and sensitizes their responses to a further acute stress. *J Neurochem* 50:1678.
- (288) Heine W, et al. 1996. α -Lactalbumin-enriched low-protein infant formulas: a comparison to breast milk feeding. *Acta Paediatr* 85:1024.
- (289) Lieberman HR, et al. 1986. The composition of lunch determines afternoon plasma tryptophan ratios in humans. *J Neural Transm* 65:211.
- (290) Markus CR. 2003. Food, stress and mood. In: Wadson D, Dodds F, eds. Performance functional foods. Cambridge, United Kingdom: Woodhead Publishing Limited, pp5.
- (291) Curzon G. 1985. Effects of food intake on brain transmitter amine precursors and amine synthesis. In: Sandler M, Silverstone T, eds. Psychopharmacology and food. Oxford, United Kingdom: Oxford University Press, pp59.
- (292) Fernstrom JD, Wurtman RJ. 1972. Brain serotonin content: physiological regulation by plasma neutral amino acids. *Science* 178:414.
- (293) Markus CR, et al. 2005. Evening intake of α -lactalbumin increases plasma tryptophan availability and improves morning alertness and brain measures of attention *American Journal of Clinical Nutrition* 81(5):1026.
- (294) McMenamy RH, Oncley JL. 1958. The specific binding of L-tryptophan to serum albumin. *J Biol Chem* 233:1436.
- (295) Knott PJ, Curzon G. 1972. Free tryptophan in plasma and brain tryptophan metabolism. *Nature* 239:452.
- (296) Curzon G, Fernando JC. 1976. Effect of aminophylline on tryptophan and other aromatic amino acids in plasma, brain and other tissues and on brain 5-hydroxytryptamine metabolism. *Br J Pharmacol* 58:533.
- (297) Fernstrom JD, et al. 1976. Tryptophan concentrations in rat brain. Failure to correlate with free serum tryptophan or its ratio to the sum of other serum neutral amino acids. *Biochem J* 160:589.
- (298) Curzon G, Knott PJ. 1975. Rapid effects of environmental disturbance on rat plasma unesterified fatty acid and tryptophan concentrations and their prevention by antilipolytic drugs. *Br J Pharmacol* 54:389.
- (299) Lipsett D, et al. 1973. Serum tryptophan level after carbohydrate ingestion: selective decline in non-albumin-bound tryptophan coincident with reduction in serum free fatty acids. *Life Sci* 12:57.
- (300) McMenamy RH, et al. 1957. Unbound amino acid concentrations in human blood plasmas. *J Clin Invest* 36:1672.
- (301) Tagliamonte A, et al. 1971. Possible role of "free" plasma tryptophan in controlling brain tryptophan concentrations. *Riv Farmacol Ter* 2:251.
- (302) Fernstrom MH, Fernstrom JD. 1993. Large changes in serum free tryptophan levels do not alter brain tryptophan levels: studies in streptozotocin-diabetic rats. *Life Sci* 52:907.
- (303) Blomstrand E, et al. 1989. Effect of sustained exercise on plasma amino acid concentrations and on 5-hydroxytryptamine metabolism in six different brain regions in the rat. *Acta Physiol Scand* 136:473.
- (304) Chaouloff F, et al. 1985. Effects of conditioned running on plasma, liver and brain tryptophan and on brain 5-hydroxytryptamine metabolism of the rat. *Br J Pharmacol* 86:33.
- (305) Chaouloff F, et al. 1986. Amino acid analysis demonstrates that increased plasma free tryptophan causes the increase of brain tryptophan during exercise in the rat. *J Neurochem* 46:1647.
- (306) Calders P, et al. 1999. Effect of branched-chain amino acids (BCAA), glucose, and glucose plus BCAA on endurance performance in rats. *Med Sci Sports Exerc* 31:583.
- (307) Madras BK, et al. 1974. Relevance of free tryptophan in serum to tissue tryptophan concentrations. *Metabolism* 23:1107.
- (308) Arner P, et al. 1990. Adrenergic regulation of lipolysis in situ at rest and during exercise. *J Clin Invest* 85:893.
- (309) Pardridge WM, Fierer G. 1990. Transport of tryptophan into brain from the circulating, albumin-bound pool in rats and in rabbits. *J Neurochem* 54:971.
- (310) Oldendorf WH. 1971. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. *Am J Physiol* 221:1629.

- (311) Tunaru S, et al. 2003. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. *Nat Med* 9:352.
- (312) Lenard NR, Dunn AJ. 2005. Potential role for nonesterified fatty acids in beta-adrenoceptor-induced increases in brain tryptophan. *Neurochem Int* 46:179.
- (313) Tork I. 1990. Anatomy of the serotonergic system. *Ann N Y Acad Sci* 600:9.
- (314) Fernstrom MH, Fernstrom JD. 1987. Protein consumption increases tyrosine concentration and in vivo tyrosine hydroxylation rate in the light-adapted rat retina. *Brain Res* 401:392.
- (315) Fernstrom MH, Fernstrom JD. 1995. Effect of chronic protein ingestion on rat central nervous system tyrosine levels and in vivo tyrosine hydroxylation rate. *Brain Res* 672:97.
- (316) Wurtman RJ, et al. 1980. Precursor control of neurotransmitter synthesis. *Pharmacol Rev* 32:315.
- (317) Fernstrom MH, et al. 1986. Effect of tyrosine administration on dopa accumulation in light- and dark-adapted retinas from normal and diabetic rats. *Life Sci* 39:2049.
- (318) Fernstrom JD, Faller DV. 1978. Neutral amino acids in the brain: changes in response to food ingestion. *J Neurochem* 30:1531.
- (319) Wurtman RJ, et al. 1974. Brain catechol synthesis: control by brain tyrosine concentration. *Science* 185:183.
- (320) Scally MC, et al. 1977. Brain tyrosine level controls striatal dopamine synthesis in haloperidol-treated rats. *J Neural Transm* 41:1.
- (321) Peters JC, Harper AE. 1985. Adaptation of rats to diets containing different levels of protein: effects on food intake, plasma and brain amino acid concentrations and brain neurotransmitter metabolism. *J Nutr* 115:382.
- (322) Gustafson JM, et al. 1986. Prediction of brain and serum free amino acid profiles in rats fed graded levels of protein. *J Nutr* 116:1667.
- (323) Fernstrom JD, Fernstrom MH. 1994. Dietary effects on tyrosine availability and catecholamine synthesis in the central nervous system: possible relevance to the control of protein intake. *Proc Nutr Soc* 53:419.
- (324) Ahlers ST, et al. 1994. Tyrosine and glucose modulation of cognitive deficits resulting from cold stress. In: Marriott BM, ed. *Food components to enhance performance*. Washington, DC: National Academy Press, pp301.
- (325) Banderet LE, Lieberman HR. 1989. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. *Brain Res Bull* 22:759.
- (326) Gelenberg AJ, et al. 1990. Tyrosine for depression: a double-blind trial. *J Affect Disord* 19:125.
- (327) Growdon JH, et al. 1982. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. *Life Sci* 30:827.
- (328) During MJ, et al. 1988. Effects of systemic tyrosine on dopamine release from rat corpus striatum and nucleus accumbens. *Brain Res* 452:378.
- (329) McTavish SFB, et al. 1999. Effect of a tyrosine-free amino acid mixture on regional brain catecholamine synthesis and release. *Psychopharmacology (Berl)* 141:182.
- (330) Gibson CJ. 1986. Dietary control of retinal dopamine synthesis. *Brain Res* 382:195.
- (331) Jaskiw GE, et al. 2006. In rats chronically treated with clozapine, tyrosine depletion attenuates the clozapine-induced in vivo increase in prefrontal cortex dopamine and norepinephrine levels. *Psychopharmacology (Berl)* 185:416.
- (332) McTavish SFB, et al. 2001. Tyrosine depletion attenuates the behavioural stimulant effects of amphetamine and cocaine in rats. *Eur J Pharmacol* 424:115.
- (333) Harmer CJ, et al. 2001. Tyrosine depletion attenuates dopamine function in healthy volunteers. *Psychopharmacology (Berl)* 154:105.
- (334) McTavish SFB, et al. 1999. Attenuation of some subjective effects of amphetamine following tyrosine depletion. *J Psychopharmacol* 13:144.
- (335) McTavish SF, et al. 2001. Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. *Br J Psychiatry* 179:356.
- (336) Leyton M, et al. 2000. Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. *Neuropsychopharmacology* 22:52.
- (337) McLean A, et al. 2004. The effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression. *Psychopharmacol (Berl)* 171:286.
- (338) Ikeda M, et al. 1965. Hydroxylation of phenylalanine by purified preparations of adrenal and brain tyrosine hydroxylase. *Biochem Biophys Res Commun* 18:482.
- (339) Biggio G, et al. 1976. Decrease of homovanillic, dihydroxyphenylacetic acid and cyclic-adenosine-3',5'-monophosphate content in

- the rat caudate nucleus induced by the acute administration of an amino acid mixture lacking tyrosine and phenylalanine. *J Neurochem* 26:1253.
- (340) Hesecker H, et al. 1992. Psychological disorder as early symptoms of a mild-to-moderate vitamin deficiency, in *Beyond Deficiency. New Views on the Function and Health Effects of Vitamins*. Sauberlich HE, Machlin LJ, Eds. New York Academy of Sciences, New York, pp. 352.
- (341) Alpert JE, Fava M. 1997. Nutrition and depression: the role of folate. *Nutr Rev* 55:145.
- (342) Hirata F, Axelrod J. 1980. Phospholipid methylation and biological signal transmission. *Science* 209:1082.
- (343) Bottiglieri T, et al. 1994. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. *Drugs* 48:137.
- (344) Turner AJ. 1977. Commentary: the roles of folate and pteridine derivatives in neurotransmitter metabolism. *Biochem Pharmacol* 26:1009.
- (345) Reynolds EH. 1968. Mental effects of anticonvulsants, and folic acid metabolism. *Brain* 91:197.
- (346) Botez MI, et al. 1979. Neuropsychological correlates of folic acid deficiency: facts and hypotheses. In: Botez MI, Reynolds EH, eds. *Folic acid in neurology, psychiatry and internal medicine*. New York: Raven, pp.435.
- (347) Bottiglieri T, et al. 1995. Folate and neuropsychiatry. In: Bailey LB, ed. *Folate in health and disease*. New York: Marcel Dekker, pp.435.
- (348) Reynolds EH. 2002. Benefits and risks of folic acid to the nervous system. *J Neurol Neurosurg Psychiatry* 72:567.
- (349) Hamon CG, et al. 1986. The effect of tetrahydrofolate on tetrahydrobiopterin metabolism. *J Ment Defic Res* 30:179.
- (350) MRC Vitamin Study Research Group. 1991. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet* 338:131.
- (351) Shorvon SD, et al. 1980. The neuropsychiatry of megaloblastic anaemia. *Br Med J* 281:1036.
- (352) Coppen A, Abou-Saleh MT. 1982. Plasma folate and affective morbidity during long-term lithium therapy. *Br J Psychiatry* 141:87.
- (353) Abou-Saleh MT, Coppen A. 1989. Serum and red blood cell folate in depression. *Acta Psychiatr Scand* 80:78.
- (354) Carney MW, et al. 1990. Red cell folate concentrations in psychiatric patients. *J Affect Disord* 19:207.
- (355) Joyal CC, et al. 1993. Are age-related behavioural disorders improved by folate administration? *Exp Aging Res* 19:367.
- (356) Paul RT, et al. 2004. Folic acid: neurochemistry, metabolism and relationship to depression. *Hum Psychopharmacol* 19:477.
- (357) Coppen A, Bailey J. 2000. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. *J Affect Disord* 60:121.
- (358) Coppen A, et al. 1986. Folic acid enhances lithium prophylaxis. *J Affect Disord* 10:9.
- (359) Godfrey PS, et al. 1990. Enhancement of recovery from psychiatric illness by methylfolate. *Lancet* 336:392.
- (360) Goodwin JS, et al. 1983. Association between nutritional status and cognitive functioning in a healthy elderly population. *JAMA* 249:2917.
- (361) La Rue A, et al. 1997. Nutritional status and cognitive functioning in a normally aging sample: a six year reassessment. *Am J Clin Nutr* 65:20.
- (362) Botez MI, et al. 1977. Folate-responsive neurological and mental disorders: report of 16 cases. *Eur Neurol* 16:230.
- (363) Reynolds EH, et al. 1973. Neurological disease associated with folate deficiency. *BMJ* ii:398.
- (364) Runcie J. 1979. Folate deficiency in the elderly. In: Botez MI, Reynolds EH, eds. *Folic acid in neurology, psychiatry and internal medicine*. New York: Raven, pp. 493.
- (365) Pogribny IP, et al. 1995. Differential sensitivity to loss of cytosine methyl groups within the hepatic p53 gene of folate/methyl deficient rats. *Carcinogenesis* 16: 2863.
- (366) Wainfan E, Poirier LA. 1992. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. *Cancer Res* 52:2068.
- (367) Kruman II, et al. 2002. Folic acid deficiency and homocysteine impair DNA repair and sensitize hippocampal neurons to death in experimental models of Alzheimer's disease. *J Neurosci* 22:1752.
- (368) Pita ML, Delgado MJ. 2000. Folate administration increases n-3 polyunsaturated fatty acids in rat plasma and tissue lipids. *Thromb Haemost* 84:420.
- (369) Durand P, et al. 1996. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine

- and decreased n-3 polyunsaturated fatty acids. *Atherosclerosis* 121:231.
- (370) Etchamendy N, et al. 2001. Alleviation of a selective age-related relational memory deficit in mice by pharmacologically induced nonnalization of brain retinoid signaling. *J Neurosci* 21:6423.
- (371) Guilarte TR. 1989. Effect of vitamin B-6 nutrition on the levels of dopamine, dopamine metabolites, dopa decarboxylase activity, tyrosine, and GABA in the developing rat corpus striatum. *Neurochem Res* 14:571.
- (372) Dakshinamurti K, et al. 1988. Neuroendocrinology of pyridoxine deficiency. *Neurosci. Biobehav Rev* 12:189.
- (373) Riggs KM, et al. 1996. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. *Am J Clin Nutr* 63:306.
- (374) Schaeffer MC. 1993. Excess dietary vitamin B-6 alters startle behaviour of rats. *J Nutr* 123:1444.
- (375) Lee NS, et al. 1988. Dietary pyridoxine interaction with tryptophan or histidine on brain serotonin and histamine metabolism. *Pharmacol Biochem Behav* 29:559.
- (376) Dakshinamurti K, et al. 1990. Influence of B vitamins on binding properties of serotonin receptors in the CNS of rats. *Klin Wochenschr* 68:142.
- (377) Allgood VE, et al. 1990. The influence of vitamin B6 on the structure and function of the glucocorticoid receptor. In vitamin B6. Dakshinamurti K, Ed., New York Academy of Sciences, New York, pp.452.
- (378) Bernstein AL. 1990. Vitamin B6 in clinical neurology. In Vitamin B6. Dakshinamurti K, Eds., New York Academy of Sciences, New York, pp.250.
- (379) Dakshinamurti K, et al. 1985. Neurobiology of pyndoxine. In: Reynolds RD, Leklem JE, eds. Vitamin B-6: its role in health and disease. New York: Alan R Liss, Inc., pp99.
- (380) Carney MWP, et al. 1987. S-Adenosylmethionine and affective disorder. *Am J Med* 83(suppl 5A):104.
- (381) Levitt AL, loffe RT. 1989. Folate, vitamin B-12, and life course of depressive illness. *Biol Psychiatry* 25:867.
- (382) Shane B, Stokstad ELR. 1985. Vitamin B-12-folate interrelationships. *Annu Rev Nutr* 5:115.
- (383) Healton EB, et al. 1991. Neurologic aspects of cobalamin deficiency. *Medicine (Baltimore)* 70:229.
- (384) Meadows ME, et al. 1994. Cognitive recovery with vitamin B12 therapy: a longitudinal neuropsychological assessment. *Neurology* 44:1764.
- (385) Bar-Sella P, et al. 1990. Vitamin B12 and folate levels in long-term vegans. *Isr J Med Sci* 26:309.
- (386) Graham SM, et al. 1992. Long-term neurologic consequences of nutritional vitamin B12 deficiency in infants. *J Pediatr* 121:710.
- (387) Sauberlich HE. 1991. Relationship of vitamin B-6, vitamin B-12, and folate to neurological and neuropsychiatric disorders. In: Bendich A, Butterworth CE Jr. eds. *Micronutrients in health and in disease prevention*. New York: Marcel Dekker, Inc., pp.187.
- (388) Wolters M, et al. 2004. Cobalamin: a critical vitamin in the elderly. *Prev Med* 39:1256.
- (389) Masalha R, et al. 2001. Cobalamin-responsive psychosis as the sole manifestation of vitamin B12 deficiency. *IMAJ* 3:701.
- (390) Goralczyk R, et al. 1992. Regulation of steroid hormone metabolism requires L-ascorbic acid, in *Beyond Deficiency. New Views on the Function and Health Effects of Vitamins*. Sauberlich HE, Machlin LJ, Eds. New York Academy of Sciences, New York, pp.349.
- (391) Degkwitz E. 1985. Neue Aspekte der Biochemie des Vitamins C. *Z Ernahrungswiss* 24(4):219.
- (392) Enwonwu CO, et al. 1995. Effect of marginal ascorbic acid deficiency on saliva level of cortisol in the uinea pig. *Arch Oral Biol* 40(8):737.
- (393) Redmann A, et al. 1995. Ascorbate depletion prevents aldosterone stimulation by sodium deficiency in the guinea pig. *Eur J Endocrinol* 133(4):499.
- (394) Kodama M, et al. 1996. Interperitoneal administration of ascorbic acid delays the turnover of 3H-labelled cortisol in plasma of an ODS rat, but not in the Wistar rat. Evidence in support of the cardinal role of vitamin C in the progression of glucocorticoid synthesis. *In Vivo* 10(1):97.
- (395) Kodama M, et al. 1994. Autoimmune disease and allergy are controlled by vitamin C treatment. *In Vivo* 8:251.
- (396) Morris KL, Zemel MB. 2005. 1,25-Dihydroxyvitamin D3 Modulation of Adipocyte Glucocorticoid Function. *Obesity Research* 13:670.
- (397) Ottosson M, et al. 2000. Effects of cortisol and growth hormone on lipolysis in human adipose tissue *J Clin Endocrinol Metab* 85:799.

- (398) Shi, H, et al. 2001. Effects of dietary calcium on adipocyte lipid metabolism and body weight regulation in energy-restricted aP2-agouti mice *FASEB J* 15:291.
- (399) Sheffy BE, Schultz RD. 1979. Influence of vitamin E and selenium on immune response mechanisms. *Fed Proc* 38:2139.
- (400) Southam E, et al. 1991. Experimental vitamin E deficiency in rats. *Brain* 114:915.
- (401) Vatassery GT. 1992. Vitamin E, neurochemistry and implications for neurodegeneration in Parkinson's disease. In *Beyond deficiency. New views on the function and health effects of vitamins*. Sauberlich HE, Machlin L, Eds, New York Academy of Sciences, New York, pp.97.
- (402) Sokol RJ. 1989. Vitamin E and neurologic function in men. *Free Rad Biol Med* 6:189.
- (403) Muller DPR, et al. 1983. Vitamin E and neurological function. *Lancet* 1(8318):225.
- (404) Grantham-McGregor S, Ani C. 1999. The role of micronutrients in psychomotor and cognitive development. *Br Med Bull* 55:511.
- (405) Allen LH, et al. 1999. Cognitive and neuromotor performance of Guatemalan schoolers with deficient, marginal and normal plasma B-12. *FASEB J* 13:A544(abstr).
- (406) Zemel MB, et al. 2000. Regulation of adiposity by dietary calcium *FASEB J* 14:1132.
- (407) Melanson EL, et al. 2003. Relation between calcium intake and fat oxidation in adult humans *Int J Obes Relat Metab Disord* 27:196.
- (408) Lin Y-C, et al. 2000. Dairy calcium is related to changes in body composition during a two-year exercise intervention in young women *J Am Coll Nutr* 19:754.
- (409) Lovejoy JC, et al. 2001. Ethnic differences in dietary intakes, physical activity, and energy expenditure in middle-aged, premenopausal women: the Healthy Transitions study *Am J Clin Nutr* 74:90.
- (410) Buchowski MS, et al. 2002. Dietary calcium intake in lactose maldigesting intolerant and tolerant African-American women *J Am Coll Nutr* 21:47.
- (411) Tanasescu M, et al. 2000. Biobehavioral factors are associated with obesity in Puerto Rican children *J Nutr* 130:1734.
- (412) Carruth BR, Skinner JD. 2001. The role of dietary calcium and other nutrients in moderating body fat in preschool children *Int J Obes Relat Metab Disord* 25:559.
- (413) Davies KM, et al. 2000. Calcium intake and body weight *J Clin Endocrinol Metab* 85:4635.
- (414) McCarron DA, et al. 1984. Blood pressure and nutrient intake in the United States *Science* 224:1392.
- (415) Fleming KH, Heimbach JT. 1994. Consumption of calcium in the U.S.: food sources and intake levels *J Nutr* 124:1426s.
- (416) Andersen T, et al. 1986. Increased parathyroid hormone as a consequence of changed complex binding of plasma calcium in morbid obesity *Metabolism* 35:147.
- (417) Lind L, et al. 1993. The relationships between mineral metabolism, obesity and fat distribution *Eur J Clin Invest* 23:307.
- (418) Jones BH, et al. 1996. Upregulation of adipocyte metabolism by agouti protein: possible paracrine actions in yellow mouse obesity *Am J Physiol* 270:E192.
- (419) Xue BZ, et al. 1998. The agouti gene product inhibits lipolysis in human adipocytes via a Ca²⁺-dependent mechanism *FASEB J* 12:1391.
- (420) Xue B, et al. 2001. Mechanism of intracellular Ca²⁺ ([Ca²⁺]_i) inhibition of lipolysis in human adipocytes *FASEB J* 15:2527.
- (421) Kim JH, et al. 1996. The effects of calcium channel blockade on agouti induced obesity *FASEB J* 10:1646.
- (422) Zemel MB, et al. 2004. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults *Obes Res* 12:582.
- (423) Azizi F, et al. 1993. Impairment of neuromotor and cognitive development in iodine-deficient schoolchildren with normal physical growth *Acta Endocrinol. Copenh* 129:501.
- (424) Azizi F, et al. 1995. Physical, neuromotor and intellectual impairment in non-cretinous schoolchildren with iodine deficiency. *Int J Vitam Nutr Res* 65:199.
- (425) Fenzi GF, et al. 1990. Neuropsychological assessment in schoolchildren from an area of moderate iodine deficiency. *J Endocrinol Invest* 13:427.
- (426) Huda SN, et al. 1999. Biochemical Hypothyroidism Secondary to Iodine Deficiency Is Associated with Poor School Achievement and Cognition in Bangladeshi Children. *J Nutr* 129:980.
- (427) Tiwari BD, et al. 1996. Learning disabilities and poor motivation to achieve due to prolonged iodine deficiency. *Am J Clin Nutr* 63:782.
- (428) Vermiglio F, et al. 1990. Defective neuromotor and cognitive ability in iodine-

- deficient schoolchildren of an endemic goiter region in Sicily. *J Clin Endocrinol Metab* 70:379.
- (429) Larson PR, Ingbar SH. 1992. The thyroid gland. Wilson J. D. Foster D. W. eds. *Williams Textbook of Endocrinology*, pp.357.
- (430) Pharoah POD, Connolly KJ. 1994. Iodine deficiency in Papua New Guinea. Stanbury J. B. eds. *The Damaged Brain of Iodine Deficiency*. Cognizant Communication Corporation New York, NY, pp.299.
- (431) Hetzel BS. 1994. Historical development of the concepts of the brain-thyroid relationships. Stanbury J. B. eds. *The Damaged Brain of Iodine Deficiency*. Cognizant Communication Corporation New York, NY, pp.1.
- (432) Ruiz de Ona C, et al. 1988. Developmental changes in rat brain 5-deiodinase and thyroid hormones during the fetal period: the effects of fetal hypothyroidism and maternal thyroid hormones. *Pediatr Res* 24:588.
- (433) Larson PR. 1989. Maternal thyroxine and congenital hypothyroidism. *N Engl J Med* 321:44.
- (434) Vulsma T, et al. 1989. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. *N Engl J Med* 321:13.
- (435) Beard JL, et al. 1993. Iron on the brain. *Nutr Rev* 51:157.
- (436) Pollitt E. 1997. Iron deficiency and educational deficiency. *Nutr Rev* 55:133.
- (437) Davies KJ, et al. 1982. Muscle mitochondrial bioenergetics, oxygen supply, and work capacity during dietary iron deficiency and repletion. *Am J Physiol* 242:E418.
- (438) Earley CJ, et al. 2000. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. *Neurology* 54:1698.
- (439) Qian ZM, Shen X. 2001. Brain iron transport and neurodegeneration. *Trends Mol Med* 7:103.
- (440) Han J, et al. 2002. H and L ferritin subunit mRNA expression differs in brains of control and iron-deficient rats. *J Nutr* 132:2769.
- (441) Morgane PJ, et al. 1993. Prenatal malnutrition and development of the brain. *Neurosci. Biobehav. Rev* 17:91.
- (442) Idjradinata P, Pollitt E. 1993. Reversal of developmental delays in iron-deficient anaemic infants treated with iron. *Lancet* 341:1.
- (443) Pollitt E, et al. 1986. Iron deficiency and behavioral development in infants and preschool children. *Am J Clin Nutr* 43:555.
- (444) Seshadri S, Gopaldas T. 1989. Impact of iron supplementation on cognitive functions in preschool and school-aged children: the Indian experience. *Am J Clin Nutr* 50:675.
- (445) Soewondo S, et al. 1989. Effects of iron deficiency on attention and learning processes in preschool children: Bandung, Indonesia. *Am J Clin Nutr* 50:667.
- (446) Bruner AB, 1996. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. *Lancet* 348:992.
- (447) Martins S, et al. Iron therapy for improving psychomotor development and cognitive function in children under the age of three with iron deficiency anaemia (Cochrane Review). In: *The Cochrane Library*, 4. Oxford, United Kingdom: Update Software, 2001.
- (448) Lozoff B, et al. 2003. Behavioral and developmental effects of preventing iron-deficiency anemia in healthy full-term infants. *Pediatrics* 112:846.
- (449) Pollitt E. 1993. Iron deficiency and cognitive function. *Ann Rev Nutr* 13:521.
- (450) Beard JL, Connor JR. 2003. Iron status and neural functioning. *Ann Rev Nutr* 23:41.
- (451) Beard JL, et al. 2003. Pre- and postweaning iron deficiency alters myelination in Sprague-Dawley rats. *Dev. Neurosci* 25:308.
- (452) Kwik-Urbe CL, et al. 2000. Chronic marginal iron intakes during early development in mice alter brain iron concentrations and behavior despite postnatal iron supplementation. *J Nutr* 130:2040.
- (453) Beard JL, et al. 2003. Neonatal iron deficiency results in irreversible changes in dopamine function in rats. *J Nutr* 133:1174.
- (454) Erikson KM, et al. 2001. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. *Pharmacol Biochem Behav* 69:409.
- (455) Pinero DJ, et al. 2000. Alterations in brain iron metabolism in response to dietary iron changes. *J Nutr* 130:254.
- (456) Nelson C, et al. 1997. In Vivo DA metabolism is altered in ID anemic rats. *J Nutr* 127:2282.
- (457) Taylor EM, et al. 1991. Transferrin and iron uptake by the brain: effects of altered iron status. *J Neurochem* 57:1584.
- (458) Erikson K, et al. 1997. Iron status and distribution of iron in the brain of developing rats. *J Nutr* 127:2030.
- (459) Henrotte JG, et al. 1977. Mice selected for low and high blood magnesium levels: a new model for stress studies. *Physiol Behav* 61:653.

- (460) Seelig MS. 1994. Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications. *J Am Coll Nutr* 13:429.
- (461) Cox IM, et al. 1991. Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. *Lancet* 337:757.
- (462) McLean RM. 1994. Magnesium and its therapeutic uses: a review. *Am J Med* 96:63.
- (463) Benton D. 2002. Selenium intake, mood and other aspects of psychological functioning. *Nutr Neurosci* 5:363.
- (464) Schafer K, et al. 2004. Effects of selenium deficiency on fatty acid metabolism in rats fed fish oil-enriched diets. *J Trace Elem Med Biol* 18:89.
- (465) Sanstead HH, et al. 2000. Zinc nutriture as related to brain. *J. Nutr.* 130:140S.
- (466) Pfeiffer CC, Braverman ER. 1997. Zinc, the brain, and behavior. *Biol. Psychol.* 17:513.
- (467) Nowak G, et al. 2003. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. *Pol J Pharmacol* 55:1143.
- (468) Frederickson CJ, et al. 2000. Importance of zinc in the central nervous system: the zinc-containing neuron. *J. Nutr.* 130:1471S.
- (469) Colvin RA, et al. 2000. Zinc transport in the brain: routes of zinc influx and efflux in neurons. *J. Nutr.* 130:1484S.
- (470) Frederickson CJ, Bush AI. 2001. Synaptically released zinc: physiological functions and pathological effects. *Biometals* 14:353.
- (471) Bhatnagar S, Taneja S. 2001. Zinc and cognitive development. *Br. J. Nutr.* 85:S139.
- (472) McLoughlin IJ, Hodge JS. 1990. Zinc in depressive disorder. *Acta Psychiatr. Scand.* 82:451.
- (473) Katz RL, et al. 1987. Zinc deficiency in anorexia nervosa. *J. Adolesc. Health Care* 8:400.
- (474) Sanstead HH, et al. 1996. Zinc deficiency in pregnant rhesus monkeys: effects on behavior of infants. *Am. J. Clin. Nutr.* 31:844.
- (475) Halas ES, et al. 1977. Intra-uterine nutrition and its effects on aggression. *Physiol. Behav.* 19:653.
- (476) Black MM, et al. 2004. Iron and zinc supplementation promote motor development and exploratory behavior among Bangladeshi infants. *American Journal of Clinical Nutrition* 80(4):903.
- (477) Penland J, et al. 1999. Zinc, iron and micronutrient supplementation effects on cognitive and psychomotor function of Mexican-American school children. *FASEB J.* 13:921(abs.).
- (478) Sanstead HH, et al. 1998. Effects of repletion with zinc and other micronutrients on neuropsychologic performance and growth of Chinese children. *Am J Clin Nutr* 68:470S.
- (479) Schlegel-Zawadzka M, et al. 2004. Zinc supplementation altered phospholipids' fatty acids pattern in young healthy women. *Asia Pac J Clin Nutr* 13(Suppl):S156.
- (480) Waladkhani AR. 2010. Effect of phytochemicals on stress management and mental health. In *Bioactive Foods and Extracts*. Watson RR, Preedy VR, eds. CRC Press, New York, pp. 257.
- (481) Cao G, et al. 1996. Antioxidant capacity of tea and common vegetables. *J Agric Food Chem* 44:3426.
- (482) Wang H, et al. 1996. Total antioxidant capacity of fruits. *J Agric Food Chem* 44:701.
- (483) Joseph JA, et al. 1999. Reversals of age-related declines in neuronal signal transduction, cognitive and motor behavioral deficits with diets supplemented with blueberry, spinach or strawberry dietary supplementation. *J Neurosci* 19:8114.
- (484) Youdim KA, et al. 2000. Short-term dietary supplementation of blueberry polyphenolics: beneficial effects on aging brain performance and peripheral tissue function. *Nutr Neurosci* 3:383.
- (485) Bickford PC, et al. 2000. Antioxidant-rich diets improve cerebellar physiology and motor learning in aged rats. *Brain Res* 866:211.
- (486) Bickford PC, et al. 1999. Effects of aging on cerebellar noradrenergic function and motor learning: nutritional interventions. *Mech Ageing Dev* 111:141.
- (487) Aidoo A, et al. 1995. In vivo antimutagenic activity of beta-carotene in rat spleen lymphocytes. *Carcinogenesis* 16:2237.
- (488) Sarker A, et al. 1994. Inhibitory effect of β -carotene on chronic 2-acetylaminofluorene-induced hepatocarcinogenesis in rat: reflection in hepatic drug metabolism. *Carcinogenesis* 15:1055.
- (489) Renner HW. 1985. Anticlastogenic effect of β -carotene in Chinese hamster. Time and dose-response studies with different mutagens. *Mutation Research* 144:251.
- (490) Uehara N, et al. 1996. Decrease levels of 2-amino-3-methylimidazol[4,5-f]quinoline-DNA adducts in rats treated with β -carotene, α -tocopherol and freeze-dried aloe. *Japanese Journal of Cancer Research* 87:324.

- (491) Basu TK, et al. 1987. Effect of dietary β -carotene on hepatic drug-metabolizing enzymes in mice. *Journal of Clinical Biochemistry and Nutrition* 3:95.
- (492) Hasegawa T. 1993. Anti-stress effect of β -carotene. In *Carotenoids in Human Health*. Canfield LM, Krinsky NI, Olson JA, eds., New York Academy of Sciences, New York, pp. 281
- (493) Kurosawa M, et al. 1986. Sympatho-adrenal medullary functions in response to intracerebroventricularly injected corticotrophin-releasing factor in anesthetized rats. *Brain Res* 367(1-2):250.
- (494) Adlercreutz H, Mazur W. 1997. Phyto-oestrogens and Western diseases. *Annals of Medicine* 29:95.
- (495) Chadman K, et al. 1997. Diets high in antioxidant activity prevent deleterious effects of oxidative stress on signal transduction and nerve growth factor. *Soc Neurosci Abstr* 23:348.
- (496) Joseph JA, et al. 1998. Long-term dietary strawberry, spinach or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioural deficits. *J Neurosci* 18(19):8047.
- (497) Schroeter H, et al. 2001. Flavonoids protect neurons from oxidative low-density-lipoprotein-induced apoptosis involving c-Jun N-terminal kinase (JNK), c-Jun and caspase-3. *Biochem J* 358:547.
- (498) Williams RJ, et al. 2004. Flavonoids: antioxidants or signalling molecules? *Free Radic Biol Med* 36:838.
- (499) Youdim KA, et al. 2004. Flavonoids and the brain: interactions at the blood brain barrier and their physiological effects on the CNS. *Free Radic Biol Med* 37:1683.
- (500) Commenges D, et al. 2000. Intake of flavonoids and risk of dementia. *Eur J Epidemiol* 16:357.
- (501) Olszanecki R, et al. 2002. Flavonoids and nitric oxide synthase. *J Physiol Pharmacol* 53:571.
- (502) Micheau J, Riedel G. 1999. Protein kinases: which one is the memory molecule? *Cell Mol Life Sci* 55:534.
- (503) Mazzucchelli C, Brambilla R. 2000. Ras-related and MAPK signalling in neuronal plasticity and memory formation. *Cell Mol Life Sci* 57:604.
- (504) Selcher JC, et al. 1999. A necessity for MAP kinase activation in mammalian spatial learning. *Learn Mem* 6:478.
- (505) Casadesus G, et al. 2004. Modulation of hippocampal plasticity and cognitive behavior by short-term blueberry supplementation in aged rats. *Nutr Neurosci* 7:309.
- (506) Shukitt-Hale B, et al. 2006. Effects of Concord grape juice on cognitive and motor deficits in aging. *Nutrition* 22:295.
- (507) Tredici G, et al. 1999. Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? *Drugs Exp Clin Res* 25:99.
- (508) Lamming DW, et al. 2004. Small molecules that regulate lifespan: evidence for xenohormesis. *Mol. Microbiol.* 53:1003.
- (509) Sardi B. 2004. *The Anti-Aging Pill*. San Dimas, CA: Here & Now Books. 189 pp.
- (510) Moriguchi T, et al. 1997. Anti-aging effect of aged garlic extract in the inbred brain atrophy mouse model. *Clin exp Pharmacol Physiol* 24:235.
- (511) Nishiyama N, et al. 1997. Beneficial effects of aged garlic extract on learning and memory impairment in the senescence-accelerated mouse. *Exp Gerontol* 32:149.
- (512) Crayhon R. 1998. *The Carnitine Miracle*. New York, NY: M. Evans and Co.
- (513) Bonavita E. 1986. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. *Int J Clin Pharmacol Ther Toxicol* 24:511.
- (514) Livingston GA, et al. 1991. Acetyl-L-carnitine in dementia. *International J Geriatr Psychiatr* 6:853.
- (515) Rai G, et al. 1990. Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer's dementia. *CurrMed Res Opin* 11:638.
- (516) Spagnoli A, et al. 1991. Longterm acetyl-L-carnitine treatment in Alzheimer's disease. *Neurology* 41:1726.
- (517) Sano M, et al. 1992. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's Disease. *Arch Neurol* 49:1137.
- (518) Thal LJ, et al. 1996. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. *Neurology* 47:705.
- (519) Tempesta E, et al. 1990. Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism. *Int J Clin Pharmacol Res* 10:101.
- (520) Sakai M, et al. 1996. Pharmacological effects of phosphatidylserine synthesized from soybean

- lecithin on brain functions in rodents. *Nutr. Sci. Vitaminol.* 42:47.
- (521) Blokland A, et al. 1999. Cognition enhancing properties of subchronic phosphatidylserine treatment in middle aged rats: comparison of bovine cortex with egg PS and soybean PS. *Nutrition* 15:778.
- (522) Suzuki S, et al. 2001. Oral administration of soybean lecithin transphosphatidylated phosphatidylserine improves memory impairment in aged rats. *J. Nutr.* 131:2951.
- (523) Benton D, et al. 2001. The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor. *Nutr. Neurosci.* 4:169.
- (524) J. Hellhammer et al. 2004. Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress. *Stress* 7:119.
- (525) Jorissen BL, et al. 2001. The influence of soy derived phosphatidylserine on cognition in age associated memory impairment. *Nutr. Neurosci.* 4:121.
- (526) Hellhammer J, et al. 2010. Effects of milk phospholipid on memory and psychological stress response. *British Food Journal*, 112 (10):1124.
- (527) Bailey MT, Coe CL. 1999. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. *Dev Psychobiol* 35:146.
- (528) Lenz HJ, Druge G. 1990. Neurohormonal pathways mediating stress-induced inhibition of gastric acid secretion in rats. *Gastroenterology* 98:1490.
- (529) Lenz HJ, et al. 1988. Central nervous system effects of corticotropin-releasing factor on gastrointestinal transit in the rat. *Gastroenterology* 94:598.
- (530) Lenz HJ. 1989. Regulation of duodenal bicarbonate secretion during stress by corticotropinreleasing factor and beta-endorphin. *Proc Natl Acad Sci U S A* 86:1417.
- (531) Holzapfel WH, et al. 1998. Overview of gut flora and probiotics. *Int J Food Microbiol* 41:85.
- (532) Gibson GR. 1998. Dietary modulation of the human gut microflora using prebiotics. *Br J Nutr* 80:S209.
- (533) Moore WE, Holdeman LV. 1974. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. *Appl Microbiol* 27:961.
- (534) Savage DC. 1977. Microbial ecology of the gastrointestinal tract. *Annu Rev Microbiol* 31:107.
- (535) Noack J, et al. 1998. Dietary guar gum and pectin stimulate intestinal microbial polyamine synthesis in rats. *J Nutr* 128:1385.
- (536) Gibson GR, Roberfroid MB. 1995. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J Nutr* 125:1401.
- (537) Gismondo MR. 1998. Antibiotic impact on intestinal microflora. *Gastroenterol Int* 11:29.
- (538) Nord CE. 1990. Studies on the ecological impact of antibiotics. *Eur J Clin Microbiol Infect Dis* 9:517.
- (539) Nord CE, Edlund C. 1990. Impact of antimicrobial agents on human intestinal microflora. *J Chemother* 2:218.
- (540) Nord CE, et al. 1986. Antimicrobial agents and the human oropharyngeal and intestinal microflora. *Ann Ist Super Sanita* 22:883.
- (541) Hentges DJ. 1992. Gut flora and disease resistance. In: Fuller R, ed. *Probiotics: the Scientific Basis*. London: Chapman and Hall, pp. 87.
- (542) Lizko NN. 1987. Stress and intestinal microflora. *Nahrung* 31:443.
- (543) Holdeman LV, et al. 1976. Human fecal flora: variation in bacterial composition within individuals and a possible effect of emotional stress. *Appl Environ Microbiol* 31:359.
- (544) Moore WE, et al. 1978. Some current concepts in intestinal bacteriology. *Am J Clin Nutr* 31:S33.
- (545) Gibson GR. 1998. Dietary modulation of the human gut microflora using prebiotics. *Br J Nutr* 80:S209.
- (546) Levitt MD, et al. 1995. Gas metabolism in the large intestine. In: Gibson GR, Macfarlane GT, eds. *Human Colonic Bacteria: Role in Nutrition, Physiology, and Pathology*. Boca Raton, FL: CRC Press, pp. 131.
- (547) Cummings JH, Macfarlane GT. 1997. Role of intestinal bacteria in nutrient metabolism. *JPEN J Parenter Enteral Nutr* 21:357.
- (548) Roediger WE, et al. 1997. Colonic sulfide in pathogenesis and treatment of ulcerative colitis. *Dig Dis Sci* 42:1571.
- (549) Christl SU, et al. 1992. Role of dietary sulphate in the regulation of methanogenesis in the human large intestine. *Gut* 33:1234.
- (550) Jones GP. 1997. Food Processing. In: Wahlqvist ML, ed. *Food and Nutrition:*

- Australasia, Asia, and the Pacific. St. Leonards, NSW: Allen and Unwin, pp. 89.
- (551) Marz R. 1997. Medical Nutrition from Marz. Portland, OR: Quiet Lion Press, pp. 297
- (552) Macfarlane GT, Gibson GR. 1994. Metabolic activities of the normal colonic flora. In: Gibson SAW, ed. Human Health: The Contribution of Microorganisms. London: Springer-Verlag, pp. 17.
- (553) Wright R, Truelove SC. 1965. A controlled therapeutic trial of various diets in ulcerative colitis. *Br Med J* 5454:138.
- (554) Macfarlane S, Macfarlane GT. 1995. Proteolysis and amino acid fermentation. In: Gibson GR, Macfarlane GT, eds. Human Colonic Bacteria: Role in Nutrition, Physiology, and Pathology. Boca Raton, FL: CRC Press, pp.75.
- (555) Smith EA, Macfarlane GT. 1997. Dissimilatory amino acid metabolism in human colonic metabolism. *Anaerobe* 3:327.
- (556) Murawaki Y, et al. 2000. Effects of lactulose on intestinal bacterial flora and fecal organic acids in patients with liver cirrhosis. *Hepatol Res* 17:56.
- (557) Cummings JH, et al. 1979. The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. *Am J Clin Nutr* 32:2094.
- (558) Birkett A, et al. 1996. Resistant starch lowers fecal concentrations of ammonia and phenols in humans. *Am J Clin Nutr* 63:766.
- (559) Kruis W, et al. 1991. Effect of diets low and high in refined sugars on gut transit, bile acid metabolism, and bacterial fermentation. *Gut* 32:367.
- (560) Lewis SJ, Heaton KW. 1999. The metabolic consequences of slow colonic transit. *Am J Gastroenterol* 94:2010.
- (561) Hudson MJ, Marsh PD. 1995. Carbohydrate metabolism in the colon. In: Gibson GR, Macfarlane GT, eds. Human Colonic Bacteria: Role in Nutrition, Physiology, and Pathology. Boca Raton, FL: CRC Press, pp. 61.
- (562) Beinfeld MC. 1983. Cholecystokinin in the central nervous system: a minireview. *Neuropeptides* 3:411.
- (563) Schick RR, et al. 1987. Neuronal cholecystokinin-like immunoreactivity is postprandially released from primate hypothalamus. *Brain Res* 418:20.
- (564) De Fanti BA, et al. 1998. Lean (Fa/Fa) but not obese (fa/fa) Zucker rats release cholecystokinin at PVN after a gavaged meal. *Am J Physiol* 275:E1.
- (565) VLW Go. 1978. The physiology of cholecystokinin. In: Gut hormones. Edinburgh: Churchill Livingstone, pp. 203
- (566) Kissileff HR, et al. 2003. Cholecystokinin and stomach distension combine to reduce food intake in humans. *Am J Physiol Regul Integr Comp Physiol* 285:R992.
- (567) Linden A, et al. 1989. Plasma concentrations of cholecystokinin octapeptide and food intake in male rats treated with cholecystokinin octapeptide. *J Endocrinol* 121:59.
- (568) Baile CA, et al. 1986. Role of cholecystokinin and opioid peptides in control of food intake. *Physiol Rev* 66:172.
- (569) Liddle RA, et al. 1986. Regulation of gastric emptying in humans by cholecystokinin. *J Clin Invest* 77:992.
- (570) Lieverse RJ, et al. 1994. Role of cholecystokinin in the regulation of satiation and satiety in humans. *Ann N Y Acad Sci* 713:268.
- (571) Lal S, et al. 2004. Cholecystokinin pathways modulate sensations induced by gastric distension in humans. *Am J Physiol Gastrointest Liver Physiol* 287:G72.
- (572) Bradwejn J, Koszycki D. 1994. The cholecystokinin hypothesis of anxiety and panic disorder. *Ann N Y Acad Sci* 713:273.
- (573) Moran TH, Schwartz GJ. 1994. Neurobiology of cholecystokinin. *Crit Rev Neurobiol* 9:1.
- (574) Crawley JN. 1985. Comparative distribution of cholecystokinin and other neuropeptides. Why is this peptide different from all other peptides? *Ann N Y Acad Sci* 448:1.
- (575) Beinfeld MC, Palkovits M. 1982. Distribution of cholecystokinin (CCK) in the rat lower brain stem nuclei. *Brain Res* 238:260.
- (576) Beinfeld MC, et al. 1981. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. *Brain Res* 212:51.
- (577) Fink H, et al. 1998. Major biological actions of CCK — a critical evaluation of research findings. *Exp Brain Res* 123:77.
- (578) Shian LR, Lin MT. 1985. Effects of cholecystokinin octapeptide on thermoregulatory responses and hypothalamic neuronal activity in the rat. *Naunyn Schmiedebergs Arch Pharmacol* 328:363.
- (579) Szelenyi Z. 2001. Cholecystokinin and thermoregulation — a minireview. *Peptides* 22:1245.

- (580) Dornan WA, et al. 1989. Microinjection of cholecystokinin into the medial preoptic nucleus facilitates lordosis behavior in the female rat. *Physiol Behav* 45:969.
- (581) Beinfeld MC. 2001. An introduction to neuronal cholecystokinin. *Peptides* 22:1197.
- (582) van Megen HJ, et al. 1996. Cholecystokinin in anxiety. *Eur Neuropsychopharmacol* 6:263.
- (583) Huston JP, et al. 1998. Modulation of memory, reinforcement and anxiety parameters by intra-amygdala injection of cholecystokinin-fragments BOC-CCK-4 and CCK-8S. *Peptides* 19:27.
- (584) Vaccarino FJ. 1994. Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors. *Neurosci Biobehav Rev* 18:207.
- (585) Alho H, et al. 1988. Subsets of GABAergic neurons in dissociated cell cultures of neonatal rat cerebral cortex show co-localization with specific modulator peptides. *Brain Res* 467:193.
- (586) Hendry SH, et al. 1984. Neuropeptide-containing neurons of the cerebral cortex are also GABAergic. *Proc Natl Acad Sci U S A* 81:6526.
- (587) Hokfelt T, et al. 1980. Evidence for coexistence of dopamine and CCK in meso-limbic neurones. *Nature* 285:476.
- (588) van der Kooy D, et al. 1981. Separate populations of cholecystokinin and 5-hydroxytryptamine-containing neuronal cells in the rat dorsal raphe, and their contribution to the ascending raphe projections. *Neurosci Lett* 26:25.
- (589) Morino P. 1994. Cholecystokinin in corticostriatal neurons in the rat: immunohistochemical studies at the light and electron microscopical level. *Eur J Neurosci* 6:681.
- (590) Smith GP, Gibbs J. 1994. Satiating effect of cholecystokinin. *Ann N Y Acad Sci* 713:236.
- (591) Moran TH. 2000. Cholecystokinin and satiety: current perspectives. *Nutrition* 16:858.
- (592) Muurahainen N, et al. 1988. Effects of cholecystokinin-octapeptide (CCK-8) on food intake and gastric emptying in man. *Physiol Behav* 44:645.
- (593) Mayer EA, et al. 2001. Depression, anxiety, and the gastrointestinal system. *J Clin Psychiatry* 62(8):28.
- (594) Naliboff BD, et al. 2004. The effect of life stress on symptoms of heartburn. *Psychosom Med* 66:426.
- (595) Stallone D, et al. 1989. Cholecystokinin-induced anorexia depends on serotonergic function. *Am J Physiol* 256:R1138.
- (596) Beresford IJ, et al. 1988. Cholecystokinin modulation of [3H]noradrenaline release from superfused hypothalamic slices. *Neurosci Lett* 88:227.
- (597) Crawley JN. 1991. Cholecystokinin-dopamine interactions. *Trends Pharmacol Sci* 12:232.
- (598) Abelson JL, Nesse RM. 1994. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses. *Biol Psychiatry* 36:73.
- (599) Abelson JL, et al. 1994. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. *Biol Psychiatry* 36:84.
- (600) Abelson JL, Liberzon I. 1999. Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin. *Neuropsychopharmacology* 21:485.
- (601) Chua ASB, Keeling PWN. 2006. Cholecystokinin hyperresponsiveness in functional dyspepsia. *World J Gastroenterol* 12(17):2688.
- (602) Crawley JN, Beinfeld MC. 1983. Rapid development of tolerance to the behavioural actions of cholecystokinin. *Nature* 302:703.
- (603) Tataranni PA, et al. 1996. Effects of glucocorticoids on energy metabolism and food intake in humans. *Am J Physiol* 271:E317.
- (604) Wolkowitz OM, et al. 2001. Stress hormone-related psychopathology: pathophysiology and treatment implications. *The World Journal of Biological Psychiatry* 2:115.
- (605) Goldstein RE, et al. 1992. Effects of acute elevations in plasma cortisol levels on alanine metabolism in the conscious dog. *Metab. Clin. Exp.* 41:1295.
- (606) Goldstein RE, et al. 1993. Effects of chronic elevation in plasma cortisol on hepatic carbohydrate metabolism. *Am. J. Physiol.* 264:E119.
- (607) Bray GA. 1985. Autonomic and endocrine factors in the regulation of food intake. *Brain Research Bulletin* 14:505.
- (608) Castonguay TW. 1991. Glucocorticoids as modulators in the control of feeding. *Brain Research Bulletin* 27:423.
- (609) Cohen MR, et al. 1984. Plasma cortisol and beta-endorphin immunoreactivity in human obesity. *Psychosom Med* 46:454.
- (610) Jayo JM, et al. 1993. Effects of exercise and stress on body fat distribution in male cynomolgus monkeys. *Int J Obes Relat Metab Disord* 17:597.

- (611) Bjorntorp P, Rosmond R. 2000. Neuroendocrine abnormalities in visceral obesity. *Int J Obes Relat Metab Disord* 24(Suppl 2):S80.
- (612) Dallman MF, et al. 2003. Chronic stress and obesity: a new view of 'comfort food'. *Proceedings of the National Academy of Sciences of the United States of America* 100:11696.
- (613) Levine M, Marcus M. 1997. Eating behavior following stress in women with and without bulimic symptoms. *Ann Behav Med* 19:132.
- (614) Greeno CG, Wing RR. 1994. Stress-induced eating. *Psychol Bull* 115:444.
- (615) Geliebter A, Aversa A. 2003. Emotional eating in overweight, normal weight, and underweight individuals. *Eat Behav* 3:341.
- (616) Cattanach L, et al. 1988. Psychologic and physiologic reactivity to stressors in eating disordered individuals. *Psychosom Med* 50:591.
- (617) Koo-Loeb JH, et al. 2000. Women with eating disorder tendencies display altered cardiovascular, neuroendocrine, and psychosocial profiles. *Psychosom Med* 62:539.
- (618) Abell TL, et al. 1987. Gastric electromechanical and neurohormonal function in anorexia nervosa. *Gastroenterology* 93:958.
- (619) Girdler S, et al. 1998. Dysregulation of cardiovascular and neuroendocrine responses to stress in premenstrual dysphoric disorder. *Psychiatry Res* 81(2):163.
- (620) Marin P, et al. 1992. Cortisol secretion in relation to body fat distribution in obese premenopausal women. *Metabolism* 41:882.
- (621) Pirke KM, et al. 1992. The effect of a mental challenge test of plasma norepinephrine and cortisol in bulimia nervosa and in controls. *Biol Psychiatry* 32:202.
- (622) Lingswiler VM, et al. 1987. Emotional reactivity and eating in binge eating and obesity. *J Behav Med* 10:287.
- (623) Telch CF, Agras WS. 1996. Do emotional states influence binge eating in the obese? *Int J Eat Disord* 20:271.
- (624) Bjorntorp P. 1992. Abdominal fat distribution and disease: an overview of epidemiological data. *Ann Med* 24:15.
- (625) Epel ES, et al. 2000. Stress and body shape: stress-induced cortisol secretion is consistently greater among women with central fat. *Psychosom Med* 62:623.
- (626) Wallerius S, et al. 2003. Rise in morning saliva cortisol is associated with abdominal obesity in men: a preliminary report. *J Endocrinol Invest* 26:616.
- (627) Gluck ME, et al. 2004. Cortisol, hunger, and desire to binge eat following a cold stress test in obese women with binge eating disorder (BED). *Psychosomatic Medicine* 66:876.
- (628) Monteleone P, et al. 1999. Immunoendocrine findings in patients with eating disorders. *Neuropsychobiology* 40:115.
- (629) Koo-Loeb JH, et al. 1998. Blunted cardiovascular and catecholamine stress reactivity in women with bulimia nervosa. *Psychiatry Res* 80:13.
- (630) Checkley S. 1996. The neuroendocrinology of depression and chronic stress. *Br Med Bull* 52:597.
- (631) Brandenberger G, et al. 1980. Plasma catecholamines and pituitary adrenal hormones related to mental task demand under quiet and noise conditions. *Biol Psychol* 10:239.
- (632) Kirschbaum C, Hellhammer DH. 1989. Salivary cortisol in psychobiological research: an overview. *Neuropsychobiology* 22:150.
- (633) Bale TL, Vale WW. 2004. CRF and CRF receptors: role in stress responsivity and other behaviors. *Annu Rev Pharmacol Toxicol* 44:525.
- (634) Taché Y, Bonaz B. 2007. Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. *J Clin Invest* 117:33.
- (635) Heinrichs SC, Koob GF. 2004. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. *J Pharmacol Exp Ther* 311:427.
- (636) Mastorakos G, Zapanti E. 2004. The hypothalamic-pituitary-adrenal axis in the neuroendocrine regulation of food intake and obesity: the role of corticotropin releasing hormone. *Nutr Neurosci* 7:271.
- (637) Menzaghi F, et al. 1993. Functional impairment of hypothalamic corticotropin-releasing factor neurons with immunotargeted toxins enhances food intake induced by neuropeptide Y. *Brain Res* 618:76.
- (638) Heinrichs SC, et al. 1993. Corticotropin-releasing factor in the paraventricular nucleus modulates feeding induced by neuropeptide Y. *Brain Res* 611:18.
- (639) Zorrilla EP, et al. 2003. Nibbling at CRF receptor control of feeding and gastrocolonic motility. *Trends Pharmacol Sci* 24:421.
- (640) Richard D, et al. 2002. The corticotropin-releasing factor family of peptides and CRF

- receptors: their roles in the regulation of energy balance. *Eur J Pharmacol* 440:189.
- (641) Miragaya JR, Harris RB. 2008. Antagonism of corticotrophin-releasing factor receptors in the fourth ventricle modifies responses to mild but not restraint stress. *Am J Physiol Regul Integr Comp Physiol* 295:R404.
- (642) Curtis AL, et al. 1997. Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity. *J Pharmacol. Exp. Ther.* 281:163.
- (643) Valentino RJ, et al. 2001. Corticotropin-releasing factor is preferentially colocalized with excitatory rather than inhibitory amino acids in axon terminals in the peri-locus coeruleus region. *Neuroscience* 106:375.
- (644) Van Bockstaele EJ, et al. 2001. Topographic architecture of stress-related pathways targeting the noradrenergic locus coeruleus. *Physiol. Behav.* 73:273.
- (645) Price ML et al. 2002. Evidence for corticotropin-releasing factor regulation of serotonin in the lateral septum during acute swim stress: adaptation produced by repeated swimming. *Psychopharmacology* 162:406.
- (646) Valentino RJ et al. 2001. Evidence for regional heterogeneity in corticotropin-releasing factor interactions in the dorsal raphe nucleus. *J. Comp. Neurol.* 435:450.
- (647) Kirby LG, et al. 2000. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. *Neuropsychopharmacology* 22:148.
- (648) Bhatnagar S, Dallman MF. 1998. Neuroanatomical basis for facilitation of hypothalamic-pituitary-adrenal responses to a novel stressor after chronic stress. *Neuroscience* 84:1025.
- (649) McNally GP, Akil H. 2002. Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal. *Neuroscience* 12:605.
- (650) Roozendaal B, et al. 2002. Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation. *Proc. Natl. Acad. Sci. USA* 99:13908.
- (651) Heinrichs SC, et al. 2001. *Handbook of Physiology*, ed. McEwen, B. S. (Oxford Univ. Press, New York), Vol. 4, pp. 125.
- (652) McGaugh JL. 2002. Memory consolidation and the amygdala: a systems perspective. *Trends Neurosci.* 25:456.
- (653) Tellam DJ, et al. 2000. Molecular integration of hypothalamo-pituitary-adrenal axis-related neurohormones on the GnRH neuron *Biochemistry and Cell Biology* 78:205.
- (654) Krysiak R, et al. 1999. Interactions between the neuropeptide Y system and the hypothalamic-pituitary-adrenal axis *European Journal of Endocrinology* 140:130.
- (655) Plata-Salaman CR. 1995. Cytokines and feeding suppression: an integrative view from neurologic to molecular levels. *Nutrition* 11(Suppl 5):674.
- (656) Hotamisligil GS, Spiegelman BM. 1994. Tumor necrosis factor- α : a key component of the obesity-diabetes link. *Diabetes* 43:1271.
- (657) Finck BN, Johnson RW. 2000. Tumor necrosis factor- α regulates secretion of the adipocyte-derived cytokine, leptin. *Microsci Res Technol* 50:209.
- (658) Medina EA, et al. 1999. Effects of tumor necrosis factor- α on leptin secretion and gene expression: relationship to changes of glucose metabolism in isolated rat adipocytes. *Int J Obes Relat Metab Disord* 23:896.
- (659) Cherrington AD. 1999. Control of glucose uptake and release in the liver in vivo. *Diabetes* 48:1198.
- (660) Hayes TB. 1995. Interdependence of corticosterone and thyroid hormones in larval toads (*Bufo boreas*). I. Thyroid hormone-dependent and independent effects of corticosterone on growth and development. *J. Exp. Zool.* 271:95.
- (661) Kitaysky AS, et al. 2003. Benefits and costs of increased levels of corticosterone in seabird chicks. *Horm. Behav.* 43:140.
- (662) Pravosudov VV. 2003. Long-term moderate elevation of corticosterone facilitates avian food-caching behaviour and enhances spatial memory. *Proc. R. Soc. Lond. B* 270:2599.
- (663) Sandi C, Rose SPR. 1997. Training-dependent biphasic effects of corticosterone in memory formation for a passive avoidance task in chicks. *Psychopharmacol.* 133:152.
- (664) Hadley ME. 1999. *Endocrinology*, 5th ed. Prentice Hall, Inc., Upper Saddle River. Hamada

- (665) Highet AB, Ruben LN. 1987. Corticosteroid regulation of IL-1 production may be responsible for deWcient immune suppressor function during the metamorphosis of *Xenopus laevis*, the South African clawedtoad. *Immunopharmacology* 13:149.
- (666) Saad AH, El Ridi R. 1988. Endogenous corticosteroids mediate seasonal cyclic changes in immunity of lizards. *Immunobiology* 177:390.
- (667) Dallman MF, et al. 2002. Corticotropin-releasing factor, corticosteroids, and sugar: energy balance, the brain, and behavior. In: Pfaff DW, Arnold AP, Etgen AM, Fahrback SE, Rubin RT, eds. *Mammalian hormone systems*. San Diego: Academic Press, pp. 571.
- (668) Dallman MF, et al. 1999. Starvation: early signals, sensors, and sequelae. *Endocrinology* 140:4015.
- (669) Hart RP, et al. 1980. Plasma corticosterone elevations in rats in response to consumption of concentrated sugar solutions. *J Comp Physiol Psychol* 94:337.
- (670) Pecoraro N, et al. 2002. Brief access to sucrose engages food-entrainable rhythms in food-deprived rats. *Behav Neurosci* 116: 757.
- (671) Levine S, et al. 1972. Expectancy and the pituitary-adrenal system. *Ciba Found Symp* 8:281.
- (672) Goldman L, et al. 1973. Bidirectional effects of reinforcement shifts on pituitary adrenal activity. *Physiol Behav* 10:209.
- (673) Krieger DT, et al. 1977. Suprachiasmatic nuclear lesions do not abolish food-shifted circadian adrenal and temperature rhythmicity. *Science* 197:398.
- (674) Fanselow MS, et al. 1988. Changes in feeding and foraging patterns as an antipredator defensive strategy: a laboratory simulation using aversive stimulation in a closed economy. *J Exp Anal Behav* 50:361.
- (675) Koob GF. 1999. Corticotropin-releasing factor, norepinephrine, and stress. *Biol Psychiatry* 46:1167.
- (676) Goeders NE. 1997. A neuroendocrine role in cocaine reinforcement. *Psychoneuroendocrinology* 22:237.
- (677) Goeders NE. 2002. The HPA axis and cocaine reinforcement. *Psychoneuroendocrinology* 27:13.
- (678) Leshner AI. 1971. The adrenals and the regulatory nature of running wheel activity. *Physiol Behav* 6:551.
- (679) Bhatnagar S, et al. 2000. Corticosterone facilitates saccharin intake in adrenalectomized rats: does corticosterone increase stimulus salience? *J Neuroendocrinol* 12:453.
- (680) Bell ME, et al. 2000. Voluntary sucrose ingestion, like corticosterone replacement, prevents the metabolic deficits of adrenalectomy. *J Neuroendocrinol* 12:461.
- (681) Levin BE. 1996. Reduced paraventricular nucleus norepinephrine responsiveness in obesity-prone rats. *Am J Physiol* 270:R456.
- (682) Epel E, et al. 2001. Stress may add bite to appetite in women: a laboratory study of stress-induced cortisol and eating behavior. *Psychoneuroendocrinology* 26:37.
- (683) Richardson RD, et al. 1995. NPY increases food intake in white-crowned sparrows: effect in short and long photoperiods. *Am. J. Physiol.* 268:R1418.
- (684) Strack AM, et al. 1995. Glucocorticoids and insulin: reciprocal signals for energy balance. *Am. J. Physiol.* 268:R142.
- (685) Zakrzewska KE, et al. 1999. Selective dependence of intracerebroventricular neuropeptide Y-elicited effects on central glucocorticoids. *Endocrinology* 140:3183.
- (686) Rothwell NJ. 1990. Central effects of CRF on metabolism and energy balance. *Neurosci. Biobehav. Res.* 14:263.
- (687) Richardson R. 1997. Regulation of Food Intake and Body Weight in the White-crowned Sparrow (*Zonotrichia leucophrys gambelii*). Ph.D. thesis, University of Washington
- (688) Cherel Y, et al. 1988. Fasting in king penguin. I. Hormonal and metabolic changes during breeding. *Am. J. Physiol.* 254:R170.
- (689) Le Ninan F, et al. 1988. Plasma hormone levels in relation to lipid and protein metabolism during prolonged fasting in king penguin chicks. *Gen. Comp. Endocrinol.* 71:331.
- (690) Astheimer LB, et al. 2000. Corticosterone treatment has no effect on reproductive hormones or aggressive behaviour in free-living male tree sparrows, *Spizella arborea*. *Horm. Behav.* 37:31.
- (691) Brown J, et al. 1992. Effects of a beta-2-adrenergic agonist cimaterol and corticosterone on growth and carcass composition of male rats. *Comp. Biochem. Physiol.* 102A:217.
- (692) Gray JM, et al. 1990. Corticosterone, foraging behaviour, and metabolism in dark-eyed juncos, *Junco hyemalis*. *Gen. Comp. Endocrinol.* 79:375.
- (693) Hickson RC, et al. 1995. Glutamine prevents downregulation of myosin heavy chain synthesis

- and muscle atrophy from glucocorticoids. *Am. J. Physiol.* 268:E730.
- (694) Simon J. 1984. Effects of daily corticosterone injections upon plasma glucose, insulin, uric acid and electrolytes and food intake pattern in the chicken. *Diabete Metab.* 10:211.
- (695) Davison TF, et al. 1983. Effects of dietary corticosterone on the growth and metabolism of immature *Gallus domesticus*. *Gen. Comp. Endocrinol.* 50:463.
- (696) Ramage-Healey L, Romero LM. 2001. Corticosterone and insulin interact to regulate glucose and triglyceride levels during stress in a bird. *Am. J. Physiol.* 281:R994.
- (697) Kawai S, Hanafusa H. 1971. The effects of reciprocal changes in temperature on the transformed state of cells infected with a rous sarcoma virus mutant. *Virology* 46:470.
- (698) Kletzien R, Perdue J. 1974. Sugar transport in chick embryo fibroblasts. II. Alterations in transport following transformation by a temperature-sensitive mutant of the Rous sarcoma virus. *J. Biol. Chem.* 249:3375.
- (699) Sellers TL, et al. 1988. Effects of exercise-induced increase in glucocorticoids on endurance in the rat. *J. Appl. Physiol.* 65:173.
- (700) Yamada F, et al. 1993. Glucoregulatory hormones in the immobilization stress-induced increase of plasma glucose in fasted and fed rats. *Endocrinology* 132:2199.
- (701) Munck A. 1971. Glucocorticoid inhibition of glucose uptake by peripheral tissues: old and new evidence, molecular mechanisms, and physiological significance. *Perspect. Biol. Med.* 14:265.
- (702) Keller-Wood M, Dallman M. 1984. Corticosteroid inhibition of ACTH secretion. *Endocr. Rev.* 5:1.
- (703) Dallman M, et al. 1987. Regulation of ACTH secretion: variations on a theme of B. *Recent Prog. Horm. Res.* 43:113.
- (704) Nazir MI, et al. 1988. Effect of corticosterone on the lipid composition of adipose tissue, plasma and liver in a lizard. *Pakistan J. Sci. Ind. Res.* 31:706.
- (705) McIntosh M, et al. 1999. Opposing actions of dehydroepiandrosterone and corticosterone in rats. *Proc. Soc. Exp. Biol. Med.* 221:198.
- (706) Dohm GL. 1986. Protein as a fuel for endurance exercise. *Exerc. Sport Sci. Rev.* 14:143.
- (707) Okada S, et al. 1992. Mifepristone (RU 486) a blocker of type II glucocorticoid and progesterin receptors, reverses a dietary form of obesity. *American Journal of Physiology* 262:R1106.
- (708) Flatt JP. 1989. Effects of corticosterone on RG, food intake, and energy balance. *International Journal of Obesity* 13:552.
- (709) Willox J, et al. 1984. Prednisolone as an appetite stimulant in patients with cancer. *Br Med J.* 288:27.
- (710) Figlewicz DP. 1999. Endocrine regulation of neurotransmitter transporters. *Epilepsy Res* 37:203.
- (711) Figlewicz DP, et al. 1999. Neurotransmitter transporters: target for endocrine regulation. *Horm Metab Res* 31:335.
- (712) Akana SF, Dallman MF. 1997. Chronic cold in adrenalectomized, corticosterone (B)-treated rats: facilitated corticotropin responses to acute restraint emerge as B increases. *Endocrinology* 138:3249.
- (713) Young EA, et al. 1995. Negative feedback regulation following administration of chronic exogenous corticosterone. *J. Neuroendocrinol.* 7:37.
- (714) Rodgers BD, et al. 1995. Corticosterone regulation of insulin-like growth factor I, IGF-binding proteins, and growth in streptozotocin-induced diabetic rats. *Diabetes* 44:1420.
- (715) Strack AM, et al. 1995. Corticosterone decreases nonshivering thermogenesis and increases lipid storage in brown adipose tissue. *Am. J. Physiol.* 268:R183.
- (716) Nakazato M, et al. 2001. A role for ghrelin in the central regulation of feeding. *Nature* 409:194.
- (717) Tschöp M, et al. 2000. Ghrelin induces adiposity in rodents. *Nature* 407:908.
- (718) Tschöp M, et al. 2001. Circulating ghrelin levels are decreased in human obesity. *Diabetes* 50:707.
- (719) Shintani M, et al. 2001. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. *Diabetes* 50:227.
- (720) Krieger DT. 1979. Central nervous system disease. *Clin Endocrinol Metab* 8:467.
- (721) Shiraishi I, et al. 1984. Ethosecretogram: relation of behavior to plasma corticosterone in freely moving rats. *Am J Physiol* 247:R40.
- (722) Lenzen S, Bailey CJ. 1984. Thyroid hormones, gonadal and adrenocortical steroids and the function of the islets of Langerhans. *Endocr Rev* 5:411.

- (723) Mantha L, et al. 1999 Modulation of triglyceride metabolism by glucocorticoids in diet-induced obesity. *Am J Physiol* 277:R455.
- (724) Kim SP, et al. 2003 Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. *Diabetes* 52:2453.
- (725) Wagenknecht LE, et al. 2003 Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) family study. *Diabetes* 52:2490.
- (726) Chapman AB, et al. 1984 Analysis of gene expression during differentiation of adipogenic cells in culture and hormonal control of the developmental program. *J Biol Chem* 259:15548.
- (727) Leibel RL, et al. 1989 Physiologic basis for control of body fat distribution in humans. *Annu Rev Nutr* 9:417.
- (728) Dallman MF, Bhatnagar S. 2001 Chronic stress and energy balance: role of the hypothalamo-pituitary-adrenal axis. Vol IV, section 7. *Coping with the environment*. Chap 10. New York: Oxford University Press, pp. 179.
- (729) Campfield LA, et al. 1995 Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. *Science*. 269:546.
- (730) Pelleymounter MM, et al. 1995. Effects of the obese gene product on body weight regulation in ob/ob mice. *Science*. 269:540.
- (731) Halaas JK, et al. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. *Science*. 269:543.
- (732) Considine RV, et al. 1996. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl J Med* 334:292.
- (733) Rosenbaum M, et al. 1996. Effects of gender, body composition, and menopause on plasma concentrations of leptin. *J Clin Endocrinol Metab* 81:3424.
- (734) Frederich RC, et al. 1995. Expression of ob mRNA and its encoded protein in rodents: impact of nutrition and obesity. *J Clin Invest* 96:1658.
- (735) Boden G, et al. 1996. Effect of fasting on serum leptin in normal human subjects. *J Clin Endocrinol Metab* 81:3419.
- (736) Schwartz MW, et al. 2000. Central nervous system control of food intake. *Nature* 404:661.
- (737) Ahima RS, et al. 1996. Role of leptin in the neuroendocrine response to fasting. *Nature*. 382:250.
- (738) Legradi G, et al. 1997. Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. *Endocrinology*. 138:2569.
- (739) Carro E, et al. 1997. Regulation of in vivo growth hormone secretion by leptin. *Endocrinology*. 138:2203.
- (740) Chehab FF, et al. 1997. Early onset of reproductive function in normal female mice treated with leptin. *Science*. 275:88.
- (741) Ahima RS, et al. 1997. Leptin accelerates the onset of puberty in normal female mice. *J. Clin. Invest*. 99:391.
- (742) Cheung CC, et al. 1997. Leptin is a metabolic gate for onset of puberty in the female rat. *Endocrinology*. 138:855.
- (743) Heiman ML, et al. 1997. Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. *Endocrinology*. 138:3859.
- (744) Costa A, et al. 1997. Stimulation of corticotropin-releasing hormone release by obese (ob) gene product, leptin, from hypothalamic explants. *Neuroreport*. 8:1131.
- (745) Raber J, et al. 1997. Corticotropin-releasing factor and adrenocorticotrophic hormone as potential central mediators of OB effects. *J. Biol. Chem*. 272:15057.
- (746) Itoh S, et al. 1980. Conditioned circadian rhythm of plasma corticosterone in the rat induced by food restriction. *Jpn. J. Physiol*. 30:365.
- (747) Morimoto Y, et al. 1977. Relationship between circadian rhythm of food intake and that of plasma corticosterone and effect of food restriction on circadian adrenocortical rhythm. *Neuroendocrinology*. 23:212.
- (748) Saladin R, et al. 1995. Transient increase in obese gene expression after food intake or insulin administration. *Nature*. 377:527.
- (749) Sinha MK, et al. 1996. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. *J. Clin. Invest*. 97:1344.
- (750) Licinio J, et al. 1997. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. *Nat. Med*. 3:575.
- (751) Ahima RS, et al. 1998. Postnatal Leptin Surge and Regulation of Circadian Rhythm of Leptin by Feeding Implications for Energy Homeostasis and Neuroendocrine Function. *J. Clin. Invest*. 101(5):1020.
- (752) Lin L, et al. 2001. Acute changes in the response to peripheral leptin with alteration in the diet composition. *Am J Physiol Regul Integr Comp Physiol* 280:R504.

- (753) Levin BE, Dunn-Meynell A. 2002. A reduced central leptin sensitivity in rats with diet-induced obesity. *Am J Physiol Regul Integr Comp Physiol* 283:R941.
- (754) Christiansen K. 1999. Hypophysen-Gonaden-Achse (Mann). In *Psychoendokrinologie und Psychoimmunologie, Enzyklopädie der Psychologie*, Eds C Kirschbaum & D Hellhammer. Göttingen: Hogrefe, pp. 141.
- (755) Longcope C, et al. 2000. Diet and sex hormone-binding globulin. *Journal of Clinical Endocrinology and Metabolism* 85:293.
- (756) Vermeulen A, et al. 1996. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. *Journal of Clinical Endocrinology and Metabolism* 81:1821.
- (757) Ohnhaus EE, Studer H. 1983. A link between liver microsomal enzyme activity and thyroid hormone metabolism in man. *Br J Clin Pharmacol* 1983;15:71-76.
- (758) Robbins J. 1981. Factors altering thyroid hormone metabolism. *Environ Health Perspect* 38:65.
- (759) McCormack PD, et al. 1998. Cold stress, reverse T3 and lymphocyte function. *Alaska Med* 40:55.
- (760) Johansson G, et al. 1987. Examination stress affects plasma levels of TSH and thyroid hormones differently in females and males. *Psychosom Med* 49:390.
- (761) Opstad K. 1994. Circadian rhythm of hormones is extinguished during prolonged physical stress, sleep and energy deficiency in young men. *Eur J Endocrinol* 131:56.
- (762) Girvent M, et al. 1998. Euthyroid sick syndrome, associated endocrine abnormalities, and outcome in elderly patients undergoing emergency operation. *Surgery* 123:560.
- (763) Boelen A. 1993. Association between serum interleukin-6 and serum 3,5,3'-triiodo-thyronine in nonthyroidal illness. *J Clin Endocrinol Metab* 77:1695.
- (764) Bartelena L, et al. 1994. Relationship of the increased serum interleukin-6 concentration to changes of thyroidal function in nonthyroidal illness. *J Endocrinol Invest* 17:269.
- (765) Torpy DJ, et al. 1998. Acute and delayed effects of a single-dose injection of interleukin-6 on thyroid function in healthy humans. *Metabolism* 47:1289.
- (766) Rubello D, et al. 1992. Acute and chronic effects of high glucocorticoid levels on hypothalamic-pituitary-thyroid axis in man. *J Endocrinol Invest* 15:437.
- (767) Banos C, et al. 1979. Effect of ACTH-stimulated glucocorticoid hypersecretion on the serum concentrations of thyroxine-binding globulin, thyroxine, triiodothyronine, reverse triiodothyronine and on the TSH response to TRH. *Acta Med Acad Sci Hung* 36:381.
- (768) Azizi F, et al. 1993. Time course of changes in free thyroid indices, rT3, TSH, cortisol and ACTH following exposure to sulfur mustard. *Exp Clin Endocrinol* 101:303.
- (769) Ben Haim S, et al. 1985. Effect of metoclopramide—a dopaminergic blocker and endogenous cortisol on TSH secretion in critically ill men. *Acta Endocrinol (Copenh)* 109:70.
- (770) Bugaresti JM, et al. 1992. Changes in thyroid hormones, thyroid stimulating hormone and cortisol in acute spinal cord injury. *Paraplegia* 30:401.
- (771) Juma AH, et al. 1991. Alterations in thyroid hormones, cortisol, and catecholamine concentration in patients after orthopedic surgery. *J Surg Res* 50:129.
- (772) Arunabh, et al. 1992. Changes in thyroid hormones in surgical trauma. *J Postgrad Med* 38:117.
- (773) Grubeck-Loebenstein B, et al. 1983. Thyroid function in adrenocortical insufficiency during withdrawal and re-administration of glucocorticoid substitution. *Acta Endocrinol (Copenh)* 103:254.
- (774) Samuels MH, McDaniel PA. 1997. Thyrotropin levels during hydrocortisone infusions that mimic fasting-induced cortisol elevations: a clinical research center study. *J Clin Endocrinol Metab* 82:3700.
- (775) Ortega E, et al. 1990. Activity of the hypothalamo-pituitary ovarian axis in hypothyroid rats with or without triiodothyronine replacement. *Life Sci*. 46:391.
- (776) Morgan MA, et al. 2000. Effect of thyroid hormone administration on estrogen-induced sex behaviour in female mice. *Horm Behav*. 37:15.
- (777) Chandrasekhar Y, et al. 1985. Spermatogenesis, seminal characteristics and reproductive hormone levels in mature rams with induced hypothyroidism and hyperthyroidism. *J Endocrinol*. 105:39.
- (778) Vriend J, et al. 1987. The effects of melatonin and hypothyroidism on estradiol and gonadotropin levels in female Syrian hamsters. *Biol Reprod*. 36:719.

- (779) Gueraud F, Paris A. 1998. Glucuronidation: a dual control. *Gen Pharmacol* 31:683.
- (780) Hood A, Klaassen CD. 2000. Differential effects of microsomal enzyme inducers on in vitro thyroxine (t(4)) and triiodothyronine (t(3)) glucuronidation. *Toxicol Sci* 55:78.
- (781) Wu SY, et al. 1995. Sulfation pathway of thyroid hormone metabolism in selenium-deficient male rats. *Am J Physiol* 268:E572.
- (782) Gupta P, Kar A. 1999. Cadmium induced thyroid dysfunction in chicken: hepatic type I iodothyronine 5'-monodeiodinase activity and role of lipid peroxidation. *Comp Biochem Physiol C Pharmacol Toxicol Endocrinol* 123:39.
- (783) Gupta P, Kar A. 1998. Role of ascorbic acid in cadmium-induced thyroid dysfunction and lipid peroxidation. *J Appl Toxicol* 18:317.
- (784) Chaurasia SS, Kar A. 1997. Protective effects of vitamin E against lead-induced deterioration of membrane associated type-I iodothyronine 5'-monodeiodinase (5'D-I) activity in male mice. *Toxicology* 124:203.
- (785) Suda AK, et al. 1978. The production and metabolism of 3', 5, 3' triiodothyronine and 3, 3', 5' triiodothyronine in normal and fasting subjects. *J Clin Endocrinol Metab* 47:1311.
- (786) Hugues JN, et al. 1984. Rapid adaptations of serum thyrotrophin, triiodothyronine and reverse triiodothyronine levels to short-term starvation and refeeding. *Acta Endocrinol (Copenh)* 105:194.
- (787) O'Brian JT, et al. 1980. Thyroid hormone homeostasis in states of relative caloric deprivation. *Metabolism* 29:721.
- (788) Reinhardt W, et al. 1993. Effect of small doses of iodine on thyroid function during caloric restriction in normal subjects. *Horm Res* 39:132.
- (789) Serog P, et al. 1982. Effects of slimming and composition of diets on VO₂ and thyroid hormones in healthy subjects. *Am J Clin Nutr* 35:24.
- (790) Langer P, et al. 1988. Effect of ethanol and linoleic acid on changes in biliary excretion of iodothyronines possibly related to thyroxine deiodination in rat liver. *Horm Metab Res* 20:218.
- (791) Keck E, et al. 1988. Alcohol and endocrinologic homeostasis. *Z Gastroenterol* 26:39.
- (792) Rommerts FFG. 1998. Testosterone: an overview of biosynthesis, transport, metabolism and nongenomic actions. In *Testosterone. Action, Deficiency, Substitution*, pp 1–31. Eds E Nieschlag & HM Behre. New York: Springer.
- (793) Longcope C. 1986. Adrenal and gonadal steroid action in normal females. *Journal of Clinical Endocrinology and Metabolism* 15:213.
- (794) Hutchinson JB. 1991. Hormonal control of behaviour: steroid action in the brain. *Current Opinion in Neurobiology* 1:562.
- (795) McEwen BS. 1992. Steroid hormones: effect on brain development and function. *Hormone Research* 3:1.
- (796) Collaer ML, Hines M. 1995. Human behavioral sex differences: a role for gonadal hormones during early development? *Psychological Bulletin* 118:55.
- (797) Schulkin J. 1993. *Hormonally Induced Changes in Mind and Brain*. San Diego: Academic Press.
- (798) Singer F, Zumoff B. 1992. Subnormal serum testosterone levels in male internal medicine residents. *Steroids* 57:86.
- (799) Chatterton RT Jr, et al. 1997. Hormonal responses to psychological stress in men preparing for skydiving. *Journal of Clinical Endocrinology and Metabolism* 82:2503.
- (800) Chatterton RT Jr, Dooley SL. 1999. Reversal of diurnal cortisol rhythm and suppression of plasma testosterone in obstetric residents on call. *Journal of the Society for Gynecological Investigation* 6:50.
- (801) Tegelman R, et al. 1988. Hormone levels in male ice hockey players during a 26-h cup tournament. *International Journal of Andrology* 11:361.
- (802) Schulz P, et al. 1996. Lower sex hormones in men during anticipatory stress. *Neuroreport* 25:3101.
- (803) Francis KT. 1981. The relationship between high and low trait psychological stress, serum testosterone and serum cortisol. *Experientia* 37:1296.
- (804) Nilsson PM, et al. 1995. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males. *Journal of Internal Medicine* 237:479.
- (805) Grossi G, et al. 1999. Psychophysiological correlates of organizational change and threat of unemployment among police inspectors. *Integrative Physiological and Behavioral Science* 34:30.
- (806) Schweiger U, et al. 1999. Testosterone gonadotropin and cortisol secretion in male patients with major depression. *Psychosomatic Medicine* 61:292.

- (807) Uden F, et al. 1988. Hypothalamic-pituitary-gonadal axis in major depressive disorders. *Acta Psychiatrica Scandinavica* 78:138.
- (808) MacLean CR, et al. 1997. Effects of the transcendental meditation program on adaptive mechanisms: changes in hormone levels and responses to stress after 4 months of practice. *Psychoneuroendocrinology* 22:277.
- (809) Kraemer WJ, et al. 1998. The effects of short-term resistance training on endocrine function in men and women. *European Journal of Applied Physiology* 78:69.
- (810) Hakkinen K, et al. 1998. Acute hormone responses to heavy resistance lower and upper extremity exercise in young versus old men. *European Journal of Applied Physiology* 77:312.
- (811) Kraemer RR, et al. 1992. Growth hormone IGF-I and testosterone responses to resistive exercise. *Medicine and Science in Sports and Exercise* 24:1346.
- (812) Jurimae T, et al. 1990. The effect of a single-circuit weight-training session on the blood biochemistry of untrained university students. *European Journal of Applied Physiology* 61:344.
- (813) Bhasin S, et al. 1996. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. *New England Journal of Medicine* 335:1.
- (814) Cumming DC, et al. 1986. Reproductive hormone increases in response to acute exercise in men. *Medicine and Science in Sports and Exercise* 18:369.
- (815) Adlercreutz H, et al. 1976. Physical activity and hormones. *Advances in Cardiology* 18:144.
- (816) Cadoux-Hudson TA, et al. 1985. The effects of exercise on the production and clearance of testosterone in well trained young men. *European Journal of Applied Physiology* 54:321.
- (817) Arce JC, De Souza MJ. 1993. Exercise and male infertility. *Sports Medicine* 15:146.
- (818) Elias AN, Wilson AF. 1993. Exercise and gonadal function. *Human Reproduction* 8:1747.
- (819) Hackney AC. 1996. The male reproductive system and endurance exercise. *Medicine and Science in Sports and Exercise* 28:180.
- (820) De Crée C, et al. 1990. The monitoring of the menstrual status of female athletes by salivary steroid determination and ultrasonography. *European Journal of Applied Physiology* 60:472.
- (821) Kuoppasalmi K. 1980. Plasma testosterone and sex hormone binding globulin capacity in physical exercise. *Scandinavian Journal of Clinical Laboratory Investigation* 40:411.
- (822) Opstad PK. 1992. The hypothalamo-pituitary regulation of androgen secretion in young men after prolonged physical stress combined with energy and sleep deprivation. *Acta Endocrinol (Copenhagen)* 127:231.
- (823) Bernton E, et al. 1995. Adaptation to chronic stress in military trainees. Adrenal androgens, testosterone, glucocorticoids, IGF-1 and immune function. *Annals of the New York Academy of Sciences* 29:217.
- (824) Vogel W, et al. 1978. Roles of the gonadal steroid hormones in psychiatric depression in men and women. *Progressions in Neurology and Psychopharmacology* 2:487.
- (825) Seidman SN, Rabkin JG. 1998. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. *Journal of Affective Disorders* 48:157.
- (826) Rejeski WJ, et al. 1988. Anabolic steroids and aggressive behaviour in cynomolgus monkeys. *Behavioral Medicine* 11:95.
- (827) Mazur A, et al. 1992. Testosterone and chess competition. *Social Psychology Quarterly* 55:70.
- (828) Mazur A, Lamb TA. 1980. Testosterone status and mood in human males. *Hormones and Behavior* 14:236.
- (829) Elias M. 1981. Serum cortisol testosterone and testosterone binding globulin responses to competitive fighting human males. *Aggressive Behaviour* 7:215.
- (830) Suay F, et al. 1999. Effects of competition and its outcome on serum testosterone cortisol and prolactin. *Psychoneuroendocrinology* 24:551.
- (831) Hellhammer DH, et al. 1985. Changes in saliva testosterone after psychological stimulation in men. *Psychoneuroendocrinology* 10:77.
- (832) Monti P, et al. 1977. Testosterone and components of aggressive and sexual behavior in man. *American Journal of Psychiatry* 134:692.
- (833) Knussmann R, et al. 1986. Relations between sex hormone levels and sexual behavior in men. *Archives of Sexual Behavior* 15:429.
- (834) Dabbs JM Jr, Mohammed S. 1992. Male and female salivary testosterone concentrations before and after sexual activity. *Physiology and Behavior* 52:195.
- (835) La Grange L, et al. 1995. Alcohol consumption: biochemical and personality correlates in a college student population. *Addictive Behaviors* 20:93.
- (836) Hill P, et al. 1979. Diet and urinary steroids in black and white North American men and black South African men. *Cancer Research* 39:5101.

- (837) Belanger A, et al. 1989. Influence of diet on plasma steroids and sex hormone-binding globulin levels in adult men. *Journal of Steroid Biochemistry and Molecular Biology* 32:829.
- (838) Key TJ, et al. 1990. Testosterone sex hormone-binding globulin, calculated free testosterone and oestradiol in male vegans and omnivores. *British Journal of Nutrition* 64:111.
- (839) Bishop DT, et al. 1988. The effect of nutritional factors on sex hormone levels in male twins. *Genetic Epidemiology* 5:43.
- (840) Reed MJ, et al. 1987. Dietary lipids: an additional regulator of plasma levels of sex hormone binding globulin. *Journal of Clinical Endocrinology and Metabolism* 64:1083.
- (841) Meikle AW, et al. 1990. Effects of a fat-containing meal on sex hormones in men. *Metabolism* 39:943.
- (842) Haffner SM, et al. 1994. Decreased testosterone and dehydroepiandrosterone sulphate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. *Metabolism* 43:599.
- (843) Daniels J, et al. 1998. Molecular genetic studies of cognitive ability. *Hum Biol* 70:281.
- (844) McGuffin P. 2000. The quantitative and molecular genetics of human intelligence. *Novartis Found Symp* 233:243.
- (845) Cournil A, Kirkwood TB. 2001. If you would live long, choose your parents well. *Trends Genet* 17:233.
- (846) Lithgow GJ, Andersen JK. 2000. The real Dorian Gray mouse. *Bioessays* 22:410.
- (847) Perls T, et al. 2000. Centenarians and the genetics of longevity. *Results Probl Cell Differ* 29:1.
- (848) Cooper B. 2001. Nature, nurture and mental disorder: old concepts in the new millennium. *Br J Psychiatry Suppl* 40:S91.
- (849) St. George-Hyslop PH. 2000. Genetic factors in the genesis of Alzheimer's disease. *Ann NY Acad Sci* 924:1.
- (850) Vaughan Davis MB, Wood NW JR. 2001. Genetics of Parkinsonism: a review. *Ann Hum Genet* 65:111.
- (851) Smith JD. 2000. Apolipoprotein E4: an allele associated with many diseases. *Ann Med* 32:118.
- (852) Bartke A, et al. 2001. Genes that prolong life: relationships of growth hormone and growth to aging and life span. *J Gerontol A Biol Sci Med Sci* 56:B340.
- (853) Caruso C, et al. 2001. Immunogenetics of longevity. Is major histocompatibility complex polymorphism relevant to the control of human longevity? A review of literature data. *Mech Ageing Dev* 122:445.
- (854) Sonntag WE, et al. 2000. The effects of growth hormone and IGF-I deficiency on cerebrovascular and brain ageing. *J Anat* 197:575.
- (855) Bertoni-Freddari C, et al. 1996. Synaptic structural dynamics and aging. *Gerontology* 42:170.
- (856) Gage FH. 2000. Mammalian neural stem cells. *Science* 287:1433.
- (857) Rao MS, Mattson MP. 2001. Stem cells and aging: expanding the possibilities. *Mech Ageing Dev* 122:713.
- (858) Mattson MP. 1992. Calcium as sculptor and destroyer of neural circuitry. *Exp Gerontol* 27:29.
- (859) Lee CK, et al. 2000. Gene-expression profile of the ageing brain in mice. *Nat Genet* 25:294.
- (860) Jin LW, Saitoh T. 1995. Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy. *Drugs Aging* 6:136.
- (861) Roth GS, Joseph JA. 1994. Cellular and molecular mechanisms of impaired dopaminergic function during aging. *Ann NY Acad Sci* 719:129.
- (862) Mattson MP, Kater SB. 1989. Excitatory and inhibitory neurotransmitters in the generation and degeneration of hippocampal neuroarchitecture. *Brain Res* 478:337.
- (863) Ben-Ari Y, et al. 1997. GABAA, NNDA and AMPA receptors: a developmentally regulated "menage a trois." *Trends Neurosci* 20:523.
- (864) Marini AM, et al. 1998. Activity-dependent release of brain-derived neurotrophic factor underlies the neuroprotective effect of N-methyl-D aspartate. *J Biol Chem* 273:29394.
- (865) Mattson MP, et al. 1993. beta-Amyloid precursor protein metabolites and loss of neuronal Ca²⁺ homeostasis in Alzheimer's disease. *Trends Neurosci* 16:409.
- (866) Fu W, et al. 1998. Catecholamines potentiate amyloid beta-peptide neurotoxicity: involvement of oxidative stress, mitochondrial dysfunction, and perturbed calcium homeostasis. *Neurobiol Dis* 5:229.
- (867) Mattson MP. 1989. Acetylcholine potentiates glutamate-induced neuro-degeneration in cultured hippocampal neurons. *Brain Res* 497:402.
- (868) Rami A, Kriegstein J. 1998. Muscarinic-receptor antagonist scopolamine rescues hippocampal neurons from death induced by glutamate. *Brain Res* 788:323.

- (869) Lebel CP, Bondy SC. 1992. Oxidative damage and cerebral aging. *Prog Neurobiol* 38:601.
- (870) Hoyer S. 1995. Age-related changes in cerebral oxidative metabolism. Implications for drug therapy. *Drugs Aging* 6:210.
- (871) Sohal RS, et al. 1994. Effect of age and caloric restriction on DNA oxidative damage in different tissues of C57BL/6 mice. *Mech Ageing Dev* 76:215.
- (872) Mattson MP. 1998. Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. *Trends Neurosci* 21:53.
- (873) Markesbery WR, et al. 2001. Oxidative alterations in neurodegenerative diseases. In: *Pathogenesis of Neurodegenerative Disorders*, edited by Mattson MP. Totowa, NJ: Humana, pp.1.
- (874) Mattson MP. 2002. *Diet-Brain Connections*. Norwell, MA: Kluwer
- (875) Bell C, et al. 2001. Tryptophan depletion and its implications for psychiatry. *Br J Psychiatry* 178:399.
- (876) Frefholm BB, et al. 1999. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacol Rev* 51:83.
- (877) Uauy R, et al. 1996. Role of essential fatty acids in the function of the developing nervous system. *Lipids* 31:S167.
- (878) Ashrafi K, et al. 2000. Sip2p and its partner snf1p kinase affect aging in *S. cerevisiae*. *Genes Dev* 14:1872.
- (879) Lane MA, et al. 2001. Caloric restriction in primates. *Ann NY Acad Sci* 928:287.
- (880) Weindruch R, Sohal RS. 1997. Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. *N Engl J Med* 337:986.
- (881) Brochu M, et al. 2000. Obesity, body fat distribution, and coronary artery disease. *J Cardiopulm Rehabil* 20:96.
- (882) Lebovitz HE. 1999. Type 2 diabetes: an overview. *Clin Chem* 45:1339.
- (883) Levi F. 1999. Cancer prevention: epidemiology and perspectives. *Eur J Cancer* 35:1912.
- (884) Dubey A, et al. 1996. Effect of age and caloric intake on protein oxidation in different brain regions and on behavioral functions of the mouse. *Arch Biochem Biophys* 333:189.
- (885) Morgan TE, et al. 1999. The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. *Neuroscience* 89:687.
- (886) Ingram DK, et al. 1987. Dietary restriction benefits learning and motor performance of aged mice. *J Gerontol* 42:78.
- (887) Stewart J, et al. 1989. The effects of life-long food restriction on spatial memory in young and aged Fischer 344 rats measured in the eight-arm radial and the Morris water mazes. *Neurobiol Aging* 10:669.
- (888) Goodrick CL, et al. 1983. Differential effects of intermittent feeding and voluntary exercise on body weight and lifespan in adult rats. *J Gerontol* 38:36.
- (889) Bruce-Keller AJ, et al. 1999. Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. *Ann Neurol* 45:8.
- (890) Duan W, Mattson MP. 1999. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. *J Neurosci Res* 57:195.
- (891) Bronner LL, et al. 1995. Primary prevention of stroke. *N Engl J Med* 333:1392.
- (892) Mayeux R, et al. 1999. Reduced risk of Alzheimer's disease among individuals with low calorie intake. *Neurology* 59:S296.
- (893) Grant W. 1997. Dietary links to Alzheimer's disease. *Alz Dis Rev* 2:42.
- (894) Logroscini G, et al. 1996. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. *Ann Neurol* 39:89.
- (895) Hendrie HC, et al. 2001. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. *JAMA* 285:739.
- (896) Duan W, et al. 2001. Brain-derived neurotrophic factor mediates an excitoprotective effect of dietary restriction in mice. *J Neurochem* 76:619.
- (897) Lee J, et al. 2000. Dietary restriction increases survival of newly-generated neural cells and induces BDNF expression in the dentate gyrus of rats. *J Mol Neurosci* 15:99.
- (898) Mattson MP. 1997. Neuroprotective signal transduction: relevance to stroke. *Neurosci Biobehav Rev* 21:193.
- (899) Guo ZH, Mattson MP. 1999. Neurotrophic factors protect synaptic terminals against

- amyloid- and oxidative stress-induced impairment of glucose transport, glutamate transport and mitochondrial function. *Cerebral Cortex* 10:50.
- (900) Jankowsky JL, Patterson PH. 1999. Cytokine and growth factor involvement in long-term potentiation. *Mol Cell Neurosci* 14:273.
- (901) Mattson MP. 1997. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. *Physiol Rev* 77:1081.
- (902) Mattson MP. 2000. Apoptosis in neurodegenerative disorders. *Nat Rev Mol Cell Biol* 1:120.
- (903) Guo Z, et al. 2000. Beneficial effects of dietary restriction on cerebral cortical synaptic terminals: preservation of glucose transport and mitochondrial function after exposure to amyloid β -peptide and oxidative and metabolic insults. *J Neurochem* 75:314.
- (904) Lee J, et al. 2002. Dietary restriction enhances neurotrophin signaling and neurogenesis in the hippocampus of adult mice. *J Neurochem* 80:539.
- (905) Bättig K, Welzl H. 1993. Psychopharmacological profile of caffeine. In: Garattini S, ed. *Caffeine, coffee and health*. New York: Raven Press, pp. 353.
- (906) Hinds TS, et al. 1996. The effect of caffeine on pregnancy outcome variables. *Nutr Rev* 54:203.
- (907) Barone JJ, Roberts HR. 1996. Caffeine consumption. *Food Chem Toxicol* 34: 119.
- (908) Debry G. 1994. *Coffee and Health* (Debry G ed) pp 1-538, John Libbey, Paris.
- (909) Marks V, Kelly JF. 1973 Absorption of caffeine from tea, coffee, and coca cola. *Lancet* 1:827.
- (910) Bonati M, et al. 1982. Caffeine disposition after oral doses. *Clin Pharmacol Ther* 32:98.
- (911) Blanchard J, Sawers SJ. 1983. The absolute bioavailability of caffeine in man. *Eur J Clin Pharmacol* 24:93.
- (912) Arnaud MJ. 1993. Metabolism of caffeine and other components of coffee, in *Caffeine, Coffee and Health* (Garattini S ed), Raven Press, New York, pp. 43.
- (913) Eichler O. 1976. Zentrale Wirkung, in *Kaffee und Coffein* (Eichler O ed), Springer-Verlag, Berlin, Heidelberg, New York, pp. 65.
- (914) Curatolo PW, Robertson D. 1983. The health consequences of caffeine. *Ann Intern Med* 98:641.
- (915) Aranda JV, et al. 1977. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. *J Pediatr* 90:467.
- (916) Le Guennec JC, Billon B. 1987. Delay in caffeine elimination in breast-fed infants. *Pediatrics* 79:264.
- (917) Parsons WD, Neims AH. 1981. Prolonged half-life of caffeine in healthy term newborn infants. *J Pediatr* 98:640.
- (918) Hart P, et al. 1976. Enhanced drug metabolism in cigarette smokers. *Br Med J* 2:147.
- (919) Joeres R, et al. 1988. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. *Hepatology* 8:575.
- (920) Murphy TL, et al. 1988. The effect of smoking on caffeine elimination: Implications for its use as a semiquantitative test of liver function. *Clin Exp Pharmacol Physiol* 15:9.
- (921) Patwardhan RV, et al. 1980. Impaired elimination of caffeine by oral contraceptive steroids. *J Lab Clin Med* 95:603.
- (922) Aldridge A, et al. 1981. The disposition of caffeine during and after pregnancy. *Semin Perinatol* 5:310.
- (923) Knutti R, et al. 1981. Effect of pregnancy on the pharmacokinetics of caffeine. *Eur J Clin Pharmacol* 21:121.
- (924) Brazier JL, et al. 1983. Pharmacokinetics of caffeine during and after pregnancy. *Dev Pharmacol Ther* 6:315.
- (925) Christian MS, Brent RL. 2001. Teratogen update: evaluation of the reproductive and developmental risks of caffeine. *Teratology* 64:51.
- (926) Gilliland K, Bullock W. 1984. Caffeine: A potential drug of abuse. *Adv Alcohol Subst Abuse* 3:53.
- (927) Holtzman SG. 1990. Caffeine as a model drug of abuse. *Trends Pharmacol Sci* 11:355.
- (928) Hughes JR, et al. 1992. Should caffeine abuse, dependence, or withdrawal be added to DSM-IV and ICD-10? *Am J Psychiatry* 149:33.
- (929) Strain EC, et al. 1994. Caffeine dependence syndrome: Evidence from case histories and experimental evaluations. *JAMA* 272:1043.
- (930) Pickworth WB. 1995. Caffeine dependence. *Lancet* 345:1066.
- (931) Hughes JR, et al. 1998. Endorsement of DSM-IV dependence criteria among caffeine users. *Drug Alcohol Depend* 52:99.
- (962) Collins TFX, et al. 1984. A study of the teratogenic potential of caffeine ingested in drinking water. *Food Cosmet Toxicol* 21:763

- (933) Daly JW. 1993. Mechanism of action of caffeine, in *Caffeine, Coffee, and Health* (Garattini S ed), Raven Press, New York, pp. 97.
- (934) Morgan ME, Vestal RE. 1989. Methylxanthine effects on caudate dopamine release as measured by in vivo electrochemistry. *Life Sci* 45:2025.
- (935) McCall AL, et al. 1982. Blood-brain barrier transport of caffeine: dose-related restriction of adenosine transport. *Life Sci* 31:2709.
- (936) Porkka-Heiskanen T. 1999. Adenosine in sleep and wakefulness. *Ann Med* 31:125.
- (937) Gervitz LM, et al. 2001. Adenosine induces initial hypoxic-ischemic depression of synaptic transmission in the rat hippocampus in vivo. *Am J Physiol Regul Integr Comp Physiol* 280:R639.
- (938) Okada M, et al. 1997. Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. *Eur J Pharmacol* 324:181.
- (939) Barraco RA, et al. 1983. Central effects of adenosine analogs on locomotor activity in mice and antagonism of caffeine. *Brain Res* 272:392.
- (940) Huston JP, et al. 1996. Extracellular adenosine levels in neostriatum and hippocampus during rest and activity periods of rats. *Neuroscience* 73:99.
- (941) Dunwiddie TV, Fredholm BB. 1991. Adenosine A1 receptors inhibit adenylyl cyclase activity and neurotransmitter release and hyperpolarize pyramidal neurons in the rat hippocampus. *J Pharmacol Exp Ther* 249:31.
- (942) Myers S, Pugsley TA. 1986. Decrease in rat striatal dopamine synthesis and metabolism in vivo by metabolically stable adenosine receptor agonists. *Brain Res* 375:193.
- (943) Hauber W, Munkle M. 1997. Motor depressant effects mediated by dopamine D2 and adenosine A2A receptors in the nucleus accumbens and the caudate putamen. *Eur J Pharmacol* 323:127.
- (944) Griffiths RR, et al. 1988. Reinforcing properties of caffeine: Studies in humans and laboratory animals. *Pharmacol Biochem Behav* 29:419.
- (945) Elkins RN, et al. 1981. Acute effects of caffeine in normal, prepubertal boys. *American Journal of Psychiatry* 138:178.
- (946) Rapoport JL, et al. 1984. Behavioral effects of caffeine in children. *Archives of General Psychiatry* 41:1073.
- (947) Rumsey JM, Rapoport JL. 1983. Assessing behavioural and cognitive effects of diet in pediatric populations. *Nutrition and the Brain* 6:101.
- (948) Rapoport JL. 1983. Effects of dietary substances in children. *Journal of Psychiatry Research* 17:187.
- (949) Baer RA. 1987. Effects of caffeine on classroom behaviour, sustained attention, and a memory task in preschool children. *Journal of Applied Behavior Analysis* 20:225.
- (950) Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised. 1987. Washington, DC, American Psychiatric Association Press
- (951) Greden JF. 1974. Anxiety or caffeinism. *Am J Psychiatry* 131:1089.
- (952) Rosenberg L, et al. 1980. Coffee drinking and myocardial infarction in young women. *Am J Epidemiol* 111:675.
- (953) MacMahon B, et al. 1981. Coffee and cancer of the pancreas. *N Engl J Med* 304:630.
- (954) Wynne KN, et al. 1987. Isolation of opiate receptor ligands in coffee. *Clin Exp Pharmacol Physiol* 14:785.
- (955) Green RM, Stiles GL. 1986. Chronic caffeine consumption sensitized the A1 adenosine receptor-adenylyl cyclase system in rat cerebral cortex. *J Clin Invest* 77:222.
- (956) Denaro CP, et al. 1991. Effects of caffeine after repeated dosing. *Eur J Clin Pharmacol* 40:273.
- (957) Linn S, et al. 1982. No association between coffee consumption and adverse outcomes of pregnancy. *N Engl J Med* 306:141.
- (958) Hallal JC. 1986. Caffeine: Is it hazardous to your patients' health? *Am J Nurs* 86:422.
- (959) Regestein QR. 1981. Pathologic sleepiness induced by caffeine. *Am J Med* 87:586.
- (960) Mathew RJ, Wilson WH. 1985. Caffeine-induced changes in cerebral circulation. *Stroke* 16:814.
- (961) Mathew RJ, Wilson WH. 1991. Substance abuse and cerebral blood flow. *Am J Psychiatry* 148:292.
- (962) James JE. 1991. *Caffeine and Health* pp 1-432, Academic Press, London
- (963) Lorist MM, et al. 1994. Influence of caffeine on information processing stages in well rested and fatigued subjects. *Psychopharmacology* 113:411.
- (964) Warburton DM. 1995. Effects of caffeine on cognition and mood without caffeine abstinence. *Psychopharmacology* 119:66.

- (965) Lieberman HR. 1988. Beneficial effects of caffeine. In: Twelfth International Scientific Colloquium on Coffee. Paris, ASIC.
- (966) Stern KN, et al. 1989. Reinforcing and subjective effects of caffeine in normal human volunteers. *Psychopharmacology* 98:81.
- (967) Loke WH. 1988. Effects of caffeine on mood and memory. *Physiology and Behavior* 44:367.
- (968) Loke WH, et al. 1985. Caffeine and diazepam: separate and combined effects on mood, memory, and psychomotor performance. *Psychopharmacology* 87:344.
- (969) Sicard BA, et al. 1996. The effects of 600 mg of slow release caffeine on mood and alertness. *Aviation, Space, and Environmental Medicine* 67:859.
- (970) Schuh KJ, Griffiths RR. 1997. Caffeine reinforcement the role of withdrawal. *Psychopharmacology* 130:320.
- (971) Silverman K, et al. 1992. Withdrawal syndrome after the double-blind cessation of caffeine consumption. *N Engl J Med* 327:1109.
- (972) Griffiths RR, et al. 1990. Low-dose caffeine discrimination in humans. *J Pharmacol Exp Ther* 252:970.
- (973) Nehlig A, Debry G. 1994. Effects of coffee on the central nervous system, in *Coffee and Health* (Debry G ed), John Libbey, Montrouge, pp. 157.
- (974) Höfer I, Bättig K. 1994. Cardiovascular, behavioral, and subjective effects of caffeine under field conditions. *Pharmacol Biochem Behav* 48:899.
- (975) Griffiths RR, Mumford GK. 1995. Caffeine: A drug of abuse? In *Psychopharmacology: The Fourth Generation of Progress* (Bloom FE and Kupfer DJ eds) pp 1699-1713, Raven Press, New York.
- (976) Barone J, Roberts H. 1984. Human consumption of caffeine, in *Caffeine: Perspectives from Recent Research* (Dews PB ed), Springer-Verlag, Heidelberg, pp. 59.
- (977) Phillips-Bute BG, Lane JD. 1998. Caffeine withdrawal symptoms following brief caffeine deprivation. *Physiol Behav* 63:35.
- (978) Robertson D, et al. 1981. Tolerance to the humoral and hemodynamic effects of caffeine in man. *J Clin Invest* 67:1111.
- (979) Holtzman SG, Finn IB. 1988. Tolerance to behavioral effects of caffeine in rats. *Pharmacol Biochem Behav* 29:411.
- (980) Fredholm BB. 1982. Adenosine actions and adenosine receptors after 1 week treatment with caffeine. *Acta Physiol Scand* 115:283.
- (981) Bona E, et al. 1995. The effect of long term caffeine treatment on hypoxic-ischemic brain damage in the neonate. *Pediatr Res* 38:312.
- (982) Johansson B, et al. 1996. Long-term treatment with some methylxanthines decreases the susceptibility to bicuculline- and pentylenetetrazol-induced seizures in mice. Relationship to c-fos expression and receptor binding. *Eur J Neurosci* 8:2447.
- (983) Johansson B, et al. 1993. Effect of long term caffeine treatment on A1 and A2 adenosine receptor binding and on mRNA levels in rat brain. *Naunyn-Schmiedeberg's Arch Pharmacol* 347:407.
- (984) Cole KJ, et al. 1996. Effect of caffeine ingestion on perception of effort and subsequent work production. *Int J Sport Nutr* 6:14.
- (985) Costill DL, et al. 1978. Effects of caffeine ingestion on metabolism and exercise performance. *Med Sci Sports* 10:155.
- (986) Graham TE, et al. 1998. Metabolic and exercise endurance effects of coffee and caffeine ingestion. *J Appl Physiol* 85:883.
- (987) Graham TE, Spriet LL. 1991. Performance and metabolic responses to a high caffeine dose during prolonged exercise. *J Appl Physiol* 71:2292.
- (988) Graham TE, Spriet LL. 1995. Metabolic, catecholamine, and exercise performance responses to various doses of caffeine. *J Appl Physiol* 78:867.
- (989) Jackman MR, et al. 1996. Metabolic, catecholamine, and endurance responses to caffeine during intense exercise. *J Appl Physiol* 81:1658.
- (990) Kovacs EMR, et al. 1998. Effect of caffeinated drinks on substrate metabolism, caffeine excretion, and performance. *J Appl Physiol* 85:709.
- (991) Ritchie JM. 1975. The xanthines, in *The Pharmacological Basis of Therapeutics* (Goodman LS and Gilman A eds), MacMillan, New York, pp. 367.
- (992) Rivenes SM, et al. 1997. Intentional caffeine poisoning in an infant. *Pediatrics* 99:736.
- (993) Silverman K, et al. 1994. Enhancing caffeine reinforcement by behavioral requirements following drug ingestion. *Psychopharmacology* 114:424.
- (994) Goldstein A, Wallace ME. 1997. Caffeine dependence in schoolchildren? *Experimental and Clinical Psychopharmacology* 5:388.

- (1995) Hughes RN .1996. Drugs which induce anxiety: Caffeine. *New Zeal J Psychol* 25:36.
- (1996) Lee MA, et al. 1985. Anxiety and caffeine consumption in people with anxiety disorders. *Psychiatry Res* 15:211.
- (1997) Rihs M, et al. 1996. Caffeine consumption in hospitalized psychiatric patients. *Eur Arch Psychiatry Clin Neurosci* 246:83.
- (1998) Mikkelsen EJ. 1978. Caffeine and schizophrenia. *J Clin Psychiatry* 39:732.
- (1999) Boulenger JP, et al. 1987. Plasma adenosine levels: measurement in humans and relationship to the anxiogenic effects of caffeine. *Psychiatry Res* 21:247.
- (1000) Revelle W, et al. 1980. The interactive effect of personality, time of day, and caffeine: A test of the arousal model. *J Exp Psychol General* 109:1.
- (1001) Temple JG, et al. 1997. The effects of caffeine on performance and stress in an abbreviated vigilance task. *Proceedings of the Human Factors and Ergonomics Society 41st Annual Meeting, Albuquerque, NM*, pp. 1293.
- (1002) Streufert S, et al. 1997. Excess coffee consumption in simulated complex work settings: detriment or facilitation of performance? *Journal of Applied Psychology* 82:774.
- (1003) Clinton WP. 1984. The chemistry of coffee, In MacMahon B, Sugimura T (Eds): *Branbury Report 17: Coffee and Health*. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 3.
- (1004) MacMahon B, Sugimura T 1984. *Branbury Report 17: Coffee and Health*. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory.
- (1005) Sawyer DA, et al. 1982. Caffeine and human behavior: Arousal, anxiety, and performance effects. *J Behav Med* 5:415.
- (1006) Booij L, et al. 2006. Diet rich in α -lactalbumin improves memory in unmedicated recovered depressed patients and matched controls. *Journal of Psychopharmacology* 20(4):526.
- (1007) Mamalakis G, et al. 1998. Anxiety and adipose essential fattyacid precursors for prostaglandin E1 and E2. *J Am Coll Nutr* 17:239.
- (1008) Vancassel S, et al. 2001. Plasma fatty acid levels in autistic children. *Prostaglandins Leukot Essent Fatty Acids* 65:1.
- (1009) Richardson AJ, Puri BK. 2002. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. *Prog Neuro-Psychopharm Biol Psychiatry* 26:233.
- (1010) Hamazaki T, et al. 2001. Effect of docosahexaenoic acid on hostility. *World Rev Nutr Diet* 88:47.
- (1011) Assies J, et al. 2001. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. *Biol Psychiatry* 49:510.
- (1012) Mattison JA, et al. 2003. Calorie restriction in rhesus monkeys. *Exp. Gerontol.* 38:35.
- (1013) Holeckova E, Chvapil M. 1965. The effect of intermittent feeding and fasting and of domestication on biological age in the rat. *Gerontologia* 11:96.
- (1014) Smith A, et al. 1994. Effects of breakfast and caffeine on cognitive performance, mood and cardiovascular functioning. *Appetite* 22:39.
- (1015) Simeon DT, Grantham-McGregor S. 1989. Effects of missing breakfast on the cognitive functions of school children of differing nutritional status. *Am J Clin Nutr* 49:646.
- (1016) Chandler AM, et al. 1995. School breakfast improves verbal fluency in undernourished Jamaican children. *J Nutr* 125:894.
- (1017) Kanarek R. 1997. Psychological effects of snacks altered meal frequency. *Br J Nutr* 77(1):105.
- (1018) Kanarek RB, Swinney D. 1990. Effects of food snacks on cognitive performance in male college students. *Appetite* 14:15.
- (1019) Smith A, et al. 1991. Influences of meal size on post-lunch changes in performance efficiency, mood and cardiovascular function. *Appetite* 16:85.
- (1020) Graig A, Richardson E. 1989. Effects of experimental and habitual lunch-size on performance, arousal, hunger and mood. *Int Arch Occup Environ Health* 61:313.
- (1021) Archer VE. 2003. Does dietary sugar and fat influence longevity? *Med Hypotheses* 60:924.
- (1022) Barrows CH, Kokkonen G. 1975. Protein synthesis, development, growth and life span. *Growth* 39:525.
- (1023) Yu BP, et al. 1985. Nutritional influences on aging of Fischer 344 rats. II. Pathology. *J Gerontol* 40:657.
- (1024) Horakova M, et al. 1988. The effect of low proteinhigh dextrin diet and subsequent food restriction upon life prolongation in Fischer 344 male rats. *Mech Ageing Dev* 45:1.

- (1025) Orentreich N, et al. 1993. Low methionine ingestion by rats extends life span. *J Nutr* 123:269.
- (1026) Sanz A, et al. 2004. Protein restriction without strong caloric restriction decreases mitochondrial oxygen radical production and oxidative DNA damage in rat liver. *J Bioenerg Biomemb* 36:545.
- (1027) Kojima M, et al. 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 402:656.
- (1028) Asakawa A, et al. 2001. A role of ghrelin in neuroendocrine and behavioural responses to stress in mice. *Neuroendocrinology* 74:143.
- (1029) Broglio F, et al. 2001. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. *J Clin Endocrinol Metab* 86:5083.
- (1030) Tschop M, et al. 2001. Circulating ghrelin are decreased in human obesity. *Diabetes* 50:707.
- (1031) Shukitt-Hale B. 1999. The effects of aging and oxidative stress on psychomotor and cognitive behavior. *Age* 22:9.
- (1032) Hauss-Wegrzyniak B, et al. 1999. The effects of a novel NSAID on chronic neuroinflammation are age dependent. *Neurobiol Aging* 20:305.
- (1033) Hauss-Wegrzyniak B, et al. 2000. Behavioral and ultrastructural changes induced by chronic neuroinflammation in young rats. *Brain Res* 859:157.
- (1034) Landfield PW, Eldridge JC. 1994. The glucocorticoid hypothesis of agerelated hippocampal neurodegeneration: role of dysregulated intraneuronal Ca^{2+} . *Ann NY Acad Sci* 746:308.
- (1035) Joseph JA, et al. 1978. Age-related changes in the nigrostriatum: a behavioral and biochemical analysis. *J Gerontol* 33:643.
- (1036) Levine MS, Cepeda C. 1998. Dopamine modulation of responses mediated by excitatory amino acids in the neostriatum. *Adv Pharmacol* 42:724.
- (1037) Egashira T, et al. 1996. Effects of bifemelane on muscarinic receptors and choline acetyltransferase in the brains of aged rats following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries. *Jpn J Pharmacol* 72:57.
- (1038) Joseph JA, et al. 1990. Selective cross-activation/ inhibition of second messenger systems and the reduction of age-related deficits in the muscarinic control of dopamine release from perfused rat striata. *Brain Res* 537:40.
- (1039) Kornhuber J, et al. 1996. Characterization of [3H]pentazocine binding sites in post-mortem human frontal cortex. *J Neural Transm* 3:45.
- (1040) Gould TJ, Bickford P. 1997. Age-related deficits in the cerebellar-adrenergic signal transduction cascade in Fischer 344 rats. *J Pharmacol Exp Ther* 281:965.
- (1041) Bartus RT. Drugs to treat age-related neurodegenerative problems: the final frontier of medical science? *J Am Geriatr Soc* 1990;38:680–95.
- (1042) Joseph JA, et al. 1983. Psychomotor performance in the senescent rodent: reduction of deficits via striatal dopamine receptor up-regulation. *Neurobiol Aging* 4:313.
- (1043) Joseph JA. 1992. The putative role of free radicals in the loss of neuronal functioning in senescence. *Integ Physiol Behav Sci* 27:216.
- (1044) Joseph JA, et al. 1998. CNS effects of heavy particle irradiation in space: behavioral implications. *Adv Space Res* 22:209.
- (1045) Joseph JA, et al. 2000. CNS-induced deficits of heavy particle irradiation in space: the aging connection. *Adv Space Res* 25:2057.
- (1046) Shukitt-Hale B, et al. 2000. Spatial learning and memory deficits induced by exposure to iron-56-particle radiation. *Radiat Res* 154:28.
- (1047) Floyd RA. 1999. Antioxidants, oxidative stress, and degenerative neurological disorders. *Proc Soc Exp Biol Med* 222:236.
- (1048) Joseph JA, et al. 1998. Agerelated neurodegeneration and oxidative stress: putative nutritional intervention. *Neurol Clin* 16:747.
- (1049) Joseph JA, et al. 1998. Membrane and receptor modifications of oxidative stress vulnerability in aging: nutritional considerations. *Ann NY Acad Sci* 854:268.
- (1050) Joseph JA, et al. 2001. Copernicus revisited: amyloid β in Alzheimer's disease. *Neurobiol Aging* 22:131.
- (1051) Youdim KA, Joseph JA. 2001. A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects. *Free Radic Biol Med* 30:583.
- (1052) Cantuti-Castelvetri I, et al. 2000. Neurobehavioral aspects of antioxidants in aging. *Int J Dev Neurosci* 18:367.
- (1053) Youdim KA, et al. 2000. Essential fatty acids and the brain: possible health implications. *Int J Dev Neurosci* 18:383.
- (1054) Joseph JA, et al. 2005. Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial

- properties of fruit polyphenolic compounds. *Am J Clin Nutr* 81(suppl):313S.
- (1055) Frigo DE, et al. 2002. Flavonoid phytochemicals regulate activator protein-1 signal transduction pathways in endometrial and kidney stable cell lines. *J Nutr* 132:1848.
- (1056) Joseph JA, et al. 1999. Reversals of age-related declines in neuronal signal transduction, cognitive and motor behavioural deficits with blueberry, spinach or strawberry dietary supplementation. *J Neurosci* 19:8114.
- (1057) Halliwell B. 2006. Oxidative stress and neurodegeneration: where are we now? *Journal of neurochemistry* 97:1634.
- (1058) Erdogan H, et al. 2004. Effect of fish oil supplementation on plasma oxidant/antioxidant status in rats. *Prostaglandins Leukot Essent Fatty Acids* 71:149.
- (1059) Watson TA, et al. 2004. Antioxidant restricted diet reduces plasma non-esterified fatty acids in trained athletes. *Asia Pac J Clin Nutr* 13(Suppl):S81.
- (1060) Kuloglu M, et al. 2002. Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsive disorder. *Neuropsychobiology* 46:27.
- (1061) Wu A, et al. 2004. The interplay between oxidative stress and brain-derived neurotrophic factor modulates the outcome of a saturated fat diet on synaptic plasticity and cognition. *Eur J Neurosci* 19:1699.
- (1062) Stefano GB, et al. 2001. The placebo effect and relaxation response: neural processes and their coupling to constitutive nitric oxide. *Brain Research Reviews* 35:1.
- (1063) Stefano GB, et al. 2001. Nitric oxide inhibits norepinephrine stimulated contraction of human internal thoracic artery and rat aorta. *Pharmacology Research* 43:199.
- (1064) Stefano GB. 2000. Endocannabinoid immune and vascular signaling. *Acta Pharmacologica Sinica* 21:1071.
- (1065) Cordellini S, Vassilieff VS. 1998. Decreased endothelium-dependent vasoconstriction to noradrenaline in acute-stressed rats is potentiated by previous chronic stress: nitric oxide involvement. *General Pharmacology* 30:79.
- (1066) Gumusel B, et al. 2001. The role of nitric oxide in mediating nonadrenergic, noncholinergic relaxation in rat pulmonary artery. *Nitric Oxide* 5:296.
- (1067) Stefano GB, et al. 2000. Basal nitric oxide limits immune, nervous and cardiovascular excitation: human endothelia express a mu opiate receptor. *Progress in Neurobiology* 60:513.
- (1068) Deutsch DG, et al. 1997. Production and Physiological Actions of Anandamide in the Vasculature of the Rat Kidney. *The Journal of Clinical Investigation* 100: 1538.
- (1069) Stefano GB, et al. 2002. The blueprint for stress can be found in invertebrates. *Neuroendocrinology Letters* 23(2):85.
- (1070) Stefano GB, et al. 1997. Morphine- and anandamidestimulated nitric oxide production inhibits presynaptic dopamine release. *Brain Research* 763:63.
- (1071) Kroenke KD, et al. 1998. Inducible nitric oxide synthase in human diseases. *Clinical and Experimental Immunology* 113:147.
- (1072) Olanow CW. 1992. An introduction to the free radical hypothesis in Parkinson's disease. *Ann Neurol* 32:S2.
- (1073) Gilissen EP, et al. 1999. Magnetic resonance microscopy of iron in the basal forebrain cholinergic structures of the aged mouse lemur. *J Neurol Sci* 168:21.
- (1074) Sadoul R. 1998. Bcl-2 family members in the development and degenerative pathologies of the nervous system. *Cell Death Differ* 5:805.
- (1075) Yu BP. 1994. Cellular defenses against damage from reactive oxygen species. *Physiol Rev* 74(1):139.
- (1076) Carney JM, et al. 1994. Aging- and oxygen-induced modifications in brain biochemistry and behaviour. *Ann NY Acad Sci* 738:44.
- (1077) Savory J, et al. 1999. Age-related hippocampal changes in Bcl-2:Bax ratio, oxidative stress, redox-active iron and apoptosis associated with aluminum-induced neurodegeneration: increased susceptibility with aging. *Neurotoxicology* 20:805.
- (1078) Denisova NA, et al. 1998. Differential effect of aging on cholesterol modulation of carbachol stimulated low-Km GTPase in striatal synaptosomes. *Exp Gerontol* 33:249.
- (1079) Socci DJ, et al. 1995. Chronic antioxidant treatment improves the cognitive performance of aged rats. *Brain Res* 693:88.
- (1080) Xie Z, Sastry BR. 1993. Induction of hippocampal long-term potentiation by alphatocopherol. *Brain Res* 604:173.
- (1081) Grundman M. 2000. Vitamin E and Alzheimer disease: the basis for additional clinical trials. *Am J Clin Nutr* 71:630S.
- (1082) Goodman Y, Mattson MP. 1994. Secreted forms of beta-amyloid precursor protein protect

- hippocampal neurons against amyloid betapeptide-induced oxidative injury. *Exp Neurol* 128:1.
- (1083) Mark RJ, et al. 1995. Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca^{2+} homeostasis and cell death. *J Neurosci* 15:6239.
- (1084) Yamada K, et al. 1999. Protective effects of idebenone and alpha-tocopherol on betaamyloid-(1042)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. *Eur J Neurosci* 11:83.
- (1085) Roghani M, Behzadi G. 2001. Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. *Brain Res* 892:211.
- (1086) Karaev AL, et al. 1993. The effect of ubiquinone Q10 and biotin on the growth and development of premature animals. *Eksp Klin Farmakol* 56:55.
- (1087) Pereira C, et al. 1999. Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants. *Neurobiol Dis* 6:209.
- (1088) Beal MF, et al. 1998. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. *Brain Res* 783:109.
- (1089) Mattson MP. 2000. Creatine: prescription for bad genes and a hostile environment? *Trends Neurosci* 23:511.
- (1090) Engelhardt M, et al. 1998. Creatine supplementation in endurance sports. *Med Sci Sports Exercise* 30:1123.
- (1091) Matthews RT, et al. 1999. Creatine and cyclocreatine attenuate MPTP neurotoxicity. *Exp Neurol* 157:142.
- (1092) Kaemmerer WF, et al. 2001. Creatine-supplemented diet extends Purkinje cell survival in spinocerebellar ataxia type 1 transgenic mice but does not prevent the ataxic phenotype. *Neuroscience* 103:713.
- (1093) Ness J, et al. 1999. Alternative medicine: what the data say about common herbal therapies. *Geriatrics* 54:33.
- (1094) Cohen-Salmon C, et al. 1997. Effects of Ginkgo biloba extract (EGb 761) on learning and possible actions on aging. *J Physiol Paris* 91:291.
- (1095) Hoyer S, et al. 1999. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). *J Neural Transm* 106:1171.
- (1096) Wesners KA, et al. 2000. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. *Psychopharmacology* 152:353.
- (1097) Turnbull S, et al. 2001. Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. *Free Radic Biol Med* 30:1163.
- (1098) Van Dongen MC, et al. 2000. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. *J Am Geriatr Soc* 48:1183.
- (1099) Ramassamy C, et al. 1990. Prevention by a Ginkgo biloba extract (GBE 761) of the dopaminergic neurotoxicity of MPTP. *J Pharm Pharmacol* 42:785.
- (1100) Martinez M, et al. 2000. N-acetylcysteine delays age-associated memory impairment in mice: role in synaptic mitochondria. *Brain Res* 855:100.
- (1101) Adair JC, et al. 2001. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. *Neurology* 57:1515.
- (1102) Malberg JE, et al. 2000. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci* 20:9104.
- (1103) Manev H, et al. 2001. Antidepressants alter cell proliferation in adult brain in vivo and in neural cell cultures in vitro. *Eur J Pharmacol* 411(1-2):67.
- (1104) Beltz BS, et al. 2007. Omega-3 fatty acids upregulate adult neurogenesis. *Neurosci Lett* 415(2):154.
- (1105) Logan AC. 2004. Omega-3 fatty acids and major depression: a primer for the mental health professional. *Lipids Health Dis* 9:3.
- (1106) Wu A, et al. 2004. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. *J Neurotrauma* 21:1457.
- (1107) Mattson MP, et al. 2004. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. *Age Res Rev* 3:445.
- (1108) Spalletta G, et al. 2006. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. *Mol Psychiatry* 11:984.

- (1109) Engelhart MJ, et al. 2002. Dietary intake of antioxidants and risk of Alzheimer disease. *JAMA* 287:3223.
- (1110) Brandeis R, et al. 1989. The use of the Morris water maze in the study of memory and learning. *Int J Neurosci* 48:29.
- (1111) Ingram DK, et al. 1994. Behavioral manifestations of aging. In: Mohr U, Cunnworth DL, Capen CC, editors. *Pathobiology of the aging rat*. Volume 2. Washington, DC: ILSI Press, pp. 149.
- (1112) Shukitt-Hale B, et al. 1998. Psychomotor and spatial memory performance in aging male Fischer 344 rats. *Exp Gerontol* 33:615.
- (1113) Olanow CW. 1993. A radical hypothesis for neurodegeneration. *Trends Neurosci* 16:439.
- (1114) Stone A, Brownell K. 1994. The stress-eating paradox: multiple daily measurements in adult males and females. *Psychology and Health* 9:425.
- (1115) Willenbring M, et al. 1986. Stress induced eating and food preference in humans: a pilot study. *Int J Eat Dis* 5:855.
- (1116) McCann BS, et al. 1990. Changes in plasma lipids and dietary intake accompanying shifts in perceived workload and stress. *Psychosom Med* 52:97.
- (1117) Weidner G, et al. 1996. The effects of academic stress on health behaviors in young adults. *Anx Stress Coping* 9:123.
- (1118) Wardle J, et al. 2000. Stress, dietary restraint and food intake. *J Psychosom Res* 48:195.
- (1119) Schotte DA, et al. 1990. Film-induced negative affect triggers overeating in restrained eaters. *J Abnorm Psychol* 99:317.
- (1120) Cools J, et al. 1992. Emotional arousal and overeating in restrained eaters. *Journal of Abnormal Psychology* 101:348.
- (1121) Heatherton TF, et al. 1991. Effects of physical threat and ego threat on eating behaviour. *J Pers Soc Psychol* 60:138.
- (1122) May R, et al. 1986. Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. *J Clin Invest* 77:614.
- (1123) Perez GO, et al. 1979. The effect of acute metabolic acidosis on plasma cortisol, renin activity and aldosterone. *Horm Res* 11:12.
- (1124) Sicuro A, et al. 1998. Effect of growth hormone on renal and systemic acid-base homeostasis in humans. *Am J Physiol Renal Physiol* 274:F650.
- (1125) Schambelan M, et al. 1987. Adrenocortical hormone secretory response to chronic NH₄Cl-induced metabolic acidosis. *Am J Physiol* 252:E454.
- (1126) Kumar R. 2001. Glucocorticoid-induced osteoporosis. *Curr Opin Nephrol Hypertens* 10:589.
- (1127) Delany AM, et al. 1994. Mechanisms of glucocorticoid action in bone cells. *J Cell Biochem* 56:295.
- (1128) Canalis E. 1996. Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis. *J Clin Endocrinol Metab* 81:3441.
- (1129) Cooper MS, et al. 1999. Glucocorticoid activity, inactivity and the osteoblast. *J Endocrinol* 163:159.
- (1130) Manolagas SC, Weinstein RS. 1999. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. *J Bone Miner Res* 14:1061.
- (1131) Lane NE. 2001. An update on glucocorticoid-induced osteoporosis. *Rheum Dis Clin North Am* 27:235.
- (1132) Hahn TJ. 1989. Steroid hormones and the skeleton. In: *Metabolic Bone Disease: Cellular and Tissue Mechanisms*, edited by Tam CS, Heersche JNM, Murray TM, Boca Raton, FL, CRC Press, Inc., pp. 223.
- (1133) Maurer M, et al. 2003. Neutralization of Western diet inhibits bone resorption independently of K intake and reduces cortisol secretion in humans. *Am J Physiol Renal Physiol* 284:F32.
- (1134) Krapf R, et al. 1991. Chronic respiratory alkalosis: the effect of sustained hyperventilation on renal regulation of acid-base equilibrium. *N. Engl. J. Med.* 324:1394.
- (1135) Kurtz I, et al. 1983. Effect of diet on plasma acid base composition in normal humans. *Kidney Int* 24:670.
- (1136) Tecott LH. 2000. Monoamine neurotransmitters. In *Kaplan & Sadock's Comprehensive Textbook of Psychiatry*. Volume Ch 1.4. 7th edition. Edited by: Sadock BJ, Sadock VA. Lippincott Williams & Wilkins, pp. 41.
- (1137) Sakata T, Yoshimatsu H. 1977. Hypothalamic neuronal histamine: Implications of homeostatic maintenance in its control of energy metabolism. *Nutrition* 13:403.
- (1138) Leibowitz SF. 1973. Histamine: a stimulatory effect on drinking behavior in the rat. *Brain Res* 63:440.

- (1139) Ookuma K, et al. 1993. Neuronal histamine in the hypothalamus suppresses food intake in rats. *Brain Res* 628:235.
- (1140) Yoshimatsu H, et al. 1999. Hypothalamic neuronal histamine as a target of leptin in feeding behavior. *Diabetes* 48:2286.
- (1141) Masaki T, et al. 2001. Targeted disruption of histamine H1 receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. *Diabetes* 50:385.
- (1142) Yoshimatsu H, et al. 1992. Abnormalities in obese Zuckers: Defective control of histaminergic functions. *Physiol Behav* 54:487.
- (1143) Bugajski J, Janusz Z. 1981. Lipolytic response induced by intra-cerebroventricular administration of histamine in the rat. *Agents Actions* 11:147.
- (1144) Tsuda K, et al. 2002. Hypothalamic histamine neurons activate lipolysis in rat adipose tissue. *Exp Biol Med* 227(3):208.
- (1145) Masaki T, et al. 2001. Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. *Diabetes* 50:376.
- (1146) Sakata T, et al. 1994. A physiological role of brain histamine during energy deficiency. *Brain Res Bull* 35:135.
- (1147) Oohara A, et al. 1994. Neuronal glucoprivation enhances hypothalamic histamine turnover in rats. *J Neurochem* 63:677.
- (1148) Fujimoto K, et al. 1990. Hypothalamic histamine modulates adaptive behavior of rats at high environmental temperature. *Experientia* 46:283.
- (1149) Kang M, et al. 1995. Hypothalamic neuronal histamine modulates physiological responses induced by interleukin-1 β . *Am J Physiol* 265:R1308.
- (1150) Boadle-Biber MC, et al. 1993. Evidence that corticotropin-releasing factor within the extended amygdala mediates the activation of tryptophan hydroxylase produced by sound stress in the rat. *Brain Res.* 628(1-2):105.
- (1151) Aldegunde M, et al. 2000. Acute effects of L-tryptophan on tryptophan hydroxylation rate in brain regions (hypothalamus and medulla) of rainbow trout (*Oncorhynchus mykiss*). *J. Exp. Zool.* 286:131.
- (1152) Winberg S, et al. 2001. Suppression of aggression in rainbow trout (*Oncorhynchus mykiss*) by dietary L-tryptophan. *J. Exp. Biol.* 204:3867.
- (1153) Azmitia EC. 2001. Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. *Brain Res. Bull.* 56:413.
- (1154) Van Kesteren RE, Spencer GE. 2003. The role of neurotransmitters in neurite outgrowth and synapse formation. *Rev. Neurosci.* 14:217.
- (1155) Chaouloff F. 1993. Physiopharmacological interactions between stress hormones and central serotonergic systems. *Brain Res. Rev.* 18:1.
- (1156) Dinan TG. 1996. Serotonin: Current understanding and the way forward. *Int. Clin. Psychopharmacol.* 11:19.
- (1157) Delbeinde C, et al. 1992. Glucocorticoids, transmitters and stress. *Br J Psychiatry* 160(15):24.
- (1158) Spooon MR. 1992. Modulatory role of serotonin in neural information processing: implications for human psychopathology. *Psychol Bull* 112:330.
- (1159) Altman HJ, Normile HJ. 1988. What is the nature of the role of the serotonergic nervous system in learning and memory: prospects for development of an effective treatment strategy for senile dementia. *Neurobiol Aging* 9:627.
- (1160) Arivazhagan P, Panneerselvam C. 2002. Neurochemical changes related to ageing in the rat brain and the effect of DL-alpha-lipoic acid. *Exp. Gerontol.* 37:1489.
- (1161) Kennett GA, et al. 1985. Enhancement of some 5-HT-dependent behavioral responses following repeated immobilisation in rats. *Brain Res* 330:253.
- (1162) Van Praag HM. 1982. Depression. *Lancet* 2:1259-64.
- (1163) Delgado PL, et al. 1994. Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug-free depressed patients. *Arch Gen Psychiatry* 51:865.
- (1164) Heninger GR, et al. 1996. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. *Pharmacopsychiatry* 29:2.
- (1165) Lieberman HR, et al. 1986. The behavioural effects of food constituents: strategies used in studies of amino acids, protein, carbohydrates and caffeine. *Nutr Rev* 44:61.
- (1166) Markus CR, et al. 2000. Effects of food on cortisol and mood in vulnerable subjects under controllable and uncontrollable stress. *Physiol. Behav.* 70:333.

- (1167) Dunn AJ. 1988. Stress-related changes in cerebral catecholamine and indoleamine metabolism: lack of effect of adrenalectomy and corticosterone. *J Neurochem.* 51(2):406.
- (1168) Dunn AJ, Welch J. 1991. Stress- and endotoxin-induced increases in brain tryptophan and serotonin metabolism depend on sympathetic nervous system activity. *J Neurochem* 57(5):1615.
- (1169) Höglund E, et al. 2000. Skin darkening, a potential signal in subordinate arctic charr (*Salvenius alpinus*): The regulation role of brain monoamines and pro-opiomelanocortin-derived peptides. *J. Exp. Biol.* 203:1711.
- (1170) Winberg S, Lepage O. 1998. Elevation of brain 5-HT activity, POMC expression and plasma cortisol in socially subordinate rainbow trout. *Am. J. Physiol.* 43:R645.
- (1171) Henry JP, Meehan P. 1981. Psychosocial stimuli, physiological specificity, and cardiovascular disease. In: Weiner H, Hofer MA, Stunkard AJ, eds. *Brain, behavior, and bodily diseases*. New York: Raven Press, pp. 305.
- (1172) Kiraly MA, Kiraly SJ. 2005. The effect of exercise on hippocampal integrity: review of recent research. *International Journal of Psychiatry in Medicine* 35(1):75.
- (1173) de Coverley Veale DM. 1987. Exercise and mental health. *Acta Psychiatr Scand* 76:113.
- (1174) Chodzko-Zajko WJ, Moore KA. 1994. Physical fitness and cognitive functioning in aging. *Exerc Sport Sci Rev* 22:195.
- (1175) Elward K, Larson EB. 1992. Benefits of exercise for older adults. A review of existing evidence and current recommendations for the general population. *Clin Geriatr Med* 8:35.
- (1176) Van Boxtel MP, et al. 1997. Aerobic capacity and cognitive performance in a cross-sectional aging study. *Med Sci Sports Exercise* 29:1357.
- (1177) Shay KA, Roth DL. 1992. Association between aerobic fitness and visuospatial performance in healthy older adults. *Psychol Aging* 7:15.
- (1178) Radak Z, et al. 2001. Regular exercise improves cognitive function and decreases oxidative damage in rat brain. *Neurochem Int* 38:17.
- (1179) Russo-Neustadt A, et al. 1999. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. *Neuropsychopharmacology* 21:679.
- (1180) Tolwani RJ, et al. 2002. BDNF overexpression increases dendrite complexity in hippocampal dentate gyrus. *Neuroscience* 114:795.
- (1181) Alonso M, et al. 2002. BDNF-triggered events in the rat hippocampus are required for both short- and long-term memory formation. *Hippocampus* 12:551.
- (1182) Carro E, et al. 2001. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. *J Neurosci* 21:5678.
- (1183) Trejo JL, et al. 2001. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. *J Neurosci* 21:1628.
- (1184) Comery TA, et al. 1996. Increased density of multiple-head dendritic spines on medium-sized spiny neurons of the striatum in rats reared in a complex environment. *Neurobiol Learn Mem* 66:93.
- (1185) Greer ER, et al. 1982. Increased branching of basal dendrites on pyramidal neurons in the occipital cortex of homozygous Brattleboro rats in standard and enriched environmental conditions: a Golgi study. *Exp Neurol* 76:254.
- (1186) Bryan GK, Riesen AH. 1989. Deprived somatosensory-motor experience in stump-tailed monkey neocortex: dendritic spine density and dendritic branching of layer IIIB pyramidal cells. *J Comp Neurol* 286:208.
- (1187) McEwen BS, et al. 2002. Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. *J Psychosom Res* 53:883.
- (1188) Biernaskie J, Corbett D. 2001. Enriched rehabilitative training promotes improved forelimb motor function and enhanced dendritic growth after focal ischemic injury. *J Neurosci* 21:5272.
- (1189) LEE IM, et al. 1999. Exercise and risk of stroke in male physicians. *Stroke* 30:1.
- (1190) JONES TA, et al. 1999. Motor skills training enhances lesion-induced structural plasticity in the motor cortex of adult rats. *J Neurosci* 19:10153.
- (1191) Mastorakos G, Pavlatou M. 2005. Exercise as a stress model and the interplay between the hypothalamus-pituitary-adrenal and the hypothalamus-pituitary-thyroid axes. *Hormone and Metabolic Research* 37:577.
- (1192) Sarbadhikari SN, Saha AK. 2006. Moderate exercise and chronic stress produce counteractive

- effects on different areas of the brain by acting through various neurotransmitter receptor subtypes: A hypothesis. *Theoretical Biology and Medical Modelling* 3:33.
- (1193) Sarbadhikari SN. 1995. Neural network aided analysis of electrophysiological signals from the brain of an animal model of depression subjected to chronic physical exercise. In PhD Thesis. Banaras Hindu University, Varanasi, India.
- (1194) Sarbadhikari SN, et al. 2005. Modeling the Role of Exercise and Stress on Depression – A System Biological Approach. In *Proceedings (Abstracts) of Sixth International Conference on Systems Biology (ICSB 2005)*. Boston, MA.
- (1195) Sarbadhikari SN, et al. 1996. Chronic Exercise Alters EEG Power Spectra in an Animal Model of Depression. *Indian J Physiol Pharmacol* 40(1):47.
- (1196) Radak Z, et al. 2005. Exercise and hormesis: oxidative stress-related adaptation for successful aging. *Biogerontology* 6:71.
- (1197) Bixby W, et al. 2001. Temporal Dynamics and Dimensional Specificity of the Affective Response to Exercise of Varying Intensity: Differing Pathways to a Common Outcome. *Journal of Sport and Exercise Psychology* 23:171.
- (1198) Tonacio AC, et al. 2006. Effects of diet and exercise training on neurovascular control during mental stress in obese women. *Brazilian Journal of Medical and Biological Research* 39:53.
- (1199) Mattson MP, et al. 2004. Prophylactic Activation of Neuroprotective Stress Response Pathways by Dietary and Behavioral Manipulations. *NeuroRx*. 1(1):111.
- (1200) Rumajogee P, et al. 2002. Up-regulation of the neuronal serotonergic phenotype in vitro: BDNF and cAMP share trkB-dependent mechanisms. *J Neurochem* 83:1525.
- (1201) Goggi J, et al. 2002. Modulation of neurotransmitter release induced by brain-derived neurotrophic factor in rat brain striatal slices in vitro. *Brain Res* 941:34.
- (1202) Conti AC, et al. 2002. cAMP response element-binding protein is essential for the up-regulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. *J Neurosci* 22:3262.
- (1203) Pellemounter MA, et al. 1995. Characteristics of BDNF-induced weight loss. *Exp Neurol* 131:229.
- (1204) Duan W, et al. 2003. Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. *Endocrinology* 144:2446.
- (1205) Wan R, et al. 2003. Intermittent fasting and dietary supplementation with 2-deoxy-D-glucose improve functional and metabolic cardiovascular risk factors in rats. *FASEB J* 17:1133.
- (1206) Wan R, et al. 2003. Intermittent fasting improves cardiovascular and neuroendocrine responses to stress. *J Nutrition* 133:1921.
- (1207) Reusens B, Remacle C. 2001. Intergenerational effect of an adverse intrauterine environment on perturbation of glucose metabolism. *Twin Res.* 4:406.
- (1208) Ghosh A. 1994. Requirement for BDNF in activity-dependent survival of cortical neurons. *Science* 263:1618.
- (1209) Lindsay RM. 1994. Neurotrophins and receptors. *Prog. Brain Res.* 103:3.
- (1210) Mattson MP, et al. 2002. Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. *Physiol. Rev.* 82:637.
- (1211) McEwen BS. 2002. Sex, stress and the hippocampus: allostasis, allostatic load and the aging process. *Neurobiol. Aging* 23:921.
- (1212) Ferrer I, et al. 2000. Brain-derived neurotrophic factor in Huntington disease. *Brain Res.* 866:257.
- (1213) Hock C, et al. 2000. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. *Arch. Neurol.* 57:846.
- (1214) Howells DW, et al. 2000. Reduced BDNF mRNA expression in Parkinson's disease substantia nigra. *Exp. Neurol.* 166:127.
- (1215) Lyons WE, et al. 1999. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. *Proc. Natl. Acad. Sci. USA* 96:15239.
- (1216) Nakagawa T, et al. 2002. Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice. *Diabetes Metab. Res. Rev.* 18:185.
- (1217) Nakagawa T, et al. 2000. Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice. *Diabetes* 49:436.

- (1218) Rios M, et al. 2001. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. *Mol. Endocrinol.* 15:1748.
- (1219) Esch T. 2002. Health in Stress: Change in the Stress Concept and its Significance for Prevention, Health and Life Style. *Gesundheitswesen* 64:73.
- (1220) Jones F, et al. 2001. Stress: Myth, Theory and Research. Prentice Hall, New York.
- (1221) Esch T. 1999. Bestimmung von Vorgängen zum aktiven Erhalt der zellulären Autonomie und Organisation mit Hilfe des Schwesterchromatid-Austausch-Verfahrens [Dissertation]. Georg-August-Universität, Göttingen.
- (1222) Esch T, et al. 2002. Stress in Cardiovascular Diseases. *Medical Science Monitor* 8(5):RA93.
- (1223) Esch T, et al. 2002. The role of stress in neurodegenerative diseases and mental disorders. *Neuroendocrinology Letters* 23(3):199.
- (1224) Jacobs SC, et al. 1994. Use of skin conductance changes during mental stress testing as an index of autonomic arousal in cardiovascular research. *American Heart Journal* 128:1170.
- (1225) Negrao AB, et al. 2000. Individual reactivity and physiology of the stress response. *Biomedicine and Pharmacotherapy* 54:122.
- (1226) Cannon W. 1914. The emergency function of the adrenal medulla in pain and the major emotions. *American Journal of Physiology* 33:356.
- (1227) Cannon WB. 1915. Bodily changes in pain, hunger, fear, and rage; an account of recent researches into the function of emotional excitement. Appleton and Company, New York, London.
- (1228) McCarty R, Gold P. 1996. Catecholamines, Stress, and Disease: A Psychobiological Perspective. *Psychosomatic Medicine* 58:590.
- (1229) Brotto LA, et al. 2001. Melatonin protects against the effects of chronic stress on sexual behaviour in male rats. *Neuroreport* 12:3465.
- (1230) Plotsky PM, et al. 1998. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. *Psychiatr Clin North Am* 21(2):293.
- (1231) Allen PIM, et al. 1985. Dissociation between emotional and endocrine responses preceding an academic examination in male medical students. *J. Endocrinol.* 107:163.
- (1232) Leedy MG, Wilson MS. 1985. Testosterone and cortisol levels in crewman of U.S. Air Force fighter and cargo planes. *Psychosom Med.* 47(4):333.
- (1233) Moller P, et al. 1996. Oxidative stress associated with exercise, psychological stress and life-style factors. *Chem.-Biol. Interact* 102:17.
- (1234) Tomei LD, et al. 1990. Psychological stress and phorbol ester inhibition of radiation-induced apoptosis in human peripheral blood leukocytes. *Psychiat. Res.* 33:59.
- (1235) Sapolsky R. 1998. Why Zebras don't get Ulcers: An Updated Guide to Stress, Stress-related Diseases, and Coping. Freeman and Co., New York, pp. 76.
- (1236) Grønli J, et al. 2004. Chronic mild stress affects sucrose intake and sleep in rats. *Behavioural Brain Research* 150:139.
- (1237) Hagan M, et al. 2002. A new animal model of binge eating. Key synergistic role of past caloric restriction and stress. *Physiology and Behaviour* 77:45.
- (1238) Hagan MM, et al. 2003. The role of palatable food and hunger as trigger factors in an animal model of stress induced binge eating. *The International Journal of Eating Disorders* 34:183.
- (1239) Oliver G, Wardle J. 1999. Perceived effects of stress on food choice. *Physiol Behav* 66:511.
- (1240) Harris RB, et al. 2002. Weight loss in rats exposed to repeated acute restraint stress is independent of energy or leptin status. *Am J Physiol Regul Integr Comp Physiol* 282: R77.
- (1241) Blair EH, et al. 1991. The effect of laboratory stressors on glycemic control and gastrointestinal transit time. *Psychosomatic Medicine* 53:133.
- (1242) Pollard TM, et al. 1995. The effects of academic examination stress on eating behaviour and blood lipid levels. *Int J Behav Med* 2:299.
- (1243) Lyman B. 1982. The nutritional values and food group characteristics of foods preferred during various emotions. *J Psychol* 112:121.
- (1244) Bellisle F, et al. 1990. Anxiety and food intake in men. *Psychosom Med* 52:452.
- (1245) Johnson WG, et al. 1990. Dietary restraint and eating behaviour in the natural environment. *Addict Behav* 15:285.
- (1246) Wardle J, et al. 1992. Eating style and eating behaviour in adolescents. *Appetite* 18:167.
- (1247) Weinstein SE, et al. 1997. Changes in food intake in response to stress in men and women: psychological factors. *Appetite* 28:7.
- (1248) Lowe MR, Fisher EB. 1983. Emotional reactivity, emotional eating and obesity: a naturalistic study. *J Behav Med* 6:135.

- (1249) Blass EM, et al. 1989. Stress-reducing effects of ingesting milk, sugars, and fats. a developmental perspective. *Ann N Y Acad Sci* 575:292.
- (1250) Mercer ME, Holder MD. 1997. Food cravings, endogenous opioid peptides, and food intake: a review. *Appetite* 29:325.
- (1251) Vazquez-Martinez R, et al. 2001. Pulsatile exocytosis is functionally associated with GnRH gene expression in immortalized GnRH-expressing cells *Endocrinology* 142:5364.
- (1252) Millar RP, et al. 1987. Gonadotrophin-releasing hormone—diversity of functions and clinical applications. *S Afr Med J*. 72:748.
- (1253) Padmanabhan V, McNeilly AS. 2001. Is there an FSH-releasing factor? *Reproduction*. 121:21.
- (1254) Miller D, et al. 1995. The role of intracerebral insulin in the effect of nutrition on gonadotrophin secretion in mature male sheep. *J Endocrinol*. 147:321.
- (1255) Hileman S, et al. 1993. Effects of acute, intracerebroventricular administration of insulin on serum concentrations of luteinizing hormone, insulin and glucose in ovariectomized lambs during restricted and ad libitum feed intake. *Biol Reprod*. 48:117.
- (1256) Kovacs P, et al. 2002. Effect of centrally administered insulin on gonadotropin-releasing hormone neuron activity and luteinizing hormone surge in the diabetic female rat. *Neuroendocrinology*. 76:357.
- (1257) Kotani M, et al. 2002. Effect of centrally administered insulin on gonadotropin-releasing hormone neuron activity and luteinizing hormone surge in the diabetic female rat. *Neuroendocrinology*. 76:357.
- (1258) Martin B, et al. 2007. Sex-dependent metabolic, neuroendocrine, and cognitive responses to dietary energy restriction and excess. *Endocrinology*. 148:4318.
- (1259) Casanueva FF, Dieguez C. 1999. Neuroendocrine regulation and actions of leptin. *Front Neuroendocrinol*. 20:317.
- (1260) Faria AC, et al. 1992. Pulsatile growth hormone release in normal women during the menstrual cycle. *Clin Endocrinol*. 36:591.
- (1261) Hartmann ML, et al. 1996. Pulsatile growth hormone secretion in older persons is enhanced by fasting without relationships to sleep stages. *J Clin Endocrinol Metab*. 81:2694.
- (1262) Altemus M, et al. 1995. Suppression of hypothalamic-pituitary-adrenal axis responses to stress in lactating women. *J Clin Endocrinol Metab* 80:2954.
- (1263) McCormick CM, et al. 1995. Sex-specific effects of prenatal stress on hypothalamic-pituitary-adrenal responses to stress and brain glucocorticoid receptor density in adult rats. *Brain Res Dev Brain Res* 84:55.
- (1264) Vallee M, et al. 1997. Prenatal stress induces high anxiety and postnatal handling induces low anxiety in adult offspring: correlation with stress-induced corticosterone secretion. *J Neurosci* 17:2626.
- (1265) Weinstock M. 2001. Alterations induced by gestational stress in brain morphology and behaviour of the offspring. *Prog Neurobiol* 65:427.
- (1266) Bosch OJ, et al. 2007. Prenatal stress increases HPA axis activity and impairs maternal care in lactating female offspring: implications for postpartum mood disorder. *Psychoneuroendocrinology* 32:267.
- (1267) Slaterry DA, Neumann ID. 2008. No stress please! Mechanisms of stress hyporesponsiveness of the maternal brain. *J Physiol* 586(2):377.
- (1268) Watson JB, et al. 1999. Prenatal teratogens and the development of adult mental illness. *Dev Psychopathol* 11:457.
- (1269) O'Connor TG, et al. 2003. Maternal antenatal anxiety and behavioural/emotional problems in children: a test of a programming hypothesis. *J Child Psychol Psychiatry* 44:1025.
- (1270) Clarke AS, et al. 1994. Long-term effects of prenatal stress on HPA axis activity in juvenile rhesus monkeys. *Dev Psychobiol* 27:257.
- (1271) Coe CL, et al. 2003. Prenatal stress diminishes neurogenesis in the dentate gyrus of juvenile rhesus monkeys. *Biol Psychiatry* 54:1025.
- (1272) Dauprat P, et al. 1984. The effects of psychosomatic stress at the end of pregnancy on maternal and fetal plasma cortisol levels and liver glycogen in guinea-pigs. *Reprod Nutr Dev* 24:45.
- (1273) Cadet R, et al. 1986. Effects of prenatal maternal stress on the pituitary adrenocortical reactivity in guinea-pig pups. *J Dev Physiol* 8:467.
- (1274) Kapoor A, Matthews SG. 2005. Short periods of prenatal stress affect growth, behaviour and hypothalamo-pituitary-adrenal axis activity in male guinea pig offspring. *J Physiol* 566.3:967.
- (1275) Owen D, Matthews SG. 2003. Glucocorticoids and sex-dependent development of brain glucocorticoid and mineralocorticoid receptors. *Endocrinology* 144:2775.

- (1276) Owen D, et al. 2005. Central regulation of the hypothalamic-pituitary-adrenal axis during fetal development in the guinea-pig. *J Neuroendocrinol* 17:220.
- (1277) Lingas R, et al. 1999. Maternal nutrient restriction (48 h) modifies brain corticosteroid receptor expression and endocrine function in the fetal guinea pig. *Brain Res* 846:236.
- (1278) Phillips DI, et al. 2000. Low birth weight predicts elevated plasma cortisol concentrations in adults from 3 populations. *Hypertension* 35:1301.
- (1279) Kind KL, et al. 2002. Effect of maternal feed restriction on blood pressure in the adult guinea pig. *Exp Physiol* 87:469.
- (1280) Lesage J, et al. 2004. Prenatal stress induces intrauterine growth restriction and programmes glucose intolerance and feeding behaviour disturbances in the aged rat. *J Endocrinol* 181:291.
- (1281) Challis BG, et al. 2004. Genetic variation in the corticotrophin-releasing factor receptors: identification of single-nucleotide polymorphisms and association studies with obesity in UK Caucasians. *Int J Obes Relat Metab Disord* 28:442.
- (1282) Laitinen J, et al. 2004. Predictors of abdominal obesity among 31-y-old men and women born in Northern Finland in 1966. *Eur J Clin Nutr* 58:180.
- (1283) McMillen IC, et al. 2005. Early origins of obesity: programming the appetite regulatory system. *J Physiol* 565:9.
- (1284) Lumbers ER, et al. 2001. The selfish brain and the barker hypothesis. *Clin Exp Pharmacol Physiol* 28:942.
- (1285) Dressino V, et al. 2002. Sexual responses to intrauterine stress: body and brain growth. *Clin Exp Obstet Gynecol* 29:100.
- (1286) Schneider ML. 1992. Prenatal stress exposure alters postnatal behavioral expression under conditions of novelty challenge in rhesus monkey infants. *Dev Psychobiol* 25:529.
- (1287) Clarke AS, Schneider ML. 1993. Prenatal stress has long-term effects on behavioral responses to stress in juvenile rhesus monkeys. *Dev Psychobiol* 26:293.
- (1288) Welberg LA, et al. 2000. Inhibition of 11beta-hydroxysteroid dehydrogenase, the foeto-placental barrier to maternal glucocorticoids, permanently programs amygdala GR mRNA expression and anxiety-like behaviour in the offspring. *Eur J Neurosci* 12:1047.
- (1289) Matthews S. 2002. Early programming of the hypothalamo-pituitary-adrenal axis. *Trends Endocrinol Metab* 13:373.
- (1290) Economides DL, et al. 1988. Plasma cortisol and adrenocorticotrophin in appropriate and small for gestational age fetuses. *Fetal Ther* 3:158.
- (1291) Clark PM, et al. 1996. Size at birth and adrenocortical function in childhood. *Clin Endocrinol* 45:721.
- (1292) Phillips DIW, Barker DJP. 1997. Association between low birthweight and high resting pulse in adult life: is the sympathetic nervous system involved in programming the insulin resistance syndrome? *Diabetic Med* 14:673.
- (1293) Phillips DIW, et al. 1998. Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome? *J Clin Endocrinol Metab* 83:757.
- (1294) Reynolds RM, et al. 2001. Altered control of cortisol secretion in adult men with low birthweight and cardiovascular risk factors. *J Clin Endocrinol Metab* 86:245.
- (1295) Levitt NS, et al. 2000. Impaired glucose tolerance and elevated blood pressure in low birthweight, non-obese, young South African adults: early programming of cortisol axis. *J Clin Endo Metab* 85:4611.
- (1296) Barker DJ 2002. Fetal programming of coronary heart disease. *Trends Endocrinol Metab* 13:364.
- (1297) Ward AM, et al. 2004. Fetal programming of the hypothalamic-pituitary-adrenal (HPA) axis: low birth weight and central HPA regulation. *J Clin Endocrinol Metab* 89:1227.
- (1298) Nilsson P, et al. 2001. Increased susceptibility to stress at a psychological assessment of stress tolerance is associated with impaired fetal growth. *Int J Epidemiol* 30:75.
- (1299) Ward AM, et al. 2004. Size at birth and cortisol responses to psychological stress: evidence for fetal programming. *J Hypertens* 122:2295.
- (1300) Phillips DIW, Jones A. 2006. Fetal programming of autonomic and HPA function: do people who were small babies have enhanced stress responses? *J Physiol* 572:1:45.
- (1301) Welberg LAM, Seckl JR 2001. Prenatal stress, glucocorticoids and the programming of the brain. *J Neuroendocrinol* 13:113.
- (1302) Jones A, et al. 2005. Autonomic nervous system and baroreflex function differs in women who were small at birth, increasing their

- cardiovascular responses to stressors. *Pediatr Res* 58:1022.
- (1303) Lahti J, et al. 2005. Small body size at birth in term infants predicts behavioural symptoms of ADHD in preschoolers. *Pediatr Res* 58:1014.
- (1304) Schlotz W, et al. 2005. Small size at birth is associated with indicators of increased hyperactivity reduced attention and reduced effortful control in young children. *Pediatr Res* 58:1014.
- (1305) Redwine L, et al. 2000. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. *J Clin Endocrinol Metab* 85 :3597.
- (1306) Shephard RJ, Shek PN. 1998. Immunological hazards from nutritional imbalance in athletes. *Exerc Immunol Rev* 4 :22.
- (1307) Irwin M, et al. 1996. Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. *FASEB J* 10 :643.
- (1308) Lange T, et al. 2003. Sleep enhances the human antibody response to Hepatitis A vaccination. *Psychosom Med* 65 :831.
- (1309) Boyum A, et al. 1996. The effect of strenuous exercise, calorie deficiency and sleep deprivation on white blood cells, plasma immunoglobulins and cytokines. *Scand J Immunol* 43 :228.
- (1310) Glaser R, et al. 1999. The differential impact of training stress and final examination stress on herpesvirus latency at the United States Military Academy at West Point. *Brain Behav Immun* 13 :240.
- (1311) Mattson MP. 2003. Gene-diet interactions in brain aging and neurodegenerative disorders. *Ann. Intern. Med.* 139:441.
- (1312) Merry BJ. 2004. Oxidative stress and mitochondrial function with aging—the effects of calorie restriction. *Aging Cell* 3:7.
- (1313) Frame LT, et al. 1998. Caloric restriction as a mechanism mediating resistance to environmental disease. *Environ. Health Perspect.* 106:S313.
- (1314) Kim KY, et al. 2004. Neuronal susceptibility to damage: comparison of the retinas of young, old and old/caloric restricted rats before and after transient ischemia. *Neurobiol. Aging* 25:491.
- (1315) Sreekumar R, et al. 2002. Effects of caloric restriction on mitochondrial function and gene transcripts in rat muscle. *Am. J. Physiol. Endocrinol. Metab.* 283:E38.
- (1316) Zhu H, et al. 1999. Dietary restriction protects hippocampal neurons against the death-promoting action of a presenilin-1 mutation. *Brain Res* 842:224.
- (1317) Duan W, et al. 2003. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression and increases survival in huntingtin mutant mice. *Proc Natl Acad Sci USA* 100:2911.
- (1318) Yu ZF, Mattson MP. 1999. Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. *J Neurosci Res* 57:830.
- (1319) Shors TJ, et al. 2001. Neurogenesis in the adult is involved in the formation of trace memories. *Nature* 410:372.
- (1320) Mattson MP. 2002. Brain evolution and lifespan regulation: conservation of signal transduction pathways that regulate energy metabolism. *Aging Res Rev.* 123(8):947.
- (1321) Wolkow CA, et al. 2000. Regulation of *C.elegans* life-span by insulinlike signaling in the nervous system. *Science* 290:147.
- (1322) Masoro EJ, Austad SN 1996. The evolution of the antiaging action of dietary restriction: a hypothesis. *J Gerontol Biol Sci* 51A:B387.
- (1323) Patel NV, Finch CE. 2002. The glucocorticoid paradox of caloric restriction in slowing brain aging. *Neurobiol Aging* 23:707.
- (1324) Nelson JF, et al. 1995. Neuroendocrine involvement in aging: evidence from studies of reproductive aging and caloric restriction. *Neurobiol Aging* 16:837.
- (1325) Sapolsky RM. 1999. Glucocorticoids, stress, and their adverse neurological effects: relevance to aging. *Exp Neurol* 34:721.
- (1326) Cameron HA, et al. 1998. Adrenal steroids and Nmethyl-D-aspartate receptor activation regulate neurogenesis in the dentate gyrus of adult rats through a common pathway. *Neuroscience* 82:349.
- (1327) Lee J, et al. 2000. Dietary restriction selectively decreases glucocorticoid receptor expression in the hippocampus and cerebral cortex of rats. *Exp Neurol* 166:435.
- (1328) Smith MA, et al. 1995. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. *J Neurosci* 15:1768.
- (1329) Nitta A, et al. 1999. Brain-derived neurotrophic factor prevents neuronal cell death induced by corticosterone. *J Neurosci Res* 57:227.

- (1330) Swart, I, et al. 2002. Hypothalamic NPY, AGRP, and POMC mRNA responses to leptin and refeeding in mice. *Am J Physiol Regul Integr Comp Physiol* 283:R1020.
- (1331) Lee J, et al. 2002. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. *J Neurochem* 82:1367.
- (1332) Yamada K, et al. 2002. Role for brain-derived neurotrophic factor in learning and memory. *Life Sci* 70:735.
- (1333) Mattson MP, et al. 1993. Mechanisms of neurotrophic factor protection against calcium- and free radical-mediated excitotoxic injury: implications for treating neurodegenerative disorders. *Exp Neurol* 124:89.
- (1334) Mattson MP, et al. 2000. Apoptotic and antiapoptotic mechanisms in stroke. *Cell Tissue Res* 301:173.
- (1335) Walford RL, et al. 2002. Calorie restriction in Biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. *J. Gerontol. A Biol. Sci. Med. Sci.* 57:B211.
- (1336) Fabry P, et al. 1964. The frequency of meals and its relation to overweight, hypercholesterolemia and decreased glucose tolerance. *Lancet* 18:614.
- (1337) Jenkins JD, et al. 1989. Nibbling versus gorging: metabolic advantages of increased meal frequency. *N. Engl. J. Med.* 321:929.
- (1338) Keski-Rahkonen A, et al. 2003. Breakfast skipping and health-compromising behaviors in adolescents and adults. *Eur. J. Clin. Nutr.* 57:842.
- (1339) Vega VL, et al. 2004. Age and caloric restriction diets are confounding factors that modify the response to lipopolysaccharide by peritoneal macrophages in C57BL/6 mice. *Shock* 22:248.
- (1340) Tanaka S, et al. 1993. Impaired immunity in obesity: suppressed but reversible lymphocyte responsiveness. *Int. J. Obes. Relat. Metab. Disord.* 17:631.
- (1341) Ingram DK, et al. 1987. Dietary restriction benefits learning and motor performance of aged mice. *J. Gerontol.* 42:78.
- (1342) London ED, et al. 1985. Effects of intermittent feeding on neurochemical markers in aging rat brain. *Neurobiol. Aging* 6:199.
- (1343) Lee J, et al. 2002. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. *J. Neurochem.* 82:1367.
- (1344) Bondolfi L, et al. 2004. Impact of age and caloric restriction on neurogenesis in the dentate gyrus of C57BL/6 mice. *Neurobiol. Aging* 25:333.
- (1345) Adlouni A, et al. 1997. Fasting during Ramadan induces a marked increase in high-density lipoprotein cholesterol and decrease in low-density lipoprotein cholesterol. *Ann. Nutr. Metab.* 41:24.
- (1346) Roky R, et al. 2004. Physiological and chronobiological changes during Ramadan intermittent fasting. *Ann. Nutr. Metab.* 48:296.
- (1347) Lat J, Holeckova E. 1971. The effect of intermittent feeding and fasting on the non-specific excitability level of the central nervous system in the rat. *Physiol. Bohemoslov.* 20:441.
- (1348) Young JB, Landsberg L. 1982. Diet-induced changes in sympathetic nervous system activity: possible implications for obesity and hypertension. *J. Chronic Dis.* 35:879.
- (1349) Berner YN, Stern F. 2004. Energy restriction controls aging through neuroendocrine signal transduction. *Ageing Res. Rev.* 3:189.
- (1350) Flier JS, Maratos-Flier E. 1998. Obesity and the hypothalamus: novel peptides for new pathways *Cell* 92:437.
- (1351) Even PC, Nicolaïdis S. 1986. Short-term control of feeding: limitation of the glucostatic theory. *Brain Res Bull* 17:621.
- (1352) Mayer J. 1955. Regulation of energy intake and the body weight: the glucostatic theory and the lipostatic hypothesis. *Ann NY Acad Sci* 63:15.
- (1353) Weinstock M. 2002. Can the behaviour abnormalities induced by gestational stress in rats be prevented or reversed? *Stress* 5(3):167.
- (1354) Kinney DK, et al. 2008. Prenatal stress and risk for autism. *Neurosci Biobehav Rev* 32(8):1519.
- (1355) Weinstock, M. 1997. Does prenatal stress impair coping and regulation of hypothalamic-pituitary-adrenal axis? *Neuroscience and Biobehavioral Reviews.* 21(1):1.
- (1356) Mulder EJ, et al. 2002. Prenatal maternal stress: Effects on pregnancy and the (unborn) child. *Early Human Development* 70(1-2):3.
- (1357) Glover V. 1997. Maternal stress or anxiety in pregnancy and emotional development of the child. *The British Journal of Psychiatry : the Journal of Mental Science* 171:105.

- (1358) Herrenkohl, LR. 1986. Prenatal stress disrupts reproductive behavior and physiology in offspring. *Annals of the New York Academy of Sciences* 474:120.
- (1359) Uno H, et al. 1994. Neurotoxicity of glucocorticoids in the primate brain. *Hormones and Behavior* 28(4):336.
- (1360) Meaney MJ, Szyf M. 2005. Environmental programming of stress responses through DNA methylation: Life at the interface between a dynamic environment and a fixed genome. *Dialogues in Clinical Neuroscience* 7(2):103.
- (1361) Matthews SG. 2000. Antenatal glucocorticoids and programming of the developing CNS. *Pediatric Research* 47(3):291.
- (1362) Seckl, JR; Meaney, MJ. 2006. Glucocorticoid "programming" and PTSD risk. *Annals of the New York Academy of Sciences* 1071:351.
- (1363) Langley-Evans SC. 1997. Hypertension induced by foetal exposure to a maternal low-protein diet, in the rat, is prevented by pharmacological blockade of maternal glucocorticoid synthesis. *Journal of Hypertension* 15(5):537.
- (1364) Beglinger C, et al. 2001. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. *Am J Physiol Regul Integr Comp Physiol* 280:R1149.
- (1365) Shemyakin A, Kapas L. 2001. L-364,718, a cholecystokinin-A receptor antagonist, suppresses feeding-induced sleep in rats. *Am J Physiol Regul Integr Comp Physiol* 280:R1420.
- (1366) Baldo BA, Kelley AE. 2001. Amylin infusion into rat nucleus accumbens potently depresses motor activity and ingestive behavior. *Am J Physiol Regul Integr Comp Physiol* 281:R1232.
- (1367) Riediger T, et al. 2001. Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP. *Am J Physiol Regul Integr Comp Physiol* 281:R1833.
- (1368) Lutz TA, et al. 2001. Dopamine D2 receptors mediate amylin's acute satiety effect. *Am J Physiol Regul Integr Comp Physiol* 280:R1697.
- (1369) Mollet A, et al. 2001. Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. *Am J Physiol Regul Integr Comp Physiol* 281:R1442.
- (1370) Wallis DJ, Hetherington MM. 2004. Stress and eating: The effects of ego-threat and cognitive demand on food intake in restrained and emotional eaters. *Appetite* 43:39.
- (1371) Lattimore P, Caswell N. 2004. Differential effects of active and passive stress on food intake in restrained and unrestrained eaters. *Appetite* 42:167.
- (1372) Stroud LR, et al. 2000. The Yale interpersonal stressor (YIPS): Affective, physiological, and behavioral responses to a novel interpersonal rejection paradigm. *Annals of Behavioral Medicine* 22:204.
- (1373) Tanofsky-Kraff M, et al. 2000. Impact of interpersonal and ego-related stress on restrained eaters. *The International Journal of Eating Disorders* 27:411.
- (1374) Tuschen-Caffier B, Vogele C. 1999. Psychological and physiological reactivity to stress: An experimental study on bulimic patients, restrained eaters, and controls. *Psychotherapy and Psychosomatics* 68:333.
- (1375) Shimizu N, et al. 1989. Oomura Y, Kai Y. Stress-induced anorexia in rats mediated by serotonergic mechanisms in the hypothalamus. *Physiol Behav.* 46(5):835.
- (1376) Sapolsky RM, et al. 2000. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. *Endocrine Reviews* 21:55.
- (1377) Bjorntorp P. Obesity. *Lancet* 1997; 350:423–426
- (1378) Bjorntorp P. 1996. The regulation of adipose tissue distribution in humans. *Int J Obes.* 20:291.
- (1379) Bjorntorp P, Rosmond R. 2000. Obesity and cortisol. *Nutrition* 16:924.
- (1380) Kamara K, et al. 1998. High-fat diets and stress responsivity. *Physiol Behav* 64:1–6
- (1381) Morley JE, et al. 1983. Minireview. Stress induced eating *Life Sci.* 32:2169.
- (1382) Elfhag K, Rossner S. 2005. Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain. *Obes Rev.* 6:67.
- (1383) Herman CP, Polivy J. 1975. Anxiety, restraint, and eating behavior. *J Abnorm Psychol.* 84:66.
- (1384) Gerstein DE, et al. 2004. Clarifying concepts about macronutrients' effects on satiation and satiety. *J Am Diet Assoc.* 104:1151.
- (1385) May RC, et al. 1992. Chronic metabolic acidosis accelerates whole body proteolysis and oxidation in awake rats. *Kidney Int* 41:1535.
- (1386) Vicennati V, et al. 2002. Response of the Hypothalamic-Pituitary-Adrenocortical Axis to

- High-Protein/Fat and High-Carbohydrate Meals in Women with Different Obesity Phenotypes. *J Clin Endoc Met* 87(8):3984.
- (1387) Friedman MI, et al. 1999. Fatty acid oxidation affects food intake by altering hepatic energy status. *Am J Physiol* 276:R1046.
- (1388) Pardridge WM, Mietus LJ. 1980. Palmitate and cholesterol transport through the blood-brain barrier. *J Neurochem* 34:463.
- (1389) Kasser TR, et al. 1985. Level of satiety: fatty acid and glucose metabolism in three brain sites associated with feeding. *Am J Physiol* 248:R447.
- (1390) Loftus TM, et al. 2000. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. *Science* 288:2379.
- (1391) Makimura H, et al. 2001. Cerulenin mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulenin fails to block neuroendocrine effects of fasting. *Diabetes* 50:733.
- (1392) Horton TJ, et al. 1995. Fat and carbohydrate overfeeding: different effects on energy storage. *Am J Clin Nutr* 62:19.
- (1393) Tremblay A, et al. 1998. Impact of dietary fat content and fat oxidation on energy intake in humans. *Am J Clin Nutr* 49:799.
- (1394) Tataranni PA, Ravussin E. 1997. Effect of fat intake on energy balance. *Ann N Y Acad Sci* 819:37.
- (1395) Hill JO, et al. 1992. Development of dietary obesity in rats: influence of amount and composition of dietary fat. *Int J Obes* 16:321.
- (1396) Jamieson PM, et al. 1995. 11 β -hydroxysteroid dehydrogenase is an exclusive 11 β -reductase in primary cultures of rat hepatocytes: Effect of physiochemical and hormonal manipulations *Endocrinology* 136:4754.
- (1397) Paulmyer-Lacroix O, et al. 2002. Expression of the mRNA coding for 11 β -hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: An in Situ hybridization study *J Clin Endocrinol Metab*. 87:2701.
- (1398) Rebuffe-Scrive M, et al. 1988. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome *J Clin Endocrinol Metab*. 67:1122.
- (1399) Peterson CB, Mitchell JE. 1999. Psychosocial and pharmacological treatment of eating disorders: a review of research findings. *J Clin Psychol*. 55:685.
- (1400) Crowther JH, et al. 2001. The role of daily hassles in binge eating. *Int J Eat Disord*. 29:449.
- (1401) Grant WB, et al. 2002. The significance of environmental factors in the etiology of Alzheimer's disease. *J Alzheimers Dis* 4:179.
- (1402) Barrett-Connor E. 1990. Obesity, hypertension and stroke. *Clin Exp Hypertens A* 12:769.
- (1403) Luchsinger JA, et al. 2002. Caloric intake and the risk of Alzheimer disease. *Arch Neurol* 59:1258.
- (1404) Sakaguchi T, et al. 1988. Effect of starvation and food intake on sympathetic activity. *Am J Physiol* 255:R284.
- (1405) Pirke K, et al. 1989. Dieting causes menstrual irregularities in normal weight young women through impairment of episodic luteinizing hormone secretion. *Fertil Steril* 51:263.
- (1406) Dallman MF, et al. 1993. Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. *Front Neuroendocrinol* 14:303.
- (1407) Bergendahl M, et al. 1996. Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. *J Clin Endocrinol Metab* 81:692.
- (1408) Harris RBS, et al. 1986. Dynamics of recovery of body composition after overfeeding, food restriction or starvation of mature female rats. *J Nutr* 116:2536.
- (1409) Brady LS, et al. 1990. Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats. *Neuroendocrinology* 52:441.
- (1410) Suemaru S, et al. 1986. Starvation-induced changes in rat brain corticotropin-releasing factor (CRF) and pituitary-adrenocortical response. *Life Sci* 39:1161.
- (1411) Seeley RJ, et al. 1996. Behavioral, endocrine, and hypothalamic responses to involuntary overfeeding. *Am J Physiol* 271:R819.
- (1412) Dallman MF. 1993. Stress update: adaptation of the hypothalamic-pituitary-adrenal axis to chronic stress. *Trends Endocrinol Metab* 4:62.
- (1413) Krahn DD, et al. 1988. Behavioral effects of corticotropin-releasing factor: localization and characterization of central effects. *Brain Res* 443:63.
- (1414) Keys A, et al. 1950. The biology of human starvation. Minneapolis: University of Minnesota Press.
- (1415) Cahill GF Jr, et al. 1966. Hormone-fuel interrelationships during fasting. *J Clin Invest* 45:1751.

- (1416) Bagdade JD, et al. 1967. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. *J Clin Invest* 46:1549.
- (1417) Baura GD, et al. 1993. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo: a mechanism for regulated insulin delivery to the brain. *J Clin Invest* 92:1824.
- (1418) Pardridge WM. 1986. Receptor-mediated peptide transport through the blood-brain barrier. *Endocr Rev* 7:314.
- (1419) Woods SC, et al. 1985. Insulin: its relationship to the central nervous system and to the control of food intake and body weight. *Am J Clin Nutr* 42:1063.
- (1420) Schwartz MW, et al. 1992. Inhibition of hypothalamic neuropeptide Y gene expression by insulin. *Endocrinology* 130:3608.
- (1421) Schwartz MW, et al. 1996. Identification of targets of leptin action in rat hypothalamus. *J Clin Invest* 98:1101.
- (1422) Ponsalle P, et al. 1993. Glucocorticoids are required for food deprivation-induced increases in hypothalamic neuropeptide Y expression. *J Neuroendocrinol* 4:585.
- (1423) Stanley BG. 1993. Neuropeptide Y in multiple hypothalamic sites controls eating behavior, endocrine, and autonomic systems for body energy balance. In: Colmers WF, Wahlestedt C, eds. *The biology of neuropeptide Y and related peptides*. Totowa, N.J.: Humana Press, pp. 457.
- (1424) Zarjevski N, et al. 1993. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. *Endocrinology* 133:1753.
- (1425) Liu JP, et al. 1994. Studies of the secretion of corticotropin-releasing factor and arginine vasopressin into the hypophyseal-portal circulation of the conscious sheep. II. The central noradrenergic and neuropeptide Y pathways cause immediate and prolonged hypothalamic-pituitary-adrenal activation: potential involvement in the pseudo-Cushing's syndrome of endogenous depression and anorexia nervosa. *J Clin Invest* 93:1439.
- (1426) Schwartz MW, et al. 1995. Hypothalamic response to starvation: implications for the study of wasting disorders. *Am J Physiol* 269:R949.
- (1427) McCartney-Francis NL, et al. 2001. Selective inhibition of inducible nitric oxide synthase exacerbates erosive joint disease. *Journal of Immunology* 166:2734.
- (1428) Shi FD, et al. 2001. Control of the autoimmune response by type 2 nitric oxide synthase. *Journal of Immunology* 167:3000.
- (1429) Kahn DA, et al. 2001. Adjuvant immunotherapy is dependent on inducible nitric oxide synthase. *Journal of Experimental Medicine* 193:1261.
- (1430) Stunkard AJ, Allison KC. 2003. Two forms of disordered eating in obesity: binge eating and night eating. *Int. J. Obesity* 27:1.
- (1431) Stunkard AJ, et al. 1955. The night-eating syndrome; a pattern of food intake among certain obese patients. *Am. J. Med.* 19:78.
- (1432) Birketvedt GS, et al. 1999. Behavioral and neuroendocrine characteristics of the night-eating syndrome. *J. Am. Med. Assoc.* 282:657.
- (1433) Neudeck P, et al. 2001. Dexamethasone suppression test using saliva cortisol measurement in bulimia nervosa. *Physiol. Behav.* 72:93.
- (1434) Bogdan C. 2001. Nitric oxide and the immune response. *Nature Immunology* 2:907.
- (1435) Coker KH. 1999. Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies. *Seminars in Urologic Oncology* 17:111.
- (1436) Manjili MH, et al. 2002. Immunotherapy of cancer using heat shock proteins. *Frontiers in Bioscience* 7:43.
- (1437) Jones DR, et al. 1984. Bereavement and cancer: some data on deaths of spouses from the longitudinal study of Office of Population Censuses and Surveys. *BMJ* 289:461.
- (1438) Joffress M, et al. 1985. Psychosocial processes and cancer incidence among Japanese men in Hawaii. *Am J Epidemiol* 121:488.
- (1439) Andersen BL, et al. 1994. A biobehavioral model of cancer stress and disease course. *Am Psychol* 49:389.
- (1440) Andersen BL, et al. 1998. Stress and immune responses after surgical treatment for regional breast cancer. *J Natl Cancer Inst* 90:30.
- (1441) Bovbjerg DH. 1991. Psychoneuroimmunology: Implications for oncology? *Cancer* 67:828.
- (1442) Levy SM, et al. 1985. Prognostic risk assessment in primary breast cancer by behavioral and immunological parameters. *Health Psychol* 4:99.
- (1443) Levy S, et al. 1987. Correlation of stress factors with sustained depression of natural killer

- cell activity and predicted prognosis in patients with breast cancer. *J Clin Oncol* 5:348.
- (1444) Spiegel D, Kato PM. 1996. Psychosocial influences on cancer incidence and progression. *Harvard Rev Psychiatry* 4:10.
- (1445) Sklar L, Anisman H. 1979. Stress and coping factors influence tumor growth. *Science* 205:513.
- (1446) Riley V. 1981. Psychoneuroendocrine influences on immunocompetence and neoplasia. *Science* 212:1100.
- (1447) Fitzmaurice M. 1988. Physiological relationships among stress, viruses, and cancer in experimental animals. *Int. J. Neurosci.* 39:307.
- (1448) Justice A. 1985. Review of the effects of stress on cancer in laboratory animals: importance of time of stress application and type of tumor. *Psychol. Bull.* 98:108.
- (1449) Sapolsky R, Donnelly T. 1985. Vulnerability to stress-induced tumor growth increases with age in rats: role of glucocorticoids. *Endocrinology* 117:662.
- (1450) Kiecolt-Glaser JK, et al. 2002. Psycho-oncology and cancer: psychoneuroimmunology and Cancer. *European Society for Medical Oncology* 13(4):165.
- (1451) Cohen S, Rabin B. 1998. Psychologic stress, immunity, and cancer. *J Natl Cancer Inst* 90:3.
- (1452) Munck A, et al. 1984. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. *Endocr. Rev.* 5:25.
- (1453) Foster LW, McLellan L. 2000. Cognition and the cancer experience: Clinical implications. *Cancer Practice* 8:25.
- (1454) Hess LM, Inse KC. 2007. Chemotherapy-Related Change in Cognitive Function: A Conceptual Model. *Oncology Nursing Forum* 34:981.
- (1455) Silberfarb PM. 1983. Chemotherapy and cognitive defects in cancer patients. *Annual Review of Medicine* 34:35.
- (1456) Silberfarb PM, et al. 1980. Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. *American Journal of Psychiatry* 137:597.
- (1457) Cimprich B, Ronis DL. 2001. Attention and symptom distress in women with and without breast cancer. *Nursing Research* 50:86.
- (1458) McCracken LM, Iverson GL. 2001. Predicting complaints of impaired cognitive functioning in patients with chronic pain. *Journal of Pain and Symptom Management* 21:392.
- (1459) Smith MY, et al. 1999. Post-traumatic stress disorder in cancer: A review. *Psycho-Oncology* 8:521.
- (1460) van Dam FS, et al. 1998. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. *Journal of the National Cancer Institute* 90:210.
- (1461) Schagen SB, et al. 1999. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. *Cancer* 85:640.
- (1462) Tchen N, et al. 2003. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. *Journal of Clinical Oncology* 21:4175.
- (1463) Ahles TA, Saykin AJ. 2002. Breast cancer chemotherapy-related cognitive dysfunction. *Clinical Breast Cancer* 3(3):S84.
- (1464) Jacobsen PB, et al. 2004. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. *Journal of Pain and Symptom Management* 28:7.
- (1465) Schagen SB, et al. 2006. Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. *Journal of the National Cancer Institute* 98:1742.
- (1466) Wieneke MH, Dienst ER. 1995. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. *Psycho-Oncology* 4:61.
- (1467) Brezden CB, et al. 2000. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. *Journal of Clinical Oncology* 18:2695.
- (1468) Meyers CA, Wefel JS. 2003. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: No ifs, ands, buts, or sensitivity. *Journal of Clinical Oncology* 21:3557.
- (1469) Tannock IF, et al. 2004. Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. *Journal of Clinical Oncology* 22:2233.
- (1470) Jansen C, et al. 2005. Potential mechanisms for chemotherapy-induced impairments in cognitive function. *Oncology Nursing Forum* 32:1151.
- (1471) Staat K, Segatore M. 2005. The phenomenon of chemo brain. *Clinical Journal of Oncology Nursing* 9:713.
- (1472) Keime-Guibert F, et al. 1998. Neurological complications of radiotherapy and chemotherapy. *Journal of Neurology* 245:695.

- (1473) Schagen SB, et al. 2001. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. *Journal of Neuro-Oncology* 51:159.
- (1474) Groopman JE, Itri LM. 1999. Chemotherapy-induced anemia in adults: Incidence and treatment. *Journal of the National Cancer Institute* 91:1616.
- (1475) Cunningham RS. 2003. Anemia in the oncology patient: Cognitive function and cancer. *Cancer Nursing* 26(Suppl. 6):38S.
- (1476) Spiegel D, et al. 1989. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. *Lancet* 2:888.
- (1477) Goodwin PJ, et al. 2001. The effect of group psychosocial support on survival in metastatic breast cancer. *N Engl J Med* 345:1719.
- (1478) Juang SH, et al. 1997. Use of retroviral vectors encoding murine inducible nitric oxide synthase gene to suppress tumorigenicity and cancer metastasis of murine melanoma. *Cancer Biotherapy and Radiopharmaceuticals* 12:167.
- (1479) Jenkins DC, et al. 1995. Roles of nitric oxide in tumor growth. *Proceedings of the National Academy of Sciences of the United States of America* 92:4392.
- (1480) Thomsen LL, et al. 1995. Nitric oxide synthase activity in human breast cancer. *British Journal of Cancer* 72:41.
- (1481) Duenas-Gonzalez A, et al. 1997. Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. *Modern Pathology* 10:645.
- (1482) Pervin S, et al. 2001. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. *Proceedings of the National Academy of Sciences of the United States of America* 98:3583.
- (1483) Fujimoto H, et al. 1997. Nitric oxide synthase activity in human lung cancer. *Japanese Journal of Cancer Research* 88:1190.
- (1484) Fimiani C, et al. 1999. Mu3 opiate receptor expression in lung and lung carcinoma: ligand binding and coupling to nitric oxide release. *Cancer Letters* 146:45.
- (1485) Xiong Q, et al. 2001. Regulation of interleukin-8 expression by nitric oxide in human pancreatic adenocarcinoma. *Journal of Interferon and Cytokine Research* 21:529.
- (1486) Kwak JY, et al. 2000. Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. *Cell Immunology* 203:84.
- (1487) Lejeune P, et al. 1994. Nitric oxide involvement in tumor-induced immunosuppression. *Journal of Immunology* 152:5077.
- (1488) Ambs S, et al. 1998. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. *Cancer Research* 58:334.
- (1489) Martin MJ, et al. 2001. New issues about nitric oxide and its effects on the gastrointestinal tract. *Current Pharmaceutical Design* 7:881.
- (1490) Xie K, et al. 1996. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. *Journal of Leukocyte Biology* 59:797.
- (1491) Glaser R, et al. 1985. Effects of stress on methyltransferase synthesis: An important DNA repair enzyme. *Health Psychol* 4:403.
- (1492) Kiecolt-Glaser JK, et al. 1985. Distress and DNA repair in human lymphocytes. *J Behav Med* 8:311.
- (1493) Cohen L, et al. 2000. DNA repair capacity in healthy medical students during and after exam stress. *J Behav Med* 23:531.
- (1494) Patel C. 1997. Stress management & hypertension. *Acta Physiologica Scandinavica. Supplementum* 640:155.
- (1495) Giulumian AD, et al. 1999. Effect of behavioral stress on coronary artery relaxation altered with aging in BHR. *American Journal of Physiology* 276:435.
- (1496) Spence JD, et al. 1999. Lifestyle modifications to prevent and control hypertension 7. Recommendations on stress management. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. *Canadian Medical Association Journal* 160:46.
- (1497) Wenneberg SR, et al. 1997. A controlled study of the effects of the Transcendental Meditation program on cardiovascular reactivity and ambulatory blood pressure. *International Journal of Neuroscience* 89:15.
- (1498) Lutgendorf S, et al. 2000. Effects of relaxation and stress on the capsaicin-induced local inflammatory response. *Psychosomatic Medicine* 62:524.
- (1499) Sanders BJ, Lawler JE. 1992. The borderline hypertensive rat (BHR) as a model for environmentally-induced hypertension: a review

- and update. *Neuroscience and Biobehavioral Reviews* 16:207.
- (1500) Ritchie K, Lovestoe S. 2002. The demential. *Lancet* 360:1759.
- (1501) Selhub J, et al. 2000. B vitamins, homocysteine, and neurocognitive function in the elderly. *Am. J. Clin. Nutr.* 71:614S.
- (1502) Joosten E. 2001. Homocysteine, vascular dementia and Alzheimer's disease. *Clin. Chem. Lab. Me.* 39:717.
- (1503) Herrmann W. 2001. The importance of hyperhomocysteinemia as a risk factor for diseases: an overview. *Clin. Chem. Lab. Me.* 39:666.
- (1504) Gonzales-Gross M, et al. 2001. Nutrition and cognitive impairment in the elderly. *Br. J. Nutr.* 86:313.
- (1505) Bogdan C. 1998. The Multiplex Function of Nitric oxide in (Auto) immunity. *Journal of Experimental Medicine* 187:1361.
- (1506) Chrousos GP. 1995. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. *New England Journal of Medicine* 332:1351.
- (1507) Sternberg EM, et al. 1992. The stress response and the regulation of inflammatory disease. *Annals of Internal Medicine* 117:854.
- (1508) Munck A, et al. 1984. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. *Endocr. Rev.* 5:25.
- (1509) Zorrilla EP, et al. 2001. The relationship of depression and stressors to immunological assays: A meta-analytic review. *Brain Behav Immun* 15:199.
- (1510) Glaser R, et al. 1986. Stress depresses interferon production by leukocytes concomitant with a decrease in natural killer cell activity. *Behav Neurosci* 100:675.
- (1511) Irwin M, et al. 1987. Life events, depressive symptoms, and immune function. *Am J Psychiatry* 144:437.
- (1512) Welsh RM. 1996. Regulation of virus infections by natural killer cells. *Nat Immun Cell Growth Regul* 5:169.
- (1513) Herberman RB, Ortaldo JR. 1981. Natural killer cells: Their role in defenses against disease. *Science* 214:24.
- (1514) Irwin M, et al. 1988. Plasma cortisol and natural killer cell activity during bereavement. *Biol Psychiatry* 24:173.
- (1515) Baron RS, et al. 1990. Social support and immune function among spouses of cancer patients. *J Pers Soc Psychol* 59:344.
- (1516) Stefanski V. 2001. Social stress in laboratory rats: Behavior, immune function, and tumor metastasis. *Physiol Behav* 73:385.
- (1517) Wu W, et al. 2000. Social isolation stress enhanced liver metastasis of murine colon 26-L5 carcinoma cells by suppressing immune responses in mice. *Life Sci* 66:1827.
- (1518) Jung W, Irwin M. 1999. Reduction of natural killer cytotoxic activity in major depression: Interaction between depression and cigarette smoking. *Psychosom Med* 61:263.
- (1519) Glaser R, Kiecolt-Glaser JK. 1994. *Handbook of Human Stress and Immunity*. San Diego, CA: Academic Press.
- (1520) Kiecolt-Glaser JK, et al. 1985. Psychosocial enhancement of immuno-competence in a geriatric population. *Health Psychol* 4:25.
- (1521) Kiecolt-Glaser JK, Glaser R. 1992. Psychoneuroimmunology: can psychological interventions modulate immunity? *J Consult Clin Psychol* 60:569.
- (1522) Dobbin JP, et al. 1991. Cytokine production and lymphocyte transformation during stress. *Brain Behav Immun* 5:339.
- (1523) Glaser R, et al. 1987. Stress-related immune suppression: Health implications. *Brain Behav Immun* 1:7.
- (1524) Helzer JE, et al. 1982. A controlled study of the association between ulcerative colitis and psychiatric diagnoses. *Dig Dis Sci* 27(6):513.
- (1525) Helzer JE, et al. 1984. A study of the association between Crohn's disease and psychiatric illness. *Gastroenterology* 86(2):324.
- (1526) Fava GA, Pavan L. 1976. Large bowel disorders. I. Illness configuration and life events. *Psychother Psychosom* 27(2):93.
- (1527) Feldman F, et al. 1967. Psychiatric study of a consecutive series of 34 patients with ulcerative colitis. *BMJ* 3(556):14.
- (1528) Hislop IG. 1974. Onset setting in inflammatory bowel disease. *Med J Aust* 1(25):981.
- (1529) Mendeloff AI, et al. 1970. Illness experience and life stresses in patients with irritable colon and with ulcerative colitis. An epidemiologic study of ulcerative colitis and regional enteritis in Baltimore, 1960-64. *N Engl J Med* 282(1):14.
- (1530) Riley SA, et al. 1990. Why do patients with ulcerative colitis relapse? *Gut* 31(2):179.

- (1531) von Wietersheim J, et al. 1992. Relapse-precipitating life events and feelings in patients with inflammatory bowel disease. *Psychother Psychosom* 58(2):103.
- (1532) Levenstein S, et al. 1994. Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study [see comments]. *Am J Gastroenterol* 89(8):1219.
- (1533) Levenstein S, et al. 2000. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. *Am J Gastroenterol* 95(5):1213.
- (1534) Stout C, Snyder RL. 1969. Ulcerative colitis-like lesion in Siamang gibbons. *Gastroenterology* 57(3):256.
- (1535) Santos J, et al. 2001. Social stress induces reversible inflammation and persistent barrier dysfunction in the rat intestine. *Gastroenterology* 120:297.
- (1536) Soderholm JD, et al. 2001. Chronic psychological stress induces epithelial barrier disruption, bacterial penetration and mucosal inflammation in ileum and colon of 5 naive rats. *Gastroenterology* 120:372.
- (1537) Soderholm JD, et al. 2001. Chronic psychological stress induces mucosal inflammation in the ileum and colon of naive rats: role of mast cells. *Gastroenterology* 120:3747.
- (1538) Soderholm JD, et al. 2001. Early maternal deprivation predisposes adult rats to colonic mucosal barrier dysfunction in response to mild stress. *Gastroenterology* 120:113.
- (1539) Saunders PR, et al. 1994. Acute stressors stimulate ion secretion and increase epithelial permeability in rat intestine. *Am J Physiol* 267(5 Part 1):G794.
- (1540) Saunders PR, et al. 1997. Cholinergic nerves mediate stress-induced intestinal transport abnormalities in Wistar-Kyoto rats. *Am J Physiol* 273(2 Part 1):G486.
- (1541) Kiliaan AJ, et al. 1998. Stress stimulates transepithelial macromolecular uptake in rat jejunum. *Am J Physiol* 275(5 Part 1):G1037.
- (1542) Santos J, et al. 1999. Corticotropin releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. *Am J Physiol* 277(2 Part 1):G391.
- (1543) Santos J, et al. 2000. Chronic stress impairs rat growth and jejunal epithelial barrier function: role of mast cells. *Am J Physiol Gastrointest Liver Physiol* 278(6):G847.
- (1544) Hilsden RJ, et al. 1996. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. *Gastroenterology* 110(5):1395.
- (1545) Hollander D, et al. 1986. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. *Ann Intern Med* 105(6):883.
- (1546) May GR, et al. 1993. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? *Gastroenterology* 104(6):1627.
- (1547) Peeters M, et al. 1997. Clustering of increased small intestinal permeability in families with Crohn's disease. *Gastroenterology* 113(3):802.
- (1548) Yacyshyn BR, Meddings JB. 1995. CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. *Gastroenterology* 108(1):132.
- (1549) Wyatt J, et al. 1993. Intestinal permeability and the prediction of relapse in Crohn's disease. *Lancet* 341(8858):1437.
- (1550) Barclay GR, Turnberg LA. 1987. Effect of psychological stress on salt and water transport in the human jejunum. *Gastroenterology* 93(1):91.
- (1551) Santos J, et al. 1998. Release of mast cell mediators into the jejunum by cold pain stress in humans. *Gastroenterology* 114(4):640.
- (1552) Brandi LS, et al. 1993. Insulin resistance of stress: sites and mechanisms. *Clin Sci (Colch)* 85:525.
- (1553) Grimm JJ. 1999. Interaction of physical activity and diet: implications for insulin-glucose dynamics. *Public Health Nutr* 2:363.
- (1554) Moore MA, et al. 1998. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. *Eur J Cancer Prev* 7:89.
- (1555) Stubbs PJ, et al. 1999. Significance of an index of insulin resistance on admission in non-diabetic patients with acute coronary syndromes. *Heart* 82:443.
- (1556) Lempiainen P, et al. 1999. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. *Circulation* 100:123.
- (1557) Misra A, et al. 1999. Clustering of impaired glucose tolerance, hyperinsulinemia and dyslipidemia in young north Indian patients with coronary heart disease: a preliminary case-control study. *Indian Heart J* 51:275.
- (1558) Davis CL, et al. 1999. History of gestational diabetes, insulin resistance and coronary risk. *J Diabetes Complications* 13:216.

- (1559) Despres JP, et al. 1996. Hyperinsulinemia as an independent risk factor for ischemic heart disease. *N Engl J Med* 334:952.
- (1560) Pujol P, et al. 1997. Obesity and breast cancer risk. *Hum Reprod* 12:116.
- (1561) Stoll BA. 1998. Essential fatty acids, insulin resistance, and breast cancer risk. *Nutr Cancer* 31:72.
- (1562) Kotake H, Oikawa S. 1999. Syndrome X. *Nippon Rinsho* 57:622.
- (1563) Watanabe K, et al. 1999. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. *J Hypertens* 17:1161.
- (1564) Lender D, et al. 1997. Essential hypertension is associated with decreased insulin clearance and insulin resistance. *Hypertension* 29:111.
- (1565) Arthur LS, et al. 1999. Hyperinsulinemia in polycystic ovary disease. *J Reprod Med* 44:783.
- (1566) Baranowska B, et al. 1999. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome. *Gynecol Endocrinol* 13:344.
- (1567) Tiihonen M, et al. 1993. The severity of obstructive sleep apnoea is associated with insulin resistance. *J Sleep Res* 2:56.
- (1568) Grundy SM. 1999. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. *Am J Cardiol* 83:25F.
- (1569) Belfiore F, Iannello S. 1998. Insulin resistance in obesity: metabolic mechanisms and measurement methods. *Mol Genet Metab* 65:121.
- (1570) Samaras K, et al. 1999. Clustering of insulin resistance, total and central abdominal fat: same genes or same environment? *Twin Res* 2:218.
- (1571) Benzi L, et al. 1999. Intracellular hyperinsulinism: a metabolic characteristic of obesity with and without type 2 diabetes: intracellular insulin in obesity and type 2 diabetes. *Diabetes Res Clin Pract* 46:231.
- (1572) Goldstein RE, et al. 1993. Effects of chronic elevation in plasma cortisol on hepatic carbohydrate metabolism. *Am J Physiol* 264:E119.
- (1573) Dinneen S, et al. 1993. Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. *J Clin Invest* 92:2283.
- (1574) Zakrzewska KE, et al. 1997. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. *Diabetes* 46:717.
- (1575) Zakrzewska KE, et al. 1999. Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. *Diabetes* 48:365.
- (1576) Berneis K, et al. 1996. Effects of glucocorticoids and of growth hormone on serum leptin concentrations in man. *Eur J Endocrinol* 135(6):663.
- (1577) Donahue RP, et al. 1999. Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. *Diabetes Care* 22:1092.
- (1578) Malmstrom R, et al. 1996. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. *Diabetologia* 39:993.
- (1579) Havel PJ, et al. 1996. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. *J Clin Endocrinol Metab* 81:4406.
- (1580) Hamann A, Matthaei S. 1996. Regulation of energy balance by leptin. *Exp Clin Endocrinol Diabetes* 104:293.
- (1581) Toalson P, et al. 2004. The metabolic syndrome in patients with severe mental illnesses. *Prim. Care Companion J. Clin. Psychiatry* 6:152.
- (1582) McElroy SL, et al. 2004. Are mood disorders and obesity related? A review for the mental health professional. *J. Clin. Psychiatry* 65:634.
- (1583) Sonnichsen AC, et al. 1992. Benefit from hypocaloric diet in obese men depends on the extent of weight-loss regarding cholesterol, and on a simultaneous change in body fat distribution regarding insulin sensitivity and glucose tolerance. *Metabolism* 41:1035.
- (1584) Marshall JA, et al. 1997. High saturated fat and low starch and fibre are associated with hyperinsulinaemia in a nondiabetic population: The San Luis Valley Diabetes Study. *Diabetologia* 40:430.
- (1585) Lovejoy J, DiGirolamo M. 1992. Habitual dietary intake and insulin sensitivity in lean and obese adults. *Am J Clin Nutr* 55:1174.
- (1586) Maron DJ, et al. 1991. Saturated fat intake and insulin resistance in men with coronary artery disease. The Stanford Coronary Risk Intervention Project Investigators and Staff. *Circulation* 84:2020.
- (1587) Miller WC, et al. 1990. Diet composition, energy intake, and exercise in relation to body fat in men and women. *Am J Clin Nutr* 52:426.

- (1588) Reavan GM. 1997. Do high carbohydrate diets prevent the development or attenuate the manifestations (or both) of syndrome X? A viewpoint strongly against. *Curr Opin Lipidol* 8:23.
- (1589) Mathers JC, Daly ME. 1998. Dietary carbohydrates and insulin sensitivity. *Curr Opin Clin Nutr Metab Care* 1:553.
- (1590) Fukagawa NK, et al. 1990. High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults. *Am J Clin Nutr* 52:524.
- (1591) Chen M, et al. 1988. Insulin resistance and beta-cell dysfunction in aging: the importance of dietary carbohydrate. *J Clin Endocrinol Metab* 67:951.
- (1592) Ryan AS, et al. 1996. Resistive training increases insulin action in postmenopausal women. *J Gerontol A Biol Sci Med Sci* 51:M199.
- (1593) Facchini F, et al. 1996. Relation between dietary vitamin intake and resistance to insulin-mediated glucose disposal in healthy volunteers. *Am J Clin Nutr* 63:946.
- (1594) Sanchez M, et al. 1997. Oral calcium supplementation reduces intraplatelet free calcium concentration and insulin resistance in essential hypertensive patients. *Hypertension* 29:531.
- (1595) Hua H, et al. 1995. Magnesium transport induced ex vivo by a pharmacological dose of insulin is impaired in non-insulindependent diabetes mellitus. *Magnes Res* 8:359.
- (1596) Lima M de L, et al. 1998. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. *Diabetes Care* 21:682.
- (1597) Norbiato G, et al. 1984. Effects of potassium supplementation on insulin binding and insulin action in human obesity: protein-modified fast and refeeding. *Eur J Clin Invest* 14:414.
- (1598) Anderson RA, et al. 1991. Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. *Am J Clin Nutr* 54:909.
- (1599) Boden G, et al. 1996. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulindependent diabetes mellitus. *Metabolism* 45:1130.
- (1600) Chen MD, et al. 1991. Investigation of the relationships between zinc and obesity. *Kao Hsiung I Hsueh Ko Hsueh Tsa Chih* 7:628.
- (1601) Gomi T, et al. 1998. Strict dietary sodium reduction worsens insulin sensitivity by increasing sympathetic nervous activity in patients with primary hypertension. *Am J Hypertens* 11:1048.
- (1602) Fliser D, et al. 1995. The effect of dietary salt on insulin sensitivity. *Eur J Clin Invest* 25:39.
- (1603) Feldman RD, Schmidt ND. 1999. Moderate dietary salt restriction increases vascular and systemic insulin resistance. *Am J Hypertens* 12:643.
- (1604) Donovan DS, et al. 1993. Effect of sodium intake on insulin sensitivity. *Am J Physiol* 264:E730.
- (1605) Matsueda K. 2001. [Irritable bowel syndrome: diagnostic criteria and recent advancement of its pharmacological management]. *Nippon Rinsho* 59:30.
- (1606) Floch MH, Narayan R. 2002. Diet in the irritable bowel syndrome. *J. Clin. Gastroenterol.* 35:S45.
- (1607) Frissora CL. 2002. A new look at irritable bowel syndrome [IBS]: a neuroenteric disorder. *Compr. Ther.* 28:222.
- (1608) D'Souza DL, et al. 2001. Effect of alosetron on the pharmacokinetics of alprazolam. *J. Clin. Pharmacol.* 41:452.
- (1609) Blanchard EB, et al. 1990. The role of anxiety and depression in the irritable bowel syndrome. *Behav. Res. Ther.* 28:401.
- (1610) Haug TT, et al. 2002. Are anxiety and depression related to gastrointestinal symptoms in the general population? *Scand. J. Gastroenterol.* 37:294.
- (1611) Lydiard RB. 1997. Anxiety and the irritable bowel syndrome: psychiatric, medical, or both? *J. Clin. Psychiatry* 58:51.
- (1612) Monnikes H, et al. 2001. Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. *Dig. Dis.* 19 :201.
- (1613) Enck P, et al. 1989. Stress effects on gastrointestinal transit in the rat. *Gut* 30:455.
- (1614) Williams CL, et al. 1988. Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome. *Gastroenterology* 94, 611–621
- (1615) Hedge SS, Eglen RM. 1996. Peripheral 5-HT₄ receptors. *FASEB J.* 10, 1398–1407
- (1616) Tuladhar BR, et al. 2002. Modulation of 5-HT₄ receptor function in the rat isolated ileum by fluoxetine: the involvement of endogenous 5-

- hydroxytryptamine. *Br. J. Pharmacol.* 136, 150–156
- (1617) Sanger GJ, et al. 2000. Increased defecation during stress or after 5-hydroxytryptophan: selective inhibition by the 5-HT(4) receptor antagonist, SB-207266. *Br. J. Pharmacol.* 130:706.
- (1618) Ressler KJ, Nemeroff CB. 2000. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. *Depress. Anxiety* 12:2.
- (1619) Bharucha AE, et al. 2000. Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. *Gut* 47:667.
- (1620) Banner SE, et al. 1996. Increased defaecation caused by 5-HT₄ receptor activation in the mouse. *Eur. J. Pharmacol.* 308:181.
- (1621) Contesse V, et al. 1994. Effect of a series of 5-HT₄ receptor agonists and antagonists on steroid secretion by the adrenal gland in vitro. *Eur. J. Pharmacol.* 265:27.
- (1622) Kaumann AJ, et al. 1991. A 5-HT₄-like receptor in human right atrium. *Naunyn-Schmiedberg's Arch. Pharmacol.* 344, 50–159
- (1623) Schoemaker RG, et al. 1993. 5-Hydroxytryptamine stimulates human isolated atrium but not ventricle. *Eur. J. Pharmacol.* 230 :103.
- (1624) Kennett GA, et al. 1997. Anxiolytic-like actions of the selective 5-HT₄ receptor antagonists SB 204070A and SB 207266A in rats. *Neuropharmacology* 36:707.
- (1625) Rachal Pugh C, et al. 2001. The immune system and memory consolidation: a role for the cytokine IL-1 β . *Neuroscience and Behavioral Reviews* 25:29.
- (1626) McEwen BS. 1999. Stress and hippocampal plasticity. *Annual Review of Neuroscience* 22:105.
- (1627) McEwen BS, Sapolsky RM. 1995. Stress and cognitive function. *Current Opinion in Neurobiology* 5:205.
- (1628) Garcia R. 2001. Stress, hippocampal plasticity, and spatial learning. *Synapse*, 40:180.
- (1629) McEwen BS, et al. 1999. Corticosteroids, the Aging Brain and Cognition. *Trends in Endocrinology and Metabolism* 10:92.
- (1630) Mattson MP, et al. 1999. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. *Ann NY Acad Sci* 893:154.
- (1631) Beal MF. 1998. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. *Ann Neurol* 44:S110.
- (1632) Mattson MP. 2003. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. *Neuromolecular Med* 3:65.